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II ABSTRACT 
Background 
Angiogenesis is the formation of new blood vessels from the pre-existing 
vasculature and is crucial for the development and progression of solid tumours. 
Vascular Endothelial Growth Factor (VEGF) is the most potent angiogenic factor 
identified to date and mediates its mitogenic and angiogenic activity on endothelial 
cells via tyrosine kinase receptors VEGF-R1 and VEGF-R2. Bevacizumab (Bz) is a 
humanised antibody to VEGF and prevents VEGF binding to VEGF-R1 and 
VEGF-R2 thereby inhibiting angiogenesis, and has been shown to increase 
progression free survival in breast cancer. However, tumours treated with Bz 
eventually acquire resistance and subsequently escape treatment control.  
Aim 
The aim of the study was to assess if combining Bz with a neuropilin 1 targeted 
peptide would enhance the inhibitory effects observed with Bz on breast cancer 
growth.  
Methods 
Three cell types were utilised the in vitro studies; human dermal microvascular 
endothelial cells (HuDMECs) and two breast cancer cell (MDA-MB-231 and 
MDA-MB-436). A number of in vitro functional assays were carried out to assess 
if any of the neuropilin1 peptides demonstrated biological activity. Based on the in 
vitro data a primary sub-cutaneous tumour model was set up to assess the effects of 
Bz in combination with the neuropilin1 peptides in a more relevant and dynamic 
setting.  
Results 
Overall the Np1 peptides failed to demonstrate additive effects on inhibiting breast 
cancer growth and activity. The ‘true’ inhibitory effects of Bz were observed in the 
bone metastasis ex vivo analysis, whereby the health of the bone in a animal with 
bone metastases was significantly healthier in the Bz treated animals compared 
with the control vehicle.  
Conclusion 
To conclude the effects of the neuropilin 1 peptides in enhancing inhibitory effects 
on breast cancer growth when combined with Bz remains inconclusive due to a 
number of reasons discussed in this thesis. In addition, the thesis highlighted that 
going forward differentiating the actions of Bz from those observed with the 
vehicle control is crucial and needs to be bought to light. Finally, expanding on the 
bone metastasis model is key, as preliminary data with Bz looks promising.  
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1. Introduction 
Breast cancer is a life threatening disease that has an incidence rate of 47,693 cases per annum 
in the UK alone and is the most commonly diagnosed cancer type in the UK (Cancer Research 
UK, 2008). Surgery is the first line of treatment for primary breast cancer and current treatment 
for metastatic breast cancer (mBC) includes chemotherapy or radiotherapy used in an adjuvant 
setting sometimes in combination with anti-angiogenic drugs including Bevacizumab 
(Avastin
®
). However, since the approval of Bevacizumab (Bz) for mBC treatment in 2008, it 
has become clear that resistance to anti-angiogenic therapy is rapid and that the initial promise 
of such therapy is proving less efficacious than initially hoped. Despite disappointing outcomes 
in the clinic, the anti-angiogenic approach to mBC treatment may still hold some promise and 
greater knowledge of the mechanisms of action and a more selective use of the therapy may 
prove beneficial. This introduction discusses the clinical significance of anti-angiogenic therapy 
in breast cancer treatment with the main focus being the vascular endothelial growth factor 
pathway. The challenges that anti-angiogenic therapy has encountered in the clinic and the Food 
and Drug Administration (FDA) withdrawal of approval will also be discussed, in particular the 
potential mechanisms that lead to Bz resistance in breast cancer therapy.  
1.1 Breast Cancer 
1.1.1 Morphology of Breast Cancer 
Breast carcinomas mostly present as discrete lumps, usually within the upper quadrant of the 
breast and histological examination is required to ensure correct diagnosis (Underwood, 1996). 
A high majority of breast carcinomas are adenocarcinomas that arise from either glandular or 
ductal epithelium. The clinical manifestations of invasive breast cancer occur in a progressive 
manner. A normal duct may progress through several different proliferative conditions that will 
not necessarily result in a malignant disease; these conditions include fibrocystic changes, 
adenosis, epithelial hyperplasia and cysts. Breast carcinomas do not develop rapidly from the 
normal breast; there is a morphological change in the cells in the ducts or lobules, which 
eventually leads to a malignant disease. The following lists the morphological states in order of 
lesion severity; (1) Hyperplasia, (2) Atypical hyperplasia, (3) Ductal Carcinoma in situ (DCIS) 
and (4) Invasive Carcinoma (Underwood, 1996). However it is important to note that breast 
cancer progression does not necessarily follow each step in this order of severity, unlike the 
adenoma-carcinoma sequence in colorectal cancer (CRC) (Frank, 2007). 
 
1.1.2 Breast Cancer (Sub-Types) 
Breast cancer is not defined as one disease as there are many sub-classifications. This makes the 
treatment of the disease difficult, as sub-types can present with different risk factors, clinical 
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symptoms, pathological features and response to therapy (Weigeit et al, 2010). Recent 
microarray technology has allowed sub-classification of invasive breast cancer based on the 
molecular profile of the disease. Invasive breast cancer can now be categorised as either (1) 
Luminal A (2) Luminal B (3) Oestrogen and progesterone negative and human epidermal 
receptor positive (ER-/PR-/HER+) (4) Basal like and (5) Normal Breast-like.  
Luminal tumours are the most commonly observed sub-type of invasive breast cancer and are 
further divided into two separate groups; luminal A and Luminal B. Both are ER/PR hormone 
receptor positive however, luminal A breast tumours usually have a lower Ki67 count 
(proliferative index), have a better prognosis as they are usually classified as low/moderate 
grade tumours compared to luminal B tumours. Luminal B tumours are usually of a higher 
grade and are lymph node positive (Eroles et al, 2011). The third sub-type of invasive breast 
cancer account for 10-15% of invasive breast cancer cases and are classified as HER2 tumours 
that are ER/PR hormone receptor negative but HER2 positive, and are usually lymph node 
positive and have a poorer prognosis compared to luminal breast cancer, with patients more 
prone to recurrence and metastasis (Eroles et al, 2007).Basal like breast tumours also referred to 
as triple negative breast cancer (TNBC) lack expression of ER, PR and HER2 but are classified  
as basal like because they express genes that are commonly expressed by basal epithelial cells, 
such as cytokeratin 5/6 (Ishihara et al, 2009). Basal like breast tumours account for 15-20% of 
invasive cases and characteristically present with an aggressive phenotype and are commonly 
observed in younger patients. TNBC is one of the most difficult disease states to treat (Eroles et 
al, 2011). The best treatment strategy for basal like carcinomas is targeted systemic 
chemotherapy (Ishihara et al, 2009). The fifth sub-group is the Normal Breast-like tumours; 
these are the least common type of invasive breast cancer observed, accounting for 
approximately 6-10% of cases and are small in size and have a good prognosis. The above sub-
classification can also be applied to human breast cancer cell lines that are frequently used for 
research purposes (Holliday and Speirs, 2011). The grouping of different breast cancer cell-
lines based on the molecular profile is potentially an excellent tool in research to allow 
identification of therapy for specific breast cancer sub-types that could potentially translate to 
the clinic.  
However the onset of abnormal cell and cancer development is the initial step of the process. It 
is well understood that once a tumour has established within its primary location, the tumour 
cells must be able to create a microenvironment in which growth and progress is possible. In 
order to survive and metastasise, tumours promote the formation of a blood supply (Amini et al, 
2012). Initially tumours obtain oxygen and nutrients via simple diffusion from neighbouring 
cells; however, for tumours to grow beyond 2mm
3 
there is a requirement to stimulate the 
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formation of a new micro-vascular network by a process known as angiogenesis (Folkman, 
1971).  
 
1.2 Developing the Primary Vasculature 
The vascular system is one of the first processes to develop in the embryo, due to its importance 
in supporting and maintaining all aspects of organ development (Carmeliet, 2005). Establishing 
the primary vasculature in the early embryo occurs through a process known as vasculogenesis, 
which effectively forms the vasculature network through differentiation of endothelial 
progenitor cells, haemangioblasts (Patan, 2004) Expansion of this primary network is required 
and occurs through the process of angiogenesis, which is explained in detail in the following 
section.  
 
1.3 Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature and plays an 
important role in physiological processes such as wound healing, menstruation and 
inflammation (Papetti and Herman 2002). It is thought that in general living cells are located 
within 100-200µm of a blood supply (Carmeliet and Jain 2000) emphasising the need to 
maintain a well regulated blood system that will efficiently deliver oxygen and nutrients at the 
same time as  removing waste products from all tissues. Hence as a tissue attempts to grow, the 
metabolic demands exerted on the system are increased and therefore the vascular network must 
grow in a concurrent manner to maintain healthy growth of the tissue. This is particularly 
evident when considering the key role angiogenesis plays in many pathological diseases which 
are characterised by an increase in cell proliferation such as psoriasis and cancer. Oxygen and 
nutrients diffuse adequately over a distance of 100-200µm, subsequently for tumours to grow 
beyond 2mm
3
 in volume they must elicit a vasculature to meet nutritional requirements 
(Carmeliet and Jain 2000). 
 
1. 3.1 Physiological Angiogenesis 
Physiological angiogenesis occurs initially during early embryonic development to form a 
functional vasculature. It is a multistep process that is tightly regulated to maintain 
physiological integrity of the blood network. There are a number of different stimuli that are 
capable of inducing angiogenesis, including hypoxia and angiogenic growth factors, one of the 
most potent being vascular endothelial growth factor (VEGF) (Ferrara 2004) (section 1.3.3). 
The initial stage is once an angiogenic stimulus has been received, the de-attachment of 
pericytes from endothelial cells (ECs) to induce vascular destabilisation of the host vasculature 
which is thought to be mediated by the actions of angiopoeitin 2 (Ang-2) (von Tell et al. 2006). 
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Then proteases such as matrix metalloproteinases (MMPs) are secreted, which loosen the cell-
cell and cell-basement membrane interactions by degrading the adhesion molecules and 
surrounding matrix (Papetti and Herman 2002). The breakdown of the basement membrane 
and the extracellular matrix (ECM) not only allows EC migration but also causes the release of 
many pro angiogenic factors that are sequestered within the ECM, thereby increasing the 
number of circulating pro angiogenic factors such as VEGF (Plank and Sleeman 2003). 
Adhesion molecules including the integrins also play an important role in angiogenesis as they 
allow ECs to interact with ECM components aiding formation of the sprouting capillary. 
Integrins also have the ability to transmit signals from the extracellular environment, thus 
mediating many pro-angiogenic events including promotion of calcium signalling which in turn 
mediates cell motility (Brooks et al. 1994) and cell adhesion. 
 
ECs migrate along a concentration gradient towards the chemo-attractant e.g. VEGF and then 
proliferate, differentiate to form tubes and finally secrete a basement membrane and recruit 
pericytes to induce vascular stability (Papetti and Herman 2002). The process of physiological 
angiogenesis is subject to tight control whereby the balance between pro and anti-angiogenic 
factors shifts slightly towards the positive regulators of angiogenesis. Under normal 
physiological conditions this shift is only transient and it is this crucial difference that 
distinguishes physiological angiogenesis from tumour induced (or pathological) angiogenesis. 
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 Figure 1.1 The Process of Tumour Angiogenesis:  
Tumour angiogenesis is a complex and multi-step process that involves a number of different 
factors. Tumour cell production and secretion of pro-angiogenic factors such as VEGF can be 
initiated by a number of factors such as hypoxia. Receptor binding of VEGF leads to the 
activation of ECs and degradation of the vessel wall by proteinases such as MMP1 &2. The 
degradation of the wall facilitates EC proliferation, directional migration and invasion 
towards the angiogenic stimulus. ECM remodelling and reorganisation of ECs aid the formation 
of tubular vessel structures. The final stage of the process is vascular 
maturation/stabilisation which is facilitated by the recruitment of pericytes (via the release of 
PDGF).  
Adapted from; Angiogenesis foundation. The angiogenesis process: how do new blood vessels 
grow? 2009.  
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1. 3.2 Tumour Angiogenesis 
While the process of tumour angiogenesis (Figure 1.1) demonstrates some similarities to 
physiological angiogenesis, there are a number of key differences. The main difference is that 
during tumour angiogenesis regulatory controls are lost; the shift towards positive regulators is 
no longer transient and pro-angiogenic signals appear permanently switched on and anti-
angiogenic signals are often lost, a process known as the ‘angiogenic switch’. Moreover, the 
tumour vasculature is chaotic and tumour associated capillaries have been shown to have three 
times greater diameter than normal capillaries (Weinberg 2007). The process of tumour 
angiogenesis also gives rise to relatively unstable vessels with chaotic and sparse dispersion of 
pericytes, as well as being approximately 10 times more permeable than normal capillaries 
(Morikawa et al. 2002; Weinberg 2007). This extensive permeability seen within tumour 
vessels is thought to be due to the up regulation of VEGF which was initially defined as 
vascular permeability factor (VPF) (Senger et al, 1983). Accumulation of fluid that results from 
extensive leaking can result in high fluid pressure within the tumour mass which makes 
administration of anti-cancer therapeutic drugs difficult (Jain 2001).  
 
The basement membrane of tumour vessels also differs in protein composition, assembly and 
structure (Cao, 2004) Furthermore there is no hierarchy present within the tumour vasculature 
as there is no clear distinction between the microvascular components; arterioles, capillaries and 
venules (Shojaei and Ferrara 2008) (Figure 1.2). Regardless of the chaotic and unstable nature 
of the tumour vasculature it does have the ability to provide tumours with the required oxygen 
and nutrients needed to progress. Interestingly these differences observed between the normal 
and tumour vasculature could prove beneficial in terms of tumour targeting therapeutics, 
especially since tumour ECs divide up to 50 times more frequently and express higher levels of 
specific cell surface molecules such as αVβ3, E-selectin, endoglin, DLL4, Robo4 and VEGF 
receptor 1 and 2 (Gasparini et al, 2005).  During tumour angiogenesis the balance of pro-
angiogenic versus anti-angiogenic factors shifts to aid tumour progression (Figure 1.3) and 
although there are a plethora of pro-angiogenic factors identified, Vascular Endothelial Growth 
Factor A (VEGF-A) is the most potent stimulator of tumour angiogenesis identified to date 
(Amini et al, 2012; Prager et al, 2012).  
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VEGF, Fibroblast Growth Factors, 
Angiopoietin-1, Placental growth 
factor, Transforming growth factor-
alpha/beta, Tumour Necrosis Factor 
alpha, Interleukin 8, Tissue Factor, 
Endostatin, Angiostatin, 
Arresten, Collagen 
fragments, Thrombospondin 
1 &2, Platelet factor 4 
Figure 1.2 Differences between Physiological and Pathological Vasculature: 
(A) Shows the normal physiological blood network, with the different components of the 
vasculature being distinct and ordered. In contrast (B) shows the tumour-associated 
vasculature, the network has lost order, and distinction between the capillaries, venules and 
arterioles is difficult. The tumour associated vasculature shows evidence of increased and 
chaotic sprouting.  
Photograph reproduced by kind permission of Professor Donald McDonald. Taken from 
Imaging of angiogenesis: from microscope to clinic. Nature Medicine 9(6); 713-725 (2003). 
 
 
A B 
 Figure 1.3 Factors Involved in Angiogenesis: 
During physiological angiogenesis pro- and anti-angiogenic factors are tightly regulated.  
However, during tumour angiogenesis, a shift towards the pro-angiogenic factors occurs. This 
imbalance caused by excessive up-regulation of pro-angiogenic factors causes the ‘angiogenic 
switch’ to occur; which in turn allows tumours to assume a vascular phenotype, favouring 
progression and metastasis.  
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1.3.3 Vascular Endothelial Growth Factor 
Vascular Endothelial Growth Factor (VEGF-A/VEGF) belongs to a family of six structurally 
related glycoproteins; VEGF-A, VEGF-B, VEGF-C, VEGF-D,  viral VEGF-E and placenta 
growth factor (PLGF). VEGF is a multifunctional cytokine which was initially identified as a 
vascular permeability factor (VPF)  (Senger, et al. 1983) and,  to date  is the most extensively 
studied pro-angiogenic factor and thought to be the most potent factor involved in physiological 
and pathological angiogenesis (Holmes and Zachary 2005). 
 
VEGF gene and protein structure 
The human VEGF gene consists of eight exons that are separated by seven introns and is subject 
to alternative gene splicing, giving rise to a number of  isoforms that differ in amino acid length; 
VEGF121, VEGF145, VEGF148, VEGF162, VEGF165, VEGF183, VEGF189 and VEGF206 (Robinson 
and Stringer 2001). The VEGF isoforms differ in their ability to bind heparin sulphates (HSP) 
on both the cell surface and the ECM and it is this difference in affinity to HSP that determines 
whether the various isoforms are freely soluble or membrane bound (Park  et al. 1993; Stimpfl 
et al, 2002) (Figure 1.4 and Table 1.1).  
Until recently it was assumed that the different isoforms had similar biological activities, 
however, it is now becoming apparent that the VEGF isoforms may play distinct roles in tumour 
angiogenesis (Table 1.1) (Tozer et al, 2008; Akerman et al, 2013). The ability of the VEGF 
isoforms to bind ECM is important in the bioavailability of VEGF, to allow creation of a VEGF 
gradient. Studies have revealed VEGF121, VEGF165 and VEGF189 as the most abundant tumour 
isoforms of VEGF, with VEGF165 being the most characterised in relation to tumour 
angiogenesis (Park et al. 1993). The role of the other VEGF isoforms in cancer progression is 
however currently under investigation (Tozer et al, 2008; Akerman et al, 2013).  
The discovery of additional VEGF-A isoforms (VEGFxxxb) have also been reported, with some 
studies suggesting that these so called ‘b’ isoforms are anti-angiogenic (Rennel et al. 2008) 
however, the role of these isoforms needs to be fully elucidated. VEGF165b , in vitro binds 
VEGF-R2 with the same affinity as VEGF165, but does not transmit a signal (Woolard et al. 
2004). The ratio of VEGFxxx/VEGFxxxb present within the tumour micro-environment, could 
have implications for treatment efficacy as the VEGFxxxb isoforms also bind Bz in addition to 
VEGFxxx isoforms thus may potentially reduce the efficacy of Bz, if these VEGFxxxb isoforms 
are truly endogenous anti-angiogenic agents  (Varey et al, 2008).  
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Figure 1.4 Gene Structure of VEGF isoforms:  
The figure illustrates the gene arrangement of the eight VEGF isoforms. All eight variants 
contain exons 1-5. Exons 6-8 determine the binding to HSP and other receptors such as the 
neuropilins receptors. 
Adapted from Shibuya M. (2001) Structure & Function of VEGF/VEGF Receptor System 
Involved in Angiogenesis. Cell Structure and Function 26: 25-35 & Nowak et al. (2008) 
Expression of pro-and anti-angiogenic isoforms of VEGF is differentially regulated by 
splicing and growth factors. J Cell Sci October 15; 121 (Pt 20): 3487-3495 
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VEGF ISOFORM 
 
HEPARIN BINDING 
 
PROPERTIES 
121 No- freely diffusible  Stimulates angiogenesis 
 Induces breast cancer 
proliferation (T47Ds)  
(Liang et al, 2006). 
145 - unknown 
148 - unknown 
162 - unknown 
165 Yes- intermediate binding 
affinity thus exists as ECM 
bound and diffusible form 
 Potent pro-angiogenic 
factor 
 Induces breast cancer 
proliferation (MDA-MB-
231, MCF-7, T47Ds) 
(Liang et al, 2006). 
183 - unknown 
189 Yes- strong binding affinity 
thus is ECM bound 
unknown 
 
  
 
 
 
Regulation of VEGF Expression  
During early organ development VEGF expression can be regulated by the onset of cellular 
differentiation, cytokine regulation, hypoxia and tissue remodelling (during the formation of the 
corpus luteum, wound healing and menstruation) (Claffey 1996), with hypoxia being thought of 
as the major inducer of VEGF expression especially in tumours (Amini et al, 2012). Hypoxia or 
low oxygen tension is a common hallmark of solid tumours and it has been observed that mice 
deficient in hypoxia inducible factor 1 alpha (HIF-1α) show lower levels of angiogenic activity 
(Boudreau and Myers 2003; Hanahan and Weinberg, 2011). Under normoxic conditions, the 
HIF-1α subunit undergoes ubiquitination and protesomal degradation via the Von-Hippal 
Lindau (VHL) protein. However low oxygen tension allows HIF-1α to accumulate to threshold 
levels and translocate to the nucleus where it binds HIF-1β at the hypoxia responsive element 
(HRE) in the promoter region of the VEGF gene which leads to subsequent up-regulation of 
VEGF gene transcription and enhances VEGF mRNA stability (Jones et al, 2001) (Figure 1.5). 
Even though hypoxia is major regulator of VEGF expression, it is important to note that a 
number of tumour cells constitutively express VEGF under normoxic conditions (Heinzman et 
al, 2008) including breast cancer cells (Marxsen et al, 2001).  
Table 1.1 Properties of VEGF isoforms:  
There is increased interest in the VEGF isoforms and the distinct role played by each 
one. Research into these isoforms is important in terms of establishing response to anti-
VEGF agents such as Bz.  
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Endothelial Cells and VEGF 
 
VEGF plays a key role in vascular development as knockout a single allele of the VEGF gene 
results in embryonic lethality at day 11/12 due to vascular impairment  (Ferrara et al. 1996). 
VEGF acts as a permeability factor by inducing an up-regulation of matrix metalloproteases 
(MMPs) including MMP2, MMP9 and MTI-MMP that allows breakdown of the ECM 
(Funahashi et al, 2011), extravasation of angiogenic factors and induces proliferation and 
tubule formation of ECs. Experimental data shows that not only does VEGF induce a two-fold 
increase in human dermal microvascular endothelial cell (HuDMECs) proliferation, but it also 
protects the ECs from apoptosis in vitro (Nor et al. 1999) . The latter observation confirms the 
notion that VEGF also acts as an EC survival factor, up-regulating  a number of anti-apoptotic 
factors such as Bcl2 and A1 (5.2 & 2.7 fold increase respectively) and is important for EC 
maintenance (Gerber et al. 1998). VEGF also acts as a chemotactic factor, inducing migration 
and stimulating differentiation of ECs which is required for tubular morphogenesis.  
 
Figure 1.5  HIF-1α Regulation of VEGF Gene Expression: 
Low oxygen tension is one of the major inducers of VEGF expression.  Under normoxic 
conditions HIF-1α is modified by oxygen dependent prolyl-hydroxylases which allows for 
binding of the VHL protein to HIF-1α, which in turn results in recognition of the molecule by 
the E3 ubiquitination-protein ligase resulting in rapid degradation of HIF-1α. Whereas under 
hypoxic conditions HIF-1α is stable, reaches threshold levels and translocates to the nucleus 
where it binds to the HRE of VEGF in concordance with the β subunit and enhances VEGF 
expression.  
 
Adapted from Huang & Bao. (2004). Roles of main pro- and anti-angiogenic factors in 
tumour angiogenesis. World J Gastroenterol; 15:10463-70 
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1.3.4 VEGF Receptors 
VEGF activity is mediated via three transmembrane tyrosine kinase receptors, VEGF receptor 1 
(VEGF-R1), VEGF receptor 2 (VEGF-R2) (Figure 1.6) and VEGF receptor 3 (VEGF-R3). 
VEGF-R3 is widely expressed in the early embryonic vasculature but becomes restricted to the 
lymphatic endothelium in post natal life (Robinson and Stringer 2001). Other than EC 
expression, the profile of both receptors is quite distinct, with VEGF-R1 being found on 
inflammatory cells such as monocytes and macrophages, osteoclasts, pericytes and trophoblasts 
in the placenta (Shibuya & Claesson-Walsh et al, 2006). Whereas VEGF-R2 is commonly 
found in osteoblasts, haematopoietic stem cells and megakaryocytes.  More recently the 
neuropilins have been identified as co receptors for VEGF, augmenting signalling through 
VEGF-R1 and VEGF-R2 and can also act as direct receptors, signalling through intracellular 
neuropilin interacting protein (NIP) (Staton et al,2007).  
VEGFR1 (flt-1) is 180kDa in size and binds all forms of VEGF-A, VEGF-B and PIGF 
(Robinson and Stringer 2001). Its role in early development is important as VEGF-R1 null 
mice die at embryonic day 8.5 due to disorganised vasculature (Fong et al. 1995). VEGF-R1 is 
also present in a soluble form (sVEGFR1), and the presence of sVEGFR1 results in significant 
reduction in tumour growth in vivo (Goldman et al. 1998). VEGF-R2 (KDR) is 200-230kDa 
and binds all VEGF-A isoforms, VEGF-C, VEGF-D and VEGF-E. It is crucial for normal 
development of the embryonic vasculature as VEGF-R2 knock-out mice are embryonic lethal 
and display minimal or no vasculature (Shalaby et al. 1995; Staton 2007). 
Both VEGF-R1 and VEGF-R2 are predominantly expressed on ECs and are similar in structure. 
The two receptors contain 7 IgG-like extracellular domains, a transmembrane domain, a 
tyrosine kinase domain (that has a 70 amino acid kinase insert) followed by the C-terminus 
(Shibuya & Claesson-Walsh et al, 2006). The IgG-like domains of VEGF-R1 and VEGF-R2 
are responsible for different elements of VEGF receptor binding and signalling. Domain 2 and 3 
are responsible for ligand binding, domain 2 and 4 are required for ligand association and 
domain 5 and 6 are required for retention of bound ligand (Figure 1.6). The tyrosine kinase 
domains of both receptors share approximately 80% homology. Interestingly, the VEGF 
receptors are thought to differ from the majority of tyrosine kinase receptors (TKRs) as they 
lack a characteristic YxxM motif within the kinase insert domain, suggesting that the 
intracellular signalling associated with the VEGF receptors is distinct from other TKRs 
(Shibuya, 2010).   
 
VEGF-R3 (flt-4) is a 195kDa tyrosine kinase receptor for VEGF-C and VEGF-D and in humans 
exists as two splice variants (Cross et al, 2003) (Figure 1.7). During embryonic development, 
VEGF-R3 is expressed on both vascular and lymphatic ECs. Mice lacking VEGF-R3 die at E9.5 
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due to deficient vessel remodelling, with large vessels exhibiting a disorganised pattern which 
leads to accumulation of fluid cardio-vascular failure (Cross et al, 2003). In adults, VEGF-
R3expression is largely restricted to lymphatic endothelial cells and blocking the receptor with 
soluble VEGF-R3 causes regression of lymphatic vessels and features of lymphoedma but no 
apparent effects on the blood vasculature (Cross et al, 2003) suggesting a potential role for 
VEGF-R3 in tumour metastasis . Activation of VEGF-R3 by VEGF-C or VEGF-D induces 
proliferation, migration and survival of lymphatic ECs (Cross et al, 2003). Inhibiting VEGF-R3 
in vivo, demonstrates inhibitory effects on breast cancer induced metastasis to the lymph nodes 
and the lungs (Matsui et al, 2008 and Kodera et al, 2011). As the data concerning VEGF-R3 
suggests a role mainly in lymphangiogenesis, the role of this receptor will not be discussed 
further.  
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Figure 1.6 The Structure of VEGF Receptors 1 and 2:   
VEGF angiogenic activity is primarily mediated via two tyrosine kinase receptors; VEGF-R1 
& R2. The structure of the two receptors is similar but the associated signalling differs; 
VEGF-R2 is considered the predominant receptor for mediating angiogenic signals. Upon 
ligand binding the receptors dimerise, are autophosphorylated and activate a number of 
downstream signals leading to the activation of a number of angiogenic processes such as EC 
permeability, survival and proliferation.  
 
Adapted from; Staton et al (2007). Neuropilins in Physiological and Pathological 
Angiogenesis. Journal of Pathology; 212:237-248 
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Figure 1.7 Structure of Vascular Endothelial Growth Factor Receptors 3.   
VEGF-R3 is thought to play an important role in lymphangiogenesis. It binds to other VEGF 
family members; VEFG-C and VEGF-D and potentially has an important role in tumour 
metastasis. 
Adapted from Shibuya M. (2001) Structure and Function of VEGF/VEGF Receptor System 
Involved in Angiogenesis.  
VEGFC &  
VEGF-D 
 
 
 
 
 
 
Lymphangiogenesis 
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1.3.5 Effects of VEGF Receptors on EC function 
Upon VEGF binding, VEGF-R1 and VEGF-R2 dimerise and are autophosphorylated which 
leads to activation of downstream signalling pathways (Figure 1.6). VEGF-R1 and VEGF-R2 
can form either hetero- or homo dimers with one another (Guo et al, 2010).  
 
VEGF-R1 
VEGF-R1 is thought to act predominantly as a negative regulator of VEGF activity, with an 
increased affinity for VEGF (Kd=1-10x10
-12
M). However, the associated tyrosine kinase 
activity is thought to be considerably weaker, being approximately, one order of magnitude less 
than that associated with VEGF-R2 (Miguel JV 2008 & Shibuya, 2010).  
VEGF-R1 null mice are embryonic lethal and are characterised by the presence of excessive 
haemangioblasts (Shibuya, 2010). The same study assessed the effects of deleting the tyrosine 
kinase (TK) domain of VEGF-R1 on development and interestingly VEGF-R1 tyrosine kinase 
null embryos developed normally with no detectable defects. This suggests that the presence of 
VEGF-R1 is required solely to regulate the availability of VEGF for ECs. However, 
interestingly, the migration of macrophages towards VEGF is hindered in VEGF-R1 TK null 
mice (Fong et al, 1995 ) suggesting a potential role for VEGF-R1 in regulating this cell type in 
the tumour microenvironment, which is potentially important in cancer metastasis and priming 
the pre-metastatic niche (Kaplan et al, 2005; Shibuya 2006;).  
Experimental studies identifying the main sites for autophosphorylation on VEGF-R1 are 
Y1169, Y1213, Y1242, Y1327 & Y1333, with the Y1169 postulated as being responsible for 
regulating EC proliferation via the downstream activation of phospholipase Cγ (PLCγ) (Olsson 
et al, 2006). However a number of  other studies have shown that the interaction of VEGF with 
VEGF-R1 fails to stimulate EC proliferation (Waltenberger, 1994; Price et al. 2001) which 
may have been due to the models used. These studies, suggest that VEGF-R1 exhibits little or 
no pro-angiogenic activity which further confirms the negative feedback role that VEGF-R1 has 
on regulating VEGF activity on ECs.  
A number of studies have demonstrated that VEGF-R1 fails to induce porcine aortic endothelial 
cell (PAE) migration in response to VEGF stimulation in vitro (Waltenberger et al, 1994; Gille 
et al, 2000). Interestingly, when chimera VEGF receptors were constructed so that VEGF-R1 
contained the intracellular juxtamembrane region of VEGF-R2 and vice versa, the ability of 
VEGF-R1 chimera to transduce VEGF mediated PAE migration was dramatically enhanced. A 
VEGF-R2 chimera that contained the intracellular domain of VEGF-R1 failed to induce the 
typically observed VEGF-mediated PAE cell migration in vitro, suggesting that a sequence 
within the intracellular domain of VEGF-R2 is vital for EC migration (Gille et al, 2000). The 
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juxtamembrane region appears to be highly conserved between the two receptors; however a 
sequence of three serine residues in the juxtamembrane region of VEGF-R1 that is not present 
in VEGF-R2 appears to be responsible for the lack of PAE migration observed in the presence 
of VEGF/VEGF-R1 interactions.  Replacing the three serine residues with the corresponding 
sequence in VEGF-R2 (ANGG) or removing the serine sequence completely, results in VEGF-
R1 mediated PAE migration in vitro, comparable to migration observed in wild type VEGF-R2. 
(Gille et al, 2000).   
From the studies utilising the different VEGF receptor chimeras and mutants it appears that 
PLCγ activation is not required for PAE cell migration in vitro since the VEGF-R1 mutants with 
mutated intracellular sequences stimulate PAE cell migration but do not activate PLCγ (Gille et 
al, 2000). The role of VEGF-R1 as a regulator of VEGF signalling in endothelial cells is further 
confirmed in studies whereby VEGF-R1 inhibits both PAE and HuVEC cell proliferation 
induced by VEGF-R2 (Zeng et al, 2001). This inhibition is not due to VEGF-R1 sequestering 
VEGF or due to the formation of VEGF-R1/2 hetero-dimers but is a result of PI-3K signalling. 
In contrast however, other studies have suggested a role for VEGF-R1 in promoting tumour 
angiogenesis. VEGF-R1 appears important in VEGF-mediated tissue factor (TF) production in 
PAE cells expressing VEGF-R1 (Zeng et al, 2001). Quantification of the response to an anti-
VEGF-R1 antibody on HuVEC tube formation in a co-culture assay, demonstrated that 
inhibiting VEGF165/VEGF-R1 reduced in vitro tube formation, using several different 
parameters including total tube length and capillary connections, however, VEGF-R1 inhibition 
induced tube thickness (Bussolati et al, 2001). These studies provide evidence that VEGF-R1 
has a wider portfolio of responses than simply regulating VEGF-mediated EC activity. The role 
that VEGF-R1 plays in vascular biology needs further investigation, as therapies targeting the 
VEGF-R1 pathway, must consider the dual role of this receptor and thus design VEGF-R1 
inhibitors accordingly.  
VEGF-R2  
The role of VEGF-R2 signalling in tumour angiogenesis is well recognised with a large body of 
evidence suggesting that VEGF-R2 is involved in a diverse range of EC functions, including EC 
migration, survival, differentiation, proliferation and vascular permeability (Olsson et al, 2006). 
Over the years a number of key tyrosine residues have been identified as important in mediating 
VEGF/VEGF-R2 signals, these include Y951, Y1054, Y1059, Y1175 and Y1214 (Shibuya 
2006). Phosphorylation at the 1175 tyrosine residue appears vital for VEGF-R2 function, as a 
mutant mouse model lacking the Y1175 residue was found to be embryonic lethal (E.9) due to a 
lack of angiogenesis, displaying a phenotype similar to that observed in the VEGF-R2 null 
mouse (Sakurai et al, 2005). In addition, downstream activation of PLCγ-1 subsequent to 
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Y1175 phosphorylation induces EC mitogenesis (Cebe-Suarez et al, 2006). Vascular 
permeability was the first function of VEGF to be identified and is partly regulated by VEGF-
R2 (Olsson et al, 2006).  
VEGF-R2 signalling is important in the differentiation of vascular endothelial cells, as 
demonstrated by assessing the ability of HuVEC to undergo tubular morphogenesis (in vitro). 
VEGF mutants with varying capacity to bind either VEGF-R1 or R2 were constructed and their 
ability to induce the tubular structure formation in a 3D collagen gel HuVEC assay was assessed 
(Yang et al, 2001). Wild type VEGF in addition to the mutant VEGF is selective for VEGF-R2 
induced HuVEC cell differentiation in vitro with no comparable observations in the presence of 
the VEGF-R1 selective VEGF mutant suggesting that VEGF-R2 and not VEGF-R1 is required 
for VEGF induced HuVEC differentiation (Yang et al, 2001). This was confirmed in a follow 
up experiment whereby wild type VEGF was pre-incubated with a VEGF-R1 or R2 antibody 
prior to adding to the 3D assay. Inhibiting VEGF/VEGF-R2 interactions resulted in a dramatic 
decrease in the average tube length (microns) compared to the control and the anti-VEGF-R1 
treated cells, which was thought to be via alterations of MAPK and p38 signalling (Yang et al, 
2001).  
VEGF-R2 is also important in VEGF165 (VEGF-A isoform) induced endothelial cell 
proliferation as suggested by a number of different studies (Bernatehez et al, 1999; Cai et al, 
2006; Olsson et al, 2006). PAE cells were incubated with VEGF165 (0-100ng/ml) for 24 hours 
after which [
3
H] thymidine incorporation was measured. PAE cells transfected with VEGF-R2 
showed increased cell proliferation in the presence of VEGF165, with no stimulatory effects 
using the control PAE or the VEGF-R1 transfected cells (Waltenberger et al, 1994).  
The in vitro regulation of VEGF mediated EC proliferation by VEGF-R2 is thought to be 
enhanced in the presence of cell adhesion molecules. Adherent HuVECs have increased VEGF-
R2 phosphorylation after VEGF165 stimulation (10 min at 10ng/ml) compared to HuVECs in 
suspension (Soldi et al, 1999). HuVECs plated on vitronectin, a ligand for ανβ3 showed the 
greatest level of VEGF-R2 phosphorylation in vitro and which resulted in enhanced functional 
activity; HuVECs plated on vitronectin and fibrinogen (ligands for ανβ3) resulted in enhanced 
cell proliferation compared to cells plated on other ECM molecules such as fibronectin and 
collagen (Soldi et al, 1999).  
VEGF-R2 has also been implicated in mediating VEGF stimulated cytoskeletal reorganisation 
and migration. PAE cells transfected with VEGF-R2 and HuVECs induced changes in cell 
shape in the presence of VEGF165 (exposure to 100ng/ml for 2-20mins) as measured by the level 
of cytoplasmic protrusions and membrane ruffling with no morphological changes observed in 
control PAE or PAE/VEGF-R1 transfected cells exposed to VEGF165, suggesting that VEGF165 
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induced endothelial cell migration is mediated via VEGF-R2 (Waltenberger et al, 1994). When 
these cells were utilised in a modified Boyden chamber assay, the VEGF-R2 transfected PAE 
cells demonstrated increased migration towards VEGF165 compared to the full media control 
(Waltenberger et al, 1994).  
There are a number of different mechanisms by which VEGF-R2 is thought to mediate VEGF 
induced EC migration. VEGF/VEGF-R2 interactions result in the activation of Rho small 
GTPases (Lamalice et al, 2007). VEGF-R2 activation leads to the activation of Cdc42, which is 
involved in the formation of filopodia. Phosphorylation of Y951 and nitric oxide are also 
thought to be important regulators of VEGF-R2 mediated EC migration (Lamalice et al, 2007).  
VEGF-R2 migration of HuVEC cells may also be dependent on the urokinase receptor (uPAR) 
(Prager et al, 2004). The number of focal adhesions after VEGF165 (50ng/ml for 2h) stimulation 
increased by ~ 2.5 fold, with the number of uPAR positive focal adhesions also increasing. This 
re-distribution of uPAR at focal adhesions was mediated via VEGF-R2 since the VEGF-R1 
specific ligand, PIGF did not increase uPAR positive focal adhesions whereas VEGF-E, a 
specific ligand for VEGF-R2 did. Interestingly, the number of focal adhesions formed after 
PIGF treatment was similar to that observed with both VEGF165 and VEGF-E treated cells 
suggesting that the induction of uPAR is not required for the formation of focal adhesions in 
VEGF-R1 mediated migration (Prager et al, 2004). When uPAR expression was inhibited, the 
migration of HuVECs towards VEGF-E was blocked suggesting that VEGF-R2 mediated 
HuVEC migration is dependent on the presence of uPAR within focal adhesion formed at the 
leading edge of these cells.  
VEGF-R2 is likely to be an important mediator of EC survival via activation of the PI3K and 
Akt pathways. HuVEC cells serum starved for 4 days in the presence or absence of wildtype 
VEGF165 or VEGF165 mutants selective for binding to either VEGF-R1 or VEGF-R2, 
demonstrated that VEGF-R2 selective mutants induced a survival effect on HuVEC cells in 
vitro that was similar to the wildtype VEGF control, with no discernable survival activity 
observed in the presence of the VEGF-R1 mutants (Herber et al, 1998). HuVECs were then 
incubated with a PI3K specific inhibitor (wortmannin, 2h prior to serum starvation) in the 
absence of VEGF165 for 24-36h, after which FACS analysis was performed. The presence of 
wortmannin resulted in a loss of cell survival activity, suggesting that the initial anti-apoptotic 
effects observed on HuVEC cells by VEGF165 was a result of downstream PI3K activation. The 
addition of VEGF165 to the HuVEC cells incubated with wortmannin resulted in a slight ‘rescue’ 
effect, suggesting the importance of VEGF in this VEGF/VEGF-R2/PI3K signalling loop 
(Herber et al, 1998). VEGF-R2 mediated EC survival is also thought to be enhanced in the 
presence of certain intergrins, as when ανβ3 interacts with VEGF-R2, downstream Akt activity is 
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increased (Soldi et al, 1999).  Activation of the PI 3-kinase/Akt by VEGF-R2 is also important 
for EC survival. A study found that VE-cadherin was integral in mediating VEGF-R2 survival 
signals when in a complex with VEGR-R2, PI 3-kinase and β-catenin, since loss of VE-cadherin 
resulted in EC apoptosis (Cebe-Suarez et al, 2006).  
Upon ligand binding, VEGF-R1 and VEGF-R2 can form both homo and heterodimers, with the 
resulting downstream signalling properties in ECs varying (Huang et al, 2001). Interestingly, 
VEGF induced migration of PAE cells (after 4h in the Boyden chamber) was significantly 
(p<0.05) more efficient when VEGF-R1 and VEGF-R2 heterodimers were formed compared to 
VEGF-R2 homodimers (Huang et al, 2001).  With increasing evidence a role for VEGF-R1, 
studies utilising VEGF-R1 and R2 heterodimers, may provide more information about which 
VEGF induced signalling pathways/functions in EC overlap between the two receptors and 
which are more specific. One such study, using a ligand that binds only the heterodimer form of 
the VEGF receptors was constructed and demonstrated that EC migration, tube formation and 
NO mediated vasorelaxation was induced by the ligand to levels comparable with those 
observed with VEGF and VEGF-E alone (Cudmore et al, 2012).  
Overall, the VEGF/VEGF receptor signalling pathway is complex and induces the activation of 
various downstream signalling pathways which are summarised in Figure 1.8. This complex 
network of downstream signalling needs to be taken into account when designing inhibitors that 
target the angiogenesis pathway.    
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1.3.6 VEGF- Expression and Role in Breast Cancer 
VEGF has a large array of effects on EC function which were initially thought to be EC-specific. 
However more recently, it had been demonstrated that VEGF has effects on and is produced by 
breast cancer cells. These observations have been investigated in both an in vivo setting and in 
vitro and are explored in the following sections. 
Breast Tumour Samples 
VEGF tissue expression under physiological conditions is relatively low in comparison with 
tumour tissue; tumour tissue is thought to express approximately 7-fold higher than the 
surrounding normal tissue (Price et al, 2001). Moreover, necrotic tumours express high levels 
of VEGF mRNA in hypoxic regions that are adjacent to the necrotic to stimulate angiogenesis 
in these areas (Prudence, 1998). Increased expression of VEGF has been demonstrated in many 
human tumours, including breast (Anan 1996; Gasparini et al. 1997). The association of VEGF 
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Figure 1.8 VEGF Signalling Pathway: 
The VEGF signalling pathway way involves the interplay of a number of downstream 
effectors. Upon VEGF binding, VEGF-R2 is activated. This in turn phosphorylates major 
effectors such as PLCy, FAK, p38 and Akt, which results in EC apoptosis, migration and 
proliferation.  
Adapted from SABiosciences. VEGF signalling pathway. (www.SABiocsciences.com) 
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expression with clinically relevant factors (diagnostic and prognostic features) is important and 
has been investigated (Fuckar et al, 2006). VEGF expression is often linked to an increase in 
micro-vessel density (MVD- a surrogate measure of angiogenesis), tumour size and advanced 
disease stage along with shorter survival (Guetz, et al. 2006), suggesting that VEGF expression 
is associated with a more aggressive tumour phenotype. Correlation between VEGF expression 
in 233 breast cancer tissue samples with a number of key prognostic factors of breast cancer 
have been evaluated (Fuckar et al, 2006). Of the 233 patient samples tested, 222 were positive 
for cytoplasmic VEGF staining; however, intensity of staining was variable, potentially 
reflecting the heterogeneous nature of breast cancer, suggesting that not all cells within the same 
tumour are responsive or as susceptible to anti-VEGF therapy, making treatment difficult. In 
this cohort of patient samples, no correlation was observed between VEGF expression and (a) 
tumour size, (b) histological grade, (c) vascular invasion, (d) lymph node status, (e) Ki67 
expression, (f) PR status and (g) HER-2 expression. However, a significant inverse correlation 
between VEGF expression and ER status was observed, with ER negative samples showing 
greater VEGF expression (Fuckar et al, 2006).  
 
Another study demonstrated the use of VEGF as a predicative marker for relapse-free survival 
and overall survival in patients with invasive breast cancer (Linderholm et al, 2000). VEGF 
expression has also been demonstrated to positively correlate with HER2/neu expression in both 
node negative and node positive breast tumour samples (Konecny et al, 2004). A more recent 
study evaluating the prognostic and predicative value of VEGF mRNA in 308 patients with 
high-risk operable breast cancer, demonstrated a significant association of high VEGF 
expression with negative ER/PR status, a positive HER2 status, high histological grade (III-IV), 
no adjuvant hormonal therapy, higher age and post-menopausal status (Linardou et al, 2012), 
this contrasts to previously reported IHC data (Fuckar et al, 2006) which demonstrated no 
correlation with the majority of parameters described in the Linardou et al, 2012 paper.  The 
technique used to assess the prognostic role of VEGF in breast cancer patients differ between 
groups, as ELISA, RT-PCR and IHC analysis have been carried out. Currently, the majority of 
studies assessing the value of VEGF as a predictive marker in breast cancer report conflicting 
data.  Thus, to date the use of VEGF as a routine prognostic marker in breast cancer remains to 
be fully determined as to date there is no consistent data that correlates VEGF expression with 
routinely used clinical markers.  
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Breast Cancer Cell Lines  
VEGF expression is evident in a number of breast cancer cell lines tested. In vitro studies have 
shown that VEGF is a potent survival factor for metastatic breast cancer cells (MDA-MB-231), 
such that when VEGF is depleted from the cells and the medium, the presence of other factors 
in the serum is not sufficient to fully rescue the apoptotic effects observed in the absence of 
VEGF (Bachelder et al, 2001). The advantage of using an in vitro system is that this allows the 
direct functional effects of VEGF on the breast cancer cells to be investigated, without other 
external influences. 
VEGF has also been shown to stimulate proliferation of a range of breast cancer cells in vitro 
(including MCF-7 and MDA-MB-231) (Liang et al, 2006).  A range of VEGF concentrations 
(0-200ng/ml) were evaluated and demonstrated that the rate of proliferation of a high and low 
metastatic breast cancer cell line (MDA-MB-231 and MCF-7 respectively) both increased in 
response to VEGF but reached a saturation point (100ng/ml & 50ng/ml respectively) after 
which proliferation decreased  (Liang et al, 2006). The T47Ds which are a non-metastatic breast 
cancer cell line in contrast, continue to grow in an exponential manner in response to all VEGF 
doses. This is not surprising as it is thought that once a tumour has established itself, it 
potentially becomes less dependent on the actions of VEGF for progression and other cytokines 
may begin to play a greater role and this may be reflective in the more aggressive breast cancer 
cell types. Another explanation is that MDA-MB-231 and MCF-7 cells have higher levels of 
endogenous VEGF than the T47Ds, resulting in saturation levels of VEGF to be reached more 
rapidly, compared with those breast cancer cell lines that have low constitutive expression levels 
of basal VEGF.  
 
1.3.7 VEGF Receptor- Expression and Role in Breast Cancer 
Breast Cancer Patient Samples 
Up-regulation of the VEGFR2 has been demonstrated in some tumour tissue samples. The 
expression pattern of VEGF/VEGFR2 was analysed using IHC in tumour tissue from 102 breast 
cancer patients (Rydén et al. 2003). VEGF/VEGFR2 staining correlated significantly (p=0.005) 
and was co-expressed in the tumours. Interestingly VEGFR2 expression was only associated 
with histological grade (p=0.002) whereas VEGF expression was associated with both 
histological grade (p=0.003) and tumour size (p=0.022). It is also worth noting that neither 
VEGF nor VEGFR2 expression was associated with hormone receptor status, node status or 
tumour stage (Rydén et al. 2003) suggesting that expression of VEGF and its receptor may not 
be reliable prognostic markers of disease progression. 
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A study comprising of 642 primary breast cancer samples aimed to investigate the expression 
profile of VEGF and its receptors VEGF-R1/2 and to determine if there was any correlation 
between the expression patterns and patient outcome (Ghosh et al, 2008). VEGF and its 
receptors were mostly expressed within the membrane/cytoplasmic regions of the tumour. The 
patient data revealed a significant (p=<0.001) association of high VEGF and VEGF-R1/2 
expression with poor survival rates (Ghosh et al, 2008). However, there was insufficient data 
regarding treatment of all the patients, thus treatment-specific effects on VEGF and receptor 
expression and patient outcome could not be evaluated. Despite high levels of VEGF being 
associated with poor survival, the use of VEGF as a marker in response to anti-vascular therapy 
such as Bz, has yet to be established (Ghost et al, 2008).  
Breast Cancer Cell Lines 
VEGF receptor expression in human breast cancer cell lines is somewhat controversial with data 
showing the presence of either one or both VEGF receptors whilst other studies have failed to 
determine any expression at all. One group demonstrated that the metastatic MDA-MB-231 
breast cancer cells expressed VEGF-R2 but not VEGF-R1 mRNA whereas the low metastatic 
MCF-7 and the non-metastatic T47D breast cancer cell lines expressed both VEGF-R1/2 
mRNA. A critical question that arises from VEGF-R1 and VEGF-R2 expression profiling in 
breast cancer cells, is that when (and if) the receptors are present, do they play a functional role 
in breast cancer cell activity and behaviour. 
 
VEGF-R1 
VEGF-R1 in breast cancer cells appears to be predominantly expressed internally, localised 
within the nuclear envelope of MDA-MB-231 and MCF-7 breast cancer cells (Lee et al, 2007). 
VEGF-R1 has been shown to play a role in autocrine survival of MDA-MB-231 and MCF-7 
breast cancer cells in vitro potentially through activation of the Akt pathway (Lee et al, 2007). 
VEGF-R1 also appears important in MDA-MB-231 tumour growth in vivo (Lee et al, 2007). 
Interestingly, only siRNA knock down of VEGF-R1 inhibited breast cancer cell proliferation 
and survival, whereas VEGF antibodies or addition of soluble VEGF-R1 had no inhibitory 
effects. This suggests that the role that VEGF/VEGF-R1 play in breast cancer survival appears 
to be internally regulated (Lee et al, 2007) and inhibitors that target cell surface VEGF-R1 may 
not be therapeutically effective.  
Interestingly, a study published a year prior to the one detailed above investigated the effects of 
a human VEGF–R1 neutralising monoclonal (mAb 6.12) on a range of breast cancer cell lines 
and demonstrated inhibition of the activation of Akt in BT-474 breast cancer cells when 
stimulated with either VEGF or PIGF (Wu et al, 2006) whereas no activation of Akt via the 
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VEGF-R1 pathway was observed in MCF-7, DU4475 and MDA-MB-231 breast cancer cells. 
This suggests significant heterogeneity amongst breast cancer cell lines, with differential 
activation of VEGF receptor pathways.  Targeting VEGF-R1 in breast cancer appears to be an 
effective target as the VEGF-R1 specific mAb 6.12 significantly inhibited xenograft tumour 
growth of a number of breast cancer cell lines (DU4475, BT-474, MCF-7 and MDA-MB-231) 
in vivo. This further suggests that the role of VEGF-R1 in tumour biology has greater 
significance than initially thought (Wu et al, 2006).  
More recently a family of intracellular VEGF-R1 receptors have been identified. The 
intracellular VEGF-R1 receptors appear to have a role in MDA-MB-231 breast cancer cell 
invasion in vitro possibly through activation of the Src pathway (Mezquita et al, 2010). In 
addition, there is also evidence suggesting that VEGF-R1 signalling associated with PIGF 
ligand stimulation is important in the autocrine effects of VEGF-R1 on breast cancer cells, such 
as in vitro proliferation (Wu et al, 2006).  
 
VEGF-R2  
VEGF-R2 signalling is important in breast cancer cell activity, especially since VEGF-R2 
appears constitutively active, even in the absence of exogenous VEGF (Lee et al, 2007). 
Treatment of T47D and BT-474 breast cancer cells with a VEGF-R2 specific antibody (2C3) 
and a tyrosine kinase inhibitor (SU1498) for 72h resulted in decreased cell proliferation of both 
breast cancer cell lines in vitro compared with the VEGF alone treated cells (Liang et al, 2006). 
VEGF-R2 signalling is important for tumour survival of both ER positive MCF7 and ER 
negative MDA-MB-468 breast cancer cells lines (Aesoy et al, 2008; Svensson et al, 2005). In 
addition, VEFG-R2 signalling plays a role in tamoxifen resistance (Aesoy et al, 2008) which is 
thought to occur by increased breast cancer cell proliferation (Qu et al, 2008), which is induced 
by the interplay between VEGF and VEGF-R2, which subsequently activates the p38 signalling 
pathway (Aesoy et al, 2008).   
Overall VEGF-R2 is a critical receptor in VEGF-mediated EC activity, but less is known about 
any role in breast cancer cell activity. There is a larger body of evidence for a direct role of 
VEGF-R1 in breast cancer cell activity in vitro suggesting that the role of both classical VEGF 
receptors need to be considered when targeting different aspects of the VEGF pathway in breast 
cancer therapy (i.e. epithelial vs. endothelial cells).   
The classical VEGF receptors demonstrate a functional role on breast cancer cell activity. 
However, there is minimal literature available regarding the autocrine role of these receptors on 
breast cancer cells compared with vascular endothelial cells biology. This is not surprising as 
initially, the role of VEGF-R1 and VEGF-R2 was almost exclusively thought to be on 
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endothelial cells. In addition to this, the identification of the neuropilins, a second family of 
VEGF receptors, suggests that these alternative receptors may play a more direct role in VEGF-
mediated breast cancer activity. 
VEGF-R2 inhibition effectively reduces breast cancer growth in an MDA-MB-231 orthotopic 
model, with significant (p<0.05) inhibition by 2C3 (100μg three times weekly) after 20 days of 
treatment compared to control IgG treated animals (Zhang et al, 2002). 2C3 is a monoclonal 
mouse anti-human antibody that prevents VEGF interacting with VEGF-R2 but not VEGF-R1. 
The group suggested that the inhibition in MDA-MB-231 breast cancer growth was a result of 
direct vascular effects of 2C3, since a ~70% decrease in tumour microvessel density (MVD) 
was observed with 2C3 treated tumours and when the MVD data was plotted against the 
percentage tumour growth inhibition in individual mice a linear correlation was observed 
(R=0.82) (Zhang et al, 2002). Targeting VEGF-R2 with 2C3 caused a reduction in the tumour 
microvessel number with larger diameter vessels, but very few capillaries found in deeper 
tumour regions (Zhang et al, 2002) and only a few vessels in central regions of the tumours, 
with the tumour edges demonstrating the most expansive areas of vascularisation. Inhibition of 
VEGF-R2 also reduced the number of metastatic colonies formed in the lung (77 vs. 157 
colonies) and lung weight (0.18g vs. 0.24g), six weeks after intra-venous injection of MDA-
MB-231 breast cancer cells compared to the IgG control respectively. These studies suggest that 
VEGF-R2 is important in some aspects of the metastatic process in breast cancer.  
Another study investigated the DC101 murine VEGF-R2 antibody (Franco et al, 2006). MDA-
MB-231 breast cancer cells were implanted into the mammary fat pad of CB-17 severe 
combined immunodeficiency (SCID) and then treated with DC101 (800μg/mouse) twice weekly 
or a PBS control for 3 weeks (Franco et al, 2006). Treatment with DC101 resulted in a 
significant (p<0.001) decrease in MDA-MB-231 growth (65%) compared to the PBS treated 
group (Franco et al, 2006). The group reported (although data was not shown) that DC101 had 
no inhibitory effects on MDA-MB-231 breast cancer cell proliferation or survival in vitro. This 
result is not surprising as DC101 is an antibody that only recognises murine VEGF-R2 and 
since MDA-MB-231 breast cancer cells are of human origin, no direct effects on these cells is 
expected. However, this is an important study suggesting that inhibition of VEGF-R2 alone, can 
exert significant inhibitory effects on breast cancer growth, via an anti-angiogenic mechanism. 
This was confirmed when microvessel density (MVD) analysis demonstrated a decrease in 
CD31 positive vessels in the DC101 treated tumours compared to controls. Treatment with 
DC101 also resulted in more extensive hypoxia in treated tumours (Franco et al, 2006). This is 
an interesting finding, and might partially explain why resistance to anti-angiogenic therapy 
occurs, since hypoxic regions tend to harbour cells with a more aggressive and resilient 
phenotype.  
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DC101 appears to exhibit effects that are widespread and not confined to the tumour 
microenvironment as suggested by a study investigating the effects of anti-VEGF treatment on 
VEGF induced cancer associated systemic syndrome (CASS) (Xue et al, 2008). Over-
expression of VEGF by tumours can lead to defective vasculature in ‘healthy’ organs and result 
in CASS, which is characterised by a number of different clinical features including, defective 
haematopoiesis, endocrine system, ascites, gastrointestinal track disorders and impaired liver, 
spleen and kidney function (Xue et al, 2008).  A spontaneous breast cancer murine model, 
MMTVneu was utilised in this study along with xenografts of other cancer types. Treatment 
with DC101 (800μg/mouse i.p.) commenced when MMTVneu tumours reached approximately 
1cm
3
 in size, and was administered twice weekly for a total of two weeks, which resulted in 
normalisation of the histology and vascular networks in the liver, spleen and adrenal glands as 
well as the reversal of the severe anaemia and enlargement of the spleen and liver observed in 
the PBS treated MMTVneu tumour bearing animals (Xue et al, 2008). In this study the effects 
of DC101 on tumour growth in the spontaneous model was a secondary objective, and the group 
observed that although there was a trend towards MMTVneu tumour growth inhibition, the 
nature of the model made quantifying this inhibition difficult (Xue et al, 2008). This study 
suggests an additional mechanism by which anti-VEGF agents such as DC101 may prove 
beneficial for breast cancer patients, by blocking VEGF/VEGF-R2 interactions this aids in 
normalising function of other organs that may be affected by systemic increases in tumour 
VEGF and thus may reduce the number of complications and associated mortality that arise in 
cancer patients. Thus, VEGF-R1/2 may play a potential role in autocrine signalling on breast 
cancer cells; however, it is worth noting that the presence of other receptors on or in association 
with the breast cancer cells, such as the neuropilin receptors, may exert a greater role on the 
function of breast cancer cells.  
1.4 Neuropilins and Their Role in Breast Cancer 
1.4.1 Neuropilin Receptors 
Neuropilin 1 and 2 (Np1 and Np2) are transmembrane receptors that have an observed 
molecular weight of 130 and 135kDa respectively (Barr et al, 2005) and were originally 
identified as receptors for Class 3 Semaphorins (SEMA) with a role in axonal guidance (Staton, 
2007). Both Np1 and Np2 share approximately 45% amino acid (a.a) sequence homology and 
are structurally very similar. The neuropilin receptors consist of a large extracellular domain, a 
membrane spanning domain and a short cytoplasmic domain (40 a.a) that lack tyrosine kinase 
activity (Staton et al, 2007). The extracellular domain of Np1/2 is separated into three distinct 
domains, the a1/a2 domain, b1/b2 domain and the CUB domain (Staton et al, 2007) (Figure 
1.9). The binding region for the SEMA proteins lies within the a1/a2 domain; the b1/b2 domain 
is responsible mainly for VEGF binding. There is however a slight overlap within the b1 
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domain where both SEMA and VEGF bind Np1/2 and the CUB domain is responsible for 
receptor dimerisation. 
Due to the fact that Np1 and Np2 lack tyrosine kinase activity, it was initially assumed that Np1 
and Np2 could only mediate VEGF associated intracellular signals when complexed with other 
cell receptors and were therefore thought to act as co-receptors for the classical VEGF receptors 
(Staton et al, 2007). However, over the past few years, the ability of Np1 to transduce signals 
independently of the classical VEGF receptors has been recognised with the identification of the 
neuropilin interacting protein (NIP) which binds a highly conserved C terminal region of Np1 
(the last 3 amino acids- SEA-COOH). Interestingly the cardiovascular defects associated with 
NIP knockdown are more severe than those associated with Np1 null mice and are specific to 
arterial development and adult arteriogenesis, with reduced arterial density and branching in the 
retina, heart and kidney (Miguel, 2008). The importance of NIP in Np1signaling makes this a 
potential therapeutic target and strengthens the theory that Np1 is important in VEGF-mediated 
angiogenesis, activating signals in a VEGF-R1/2 independent manner.  
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Figure 1.9 Structures of the Neuropilin Receptors: 
The neuropilin receptors have a large extracellular domain, consisting of 860 amino acids, a short 
transmembrane domain containing 23 amino acids and an intracellular domain consists of 40 
amino acids. The extracellular domain consists of 5 subunits; a1/a2, which are responsible for 
VEGF binding and b1/b2 which are responsible for SEMA binding but can also enhance VEGF 
binding to the neuropilins and the c domain which is involved in Np1 dimersation. 
 Adapted from Staton et al (2007). Neuropilins in physiological and pathological angiogenesis. 
J.Pathol. 212;3: 237-248. 
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1.4.2 Expression and Signalling 
Neuropilin receptor expression on vascular endothelial cells is observed during the developing 
vasculature, which appears critical since Np1 null mice are embryonic lethal (E12.5-13.5) and 
exhibit cardiovascular defects (Kawasaki et al, 1999). Over-expression of Np1 results in 
excessive vessel formation and haemorrhaging, a phenotype typical of VEGF-R2 over-
expression or VEGF-R1 deletion (Kawasaki et al, 1999). Np2 null mice are viable but display 
lymphatic defects. A Np1/Np2 double knockout results in embryonic lethality earlier (E8.5) 
than a Np1 knockout (E12.5-13.5) and is characterised by impaired capillary formation, 
defective blood vessel branching and avascular embryos (Takashima et al, 2002).  
The expression profile of the two receptors differs during development, with Np1 being mostly 
expressed by arterial ECs and Np2 being expressed by venous and lymphatic ECs. Later 
expression differs with Np1 being predominantly expressed on vascular endothelial cells and 
Np2 being expressed on lymphatic endothelial cells (Favier et al, 2006). The expression of Np1 
is regulated by a number of different factors including hypoxia and an array of growth factors, 
including tumour necrosis alpha and FGF (Staton et al, 2007).  
1.4.3 Neuropilin 1 and VEGF Interactions 
Although originally identified as SEMA binding, the neuropilin receptors also act as VEGF 
isoform specific receptors (Barr et al, 2005). Np1 binds VEGF165 and VEGF189 whereas 
VEGF121 does not bind to Np1 on porcine aortic endothelial cells (PAE) (Soker et al, 1998) or 
HuVECs (Soker at al, 1996).  However there is some controversy surrounding the ability of 
VEGF121 to bind Np1 on ECs with a more recent study observing binding of VEGF121 to Np1 on 
HuVECs (Pan et al, 2007).  
Endothelial Cells 
The binding sites for VEGF-R1/2 (a.a. 8-109 across exon 3 and 4) and the neuropilin receptors 
on VEGF are distinct (a.a. 141-165 across exon 7) (Soker et al 1997; Muller et al, 1998) thus 
VEGF can simultaneously bind both receptors. The presence of Np1 on the same cell or a 
neighbouring cell forms a receptor-ligand bridge that increases the binding of VEGF to VEGF-
R2 PAE by 4 fold and enhances VEGF/VEGF-R2 signalling (Starzec et al. 2007; Soker et al, 
1998). The Soker et al study observed a 2.5 fold increase in the migration (when stimulated 
with 10ng/ml VEGF165) of VEGF-R2/Np1-expressing PAE compared to cells expressing 
VEGF-R2 only, suggesting that the interaction of Np1 with VEGF165 on EC results in functional 
activity. Interestingly, PAE cells that only expressed Np1 did not migrate towards VEGF165, 
suggesting that signalling via Np1 alone is not sufficient to induce migration of PAE. This 
supports the role of Np1 as a co-receptor for the classical VEGF receptors at least for PAE 
migration. In this study no enhanced migration was observed when the cells were stimulated 
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with VEGF121. However, VEGF121 and Np1 activity is yet to be fully determined, as in contrast 
to the above study, a different group found that VEGF121 induces EC migration via Np1 
signalling (Pan et al, 2007).  
Endothelial cell over-expression of a mutant form of Np1 (Y297A) that lacked any binding 
ability to VEGF had reduced migration towards a VEGF gradient. The Y297A mutant receptor 
also disrupted the formation of the Np1/VEGF-R2 complex, resulting in reduced 
phosphorylation of focal adhesion kinases at the tyrosine kinase 407 residue (Herzog et al, 2011) 
thus suggesting a role for Np1 in actin arrangement and cell motility.  
Np1 appears to have role in HuVEC proliferation (measured by H-Thymidine uptake and pERK 
activity), as siRNA targeted knock down of Np1 in HuVECs resulted in a modest decrease in 
cell proliferation compared to the control siRNA treated cells (Murga et al, 2005). However, 
this decrease in cell proliferation was significantly less than when VEGF-R2 was depleted in 
these cells, suggesting that Np1 alone does not regulate HuVEC cell proliferation (Murga et al, 
2005; Pan et al, 2007; Herzog et al, 2011).  
It is clear that Np1 is important in enhancing a number of VEGF-R2 associated signalling 
pathways in ECs (Starzec et al, 2007), however there is also ample evidence suggesting, that 
Np1 has more actions than simply a co-receptor for VEGF-R1/2 in ECs. One such study 
observed the importance of Np1 in a number of activities required for HuVEC functionality 
(Murga et al, 2005). Both VEGF-R2 and Np1 were equally important for HuVECs to form 
tube-like structures on Matrigel, with the decreased number of tube-like structures formed in the 
presence of the VEGF-R2 and Np1 siRNA compared with the control being comparable. This 
suggests that Np1 alone is important in tubular morphogenesis of ECs. In addition, Np1 alone is 
central for HuVEC cell migration in response to VEGF, with decreased migration of cells in 
Np1 siRNA and VEGF-R2 siRNA treated cells being comparable. Interestingly, this 
observation contrasts with previous studies in PAE, where Np1 expressing PAE failed to 
migrate when stimulated with VEGF165 (Soker et al, 1998). The observation that Np1 knock 
down had such dramatic inhibitory effects on HuVEC migration was unexpected. Further 
investigation revealed the mechanism by which Np1 alone was regulating HuVEC migration in 
response to VEGF (Murga et al, 2005), with the down regulation of Np1 reducing the ability of 
HuVECs to adhere to ECM molecules (laminin, fibronectin and gelatin. This suggests that 
VEGF-R2 and Np1 regulate VEGF-stimulated HuVEC migration via two distinct mechanisms 
since siRNA knock down of VEGF-R2 had no significant inhibitory effects on cell adhesion 
(Murga et al, 2005). In addition to observing impaired attachment to ECM components, Np1 
siRNA treated cells failed to form the stress fibers (F-actin) required for cytoskeleton re-
arrangement within the same time frame (24h after plating on gelatin). However, the Np1 
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defective HuVECs did form stress fibers after 48h gelatin incubation, similar in intensity 
compared to the control/VEGF-R2 defective cells. There is now growing evidence supporting 
these observations that Np1 plays an important role in EC actin arrangement, cell motility and 
tube formation (Wang et al, 2003; Herzog et al, 2011). Np1 mediated HuVEC migration has 
also been shown to be mediated via activation of the p130cas pathway (Wang et al. 2003)  
Over recent years a potential role for Np1 in tumour angiogenesis has become apparent, 
however the mechanism by which this angiogenic stimulation occurs is not fully understood. In 
an attempt to investigate the mechanism by which Np1 activates ECs during angiogenesis, the 
effects of dimeric rat Np1 versus that of soluble Np1 (truncated form that lacks the c domain of 
the receptor) were evaluated (Uniewicz et al, 2011). A tube formation revealed that both forms 
of the Np1 receptor were capable of inducing HuDMEC or HuVEC tube formation in vitro. 
However, the dimeric form of the receptor had a more potent effect on EC tube formation in 
vitro suggesting that either the dimerisation process of Np1 and /or the  
c domain of the receptor are important in the extent of tubular morphogenesis (Uniewicz et al, 
2011).  The level of tube formation observed with the dimeric Np1 protein alone was increased 
compared with VEGF165 and the dimeric form activated phosphorylation of VEGF-R2 even in 
the absence of recombinant VEGF165. These findings suggested that Np1 has the ability to drive 
EC angiogenesis in a VEGF-R2 dependent but VEGF165 independent manner (Uniewicz et al, 
2011). 
Breast Cancer  
Studies to further support the hypothesis that Np1 is important in tumour progression have 
shown that Np1 may act as the primary VEGF receptor on tumour cells in different cancer types 
including breast cancer (Soker et al, 1998; Starzec et al, 2006) and expression is also thought to 
correlate with tumour invasion and aggression (Starzec et al, 2006). VEGF165 (Soker et al, 1998) 
and VEGF189 (Herve et al, 2008) bind Np1 directly on breast cancer cells (MDA-MB-231) but 
not VEGF121 (Soker et al, 1998).   
VEGF is important in the autocrine survival of breast cancer cells (Bachelder et al, 2001). 
When VEGF mRNA was knocked down in MDA-MB-231 and MDA-MB-435 cells using anti-
sense oligonucleotide treatment (15h or 40h treatment respectively), the levels of apoptosis 
(Annexin V) increased by 33% and 18% respectively compared to the control sense treated cells 
(Bachelder et al, 2001). Thus, Np1 appeared to play an important role in VEGF mediated breast 
cancer survival in vitro. The group investigated this hypothesis in two ways; (1) the survival of 
MDA-MB-231 breast cancer cells in the presence of VEGF anti-sense oligonucleotides was 
determined followed by treatment with exogenous VEGF165 or VEGF121 and found that the 
MDA-MB-231 cells treated with VEGF165 demonstrated an increased survival compared to 
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those treated with VEGF121 (since VEGF121 is thought to not bind Np1 it was suggested that the 
survival potential was due to interactions of VEGF165 with Np1). (II) Secondly MDA-MB-453 
which do not express Np1 were transfected with a plasmid encoding Np1, and the level of 
apoptosis present in the transfected cells was lower compared to the control cells (26% 
apoptosis vs. 58% apoptosis respectively). A later study confirmed this initial observation 
whereby treatment with a 24-mer peptide derived from exon 7 of VEGF165 (the binding region 
for VEGF165 to Np1) for 24h significantly increased the level of apoptosis of human MDA-MB-
231 breast cancer cells and murine 4T1 breast cancer cells in vitro compared to cells that were 
either untreated or treated with a control peptide (Barr et al, 2005). Both MDA-MB-231 and 
4T1 breast cancer cells were also treated with an anti VEGF-R2 peptide but there was no 
decreased cell survival in any of these cell lines. Interestingly VEGF189 that also binds to Np1 
has been shown to induce opposing effects to VEGF165 on breast cancer cell survival in vitro 
(Vintonenko et al, 2011). The ability of MDA-MB-231 cells cloned to over-express either 
VEGF165 or VEGF189 to survive under stress conditions (0.5% serum treatment) was tested over 
a 24-96h time period and surprisingly at the 72h time point the MDA-MB-231 breast cancer 
cells that over-expressed VEGF189 had a higher level of late stage apoptotic cells compared to 
cells over-expressing VEGF165 and control transfected cells that were wild type VEGF 
expression (Vintonenko et al, 2011). This suggests that not all VEGF isoforms aid breast cancer 
progression and that the level of each splice variant present may have therapeutic implications.  
It has been suggested that Np1 is important in breast cancer migration. However, MDA-MB-
231 breast cancer cell migration in the presence of an anti-Np1 antibody was significantly 
increased (2 fold increase) compared with control cells (Bachelder et al, 2003). This study 
suggests that Np1 is potentially required for MDA-MB-231 breast cancer migration however 
the ratio of SEMA3A compared with VEGF in the breast cancer cells is important in 
determining the rate of migration observed and subsequently whether an anti-Np1 treatment 
proves effective in inhibiting breast cancer migration (Bachelder et al, 2003). The formation of 
lamellipodia on migrating cells is the first step in this process, however, when these 
lamellipodia form, weak adhesions tend to result in membrane ruffles that are visible at the edge 
of the cell (Borm et al, 2005). VEGF promotes the in vitro formation of membrane ruffles on 
breast cancer cells (Nasarre et al, 2003), which is most likely due to an inhibitory effect on 
focal adhesion molecules. The formation of weaker adhesions on the surface of breast cancer 
cells is advantageous as it increases the ability of the tumour cells to migrate and metastases and 
it is thought that Np1 may play a role in this VEGF mediated effect (Nasarre et al, 2003). In 
this study two distinct breast cancer cell lines were utilised, MCF7 cells which exhibit low 
metastatic potential and C100 (which is a derivative of MDA-MB-435 breast cancer cells) that 
are highly motile and exhibit high metastatic potential (Nasarre et al, 2003). The MCF7 cells 
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were treated with medium that contained SEMA 3F (1h) and an inhibition in MCF7 cell 
spreading and membrane ruffling was observed suggesting that the presence of SEMA 3F 
competes with VEGF for binding to the neuropilin receptors. This study supported data from the 
Bachelder group which suggested that the SEMA/VEGF ratio present in breast cancer cells an 
important determinant in the effective migration of breast cancer cells.  
Np1/VEGF interactions and breast cancer metastatic potential are regulated via SNAIL 
(Wanami et al, 2008). SNAIL is a transcriptional repressor for E-cadherin which is a 
transmembrane glycoprotein involved in epithelial cell-cell adhesion (Wanami et al, 2008) and 
it is thought to also act as a tumour suppressor (Kowalski et al, 2003). This study observed a 
reduction in cell-cell adhesion in MCF7 and T47D breast cancer cells 24h post VEGF 
transfection, with the mRNA/protein extracted from these cells showing increased SNAIL 
expression and reduced levels of E-cadherin. The addition of an anti-Np1 antibody reversed 
these effects, suggesting that Np1 mediated breast cancer cell adhesion is via regulation of 
SNAIL expression.  Interestingly, Bz had similar effect on SNAIL expression, suggesting that 
SNAIL regulation can possibly be via distinct pathways, supporting the notion that dual therapy 
(Bz/anti-Np1) may enhance efficacy of current breast cancer treatment.  
Autocrine VEGF has been shown to be important for breast cancer invasion in vitro (Bachelder 
et al, 2002). Treatment of MDA-MB-231 breast cancer cells with VEGF anti-sense 
oligonucleotides resulted in a significant decrease (64%) in the ability of these cells to invade a 
Matrigel layer (4h), with inhibition reversed by the addition of exogenous VEGF (Bachelder et 
al, 2002). This VEGF mediated breast cancer invasion is thought to be regulated by Np1 in vitro 
since the addition of a Np1 antibody significantly inhibited MDA-MB-231 breast cancer 
invasion compared to an IgG control whereas no inhibitory effects on MDA-MB-231 invasion 
in vitro were observed with the addition of a VEGF-R2 antibody (Bachelder et al, 2002). 
Np1- In vivo 
The existing literature supports a role for Np1 in regulating key activities in both EC and breast 
cancer cells in vitro. However it is important that these effects are also verified in vivo in order 
to establish Np1 as an effective and clinically relevant target for breast cancer treatment.  
ATWLPPR (A7R) is a heptapeptide that binds Np1 and subsequently blocks VEGF165 from 
binding (Starzec et al, 2006). An orthotopic breast cancer murine model using MDA-MB-231 
breast cancer cells found that A7R significantly reduced breast cancer growth by 45% compared 
with control tumours (mean volume: 1.82cm
3
 control vs. 1.00cm
3
 A7R treated) (Starzec et al, 
2006).  The mechanism by which this occurred are not clear, however the inhibition of tumour 
growth is likely to be a result of inhibitory actions on ECs rather than on the MDA-MB-231 
breast cancer cells directly since no difference was observed in the proliferation of the MDA-
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MB-231 breast cancer cells between the two groups (Ki67 staining). A modest yet significant 
decrease in tumour endothelial cell area (stained ECs measured in pixels) and intratumour 
vessel density (Chalkley grid method) was observed in the A7R treated tumours (22% reduction 
in area and 25% reduction in vessel density compared to control tumours) (Starzec et al, 2006).  
Neuropilin 1- Effects on other cancer types 
The focus of this project is on the role of Np1 in breast cancer; however the effects of Np1 on 
other cancer types may also aid our understanding of how the neuropilin receptors modulate 
tumour progression, allowing for different avenues of research in breast cancer therapy to be 
investigated. In pancreatic cancer Np1 appear to play a role in promoting chemoresistance (Wey 
et al, 2005) and in skin tumours the deletion of the Np1 gene impaired the ability of VEGF to 
promote cancer ‘stemness’ in cancer stem cells (Beck et al, 2011). The presence of cancer like 
stem cells in tumours is thought to aid the aggressive nature of tumours and cause cells to 
become chemoresistant (Abdullah and Chow, 2013). It has now thought that breast cancer cells 
with a CD44+/CD24-/ALDH
high
 phenotype are representative of a stem cell like population and 
if these cells express neuropilin receptors, this would be an important area to investigate 
especially since both chemotherapy and anti-angiogenic treatment eventually leads to resistance 
(Glinka et al, 2012).  
1.4.4 Neuropilin 2 
The majority of research into the role of the neuropilins in tumour progression has been carried 
out on Np1 however the role of Np2 is becoming more apparent. Np2 expression in breast 
cancer patient tumour samples has been correlated with a poor prognosis (Yasuoka et al, 2009). 
However there is minimal literature available on the molecular mechanisms by which Np2 
augments tumour progression.  
Endothelial Cells 
Np2 binds to both VEGF165 and VEGF145  with VEGF165 displaying a greater affinity for Np2 (5 
fold greater then that of VEGF 145 (VEGF165 -1.3x10
-10
M vs. VEGF145 7x10
-10
M) ) (Gluzman-
Poltorak et al, 2000). Despite the fact that Np2 binds to VEGF145 and VEGF165, the majority of 
literature available on the role of Np2 in cancer in mostly related to the interaction of 
Np2/VEGF-C. Np2 binding to VEGF-C is thought to lead to lymphangiogenesis. The presence 
of VEGF-C is required to promote a VEGF-R2/Np2 complex (Favier et al, 2006).  
Np2 is important in VEGF and VEGF-C EC survival in vitro (Favier et al, 2006).  HuDMECs 
that over-expressed Np2 were incubated with VEGF (10ng/ml) or VEGF-C (100 and 300ng/ml) 
for five days, after which cell viability was quantified. VEGF and VEGF-C in the presence of 
an empty vector increased HuDMEC cell survival compared to un-stimulated cells, with both 
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ligands stimulating survival to a relatively similar extent (Favier et al, 2006). Interestingly, 
over-expression of Np2, further enhanced cell survival of HuDMECs in the presence of both 
VEGF and VEGF-C, suggesting that Np2 does play an important role in EC survival of both 
vascular and lymphatic endothelial cells in vitro. Interestingly, the addition of SEMA3F 
inhibited the survival activity induced by VEGF and VEGF-C on HuDMECs. This observation 
is important as it suggests that SEMA-3F and VEGF/VEGF-C compete for Np2 binding on 
HuDMECs, and may have important implications in Np2 targeted therapy.  Np2 has also been 
implicated in HuDMEC migration in vitro. HuDMECs displayed increased cell migration 
towards both VEGF (50ng/ml) and VEGF-C (100ng/ml) after 24h, which was inhibited in the 
presence of Np2 siRNA knock down treatment (36h) (Favier et al, 2006).  Similar to the cell 
survival assay described above, the presence of SEMA3F inhibited VEGF and VEGF-C induced 
HuDMEC migration, further confirming that the SEMA proteins may compete with the VEGF 
proteins for Np2 binding on ECs. It was suggested that the role of Np2 in EC activity is a result 
of co-receptor actions since VEGF-R2 and Np2 formed complexes, however this does not rule 
out Np2 as an independent receptor for VEGF or VEGF-C mediated EC activity. The majority 
of data concerning the role of Np2 on EC biology appears to be related to lymphangiogenesis; 
however, there are suggestions that Np2 may also play an important role in tumour angiogenesis.  
Breast Cancer Cells 
Again data us scarce concerning the role of Np2 on breast cancer cells. However the limited 
data suggests that Np2 potentially plays a role in breast cancer cell motility (Yasuoka et al, 
2009). When Np2
high 
and Np2
low
 expressing breast cancer cells are isolated from an invasive 
breast tumour the ability of these two sub-populations demonstrate differential adhesion to 
ECM molecules (Goel et al, 2012). The Np2
high
 expressing breast cancer cells readily adhered to 
laminin which appeared due to interactions of Np2 with α6β1 integrin (Goel et al, 2012). MDA-
MB-435 breast cancer cells were utilised in subsequent experiments as these cells express both 
Np2 and α6β1 integrin. Interestingly it was observed that depletion of Np2 expression via short 
hairpin RNA resulted in a significant reduction in cell attachment and cell morphology when 
coated on a laminin surface but not collagen, suggesting the Np2 plays a role in α6β1 integrin 
regulation on breast cancer cells and thus potentially cell migration. (Goel et al, 2012). More 
recently, it has been suggested that Np2 may also play an important role in tumour initiation of 
triple negative breast cancer, as oncogenic transformation of normal mammary epithelial cells 
appears to be associated with increased Np2 expression whereas no increase in Np1 expression 
was observed. This suggests that Np2 may play a role in regulating the tumour initiating cell 
population in triple negative breast cancer (Goel et al, 2013). At present there is no in vivo data 
concerning a specific role for Np2 specifically on breast cancer progression.   
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The literature surrounding the neuropilin receptors supports the idea that these receptors play an 
important role in VEGF signalling on both ECs (vascular and lymphatic) and breast cancer cells. 
The nature of the neuropilins as both co-receptors and independent receptors suggests that a 
number of functional effects on different factors involved in breast cancer progression. There is 
sufficient compelling experimental evidence both in vitro and in vivo to suggest that Np1 is a 
key player in breast cancer progression and thus a valid target for breast cancer therapy.   
 
1.5 Clinical Significance for Anti-Angiogenic Therapy 
The clinical importance of angiogenesis in tumour growth was initially described in the early 
1970s, when Judah Folkman suggested that targeting the tumour vasculature would prove to be 
an effective method to prevent tumour progression (Folkman 1971). The leaky tumour 
vasculature allows tumour cells to escape from the primary tumour and circulate through the 
bloodstream to an alternative site (often liver, lungs and bone) where they seed and form 
metastases. Clinically there is a definitive correlation between angiogenesis and metastasis 
which supports the theory that a highly vascularised tumour will rapidly grow and progress 
(Guidi et al, 2000; Schneider and Miller, 2005).  
Current anti-tumour strategies include chemotherapy which targets the rapidly proliferating 
tumour cells. However these are genetically unstable and likely to acquire resistance to therapy 
after continued use. Moreover drugs must pass through endothelial barriers before reaching the 
target tumour and high interstitial pressure within tumours makes delivery of cytotoxic drugs 
difficult (Eichhorn, 2007). In contrast anti-angiogenic agents target the relatively stable ECs 
which are less likely to acquire resistance to therapy. Moreover anti-angiogenic therapies are not 
restricted to a certain histological tumour type as all solid tumours ultimately depend on 
angiogenesis, making the application of anti-angiogenic therapies across many oncology 
indications.  
Preclinical and clinical success has been observed with a number of anti-angiogenic agents, with 
the preclinical data showing elimination of tumour blood vessels and tumour burden in a 
number of murine solid tumours including breast cancer (Lin and Sessa 2004; Xue et al, 2008) 
and clinical results observing a reduction in both vascular density and tumour burden (Kerbel 
and Folkman 2002). It is thought that the anti-angiogenic agents act by causing collapse of 
immature vessels, prevent further vessel initiation, reducing vascular permeability and 
increasing pericyte coverage on vessels stimulating vascular maturity  (Lin and Sessa 2004). It 
has also been suggested that anti-angiogenic agents may produce a window of opportunity for 
more effective delivery of cytotoxic agents by ‘normalising’ the vasculature and reducing 
intratumoural pressure (Jain, 2001; Goel et al, 2011; Goel et al, 2012; Huang et al, 2012). 
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It is important that anti-angiogenic therapy may not completely remove a tumour, but by 
causing it to regress, may allow for more complete surgical removal of the tumour. The actions 
of anti-angiogenic therapy are also more specific than those associated with chemotherapy, thus 
the associated toxicities tend to be less severe, moreover they will simultaneously target any 
existing metastases (Eichhorn, 2007). Due to the pivotal role played by VEGF in tumours there 
are now a large number of inhibitors being developed to inhibit VEGF mediated activity, for 
example Bevacizumab (section 1.6 ).  
Pre-clinical data (Xue et al, 2008) and clinical data (Miller et al, 2007; Goel et al, 2011; Goel et 
al, 2012) emphasises the clinical relevance of anti-angiogenic therapy in breast cancer, however 
the complexity of the disease challenges the success of anti-angiogenic in breast cancer 
treatment, as suggested by recent ‘gap’ analysis reviews (Thompson et al, 2012).  
1.5.1 Therapeutic Strategies for Inhibiting the VEGF Pathway 
As VEGF is the most potent pro-angiogenic stimulus identified to date and its clinical 
significance appear pivotal to tumour angiogenesis, this makes it a major target for the 
development of anti-angiogenic therapy. Currently, there are a number of therapeutic measures 
targeting the VEGF pathway (Figure 1.10 and Table 1.2 ) including synthesis of antisense 
oligonucleotides to inhibit secretion of endogenous tumour VEGF, and neutralising VEGF in 
the microcirculation using soluble receptors such as VEGF-Trap (McMahon, 2000). An 
alternative method of preventing VEGF binding to its receptor and subsequent signalling is the 
use of blocking antibodies to either VEGF the ligand or to VEGF-R2. Furthermore small 
molecule drugs which target the tyrosine kinase receptors (VEGF-R1 and VEGF-R2) thereby 
preventing downstream signalling have now been developed e.g. Sunitinib. Targeting the 
mTOR (rapamycin) pathway provides an alternative method for targeting VEGF, as inhibitors 
of mTOR such as Temsirolimus inhibit the expression of VEGF in EC (Del Bufalo et al, 2006).   
There are a number of VEGF targeted agents that are currently undergoing clinical trials in a 
number of different tumour types. Targeted therapy offers the benefit in that, in theory it should 
reduce the toxicities associated with more systemic treatments such as chemotherapy. Despite 
minimal success with Bz, the approach to breast cancer treatment and other such tumours ins 
promising. However, more bench to bedside research needs to be performed to establish the 
mechanism of these different targeting agents (Table 1.2).  
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Figure 1.10 VEGF Targeting Agents : 
There are a number of different strategies currently being investigated for inhibiting the VEGF 
pathway and thus inhibiting angiogenesis. The main focus for my project is Bz, which is a mAb 
that inhibits VEGF from binding to its receptors; VEGF-R1/R2 and thus subsequent signalling. 
The targets for therapy are vast and, developed for a number of different stages in the VEGF 
pathway from inhibiting EC survival signals (Rapamycin) through to intracellular tyrosine 
kinase inhibitors that targets downstream signalling molecules such as ras & raf.  
Adapted from Eichhorn et al, 2007.Angiogenesis in cancer: molecular mechanisms, clinical 
impact. Langenbecks Arch Surg 392; 3:371-9 
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AGENT TARGET STATUS 
Aflibercept Binds VEGF isoforms and 
PIGF and inhibits interaction 
with VEGF-R1 and VEGF-R2 
Clinical Trials- for use for mCRC patients 
in combination with chemotherapy – 
clinically successful, demonstrated 
extension of PFS and OS. 
Potential second line treated for non-
responders to Bz  
Vandetanib Oral inhibitor, blocks VEGF 
receptor signalling via 
downstream kinase blockade 
Clinical Trials- for use in advanced breast 
cancer patients in combination with 
docetaxel 
Cilengitide Αvβ3/5 integrin inhibitor  Clinical Trials- for use in glioblastoma 
and other cancer types including breast 
cancer 
Pazopanib Tyrosine kinase inhibitor that 
targets VEGF-R1, VEGF-R2, 
VEGF-R3, PDGFR and c-kit 
Approved for use in renal 
cell carcinoma 
Angiostatin/ 
Endostatin 
Inhibits the expression of 
VEGF-A, VEGF-C and VEGF-
D 
Pre-clinical studies for colon cancer 
 
 
 
 
 
 
1.6 Bevacizumab in the Treatment of Breast Cancer 
When this current project commenced (2008), Bevacizumab (Bz) had recently been approved 
for the mBC indication and was at the fore-front of anti-angiogenic therapy. However, over the 
past four years the clinical studies data have failed to reach clinically meaningful study 
outcomes. The lack of significant benefit to patients and a rise in safety concerns led to the 
withdrawal of Bz in mBC by the FDA (Nov 2011). This section discusses the early clinical data, 
the challenges faced in the clinic and the new knowledge that can be exploited to overcome 
these challenges. It is important to state that the clinical use of Bz in combination with 
chemotherapy in other solid tumours such as metastatic colorectal cancer (FDA) has proved 
successful. Thus, the question remains is to why Bz, an anti-angiogenic agent which in theory 
has the same mechanism of action across all solid tumours is not translating to successful 
application in mBC.  
 
Bevacizumab is the first angiogenic inhibitor to be approved for use in the clinic by the FDA. 
Metastatic colorectal cancer was the first indication for which Bz was approved followed by 
breast cancer in February 2008; where it was granted accelerated approval for use in advanced 
(HER2/neu negative) breast cancer treatment (FDA) (section 1.6.5 for clinical studies in breast 
cancer). It is a humanised monoclonal antibody that binds all known human VEGF isoforms, 
Table 1.2  VEGF Targeting Agents:  
Outlines some of the targeted therapies that are currently undergoing clinical trials or have been 
approved for use in a number of cancer patients, including breast cancer.  
Adapted from Angiogenesis in cancer: anti-VEGF escape mechanisms. Prager et al, 2012. 
Translational lung cancer research; 1(1): 14-25 
INTRODUCTION 
 
SAPNA LUNJ Page 40 
 
preventing interactions with VEGF-R1 and VEGF-R2 and subsequent signalling (Shih and 
Lindley 2006). The human region (93%) constitutes the framework of the antibody and the 
murine region (7%) constitutes the complementary determining regions that bind VEGF (Shih 
and Lindley 2006). The biochemical and pharmacological properties of Bz are the same as its 
parent antibody A4.6.1. (murine antihuman antibody), however has the advantage of inducing a 
reduced immune response and exhibiting a longer biological half-life of 17-21 days in humans 
(Gerber and Ferrara 2005).  
 
1.6.1 In vitro effects of Bz on 
Endothelial Cells 
A dose dependent inhibition on VEGF165 mediated HuVECs cell proliferation in vitro was 
observed with the addition of Bz (96h experimental time point) at a range of doses with 
maximum inhibition of HuVECs cell proliferation observed with Bz at 500ng/ml (Wang et al, 
2004). VEGF165 (50ng/ml) and Bz were pre-incubated for 2h prior to addition to the cells. An 
IgG1 control was also used to assess any non-specific effects observed with the addition of a 
monoclonal antibody; however the data from these control experiments were not shown (Wang 
et al, 2004).  Similarly, VEGF165 mediated HuVECs cell survival was also inhibited in a dose 
dependent (100, 200 and 500ng/ml) manner by Bz (Wang et al, 2004). No inhibitory effects 
were observed on HuVECs cell survival in the presence of a control IgG (500ng/ml).  Bz also 
inhibited the in vitro vascular permeability effects of VEGF165 on HuVECs. Minimal inhibitory 
effects were also observed with the control IgG but the level of permeability observed with 
VEGF165 alone and VEGF165 plus the control IgG was not significant (it is important to note that 
statistical analysis was not presented) (Wang et al, 2004).  Nitric oxide (NO) production is 
important in a number of EC associated process such as permeability and migration (Wang et al, 
2004) and likely to be regulated by VEGF , thus the effects of Bz on NO production by 
HuVECs were also evaluated. Again, Bz exerted an inhibitory effect on NO production 
compared to cells treated with VEGF165 alone, with no effect with the control IgG (Wang et al, 
2004).   
VEGF-induced tissue factor expression in HuVECs was also inhibited by Bz (62.5ng/ml-
1000ng/ml). Interestingly, when Bz (500ng/ml) was pre-incubated with a range of VEGF165 
doses (2.5-50ng/ml) an inhibitory effect with Bz on HuVECs migration was observed in the 
presence of three VEGF165 doses (2.5, 5 and 10ng/ml) however this inhibitory effect was 
negated in the presence of Bz and 50ng/ml VEGF165, suggesting that a much higher Bz/VEGF165 
ratio is required to maintain inhibitory effects on HuVECs migration in vitro (Wang et al, 2004).  
It is interesting that inhibition of VEGF165 mediated tissue factor production and HuVECs cell 
migration required much higher doses of Bz compared to the doses used in the other functional 
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assays in these experiments, suggesting differences in the extent to which downstream HuVEC 
pathways are activated by VEGF165 in the different cellular processes in vitro.  
Another study investigated the effects of Bz on functional HuVEC activity in vitro (Carneiro et 
al, 2008). Exogenous VEGF was not added but assays were carried out in the presence 2% 
serum containing media, thus creating a different micro-environmental setting from the studies 
above (Wang et al, 2004), where VEGF165 was pre-incubated with Bz 2h prior to adding to the 
HuVECs. In this more recent study the appropriate vehicle control was used rather than an IgG 
control since Bz is purchased as a re-suspended liquid, with the vehicle control  containing 
(51mM sodium phosphate ph 6.2, 60mg/ml Trehalose.2H2O, 0.04% polysorbate 20) European 
Medicines Agency 2005. No in vitro cytotoxic effect on HuVECs was observed 24h after 
treatment with Bz (0.25-2.5mg/ml) (Carneiro et al, 2008). Bz significantly (p<0.01) inhibited 
HuVECs cell proliferation at all doses tested (0.25-2.5mg/ml) compared to vehicle control 
treated cells (Carneiro et al, 2008), at a much earlier time point (24h) then previously reported 
(96h) (Wang et al, 2004). Bz significantly (p<0.01) inhibited HuVECs cell survival in a dose 
dependent manner, compared to the vehicle control treated cells (Carneiro et al, 2008). The 
effects of Bz on HuVECs cell migration was tested using the 0.25mg/ml and 2.5mg/ml dose 
only, with the higher dose of Bz (2.5mg/ml) significantly (p<0.05) inhibiting HuVECs cell 
migration in vitro compared to the vehicle control. Low and high Bz doses (0.25 and 2.5mg/ml 
respectively) significantly (p<0.05) inhibited HuVECs cord formation compared to the vehicle 
control (Carneiro et al, 2008). These two studies described, are important even using different 
experimental conditions both confirm that ability of Bz to effectively inhibit cellular functions 
associated with HuVECs in vitro. However, it is important to note that the majority of in vitro 
studies thus far have assessed the effects of Bz on HuVECs rather than HuDMECs. HuDMECs 
are microvascular ECs and thus a more relevant cell type when studying angiogenesis in vivo. 
However, they are technically more demanding than HuVECs to culture. However, recently, 
during the review of this current project the effects of Bz on the microvascular ECs have been 
investigated. 
Bz used at two different doses (0.125 and 0.25mg/ml) demonstrated similar inhibitory effects on 
HuDMECs function in vitro when compared to HuVECs despite the use of lower concentrations 
of Bz (Costa et al, 2009). Bz (0.25mg/ml) significantly inhibited in vitro HuDMEC cell 
proliferation and survival after 24h treatment compared to the vehicle control (Costa et al, 
2009). Interestingly, both doses of Bz (0.125 and 0.25mg/ml) significantly (p<0.05) inhibited 
HuDMEC cell migration and cord formation after 24h compared to the vehicle control. The 
presence of Bz reduced the level of VEGF released by the HuDMEC cells with a significant 
(p<0.001) reduction in response to higher dose (0.25mg/ml) compared with the vehicle control 
(Costa et al, 2009).  
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Breast Cancer Cells  
With the controversy surrounding the expression of VEGF-R1 and VEGF-R2 on breast cancer 
cells and the mechanism of anti-angiogenic agents are thought to predominantly target ECS. 
Consequently, there is limited literature available on any direct effects of Bz on breast cancer 
cells in vitro. However a few studies have been performed in vitro.  
Treatment of Luciferase labelled MDA-MB-231 (Luc-MDA-MB-231) breast cancer cells with 
Bz alone with a dose much lower then used for ECs (10μg/ml)) for 14 days resulted a decrease 
(23%) in the number of colonies formed compared to the control (Volk et al, 2008). Combining 
Bz with nab- paclitaxel (a albumin bound form of paclitaxel), dramatically enhanced the 
inhibition on Luc-MDA-MB-231 colony-formation compared to nab-paclitaxel alone (43% vs. 
76%) (Volk et al, 2008). It is possible that increasing the molecular weight of paclitaxel by the 
addition of albumin leads to greater retention of the drug, thus more effective delivery into the 
tumour, resulting in enhanced inhibitory effects. However, a separate study demonstrated 
conflicting results with no inhibition of breast cancer cell proliferation in the presence of Bz 
(Gerber & Ferrara, 2005). Breast cancer cells that express HER2 at high levels may respond to 
Bz treatment to a greater extent, demonstrated by using the HER2 positive SKBR3 cell line, 
which demonstrated enhanced inhibition of cell proliferation when compared to the low HER2 
expressing breast cancer cell lines, MCF7 and MDA-MB-231 (Emlet et al, 2007).  
1.6.2 Pre-clinical Studies 
A4.6.1 and Bz 
Over the years since the approval of Bz for clinical use in breast cancer patients, a number of 
pre-clinical in vivo studies have been performed assessing the effects of A4.6.1 or Bz in 
combination with a number of different agents.  
Preclinical studies using the murine parent antibody, A4.6.1 against a breast carcinoma cell line 
(MDA-MB-435) revealed a significant decrease (p<0.05) in tumour permeability but no change 
in tumour fractional blood volume 24 hours after a single dose of A4.6.1 (1mg dose) (Brasch, 
1997). A further study demonstrated a reduction in tumour growth rates and microvascular 
permeability after three 1mg doses of A4.6.1 at 3 day intervals (Pham et al. 1998). The efficacy 
of A4.6.1 in combination with doxorubicin was also investigated in three different human breast 
cancer cell lines implanted as xenografts in nude mice. The combination of A4.6.1 with 
doxorubicin significantly reduced tumour mass (P<0.001) in all three cell lines tested (Gerber 
and Ferrara 2005).  
Pre-clinical studies investigating A4.6.1 efficacy demonstrated incomplete tumour inhibition  
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as A4.6.1 only inhibits human VEGF isoforms, and therefore endogenous murine forms of 
VEGF are freely available to bind and activate VEGF receptors (Ryan et al. 1999). Indeed, 
studies have shown that the degree of inhibition of Bz is inversely related to the content of 
stromal-derived mouse VEGF that is present within the tumour xenografts (Ferrara et al. 2005). 
A recent pre-clinical study assessed the effects of Bz on HCC1806, a cancer cell line thought to 
represent a clinically relevant model for triple negative breast cancer (Volk-Draper et al, 2012). 
HCC1806 breast cancer cells were injected orthotopically, tumours were allowed to grow to 
150mm
3
 after which treatment with either saline control or nab-paclitaxel alone (10mg/kg i.v.) 
for five consecutive days, Bz alone (4mg/kg i.p.) twice weekly or a combination of nab-
paclitaxel and Bz commenced (Volk-Draper et al, 2012).  Interestingly, Bz had no significantly 
inhibitory effect on HCC1806 breast cancer growth in vivo compared with the saline control 
(mean±SEM tumour volume, mm
3
; Bz vs. control; 2126 vs. 1799mm
3
). In contrast, Nab-
paclitaxel alone significantly (p<0.01) inhibited HCC1806 breast cancer growth (180mm
3
) 
compared with the saline control. However, when nab-paclitaxel treatment was discontinued 
approximately 15 days later, the nab-paclitaxel alone treated tumours all started to re-grow, 
which was not evident when Bz was combined with nab-paclitaxel using a similar regime 
(Volk-Draper et al, 2012). The data from this HCC1806 study is important for future pre-
clinical studies investigating the more aggressive sub-type of breast cancer that frequently 
present in clinical setting.  
The majority of breast cancer pre-clinical studies begin treatment once palpable tumours of 
approximately100-200mm
3
 are reached. However in the clinic, breast cancer patients are 
routinely diagnosed when they present with metastatic breast cancer. Thus the following group 
designed a pre-clinical study that commenced treatment when tumours were larger in volume 
(450-600mm
3
) and distant metastases were present. Luc-MDA-MB-231 and Luc-MDA-MB-
435 breast cancer cells were injected into the mammary fat pad of SCID mice, tumours were 
allowed to grow and then treated with a saline control, nab-paclitaxel alone (10 or 30mg/kg i.v.) 
for five consecutive days, Bz alone (4mg/kg i.p.) twice weekly or a combination of nab-
paclitaxel and Bz began (Volk et al, 2011). Interestingly, in the Bz  (4mg/kg) treated group, a 
varied response in the Luc-MDA-MB-231 tumours was observed in the two different cohorts, 
with the first cohort demonstrating a significant (p=0.006) inhibitory effect on advanced Luc-
MDA-MB-231 breast cancer growth compared to the control group (1332 vs. 2095mm
3
  
respectively). In the second cohort Bz at the same dose demonstrated no inhibitory effects on 
Luc-MDA-MB-241 tumour growth compared to the control (1933 vs. 1973mm
3
 respectively). 
This suggests that tumour responses to Bz are diverse and that personalised treatment is 
required to identify patients that are likely to respond to anti-angiogenic treatment.  
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Bz significantly (p<0.001) inhibited advanced Luc-MDA-MB-435growth compared to the 
control group (1030 2157 and 2151mm
3
 respectively) (Volk et al, 2011). Nab paclitaxel (10 and 
30mg/kg) significantly (p<0.001) inhibited both breast cancer cell lines at the advanced stage 
compared to the control with a further inhibition in tumour growth being observed when Bz was 
combined with nab paclitaxel (Luc-MDA-MB-231-10mg/kg nab-paclitaxel dose; 469 vs. 
26mm
3
 respectively: Luc-MDA-MB-435-10mg/kg nab-paclitaxel dose; 642 vs. 174mm
3
 
respectively) (Volk et al, 2011).  The effects of Bz on distant metastasis in the lungs and lymph 
nodes was also assessed in this study. Bz alone had no effect on the incidence of metastasis in 
the lymph node (LN) however, Bz alone significantly (p=0.005) reduced the Luc-MDA-MB-
231 metastatic tumour burden in the LN present in the advanced diseased state compared to the 
control group (Volk et al, 2011). Nab paclitaxel alone (10 and 30mg/kg) also significantly 
(p=0.003 and p=0.001 respectively) reduced Luc-MDA-MB-231 tumour burden in the LN and 
combining Bz with nab paclitaxel further reduced the metastatic burden present in the LN. 
Interestingly, advanced tumour growth of the primary tumour formed by the Luc-MDA-MB-
435 cells responded to both Bz alone and nab paclitaxel but no such response was observed in 
the metastatic setting (Volk et al, 2011).  Nab-paclitaxel alone increased incidence of distant 
metastasis in the LN compared to the control group, this was significant (p=0.041).  
Preclinical efficacy of A4.6.1/Bz has also been shown in a variety of solid tumours other than 
breast carcinoma. Preclinical studies showed 90-95% growth reduction in rhabdomyosarcoma 
xenografts when the drug was administered at the same time or shortly after injection of the 
tumour cell lines into nude mice. Administration of Bz or A4.6.1 in a colorectal cancer 
xenograft showed 90% inhibition of primary tumour and a 10-18 fold reduction in the number 
of liver metastases present (Melnyk et al. 1999; Gerber and Ferrara 2005). Tumour inhibition 
occurred in a dose dependent manner irrespective of the route of administration or tumour 
location (Gerber et al. 2000) suggesting that bioavailability or barrier problems are not 
encountered and suggested that Bz offered an advantage over cytotoxic drugs. Interestingly if 
tumour growth was significant prior to the addition of Bz, the tumour was able to escape 
treatment and continue to progress (Gerber et al. 2000), providing possible evidence that 
tumours may eventually become VEGF independent. Therefore, the screening for VEGF levels 
prior to VEGF based therapy may assist in stratification of patients who may respond to VEGF 
therapy.  
1.6.3 Mechanism of action of  Bz   
It is thought that Bz reduces tumour growth by causing regression of existing vessels and 
eventually inhibiting new blood vessel formation which supports tumour growth (Gerber and 
Ferrara 2005) (Figure 1.11). Since Bz targets tumour-associated vasculature, it is accepted that 
Bz suppresses tumour growth via indirect effects on tumour cells. Bz treatment appears to 
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increase pericyte coverage on tumour associated vessels thus leading to restoration of a mature 
vascular lining. It has been speculated that the ‘normalisation’ of the tumour associated 
vasculature leads to restoration of blood flow and interstitial pressure, thereby creating  a 
window of opportunity which allows for more efficient delivery of chemotherapeutic drugs and 
radiotherapy (Goel et al, 2011; Goel et al, 2012; Jain et al, 2013). Thus vascular normalisation 
may explain why the clinical effects of Bz are increased when Bz is combined with 
chemotherapy. There is also a suggestion that Bz reduces the level of bone marrow derived cells 
infiltrating into the tumour, which may reduce the chance of the vascular ‘rebound’ (Roland et 
al, 2009).  
 
 
 
1.6.4 Toxicity Profile  
Pre-clinical safety of Bz in monkeys (share 99% homology to human VEGF) showed no real 
toxicities, pathological changes or unexpected adverse effects after Bz treatment even after 
prolonged treatment with high doses of Bz (up to 50mg/kg/dose for 13 weeks). Pre-clinical 
trials confirmed that anti-VEGF therapy with Bz/A4.6.1 exhibited significant anti-tumour 
activity in a range of primary and metastatic tumours including breast, with relatively mild 
associated side effects, which resulted in the progression of Bz to clinical trials to assess safety 
and efficacy in humans (Ryan et al. 1999). 
Figure 1.11 Chemotherapy  
versus Angiogenesis Inhibitors. 
 
This diagrammatic representation shows the 
different mechanisms of action observed 
with chemotherapy and anti-angiogenic 
inhibitors. Anti-angiogenic inhibitors will 
primarily target tumour cells indirectly by 
acting on the blood vessels that have 
established within the tumour, whereas 
standard chemotherapy directly targets and 
kills the tumour cells. Although some 
chemotherapeutic agents, such as Paclitaxel 
have been shown possess anti-angiogenic 
activity. The different targets for the two 
therapies results in different outcomes. 
Treatment with chemotherapy, results in 
shrinkage of the tumour and if successful, 
elimination of the primary tumour 
(cytotoxic effects). Anti-angiogenic agents 
cause regression of the tumour but more 
notably stabilisation of the disease 
(cytostatic) due to reduced oxygen and 
nutrients required for growth. 
Adapted from Loges et al, 2009. Silencing 
or Fuelling Metastasis with VEGF 
inhibitors: Anti-angiogenesis Revisited. 
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1.6.5 Clinical Trials 
Monotherapy 
The first Phase I trial measuring the safety and pharmacokinetic profile of Bz recruited 25 
patients with solid tumours; sarcoma (n=8), renal cell carcinoma (n=7), breast cancer (n=5), 
lung cancer (n=2) and other (n=3) (Gordon et al, 2001).   The patients were treated with a range 
of Bz doses (0.1-10mg/kg) with 90 minute i.v infusions at day 0, 28, 35 & 42, with a linear 
pharmacokinetic profile being observed between 0.3-10mg/kg, and inhibition of serum free 
VEGF being observed within this range (Gordon et al, 2001). Bz was reasonably tolerated; the 
majority of patients presented with manageable grade 1-2 side effects (asthenia, nausea, low-
grade fever and head-ache), with grade 3-4 adverse events (anaemia, dyspnea and serious 
bleeding) occurring in four patients only, over the entire course of the study (6 weeks). These 
adverse events were thought not to be a result of Bz dose-dependent treatment but due to disease 
progression (Gordon et al, 2001).  
Bz as a single agent in the treatment of previously treated (chemotherapy) metastatic breast 
cancer (mBC) patients was evaluated in a Phase I/II trial. This trial that assessed the safety and 
efficacy of Bz administered at increasing doses of 3, 10 & 20mg/kg twice weekly as i.v. 
infusion until disease progression or to a maximum of 13 doses, with tumour response being 
assessed on days 70 & 154 after start of the  initial treatment (Cobleigh et al, 2003). The aim of 
the study was to establish an optimal dosage to be used in subsequent trials and the primary end 
point of the study was objective response rate (ORR). The trial observed an ORR of 9.3% with 
median duration of response observed at 5.5%; ~17% had stable disease or showed ongoing 
objective response (Eskens and Sleijfer, 2008).  Adverse effects at higher doses of Bz 
(20mg/kg) were detected, such as severe headaches, nausea and vomiting in 4/16 patients 
treated at this dose. From this study, the optimal dose was administration of Bz at 10mg/kg (i.v. 
infusion) every other week. These Phase I/II trials using Bz alone showed Bz to generally be 
well tolerated but overall Bz monotherapy had proven to have only modest anti-tumour effects 
(Eskens and Sleijfer ,2008; Gerber and Ferrara, 2005).  
Combination Therapy   
Preclinical experiments suggested that the anti-tumour activity of Bz was enhanced by 
combining with cytotoxic chemotherapy, radiation and other angiogenic inhibitors (Gerber and 
Ferrara 2005).  The first successful clinical trial that led to the approval of Bz in combination 
with standard chemotherapy was in 2004 for the treatment of untreated metastatic colorectal 
cancer (mCRC) (Hurwitz et al, 2004). In this study, patients received Iriontecan, Fluorouracil 
and Leucovorin (IFL) in combination with Bz (5mg/kg every two weeks) or IFL with a placebo. 
The primary endpoint of overall survival (OS) and the secondary end point progression free 
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survival (PFS), response rate (RR), duration of response (DR), safety and quality of life were all 
successfully met. The patients in the Bz group demonstrated a significant (p<0.001) increase in 
OS compared to the placebo group (20.3 vs. 15.6 months respectively). Progression free 
survival, RR and DR (10.6months, 44.8% and 10.4months respectively) were also significantly 
improved in the patients receiving Bz and chemotherapy compared to the chemotherapy alone 
group (6.2months, 34.8% and 7.1months respectively). Grade 3 hypertension was considerably 
increased in the Bz treated patients compared to placebo (11% vs. 2.3% respectively) however 
this was stated to be managed with the use of standard anti-hypertensive agents (Hurwitz et al, 
2004). With the successful trial in mCRC and the pre-clinical data suggesting that combining Bz 
with standard chemotherapy regimens did not result in enhanced chemotherapy-associated 
toxicities (Margolin et al. 2001) the majority of clinical studies in breast cancer focused on the 
role of Bz in adjuvant therapy for the first line treatment of MBC.  
 
Phase II Trial 
XCALIBr, a Phase II clinical trial investigating capecitabine alone (1000mg/m
2
) vs 
capecitabine/Bz (15mg/kg every 3weeks) in 106 mBC patients observed an increase in time to 
progression in the combination arm (4mths vs 5.7 mths) in addition to therapeutic response rate. 
Interestingly, the study also observed combination therapy to be more efficacious in mBC 
patients with HER
 
positive status; this however is undergoing further investigation in further 
trials (Roche).
 
 
Phase III Trial 
Unfortunately the first published Phase III trial proved unsuccessful. The study evaluated 
second line treatment of mBC patients using Bz in combination with capecitabine 
(2500mg/m2/d, twice daily for 14 days followed by a 7 day rest period then Bz 15mg/kg on day 
one of each 3 week cycle) compared with capecitabine monotherapy (2500mg/m2/d, twice daily 
for 14 days followed by a 7 day rest period) in 462 patients who had undergone previous 
anthracyclines and taxanes treatment (Miller et al. 2005). There was increased overall response 
rate (9.1 vs. 19.8%) in patients treated with the combination therapy; however median 
progression free survival (PFS; 4.9 vs. 4.2 months) and overall survival (OS; 15.1 vs. 14.5 
months) remained relatively unchanged between the two groups  (Miller et al. 2005).  
 
However, a second Phase III (E2100) trial followed, where previously untreated mBC patients 
were administered with either paclitaxel alone (90mg/m
2
 weekly for 3 of 4 weeks) or in 
combination with Bz (10mg/kg every 2 weeks). There were significant increases in PFS in the 
combination group (11.8 vs. 5.9 months), increased ORR (36.9%vs. 21.2%) but the OS however 
remained unchanged (Miller et al. 2007). Interestingly a follow up investigated any role of 
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polymorphisms in the VEGF or VEGF-R2 gene on the efficacy and safety profile of Bz 
combination treatment and any value as  biomarkers, found that certain SNPs increased the OS 
observed in response to Bz combination therapy (Schneider et al. 2008). The E2100 study 
resulted in Bz being granted FDA accelerated approval on the basis that further investigations 
would follow, thus the AVADO and RiBBON studies were instigated.  
AVADO  
The AVADO study was a randomised, double-blind trial that investigated the effects of Bz 
(7.5mg/kg and 15mg/kg every 3 weeks) in combination with 3-weekly docetaxel (100mg/m2) as 
first line treatment for HER2 negative mBC (Miles et al, 2010). The primary endpoint for this 
study was PFS and a large number of other parameters such as OS, DR, safety, premature 
withdrawal due to adverse effects and best overall response observed at secondary endpoints. 
The primary endpoint of this study was met, with PFS being statistically (p=0.006) increased in 
the Bz (15mg/kg) combination treated patients compared to the placebo group (10.1 vs. 8.2 
months respectively). The lower dose of Bz (7.5mg/kg) also resulted in increased PFS compared 
to the placebo (9.0 vs. 8.2 months respectively) however this increase was not statistically 
significant (Miles et al, 2010).  Of the secondary endpoints only the overall response rate was 
statistically improved in Bz treated groups, with no significant differences being observed in OS, 
a similar finding to the E2100 trial. Grade 3-4 adverse events of particular interest (e.g. 
hypertension, neutropenia and febrile neutropenia) were more commonly observed in both the 
Bz groups compared to the placebo group (78% and 75% vs. 67% respectively). In addition, 
other grade 3-4 events (such as peripheral odema) were higher in the placebo group compared to 
the Bz treated groups (2.6% vs. 1.2% and 0.4% respectively). However this is largely expected 
as, Bz potentially acts by ‘normalising’ the vasculature, thus making it less leaky, hence 
decreasing the incidence of odema present. However, the overall safety profile of Bz was 
reported in the AVADO trial was that of reasonable tolerance.  
The first clinical investigation combining Bz with standard chemotherapy in breast cancer 
observed that previously treated patients exhibited a 2.2% increase in congestive heart failure 
(3.1% vs. 0.9%) (Miller et al. 2005). The safety profile of Bz is still under investigation and the 
RiBBON1/2 studies have been designed to determine whether previous treatment increases the 
incidence and severity of adverse effects of Bz combination therapy (O'Shaughnessy and 
Brufsky 2008). 
RiBBON-1 and RiBBON-2 
Despite the accelerated approval of Bz following the E2100 trial, there were still a number of 
key questions that needed further addressing with regards to Bz treatment in mBC, in particular 
the safety profile of Bz. The RiBBON trials have been designed to determine whether previous 
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treatment increases the incidence and severity of the adverse effects of Bz combination therapy, 
since previous studies looked at Bz in the first line therapy setting (O’Shaughnessy and 
Brufsky, 2008).  The Phase III RiBBON-1 and RiBBON-2 studies assessed the safety and 
efficacy of Bz in combination with a broad spectrum of chemotherapeutic agents (taxane based 
therapy, anthracycline based regimens or capecitabine) in two groups of  HER2 negative 
patients, (1) patients with untreated mBC (RiBBON-1) and (2) patients with previously treated 
mBC (RiBBON-2).  
The RiBBON-1 trial demonstrated a similar profile of response to the AVADO study, whereby 
the more severe adverse events were higher in the Bz combination (Robert et al, 2011). Due to 
the high incidence of adverse events that were grade 3 or above associated with the addition of 
Bz to the chemotherapeutic drugs, the addition of further treatment agents are limited.  
In the RiBBON-2 trial the addition of Bz to taxane, gemcitabine or capecitabine improved PFS 
marginally (~2.1 month improvement) whereas adding Bz to vinorelbine resulted in no further 
efficacy. In the RiBBON-2 study the number of severe events was much higher in the Bz treated 
group, and the number of patients that discontinued treatment due to severe adverse events was 
twice that in the Bz treated group compared to the control group (13.3% vs. 7.2% respectively) 
(Brufsky et al, 2011). 
 Recent/On-going Trials with Bevacizumab 
In 2011, Bz was withdrawn by the FDA for use in mBC, following much deliberation. 
Withdrawal of Bz in the indication of mBC treatment was due to the lack of clinical benefit in 
patients and severe toxicity. However despite the withdrawal of Bz from breast cancer treatment 
by the FDA, clinical trials assessing Bz in combination with a number of different agents under 
different clinical settings are currently still underway. These studies are important to determine 
the reasons that Bz failed to reach the initial expectations for use in breast cancer, and may 
allow more optimal regimes of the drug to be instigated. 
A recent study consisting of 1206 patients with primary operable HER2 negative breast cancer, 
evaluated the effects of Bz in combination with capecitabine or gemcitabine plus docetaxel 
followed by doxorubicin and cyclophosphamide (Bear et al, 2012).  Patients were randomised 
into one of three chemotherapy groups and received either (1) four cycles of docetaxel (100mg 
per square metre, i.v. on day one of each cycle) every three weeks followed by four cycles of 
doxorubicin-cyclophosphamide (60mg and 600mg per square metre respectively, i.v.) every 
three weeks,  (2) capecitabine (825mg per square metre, orally) twice a day for the first 14 days 
followed by docetaxel (75mg per square metre, i.v. on day one) followed by doxorubicin-
cyclophosphamide (as above)  or (3) gemcitabine (1000mg per square metre, i.v.) on day 1 and 
8 followed by docetaxel (75mg per square metre, i.v. on day one) followed by doxorubicin-
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cyclophosphamide (as above).  From the three chemotherapy groups, half of the patients in each 
group was randomised to receive Bz (15mg/kg i.v.) every three weeks (Bear et al, 2012).  
Pathological complete response (pCR) was the primary endpoint for the trial. This trial suggests 
that in this particular cohort of patients, the addition of capecitabine or gemcitabine to the 
docetaxel/doxorubicin/cyclophosphamide (DDC) regimen has no additive effect on the pCR 
rate compared to DDC alone (29.7%, 31.8% and 32.7% respectively) (Bear et al, 2012). 
Interestingly the addition of Bz improved the rate of pCR, with hormone receptor positive 
tumours demonstrating an increased response to Bz treatment compared to hormone receptor 
negative (Bear et al, 2012), suggesting that Bz may be more effective in the less aggressive 
hormone positive phenotype.   
Bz was initially approved as first line therapy for patients with HER2 negative metastatic breast 
cancer however after the withdrawal of Bz in the over-arching classification of patients, the use 
of Bz in other breast cancer settings is being investigated. A single-arm Phase II clinical trial 
(EGF103890) assessed the efficacy and safety of combining Bz with lapatinib (dual tyrosine 
kinase inhibitor of both HER2 and epidermal growth factor receptor) on 52 patients with HER2 
positive metastatic breast cancer (Rugo et al, 2012). It has previously been shown that HER2 
over-expressing tumours also have increased expression of VEGF (Rugo et al, 2012) thus 
combining a HER2 targeting antibody with Bz is a valid approach in overcoming the resistance 
observed in breast cancer patients treated with HER2 targeting agents alone. Most patients in 
this study had previously been treated with chemotherapy and/or Herceptin prior to participation. 
The patients were considered as heavily pre-treated, as most had previously received a median 
of 3 chemotherapy regimes and Herceptin (median exposure 84.1 weeks) treatment for the 
metastatic disease (Rugo et al, 2012). Patients received lapatinib (1500mg, orally) daily with Bz 
(10mg/kg i.v.) every two weeks until disease progression, the presence of severe toxicities or 
withdrawal of consent from the patient with the primary endpoint being PFS at the end of week 
12 of the trial (clinical data not yet published) (Rugo et al, 2012) 
In addition to the trials described, there are still a large number of clinical trials underway, 
evaluating the most appropriate regime for using Bz in the treatment of breast cancer, these 
include; BEATRICE (triple negative patients, treated with Bz after surgery), BETH (HER2 
positive patients after tumour has been resected), MO19391 (safety trial of Bz in combination 
with taxane based chemotherapy) and the E5103 (non-metastatic BC) trials.  
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1.6.6 Clinical side effects of Bz 
Since Bz targets VEGF signalling but does not differentiate between the tumour vasculature and 
the normal vasculature, it is possible that side effects such as impaired wound healing may be 
present with Bz treatment. The clinical side effects of Bz as stated by the FDA are divided into 
(1) serious side effects associated with Bz and (2) milder, more commonly observed side effects 
due to drug interaction. The serious side effects caused by Bz administration include 
gastrointestinal perforation, impaired wound healing, serious bleeding that potentially leading to 
stroke or death, heart failure and kidney damage. The more commonly seen adverse effects 
include high blood pressure, proteinuria, weakness, thrombophlebitis, diarrhoea, reduced white 
cell count, headaches, loss of appetite and mouth sores. 
All of the studies following on from the E2100 trial, although have shown an increase PFS and 
ORR with Bz added to a number of different standard chemotherapeutic agents currently used 
for the treatment of mBC, no study has reproduced the results originally observed in the E2100, 
where a doubling of the PFS was observed in the Bz arm. Thus, with the results from the 
AVADO and RiBBON trials, actual clinical benefit of Bz when compared to the increased 
severe adverse events must be considered. The use of Bz in mCRC has proven successful in the 
clinic which further questions the benefit of using Bz for the treatment of mBC, especially with 
Bz being an extremely costly drug. Consequently Bz was withdrawn by the FDA in 20122 for 
use in mBC, however there are still a number of ongoing studies evaluating the use of Bz in 
different breast cancer sub-types and biomarker based studies suggest that the clinical benefit of 
Bz may be masked by treatment of a  mixed population of breast cancer patients. The 
identification of breast cancer sub-populations from these biomarker studies may indicate which 
patients are most likely to benefit from Bz treatment (Schneider et al, 2008; Miles et al, 2013). 
These biomarker studies may also allow potential identification of resistance pathways to Bz 
treatment.   
 
1.7 Modes of Anti-Angiogenic Resistance 
Despite some clinical success being observed with Bz in the treatment of mBC, OS remains 
relatively unchanged and eventually patients relapse. There are several possibilities as to why 
initial response to Bz treatment is not maintained and tumours escape this therapy. One reason 
for eventual resistance to Bz therapy is that tumours become less dependent on VEGF. VEGF is 
crucial in stimulating the process of blood vessel development but maintenance of the 
vasculature may not be dependent on the continual presence of VEGF. Inhibition of VEGF 
signalling may initiate production of other pro-angiogenic factors (FGF-2, PDGF, Delta/Jagged 
family and Angiopoietins) by the tumour or surrounding stroma (Prager et al, 2012) thereby 
allowing progression of the tumour in the presence of Bz. This re-iterates that VEGF targeted 
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treatment such as Bz would prove to be more efficient if administered as first line therapy. 
Secondly, other components of the tumour vasculature, such as pericytes, fibroblasts, 
macrophages and mesenchymal stem cells are not targeted by Bz and have not been considered 
in terms of the role that they may play in the efficacy of drug treatment (Shojaei and Ferrara 
2008; Roland et al, 2009; Prager et al, 2012). Thirdly, anti-angiogenic agents such as Bz, 
although thought to normalise the vasculature, if successful, eventually cause the collapse of 
existing tumour associated vessels. Following this, intra-tumoural hypoxia levels are thought to 
increase. Hypoxia induced post treatment, can induce a number of mechanisms which lead to 
resistance, potentially resulting in selection of more aggressive tumour cells leading to increased 
metastasis (Grepin and Pages, 2010; Loges et al, 2010;  Shojaei, 2012). Fourthly, sprouting 
angiogenesis is not the only process by which a functional vasculature is formed, other 
processes include vasculogenesis, vessel ‘cooption’ and vascular mimicry, which are not 
necessarily dependent on VEGF (Azam et al, 2010 ; Loges et al, 2010). 
 
The existence of biomarkers and polymorphic genetic analysis indicate that certain mutations in 
the VEGF or VEGF receptor gene may render the patients more or less likely to respond to Bz 
treatment. This is turn suggests that only certain individuals will benefit from Bz treatment and 
thus identifying these niche patients may be the key to improving the efficacy of Bz treatment in 
mBC (Schneider et al, 2008; Shojaei, 2012). Lastly, the other possible reason for resistance to 
Bz treatment is the existence of alternative VEGF signalling pathways (Shojaei, 2012). It is 
possible that continual inhibition of VEGF receptor signalling prompts VEGF to find alternative 
receptor pathways such as the recently identified neuropilin receptors. This possibility forms the 
basis of the hypothesis for my PhD project and is discussed in further detail in (section 1. 4).   
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Figure 1.12 Modes of Resistance. There are a number of mechanism of escape for tumours, 
especially after treatment (bottom panel), a more aggressive phenotype evoked by the harsh micro-
environment induced by either targeted vasculature therapy or chemotherapy. Adapted from Loges 
et al, 2010, Mechanism of Resistance to anti-angiogenic therapy and development of third 
generation anti-angiogenic drug candidates. 
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1.7.1 Targeting Neuropilin Receptors 
The rationale for targeting the neuropilin receptors is twofold, (I); there is a wealth of in vitro 
and in vivo data suggesting that the neuropilin receptors are important during the angiogenic 
process and may also directly influence breast cancer activity and (II); in the presence of Bz, the 
neuropilin receptor binding site on VEGF is not inhibited (Figure 1.13). Therefore, it is possible 
that the neuropilin receptors provide an alternative signalling pathway for VEGF165 (Loges et al, 
2010). Additionally treatment with Bz results in increased Np1 expression in patients with rectal 
cancer (Xu et al, 2009) thus may be demonstrated in breast cancer patients. More recently, a 
retrospective biomarker analysis of a proportion of tumour samples (n=462) from AVF2119g 
study (Miller et al, 2005) identified that patients with lower EC Np1 expression tended to 
respond better to combined capecitabine/Bz treatment when considering PFS, however this 
trend did not reach significance (Jubb et al, 2011). Despite this observation not proving 
significant, it provides evidence that Np1 may be a route via which there is escape from VEGF 
from anti-angiogenic therapy. Identifying relevant sub-groups of breast cancer patients is crucial 
in isolating those more likely to respond to Bz treatment. Possible mechanisms for inhibiting 
VEGF165 and Np1 interactions for therapeutic targeting can be categorised as (I) inhibiting Np1 
protein expression, (II) administration of a  peptide that competes with VEGF165 for the Np1 
binding site and (III) inhibition of the  interactions between the neuropilins and the VEGF 
receptors (Gabhann and Popel 2006).  
 
1.8 Conclusion & Hypothesis 
It is evident that tumour angiogenesis is not only a critical but also a complex process in tumour 
progression. The fact that tumour angiogenesis is a multi-step pathway offers many targeting 
options and a number of ‘windows of opportunities’. However, the complexity and mechanism 
of the components regulating the process must be fully understood if successful long term 
therapy is to be achieved. VEGF is a key player in both initiating and maintaining tumour 
angiogenesis and thus is an ideal candidate for anti-tumour targeting. Anti-VEGF therapies have 
shown some clinical success, such as Bz, but unfortunately the efficacy of the treatment is short-
lived since OS of mBC patients remains relatively unchanged in the presence of Bz in 
combination with chemotherapy. The introduction to this project discusses the possible 
mechanisms of tumour escape from Bz treatment, with a particular focus on neuropilins. The 
neuropilins evidently play a role in both enhancing VEGF signalling via VEGF-R1/R2 and by 
independent signalling via NIP, with experimental data revealing the reduction of tumour 
growth via EC regulation in the presence of anti-neuropilin treatment. Based on the information 
available in the literature, the following hypothesis has been proposed (Figure 1.13) and will be 
evaluated in this thesis.  
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Hypothesis: 
“The addition of a neuropilin peptide will increase efficacy of Bz 
therapy in breast cancer.” 
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Bz binding (8-109) 
 
 
NP1/2 
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Figure 1.13Possible Mechanism of Escape:  
A diagram to illustrate the proposed mechanism by which may escape Bz treatment control. (A) 
VEGF can to bind either VEGFR1 or VEGFR2 and neuropilin receptors simultaneously as the 
binding sites on the VEGF gene differ, with VEGFR1 & R2 binding at VEGF exon 3 and 4 
respectively and neuropilin binding occurring at exon 7 of the VEGF gene. (B) In the presence of 
Bz, the VEGF binding site for the neuropilin receptors remains uninhibited potentially providing 
VEGF with an alternative pathway for action.  
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1.8. 1 Project Aims 
The hypothesis will be tested by the following aims: 
1. Investigate protein expression of VEGF165 and it’s four receptors, VEGFR1, VEGFR2, Np1 
& Np2 in the following cell lines: (1) Human Dermal Micro-Vascular Endothelial cells 
(HuDMECs) and (2)  two breast cancer cell lines ( two highly metastatic; MDA-MB-231 
and MDA-MB-436  ). 
2. Investigate the in vitro effects of Bz and four Np1 binding peptides either alone or in 
combination on the functional activity of both endothelial and breast cancer cells. 
Evaluate the most active Np1 peptides identified in vitro, in both the primary and metastatic 
disease in vivo model.  
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EQUIPMENT AND PLASTICS 
ITEM SUPPLIER 
Anaesthetic Machine Biological Services 
7ml Bijou Tubes Corning 
Centrifuge Sanyo Harrier 18/80 
Coverslips Fischer Scientific 
0.5ml and 1.5ml Eppendorf Sarstedt 
Filter Pads Biorad 
Glass Slides Fischer 
1ml Insulin Syringes Biological Services 
Inverted Phase Contrast Microscope Leica 
IVIS Lumina II Caliper 
Micro-CT Machine SkyScanner 
Pasteur Pipettes Costar 
8μM Pore Membrane (Polycarbonate) Neuro Probe 
Pipette Bouy Starlabs 
P2, P10, P20, P200 and P1000 Pipettes Gilson 
P2, P10, P20, P200 and P1000 Pipette Tips StarLabs 
Plate Reader Fluorstar 
Rocking Platform Sanyo 
SDS PAGE Tank Biorad 
Semi-Dry Western Blot Transfer  Biorad 
5ml, 10ml and 25ml Stripettes Corning 
96-well Tissue Culture Flat Bottomed 
Plate 
Costar 
T25cm
3
, T75cm3 and T`175cm
3
 Tissue 
Culture Vented Flasks 
Corning 
Tissue Culture Cabinet Hoods  
(Cell Line & Primary Cells).  
Heraeus 
Vortex Whirlmixer 
ViCell Counter Beckman Coulter 
Western Blot Film GE Healthscience 
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REAGENTS 
REAGENT SUPPLIER 
ABC Standard Peroxidase Kit  Vector 
Acetic acid (Analar)  VWR 
30% Acrlaymide Geneflow 
APS (10%) 
50mg stored at r.tp (500μl dH2O added prior to 
use).  
Sigma 
BCA Solution Sigma 
Bz Roche 
Blocking Milk 
5g dried milk powder in 100ml PBST/TBST 
Marvel 
BSA Sigma 
BSA Standards 
 2mg/ml stock diluted to various 
concentrations (0-1mg/ml) using dH2O. Store 
at 4
0
C. 
Sigma 
saturated Butan-2-ol Sigma 
Caesin Vector 
anti-Caspase 3 antibody () Abcam 
anti-CD34 antibody (ab8158) Abcam 
Copper II Sulphate Solution Sigma 
DAB  
In 2.5ml add 1 drop of buffer, 2 drops DAB 
solution and 1 drop  
Vector 
Developing Solution 
Add 105ml developing solution to 473ml 
dH2O. 
Kodak 
Dimethylformamide  Fischer 
DMEM Media ( with ultraglutamine) 
Cell culture medium used for culturing human 
MDA-MB231 breast cancer cells. 
Supplemented with 5%v/v P/S, 5% Fungizome 
and 10% v/v FCS. Media was stored at 4
o
C 
and was brought to r.t.p prior to use. 
Lonza 
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EBM2 Media Lonza 
Eosin Sigma 
Ethanol (100%) Sigma 
FCS Lonza 
Fibronectin Sigma 
Fixing Solution 
Add 105ml fixing solution to 473ml dH2O. 
Kodak 
Fungizone Lonza 
Gill’s Haematoxylin Sigma 
Anti-goat biotinylated secondary antibody Vector 
Goat Serum Vector 
Growth Factor Reduced Matrigel 
Aliquot and stored at -20
O
c. Defrosted on ice 
prior to use.  
BD Biosciences (VWR Supplier) 
L-Glutamine Lonza 
Hamatoxylin Solution Sigma 
HBSS Promo Cell 
HCL Sigma 
Horse Serum Vector 
Hydrogen Peroxidase Sigma 
HuDMECs Promo Cell 
Isoflurane Biological Services 
anti-Ki67 DAKO 
Lectin Vector 
D-Luciferin, Potassium Salt (#122796) Caliper Life Science 
Mammalian Cell Lysis Kit 
Stored at 4
0
c, bring to r.t.p prior to use.  Add 
200μl of each component to adherent cells in 
culture prior to use 
Sigma 
MDA-MB-231 Human Breast Cancer Cells ATTC- kindly gifted by Dr. Ingunn Holen 
MDA-MB-231 Luciferase Labelled Human 
Breast Cancer Cells 
Caliper Life Sciences, UK 
MDA-MB-436 Human  Breast Cancer Cells ATTC 
Methanol Sigma 
MITC Sigma 
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Anti-mouse biotinylated secondary antibody Vector 
Mouse Serum Vector 
MTS Reagent Promega 
NaOH Sigma 
Naphthol AS-BI phosphate (sodium salt)
  
Sigma 
Anti-Neuropilin 1 (Western Blot Analysis ) Abcam 
Anti-Neuropilin 1 (IHC Analysis) Santa Cruz Biotechnology 
Neuropilin 1 Binding Peptides Prof. Kurt Ballmer-Hofer (in vitro use) 
Severn  (in vivo use) 
Anti-Neuropilin 2 (Western Blot Analysis ) Abcam 
Anti-Neuropilin 2 (IHC Analysis) Santa Cruz Biotechnology 
Paraformaldehye Sigma 
Pararosaniline Sigma 
Penicillin/Streptomycin 
Store at -20
o
C in 5ml aliquots. 
Invitrogen 
PBS for tissue culture Lonza 
PBS Tablets Lonza 
PBST Sigma 
Pimo Hydroprobe 
Pimo antibody () Hydroprobe 
Protease Inhibitor Tablets Roche 
Protein plus Precision Standards Biorad 
PVDF Membrane Millipore 
Rabbit Serum Vector 
Anti-rat Biotinylated Vector 
Resolving Gel 
1.5M Tris HCL pH 8.8 
Geneflow 
RPMI Media 
Used for culturing human MDA-MB-436 
breast cancer cells. Supplemented with 5%v/v 
P/S, 5% Fungizome, 1% L-Glutamine and 
10% v/v FCS. Once supplemented, media was 
stored at 4
o
C and was brought to r.t.p prior to 
use. 
Lonza 
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Saline Field Labs 
SDS (10%) 
10g in 100ml dH2O. Stored at r.t.p 
Biorad 
Sodium acetate trihydrate Sigma 
Sodium Citrate Sigma 
Sodium nitrite  Sigma 
Sodium tartrate (dihydrate) Sigma 
Stacking Gel 
0.5M Tris HCL pH 6/8 
Geneflow 
Stripping Buffer Pierce 
Super Signal West Dura 
Mix 1ml Reagent A and B 
Pierce 
TEMED Sigma 
Transfer Buffer (10x) 
For 1x buffer, add 100ml methonal to 100mls 
10x buffer and make up to 1L with dH2O. 
Stored at r.t.p 
Geneflow 
Tris Base Sigma 
Trypsin/EDTA 
Store at -20
o
C in 50ml aliquots.  
Sigma 
Tween20 Sigma  
anti-VEGF antibody (IHC) Santa Cruz Biotechnology 
anti-VEGF antibody (Western Blotting) Abcam 
anti-VEGF165b R&D systems 
Recombinant VEGF165 
Stock concentration at 2μg/ml stored at -200C. 
R&D systems 
Recombinant VEGF165b 
Stock concentration at 2μg/ml stored at -200C. 
R&D systems 
anti-VEGF-R1 antibody (IHC) abcam 
anti-VEGF-R1 antibody (Western Blotting) Santa-Cruz Biotechnology 
anti-VEGF-R2 antibody (IHC) abcam 
anti-VEGF-R2 antibody (Western Blotting) Santa-Cruz Biotechnology 
Wax pen (IHC) Vector 
Xylene VWR 
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2.1 Cell Culture 
All cell culture work was carried out in a Class II safety cabinet under sterile conditions. The 
cabinets were switched on 15 minutes prior to use and were thoroughly cleaned with 70% 
ethanol before and after use and between different cells lines. A lab coat and gloves were 
worn at all times and all equipment and bottles were cleaned with 70% ethanol prior to 
placing in the cabinet. All reagents used during cell work were opened in the cabinet to 
sustain sterile conditions. A change over time of 10-15 minutes was allowed between 
different cell lines to minimise potential cross contamination.  
2.1.1.Cell Line Characteristics 
The human dermal microvascular endothelial cells (HuDMECs) used for experiments are 
primary endothelial cells derived from the dermis, purchased as proliferating cells from 
Promo Cell, UK: (it is also important to note that the HuDMECs reach senescence at higher 
passages and can also differentiate over time; therefore were always used at passage 6 or 
less). The MDA-MB-436 breast cancer cell lines were obtained from the American Type 
Tissue Culture Collection (ATCC), USA: and the MDA-MB-231 cells (from the ATCC) 
were kindly donated by Dr Ingunn Holen. Both breast cancer cells were isolated by pleural 
effusion from patients with primary adenocarcinomas in the mammary gland. Both the 
MDA-MB-231 and MDA-MB-436 breast cancer cells lines are oestrogen (ER) and 
progesterone (PR) receptor negative and are tumourgenic in vivo (Table 2.1). Two 
metastatic breast cancer cells were used as the main focus was targeting breast cancer cells 
with a metastatic potential. In addition, with the increased interest in personalised medicine 
(Cho et al, 2012)  and the further sub-classification of breast cancer (Kao et al, 200; 
Holliday and Speirs, 2011 ), the use of two metastatic breast cancer cell lines, that are 
seemingly similar were used to allow identification of downstream effectors that may be 
responsible for any differential responses to therapy.  
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 ER 
receptor 
status 
PR 
receptor 
status 
HER 
status 
p53 
status 
Tumourgenicity Breast 
Classification 
MDA-
MB-231 
Negative Negative Negative Mutant Highly 
Metastatic 
Basal-like 
MDA-
MB-436 
Negative Negative Negative Mutant Metastatic Basal-like 
 
 
 
 
 
2.1.2 Cell Sub-Culture 
The HuDMECs were maintained in Microvascular Endothelial Media (EBM-2) 
supplemented with 0.4% ECGS/H, 5% FCS, 10ng/ml epidermal growth factor and 1µg/ml 
hydrocortisone. The breast cancer cell lines were maintained in either DMEM 
Ultraglutamine (MDA-MB-231) or RPMI 1640 media supplemented with 1% L-Glutamine 
(MDA-MB-436) with 10% FCS, 1% P/S & 1% fungizone. Cells were monitored daily using 
an inverted phase light microscope and alternate days cells were washed with PBS/HBSS 
and media replaced to keep the cells nourished. Cells were allowed to proliferate to x~80% 
confluency after which they were harvested. Prior to harvesting, the cell media, trypsin-
EDTA, trypsin inhibitor and PBS/HBSS were brought to room temperature to avoid any cell 
damage.   
When harvesting the HuDMECs, old media was aspirated and discarded, and cells were then 
washed twice with 5ml HBSS to remove any excess FCS in the media, that may have 
inhibited the detachment of the cells from the flask. The adherent HuDMECs were detached 
from the flask by adding 3ml trypsin solution; the detachment of the cells was monitored 
under the microscope until ~90% of the cells were observed to be rounded up. At this point 
the flask was gently tapped to lift the cells from the surface and 3ml of trypsin neutralising 
solution was added. Cells were then centrifuged at room temperature for 5 minutes at 
1000rpm, the supernatant discarded and the cells re-suspended in 3-4ml of cell culture media, 
and the relevant volume of cells was added to a new, sterile T75 flask containing 10ml media 
and then placed in the primary cell incubator (37
0
C, 5% CO2). 
Table 2.1 Breast Cancer Cell Line Characteristics:  
Summarises the properties of the two human breast cancer cell lines used. Although the breast 
cancer cell lines are similar in many aspects, there are mutational differences that could result in 
differential response to treatment. The use of two metastatic breast cancer cell lines may provide 
means of identifying markers or downstream activators involved in resistance to therapy in 
advanced breast cancer. 
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When harvesting the breast cancer cell lines, the same procedure was followed as described 
above except that detachment of the cells was carried out by adding 3ml trypsin solution 
followed by incubation of the cells for no longer than 5 minutes in the 37
o
C cell line 
incubator. The trypsin reaction was inhibited by adding, 7ml of the relevant cell culture 
media; cells were then pelleted at 1000rpm for 5 minutes and re-suspended as previously 
described for the HuDMECs.  
2.1.3 Freezing Cells 
HuDMECs 
Upon receiving a fresh batch of HuDMEC cells, the cells were placed in the 37
o
C incubator 
for a minimum of 2 hours to allow the cells to acclimatise, after which the cells were 
trypsinised and pelleted (section 2.1.2). The cells were re-suspended in Cryo-SFM (serum 
free media) and counted before diluting to a minimum of 1x10
6
 cells/ml. The cryogenic vials 
containing 1ml cells were placed in a Mr Frosty, containing isopropanol solution and stored 
at -20
o
C for an hour and than -80
0
C overnight, to freeze the cells gently,  after which the 
cells were placed in liquid nitrogen.   
Breast Cancer Cells 
The breast cancer cells were frozen down when they were ~ 70% confluent and were still in 
exponential growth phase to ensure that cells would be healthy when thawed for use. Breast 
cancer cells were trypsinised as described above (2.2.1) and centrifuged at 1000rpm for 5 
minutes, the supernatant was discarded and the cells were re-suspended in normal culture 
media containing 10% DMSO. 1ml of the cell solution at a minimum cell density of 5x10
5
 
cells/ml was then aliquoted into cryovials and stored at -20
o
C for an hour and than -80
0
C 
overnight, before moving into liquid nitrogen storage.   
2.1.4 Thawing Cells 
Prior to removing the cells from liquid nitrogen the relevant culture media was pre-warmed 
and 9ml was added to a sterile T75cm
3
 flask. The vial of cells was placed in the 37
o
C water-
bath until ~ 90% of the cell solution had thawed. The vial was thoroughly wiped with 70% 
ethanol, after which the cells were added to the sterile flask and placed in the incubator.  
After 24 hours the media containing DMSO was replaced with fresh media and the cells 
cultured as described previously.  
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2.1.5 Mycoplasma Testing 
Routine mycoplasma testing was carried out by PCR on cell culture on initial arrival and 
every six months thereafter. The cell cultures were also tested after revival from frozen 
stocks.  
2.2 Protein Expression-Western Blotting 
Protein expression was determined using SDS-PAGE/Western Blot analysis, which is a 
highly selective technique that is used for detecting proteins in a given sample.  The proteins 
are resolved by SDS-PAGE and are then detected using specific antibodies raised against the 
protein of interest.  
2.2.1 Protein Extraction 
Cells were grown to 70-80% confluency, then serum starved overnight prior to protein 
extraction. 70-80% confluency is considered optimum for protein extraction as over 
confluent cells generally show reduced levels of protein production. Prior to carrying out the 
cell lysis procedure, the cell lysis buffers were allowed to reach room temperature. 
Following this, conditioned media from the cells was aspirated and collected in a 15ml 
falcon tube for analysis of proteins released by the cells. The media was centrifuged at 
1000rpm for 4-5minutes to remove any debris and 5ml of this conditioned media was 
retained and stored at -20
o
C until use. Protein extraction was carried out using a mammalian 
cell lysis kit (Sigma) which contained 200μl of each of five different denaturing detergents 
(section 2.1) that cause the cell membrane to rupture, allowing cellular proteins to be 
suspended in the solution for subsequent isolation. The cells were washed twice with 5ml 
PBS to remove any residual FCS followed by the addition of 1ml of the mammalian cell 
lysis buffer containing 20µl of protease inhibitor. The cells were then placed on a 
mechanical rocker for 20 minutes at room temperature, then scraped off the surface of the 
flask and added to a 15ml falcon tube. The cell suspension was then syringed using a 25mm 
gauge needle to further disrupt the cell membrane before centrifugation at 1000rpm for 4-5 
minute.  The supernatant containing the proteins of interest was then pipetted into a sterile 
1.5ml eppendorf tube and stored at -20
o
C till required or -80
o
C for long term storage.  
2.2.2 Protein Estimation: Bicinchonic Acid Protein Assay  
Protein quantification is a vital step when investigating protein expression, especially when 
comparing expression levels of a particular protein in a number of different cell types as it 
allows the protein concentration to be normalised between different samples so that the 
differences observed in protein expression can be confidently assumed as a difference in the 
microenvironment in different cell types or treatment groups rather than  any inconsistency 
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in protein levels loaded onto the SDS-PAGE gel. Ideally a minimum of 20µg/sample should 
be loaded on the gel to ensure detection.  
The Bicinchonic Acid Protein Assay (BCA) quantifies protein concentration on the ability of 
proteins to reduce Cu
2+
 to Cu
1+
. BCA is able to then form a complex with the Cu1
+
 ion, 
which in turn causes a colorimetric reaction (from light green to purple) and the intensity of 
the purple colour is directly proportional to the levels of protein in the solution. The assay 
works by generating a standard curve of known protein concentrations (Bovine serum 
albumin, BSA) and then extrapolating the concentrations of the unknown samples from the 
graph plotted (Figure 2.1). The BCA assay was performed in triplicate for individual 
samples each time protein extracts were isolated. 
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2.2.3 SDS-PAGE 
In order to separate the different proteins contained within the each sample, the protein 
samples were resolved on a Sodium Dodecyl Sulfate Polyacrylamide gel Electrophoresis 
(SDS-PAGE) gel. The SDS-gel technique allows separation of proteins on the basis of size 
in the presence of an electrical field.  
Prior to casting the SDS gel, 1.5mm Biorad glass plates were cleaned using 70% ethanol to 
remove any residual particles that may interfere with the even running of the gel. The 
resolving gel was then pipetted between the two glass plates using a 5ml pipette, leaving a 
gap of approximately 1-1.5cm from the top of the plates. A thin layer of water saturated 
Figure 2.1 Protein Estimation-BCA Assay: 
Absorbance values of the standards were plotted onto a graph and then the protein 
concentration of the cell lines were extrapolated from the line of best fit from the standard 
curve. The BCA assay was repeated each time protein lysates were extracted.  
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butan-2-ol was added to the resolving gel (see appendix) to ensure that an even surface was 
produced thus allowing uniform separation of the individual bands in the sample to occur. 
The gel was left to set for ~45 minutes, using the excess resolving gel as a guide and once 
the gel had set, the butan-2-ol was thoroughly washed off using distilled water. The stacking 
gel (see appendix) was then added on top of the resolving gel and a 9 well (1.5mm) comb 
was placed between the two glass plates. The gel was then left to set for 20-30 minutes, 
again using the excess gel as a guide. Once the stacking gel had set, the well combs were 
carefully removed to avoid tearing of the wells. The plates were then placed in the Biorad gel 
running apparatus, the tank was filled and the wells rinsed out with 1x Running Buffer (see 
appendix) to remove any unattached acrylamide. 
Samples were diluted to the same concentration (~20μg/well) and 4x loading dye or 10x 
reducing agent (see appendix) was added to each sample. The samples were then mixed by 
briefly vortexing and centrifuging, prior to further denaturation by heating to 95
o
C for 5 
minutes, with the lids of the tubes open. Using the fine western pipette tips, 10µl of the 
Precision Plus Kaleidoscope protein marker was loaded into the first well and 60μl of each 
sample in the subsequent wells. The SDS tank lid was connected to the Biorad power pack 
and the gel was then left to run at 100V until the markers had appropriately separated. Once 
the gel had finished running, the plates were removed from the apparatus and were carefully 
opened. The stacking gel was removed using the Biorad plate separator and discarded and 
the resolving gel was then placed in 1x transfer buffer (see appendix). 
2.2.4 Western Blotting 
Once the proteins had been separated on the SDS gel, they were transferred onto a PVDF 
membrane using the Semi-Dry western blotter. Prior to loading on the semi-dry blotter, the 
filter pads and the SDS gel were equilibrated in 1x transfer buffer for approximately 20 
minutes. The PVDF membrane was activated prior to use by incubation for 5 minutes in 
methanol and then transferred to the 1x transfer buffer for ~ 10 minutes. Forceps were 
always used to handle the PVDF membrane to minimise any background interference that 
may arise from non-specific proteins.  
Once all the separate components of the western were fully equilibrated, they were loaded 
onto the Semi-Dry transfer blot apparatus. Firstly one of the pre-soaked filter pads was 
placed on the anode side of the apparatus and rolled out using a sterile pipette to ensure 
removal of air bubbles that may interfere with the transfer process. The PVDF membrane 
was then placed on top of the filter pad using tweezers and again rolled out to remove any air 
bubbles. An incision was made at the bottom right hand corner of the membrane for 
orientation in later stages. The SDS gel was then carefully placed on top of the membrane, 
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taking care not to tear the gel and lastly the second filter pad was placed on top if the gel and 
rolled out (Figure 2.2). The power pack was then set at 15V and the blot was left to transfer, 
with the transfer time being dependent on the size of the protein of interest. It is important to 
optimise transfer time, as too little transfer time meant that the proteins did not fully transfer 
onto the membrane and if the transfer time was too long then there was a risk that the 
proteins may transfer through the membrane onto the filter pad.  
 
 
 
 
 
Once the transfer was complete the gel was placed in Commassie Blue Dye to check the 
efficiency of the transfer process. The membrane was transferred to a clear box and blocked 
with either 5% milk or a combination of 3% BSA/5% milk solution for 1 hour to minimise 
non-specific interactions occurring with the antibodies. The blocking solution was then 
removed and the primary antibody, which is raised to recognise a specific epitope within the 
protein of interest was added to the membrane and left to incubate overnight at 4
0
C in milk.  
After the overnight incubation, the membrane was incubated in the primary antibody for a 
further 2 hours at room temperature on the shaker to maximise binding. The membrane was 
then washed with PBST/TBST (see appendix) 3 x10 minutes after which the secondary 
antibody was added to the membrane and left on the shaker for 1.5 hours at room 
temperature. The secondary antibody was specific to the species in which the primary 
antibody was raised and was conjugated with Horse Radish Peroxidise (HRP). The 
membrane was then washed with PBST/TBST 4x 10 minutes following which 500μl of 
chemilluminescence super signal mix (1ml of reagent A & 1ml of reagent B) was added to 
each membrane and incubated for 5 minutes. Excess substrate was removed by blotting 
tissue paper and the membrane was placed between the plastic sheets of an x-ray cassette. 
Figure 2.2: Semi-dry protein transfer set up: 
Proteins move from the negatively charged anode to the positive cathode and are transferred onto 
the PVDF membrane during this movement. The rate of transfer is determined by the size of the 
protein of interest and the voltage set. 
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In the dark room under a red light, an x-ray film was placed above the plastic sheets and the 
lid of the cassette was then closed and the film was exposed for different time intervals.   
After exposure the film was placed in developing solution and gently swirled until bands 
appeared, at which point it was placed into a tray of water to remove any excess developing 
solution prior to placing in fixing solution until the film turned clear. Finally the film was 
rinsed in water and allowed to dry. A number of pilot studies were performed to optimise the 
conditions for each protein and these are detailed in Table 2.2. 
Protein VEGF165 VEGF165b VEGF-
R1 
VEGF-
R2 
NP1 NP2 
Blocking 
Reagent 
5% milk 
in 
1XPBST 
- 5% milk 
in 
1XPBST 
5% milk 
in 
1XPBST 
5% milk 
in 
1XTBST 
5% milk 
in 
1XTBST 
Company Abcam RnD 
Systems 
RnD 
Systems 
Cell 
Signalling 
RnD 
Systems 
RnD 
Systems 
Concentration 1:500 - 1:500 1:1000 1:1000 1:500 
Incubation 
Time 
overnight - overnight overnight overnight overnight 
Temperature 4
o
C - 4
o
C 4
o
C 4
o
C 4
o
C 
Secondary 
antibody 
Anti- 
rabbit 
- Anti-
rabbit 
Anti-
rabbit 
Anti-
sheep 
Anti-
rabbit 
Concentration 1:5000 - 1:5000 1:5000 1:5000 1:5000 
Incubation 
Time 
2 hours - 2 hours 2 hours 2 hours 2 hours 
Temperature rtp - rtp Rtp rtp rtp 
Exposure Time 1 minute - 10 
minutes 
1 hour 5 
minutes 
10 
minutes 
 
 
 
2.2.5 Beta actin Control 
Beta actin (β-actin) is a house keeping gene that is present in all human cells, thus probing 
for it enables protein levels to be measured in each sample and hence acts as a loading 
control. Therefore after exposure and development, the membrane was stripped and re-
probed for β-actin as follows. Firstly the membrane was incubated with 5ml stripping buffer 
Table 2.2 Optimised Protein Detection: 
 The above table summarises the conditions used for the detection of protein expression of 
VEGF165 & VEGF65b and the four receptors. VEGF165b was not detected in any of the cell lines; 
therefore appropriate conditions were not determined. 
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on a shaker for 10 minutes. The membrane was then washed thoroughly with PBST to 
ensure that any trace of the stripping buffer was removed, to avoid the protein of interest 
being removed from the membrane. The membrane was then incubated with a β actin 
primary antibody (1:15,000) for 20 minutes on a shaker at room temperature and then 
washed with PBST on three occasions for 15 minutes. This was followed by 30 minute 
incubation with the secondary antibody (1:30,000) and three further, 15 minute washes, after 
which the membrane was developed (section 2.2.4). Western blotting analysis was 
performed a minimum of three times for each protein of interest in each cell type.  
2.3 Neuropilin 1 Peptides  
Targeting the neuropilin receptors is a feasible option for anti-tumour therapy as not only is 
the receptor expressed on cancer cells but also has shown to influence cancer cell activity. 
ECs also express the neuropilin receptors therefore offering a potential for dual targeting. 
Np1 or Np2 may provide VEGF with an alternative pathway when the classical receptors are 
blocked, thus providing an escape mechanism for the tumours.  
The four neuropilin peptides used in my in vitro experiments were created and kindly 
supplied by Prof. Ballmer-Hofer (Paul Scherrer Institute). The ability of these four peptides 
to bind Np1 has previously been measured using surface plasmon resonance (SPR) analysis 
(Cebe-Suarez et al, 2008). Peptide 1(p1) was derived from the viral member of the VEGF-E 
super-family, and peptide 2 (p2) was essentially designed as a control peptide as it does not 
bind Np1. Peptide 7b (p7b) binds Np1 and is a human VEGF165 variant, whilst peptide 10 
(p10) is a VEGF-E derived peptide that bind Np1 and has the potential to bind Np2 also, but 
this was not confirmed (Table 2.3). Peptides were supplied as lyophilised powder. Upon 
arrival in the laboratory, peptides were dissolved in PBS at a concentration of 1mg/ml and 
then aliquoted and stored in the -80
0
C freezer until use in the phenotypic assays. Due to the 
quantities required for the in vivo studies, additional peptides were ordered from a 
commercial source (Severn Biotech) and treated the same way. 
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PEPTIDE ORIGIN SEQUENCE NP1 BINDING 
1 Viral VEGF-E protein GSGSTRPPR Yes 
2 Human VEGF-A 
protein 
(control) 
GSGSTEPPR No 
7b Human VEGF-A 
protein 
GSGSTDKPRR Yes 
10 Viral VEGF-E protein GSGSTRPPRRRR Yes 
 
.  
 
2.4 Cell Differentiation-Matrigel Assay 
Microvascular endothelial cells are the primary cells involved in angiogenesis and in vitro 
the human dermal micro-vascular endothelial cells (HuDMECs) have the ability to mimic 
the in vivo process of capillary formation when plated on Matrigel. Matrigel is a basement 
membrane preparation isolated from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, 
which is rich in proteins found in the extracellular matrix (BD Biosciences). The major 
component of Matrigel is laminin but it also contains other essential proteins that stimulate 
endothelial cell differentiation (Table 2.4). The Matrigel used in this thesis was growth 
factor-reduced to ensure that sufficient stimulation was observed with the addition of 
exogenous VEGF; if cells have ample growth factors present prior to the assay then the cells 
will be unresponsive to additional growth factors due to saturation. 
Matrigel  Component Properties Reference 
 60% Laminin Stimulates cell adhesion, 
growth, differentiation & 
migration 
Kubota et al,1988 
 30% Collagen IV Promotes adhesion Kubota et al,1988 
Heparan sulphate 
proteoglycans (perlecan) 
- - 
8% Entactin Briding molecule, involved 
in structutal organisation of 
ECM molecules 
BD Biosciences 
 
 
 
Table 2.3 Np1 Binding Peptides: 
Summaries the key properties of the four Np1 peptides that were used in the in vitro and in 
vivo experiments. The peptides were derived from the VEGF-A and VEGF-E (based on the 
Np1 binding sequence of each respective variant).  
Table 2.4 Components of Growth-Factor Reduced Matrigel: 
The different components that are present in the Matrigel are summarised above. Each 
component displays varying properties that allow for the formation of cord-like structures.  
(Table adapted from BD Biosciences datasheet). 
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A confluent flask of HuDMECs (70-80% confluency) was serum starved (using EBM2 
media with 1% FCS) for 6 hours prior to starting the Matrigel assay. The required volume of 
Matrigel was removed from the -20
o
C freezer and allowed to thaw on ice in a fridge 
(Matrigel will set even at slightly elevated temperatures in a fridge-see section 2.4.1 for 
optimisation of the Matrigel assay and Table 2.5 for finalised conditions). All tips and the 96 
well plate(s) used during the assay were pre-chilled at -20
o
C.  
Thirty minutes prior to the end of the 6 hour time point, 40μl of Matrigel was added to each 
test well of the 96 well plate and then placed into a 37
o
C incubator for 30 minutes to allow 
the Matrigel to set. During this time, the HuDMECs were trypinised and re-suspended in 
1.5mls of 1% EBM2 media; 0.5mls of the cell solution was counted using the Vi-Cell 
counter, which gave a total cell count of cells/ml. The relevant volume of cells was then 
added to sterile 1.5ml eppendorfs containing the relevant treatments and mixed by gently 
pipetting. 100μl of the cell/treatment solution was then added to the corresponding wells in 
the 96-well plate, which was allowed to sit without movement to allow the cells to adhere for 
20 minutes prior to incubation at 37
o
C incubator. Each test condition was repeated four times 
per experiment and each experiment was repeated a minimum of three times to allow for 
reproducibility and statistical analysis to be performed (student’s T test or Mann Whitney U 
test, Sigmaplot 11 software). The cells were incubated for 16 hours, after which photographs 
of the whole well were taken. Two parameters for the Matrigel assay were measured; the 
average number of cords per field of view and the average number of branch points (Figure 
2.3).  
          
Cord 
Proliferating 
Island 
 
Branch 
Points 
Figure 2.3 Matrigel  
Representative image of a 
well (96 well plate) in the 
Matrigel assay observed 
using a phase contrast 
light microscope. The 
parameters measured for 
the assay were average 
number of cords and 
branch points. 
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2.4.1 Optimisation of the Matrigel Assay 
Seeding Density 
Optimisation of the number of cells seeded per well in a 96 well plate was carried out prior 
to beginning the test experiments. The seeding densities tested were as follows; 7x10
3
, 
10x10
3
, 12x10
3
 and 15x10
3
 cells per well (Figure 2.4). It was decided that 7x10
3
 and 10x10
3
 
cells per well were too few cells and resulted in minimal cord formation, whereas 15x10
3
 
cells/well resulted in optimal cord formation and thus would be used for subsequent 
experiments.  
 
 
 
 
7x10
3 
cells/well 10x10
3 
cells/well 
12x10
3 
cells/well 15x10
3 
cells/well 
Figure 2.4 Matrigel Seeding Density:  
Cells were plated at varying densities in the presence of 20ng/ml recombinant VEGF165. 
Optimisation of the Matrigel assay determined that sufficient cord-like structures were formed 
using 12x10
3
 cells/well after a 16 hour incubation period.  
 
In Vitro Methods 
 
SAPNA LUNJ Page 74 
 
Determination of VEGF Concentration for the Differentiation Assay 
VEGF is a potent stimulator and required for EC differentiation in vivo and in vitro and thus 
optimising the concentration of VEGF was necessary. A range of VEGF165 concentrations 
(0-50ng/ml) were assessed (Figure 2.5).  From the data obtained it was decided that 20ng/ml 
VEGF165 would be used for subsequent experiments as this yielded a good network of cords, 
demonstrating defined cord formation , minimal proliferating islands and a reasonable 
number of cords which could be modified by treatment. This concentration also correlated 
with the concentration of VEGF used in the literature, where 20ng/ml of VEGF165 is used in 
standard in vitro assays using HuDMECs (Cross et al, 2005; Hsu et al, 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.5 VEGF Concentration Curve.: 
Representative images of the stimulatory effects seen with a range of exogenous VEGF165 
concentrations. From the images it can be observed that HuDMEC tube formation in vitro is 
VEGF165 dose dependent, with stimulatory effects plateuing at 20ng/ml. 20ng/ml was decided 
upon as the optimal dose of VEGF165, with saturation being observed at 50ng/ml VEGF. 
 
10ng/ml no VEGF 5ng/ml 
20ng/ml 50ng/ml 
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Conditions to Optimise Comments Finalised conditions 
Matrigel volume Too little causes meniscus 
effect 
40μl 
Seeding density Too few = no tubule 
formation 
Too many = large clumps 
15,000 cells/well 
Serum starvation time Too short = no response to 
VEGF 
Too long = cell death 
6 hours 
VEGF concentration There is a bell shaped curve 
of response 
20ng/ml 
Experiment incubation 
time 
Too short = little/no tubule 
formation 
Too long = cell death 
16 hours 
 
 
 
2.5 Cell Proliferation 
Cell proliferation is an important step in tumour angiogenesis and tumour development. 
During capillary formation proliferation of endothelial cells behind the leading migrating tip 
cell is important in forming the newly sprouted tubes that give rise to the new tumour 
microvasculature (Gerhardt et al, 2003).  
2.5.1 MTS Assay 
The MTS (3-4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium), assay differs from some of the more classical techniques used for measuring 
cell proliferation e.g. BrDU,  as rather than measuring DNA incorporation, the assay 
quantifies mitochondrial metabolic activity and thus is thought to be a more accurate 
measure of cell viability rather than cell proliferation per se. (Mo et al, 2013; Prabhakaran 
et al, 2013) However, cell metabolic activity it is accepted as an alternative measure for cell 
proliferation. The MTS assay involves a reduction reaction, whereby the MTS compound is 
reduced into formazan (a yellow coloured product) by NO reductase, a mitochondrial 
enzyme, which is produced by metabolically active cells. The quantity of formazan produced 
Table 2.5 Optimised Matrigel Conditions: 
Summaries the optimised conditions to be used in all subsequent Matrigel assays. All aspects of the 
assay are important in ensuring the assay is working effectively to allow for standardised 
conditions when adding different drug treatments. 
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(measured as absorbance at 490nm) is directionally proportional to the number of actively 
metabolic and therefore viable cells present (Promega Datasheet).  
A confluent flask of cells (70-80% confluency) was serum starved (1% FCS medium) for 6 
hours prior to starting the MTS assay. After this time the cells were trypinised and re-
suspended in 1.5ml of 1% FCS media, 0.5ml of which was counted using the Vi Cell counter, 
which gave a total cell count of cells/ml. The relevant volume of cells was then added to 
sterile 1.5ml eppendorfs containing the treatments and mixed by gently pipetting (see section 
2.5.2 for MTS optimisation). 100μl of the treatment solution (treatments made up in 1% 
serum media) was then added to the corresponding wells in the 96-well plate and incubate at 
37
o
C for 24 and 48 hours.  
The experimental incubation times for the assay were optimised at 24 and 48 hours (see 
section), and 3 hours prior to the end of each time point, 20µl of MTS solution was added to 
each well, including the background control wells, the plate was then wrapped tightly with 
tin foil  and then returned to the 37
o
C incubator. Note, the MTS solution is light sensitive, 
thus all experiments were performed in the dark, with all MTS solutions wrapped and stored 
in tin foil to minimise the exposure to natural light. At the end of each experimental time 
point, the absorbance of the samples was measured at 490nm.  
Each test condition was repeated 6 times per experiment and each experiment was carried 
out a minimum of 3 times to allow for reproducibility and subsequent statistical analysis 
(student’s t test or Mann Whitney U test, Sigmaplot 11 software). Analysis of the raw data 
was carried out by subtracting the background control values from each of the test wells, and 
then the data was presented as percentage proliferation compared with the 24 hour cells 
alone control.  
2.5.2 Optimisation of the MTS Assay 
When measuring the effects of drugs on cell proliferation it is essential to establish a time 
point in which the cells are in the exponential stage of growth, thus optimisation of the cell 
density and time were carried out. Also, VEGF has been shown to stimulate endothelial cell 
proliferation therefore optimisation was carried out in the presence and absence of 
exogenous VEGF165. The optimisation of the MTS assay outlined in (Figure 2.6), led to the 
following conditions; 5000cells/well for all four cell types tested and an experimental time 
point of 24 and 48 hours (after 48 hours the rate of proliferation decreased). Only HuDMEC 
proliferation was increased in the presence of exogenous VEGF (20ng/ml) therefore it was 
decided that the MTS for the HuDMECs would be carried out in the presence of recombinant 
VEGF165 (Figure 2.6). The addition of exogenous VEGF165 did not further enhance the rate 
of proliferation of the two breast cancer cell lines; this was expected, as the breast cancer 
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cells already express relatively high levels of endogenous VEGF and the VEGF165 response 
may already be saturated. 
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Figure 2.6 Optimisation of the MTS Assay: 
Experimental variables being measured were cell density, experimental time point and the effects 
of exogenous VEGF on cell proliferation.  The HuDMEC cell proliferation was increased in the 
presence of exogenous VEGF165, whereas no change in the rate of MDA-MB-231 or MDA-
MB-436 breast cancer proliferation was observed when VEGF165 was added to the cells. The 24 
and 48 hour time-points were chosen as optimal experimental times to assess cell proliferation in 
vitro.  
Data presented as mean ±SEM of the raw absorbance data minus the background controls. 
n=2 
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2.6 Cell Migration 
Cell migration is an extremely important step in tumour angiogenesis and metastasis. The 
ECs must be able to move towards a chemotactic factor effectively, to establish local new 
vessels in the developing tumours and the breast cancer cells must be able to effectively 
move through the tumour micro-environment and vascular system to disseminate to distant 
organs to form metastasis.  
2.6.1 Scratch/Wound Healing Assay 
The scratch assay or ‘wound healing’ assay unlike the Boyden Chamber or Transwell 
method does not work on the principle that cells must migrate from an upper chamber to a 
lower chamber towards a chemo-attractant nor does it create a chemo-attractant gradient for 
cells to migrate towards (Figure 2.7). Since cells in the scratch assay are not moving towards 
a growth factor in a unidirectional manner, through a membrane, an anti-proliferative agent 
is usually used to ensure that any observations made in this assay are largely due to effects 
on cell migration and not cell proliferation.  
 
 
 
For this assay, cells were plated (1.5x10
4
 and 2x10
4
, HuDMECs and breast cancer cells 
respectively) into a 96 well plate and left overnight in the 37
o
C incubator to allow the cells in 
each well to form a confluent monolayer. Once a confluent monolayer was achieved, 3µg/ml  
and 30 µg/ml Mitomycin C (MITC) (breast cancer cells and HuDMECs respectively) added 
to each test well and left to incubate for an hour at 37
o
C (see section for scratch optimisation). 
MITC is an anti-proliferative agent and was used to prevent cell proliferation. Since it is a 
Figure 2.7 Principles of the Scratch 
Assay versus the Boyden Chamber 
for measuring cell migration: 
The Boyden Chamber allows for 
directional migration to be assessed 
as the use of a top and bottom 
chamber allows for a chemotactic 
(e.g.VEGF) gradient  
Cells 
Scratch 
Well 
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toxic agent, all media, tips, plates and eppendorff tubes that were in contact with MITC were 
soaked in 4% sodium hydroxide solution for a minimum of 12 hours to neutralise the toxic 
activity of MITC after which they were washed with running tap water and disposed of as 
usual.  
After incubating the cells with MITC for an hour, the media was removed and 100µl fresh 
media was added to the cells and replaced in the incubator for 30 minutes, during which time 
the relevant treatment solutions were prepared. After 30 minutes, a scratch was made in the 
middle of each well using a 100µl Gilson pipette tip. The media was then aspirated off and 
the cells were gently washed once with 100µl PBS to remove any cells and debris from each 
well. 100µl of the treatment solution (treatments made up in 1% serum media) was then 
added to each relevant well, after which the cells were imaged at 0 hours time point and then 
left to incubate until the next time point (32 hours and 24/48 hours, HuDMECs and breast 
cancer cells respectively).  
Each test condition was repeated 4 times per experiment and each experiment was carried 
out a minimum of 3 times to allow for reproducibility and statistical analysis (student’s t test 
or Mann Whitney U test, Sigmaplot 11 software). Analysis of the raw data was carried out as 
follows, the percentage closure of the gap was calculated using Image J software (distance of 
gap in pixels) and then presented as  percentage gap closure compared with the relevant 
control (VEGF alone control for the HuDMECs and the cells alone control for the breast 
cancer cells).  
Optimisation of the Scratch Assay 
The stimulatory effects of exogenous VEGF165 on breast cancer cell migration in a 96 well 
format were assessed. However, addition of VEGF165 did not enhance breast cancer cell 
migration, so this was not included in the assay (Figure 2.8). Optimisation of the HuDMECs 
in this assay had recently been carried out within the lab and therefore was not repeated.  
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MITC Optimisation  
MITC was used in the scratch assay to minimise cell proliferation to ensure that the gap 
closure measured was due to cell migration. The concentration of MITC when working with 
the HuDMECs had been previously optimised at 30µg/ml and therefore was not repeated. 
The breast cancer cells appeared more sensitive to MITC treatment in comparison to the 
HuDMECs and therefore a lower concentration was used (1-5µg/ml) (Figure 2.9).  A final 
concentration of 3µg/ml MITC was determined as optimal with a balance between the anti-
proliferative effects of MITC without being cytotoxic to the cells or causing complete 
detachment from the surface of the wells.  
 
 
Figure 2.8 Optimisation of the Scratch Assay  
(A)Representative image of MDA-MB-231 migration in scratch assay (in the absence of 
MITC). A scratch was made in a confluent monolayer of cells, after which treatments were 
added. Cell migration was measured by the ability of both the HuDMECs and the breast cancer 
cells to ‘close’ the gap created by the initial scratch (B) Assessing the effects of exogenous 
VEGF165 on breast cancer migration.  
 
0 Hours 48 Hours A 
B 
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2.6.2 Boyden Chamber 
The Boyden chamber was used to confirm the data observed with the scratch assay. 
HuDMECs and the breast cancer cells were serum starved for 24 and 6 hours respectively 
prior to setting up the assay.  
The 8μM pore membrane was coated in 50ng/ml fibronectin on both sides for 10 minutes 
each and then air dried for a further 10 minutes. The membrane was than equilibrated in 
growth medium for 10 minutes on both sides and then air-dried again for 10 minutes.  Whilst 
the membrane was being coated the cells were trypinised, pelleted and counted. 
Approximately 27.5μl-28μl of treatment media was pipetted into the bottom chamber, the 
fibronectin membrane was then laid on top followed by the gasket and the top chamber 
which was bolted into place. 1.5x10
3
 and 2.0x10
3 
cells/well (HuDMECs and breast cancer 
cells respectively) were pipetted into the top chamber and the chamber was then incubated at 
37
o
C for 4 or 24 hours (HuDMECs and breast cancer cells respectively). After the incubation 
period, the chamber was removed from the incubator and disassembled, the membrane was 
removed using tweezers and the top side of the membrane was scraped gently to remove any 
cells that had not migrated during the 4 or 24 hour experimental time. The membrane was 
then washed with PBS for 5 minutes and the cells were fixed by washing the membrane with 
100% methanol for 5 minutes. Gills hemotoxylin (4%) was then used to stain the cells (for 5 
minutes) after which any excess stain was removed by washing the membrane with distilled 
water for 5 minutes. The membrane was then mounted using DPX on a slide, and was 
imaged for analysis (Figure 2.10). One central image was taken of each well and the number 
Figure 2.9 MITC Concentration Curve: 
The above graphs show the effects of MITC treatment on (A) MDA-MB-436 and (B) MDA-
MB-231 breast cancer cell proliferation after 48 hours incubation with MITC. The 
concentration curve was carried out to allow the optimal concentration of MITC to be used in 
the scratch assay.  
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of cells that had migrated per field of view were counted and presented as a % of the VEGF 
control cell migration. The Boyden chamber was carried out in triplicate to allow for 
reproducibility and statistical analysis to be performed (student’s t test or Mann Whitney u 
test, Sigmaplot 11 software).  
    
 
 
 
2.7 Statistical Analysis 
For all the in vitro assays, all experiments were carried out in triplicate (minimum). 
Following assessment of normality, statistical analysis was performed using either the 
student’s t test or the Mann Whitney U test (Sigmaplot 11 software). Statistical significance 
was considered at p=0.05.  
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Boyden Chamber: 
Representative image of MDA-MB-231 breast cancer cell migration after 48 hours (x20 and x 
40 magnification) 
 
In Vivo Methods 
 
SAPNA LUNJ Page 83 
 
2.8 In Vivo Studies 
In vivo experiments for cancer research play an important part in understanding the 
mechanism by which different anti-cancer treatments exert inhibitory effects. In vitro work is 
important when focusing on a particular pathway or receptor/ligand interactions whereas in 
vivo work allows for a more dynamic assessment, with all components of the tumour micro-
environment potentially influencing response. 
2.8.1 Primary Breast Cancer Growth: Sub-Cutaneous Model 
Animal Husbandry 
CD1 nude female mice were delivered at 4-5weeks of age from Charles River, the animals 
were allowed to acclimatise to the housing facility (University of Sheffield, Field Labs) for a 
one week period following which experimental procedures were performed. Animals were 
exposed to a 12:12 hour light-dark cycle in humidity and temperature controlled 
environment and allowed access to water and food ad libitum. CD1 nude mice are immuno-
compromised used in xenograft models, which allow for the growth of human tumour cells, 
and are therefore housed in a ‘sterile’ environment, where all food and bedding is 
appropriately autoclaved. For recovery procedures such as tumour implantation, sterile 
techniques were essential and were carried out where possible. All surfaces and equipment to 
be in direct contact with the animals were sprayed and cleaned with 70% ethanol. All 
procedures were performed in accordance with UK Home Office Animal Procedures Act 
(1986) under project license number 40/3531 (NJB). 
Growth Kinetics 
MDA-MB-436 green fluorescent protein (GFP) labelled breast cancer cells were used for the 
in vivo experiments as a result of the in vitro characterisation stage (Chapter 4). A pilot 
study was initially performed to determine the appropriate cell densities to determine growth 
kinetics and to establish a minimum treatment window. MDA-MB-436 breast cancer cells 
were implanted (1 x 105, 1x106 and 5x106; in a total volume of 100µl) via a sub-cutaneous 
(s.c.) injection into the left flank of CD1 nude females (n=3/4 per group) under gas 
anaesthesia (isoflurane).  
The animals were then monitored for signs of tumour development three times a week. Once 
a palpable tumour developed, tumour volume was measured three times a week using 
callipers until the end of procedure (EOP).  Tumour volume was calculated using the 
following calculation: (a2 x b)/2, where a, is the smaller tumour diameter and b is the larger 
diameter. The EOP was determined when either (1) Home Office maximum tumour diameter 
permissible was reached (15mm, NCRI guidelines, Workman et al. 2010), (2) the tumour 
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ulcerated or (3) animals lost greater than 10% body weight due to tumour development. 
Following cull, tumours were excised, divided into two and either formalin (10%) or zinc 
fixed prior to wax embedding. Tumour sections were cut (5μM from the blocks) and used for 
optimisation of the immunohistochemistry (IHC) staining protocols (Section 2.8.2). The 
growth kinetics study determined that the optimal cell density for MDA-MB-436 tumour 
implantation into the flank (s.c) as 1x106/100μl as this cell density demonstrated 100% 
tumour take and a minimum treatment period of approximately four weeks thus was used in 
all subsequent sub-cutaneous studies.  
Combination Studies  
CD1 nude females were anaesthetised using isoflurane and each mouse was subsequently 
injected subcutaneously (s.c.) with 1x106 (in a total volume of 100µl) MDA-MB-436 breast 
cancer cells into the left flank region. The animals were placed in a 37oC incubator to allow 
recovery from the anaesthesia and then returned to the cages. The animals were monitored 
three times a week for signs of tumour development and body weight was measured 
throughout the entire experiments. Once a palpable tumour was detected (on average 2 
weeks post implantation of MDA-MB-436 GFP breast cancer cells), calliper measurements 
were taken three times a week, when tumour volume reached 100mm3 treatment began 
(approximately four weeks post implantation of MDA-MB-436 GFP cells). A treatment 
regime was established on the basis of previous literature available on pre-clinical work 
carried out using Bz (Higgins et al, 2007; Xue et al, 2008; Borgan et al, 2012). Bz and the 
control vehicle for Bz (CV) were administered via intra-peritoneal (i.p.) injection, twice 
weekly as was administration of p7b and p10. In the Bz and peptide combination groups, Bz 
was administered 1 hour prior to peptide injection. 
During the treatment period tumour growth was quantified three times a week and EOP was 
determined as described in the growth kinetics section. Fluorescently labelled pectin (inject a 
1/4 dilution in 200μl from 1mg/ml stock/ 20g mouse) and pimonidazole (pimo; 60mg/kg) 
were injected intravenously (i.v.) five minutes and two hours prior to culling respectively to 
allow for post in vivo staining. Lectin identifies functional vessels (Hunter et al, 2006) and 
pimo is a standard marker used to identify areas of hypoxia (Przybyla et al, 2012; Sun et al, 
2012). After culling tumours were removed, divided in two, formalin fixed prior to wax 
embedding for IHC analysis or snap frozen (in OCT buffer) using liquid nitrogen for protein, 
RNA, lectin or pimo analysis. In addition, lungs, liver, kidney and spleen were also removed, 
divided in two and formalin fixed or frozen.  
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2.8.2 Ex Vivo Analysis of Tumour Sections and Normal Tissue 
Post in vivo analysis of the tumour is important as it allows for differences in morphology, 
receptor/ligand expression and the vasculature in the control and treated tumour sections to 
be determined. This is allows for assessment of how a drug exerts its effects which is 
especially important in cancer research especially when determining how tumours initiate a 
resistance response to therapy. Analysis of normal tissue is also important to determine any 
off-target effects of drug treatment. 
Haematoxylin and Eosin (H&E) Staining 
Morphology of the tumour and the organs is assessed using H&E staining. Tumour necrosis 
can also be quantified using a H&E stain. The sections were de-waxed in xylene twice for 5 
minutes each to remove the paraffin from the tissue sections. After which the sections were 
dehydrated in a series of alcohol incubations for 3 minutes each (100% EtOH, 100% EtOH, 
95% EtOH and 70% EtOH).  The sections were then washed with dH20 twice for 3 minutes 
each and then stained in Gill’s Haematoxylin (for nuclei staining) for 5 minutes and then 
‘blued’ under running water until the excess stain was removed. The sections were then 
counterstained with Eosin (cytoplasmic staining) for 1 minute and then re-hydrated through 
the alcohols, incubated in xylene twice for 15 minutes each and then mounted with 
coverslips with DPX and left to dry for a minimum of 48 hours. 
Immunohistochemistry  
Post analysis of the tumour sections was carried out using Immunohistochemistry (IHC). 
IHC staining is a useful tool for assessing differences in the molecular phenotype of the 
tumour under different treatment conditions. It is important to be able to measure these 
differences as it provides useful information with regards to the potential mechanism of a 
drug or specific treatment group.  
Paraffin embedded tumour sections were de-waxed in xylene twice for 5 minutes each to 
remove the paraffin from the tissue sections. After which the sections were hydrated in a 
series of alcohol incubations for 3 minutes each (100% EtOH, 100% EtOH, 95% EtOH and 
70% EtOH).  The sections were then washed with dH20 twice for 3 minutes each. 
Horseradish Peroxidise (HRP) was used as the antigen detecting method in this project, thus, 
endogenous peroxidises activity must be blocked to minimise non-specific staining. In order 
to minimise endogenous peroxidise activity, the tumour sections were quenched with 
3%methnaol/hydrogen peroxidise for 30 minutes at room temperature. The sections were 
then washed once in PBS for 5 minutes and then antigen retrieval was carried out in sodium 
citrate buffer (appendix). Antigen retrieval is required when working with formalin fixed 
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sections, as the formalin can form cross links in the sample, and potentially mask the antigen 
epitopes, which require unmasking to allow the antibody access to the desired antigen 
epitope in the tissue section.  
After antigen retrieval, the sections were washed in PBS once for 5 minutes and then 
blocked in blocking serum for an hour at room temperature to minimise non-specific binding 
of the antibody to other non-relevant epitopes. The blocking serum was made up of 10% 
from the species in which the secondary antibody was raised. After the blocking step, the 
primary antibody was added to the tissue and incubated for either an hour at room 
temperature or overnight at 4oC, depending on the stain (Table 2.6). The sections were then 
washed three times for 5 minutes each in PBST after which the biotinylated secondary 
antibody was added to the sections and incubated at room temperature for an hour. During 
this secondary antibody incubation the ABC (Avidin Biotin Complex) solution required for 
recognising the biotiylated secondary antibody was prepared and allowed to set for a 
minimum of 30 minutes. After the secondary antibody step, the tissue was washed 3 times 
for 5 minutes each in PBST and then the ABC solution was added and allowed to incubate 
for 30 minutes at room temperature. The sections were then washed twice for 5 minutes each 
in PBST and incubated with DAB solution for 2-10 minutes or until brown the DAB stain 
was visible. The sections were then washed in dH2O for 5 minutes, and then ‘blued’ for 30 
seconds in Gill’s Haematoxylin. After which the sections were washed in running water for 3 
minutes (or until all the excess haematoxylin was removed) and then de-hydrated through a 
series of EtOH washes for 3 minutes each (70%, 95%, 100% and 100%). The sections were 
then left in xylene mount twice for 10 minutes each and then mounted with a glass coverslip 
using DPX. The slides were allowed to dry for 48 hours before imaging or analysis could be 
carried out. The conditions used for each protein/receptor is detailed in Table 2.6. 
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Factor Company Antigen 
Retrieval 
Method 
Antigen 
Retrieval 
Buffer 
Blocking  10an 
Conc. 
20 Ab Conc. 
VEGF Santa-
Cruz 
Microwave Sodium 
citrate 
serum 1:100 
overnight at 
40C 
1:250 for 1 
hour 
VEGF-R1 Santa-
Cruz 
Heat 
Pressure 
Sodium 
citrate 
serum 1:100 
overnight at 
40C 
1:250 for 1 
hour 
VEGF-R2 Santa-
Cruz 
Heat 
Pressure 
Sodium 
citrate 
serum 1:100 
overnight at 
40C 
1:250 for 1 
hour 
Np1 Santa-
Cruz 
Heat 
Pressure 
Sodium 
citrate 
serum 1:100 
overnight at 
40C 
1:250 gor 1 
hour 
Np2  Heat 
Pressure 
Sodium 
citrate 
serum 1:100 
overnight at 
40C 
1:250 for 1 
hour 
CD34 Abcam Heat 
Pressure 
Sodium 
citrate 
serum 1:50 
overnight at 
40C 
1:250 for 1 
hour 
Ki67 DAKO Heat 
Pressure 
Sodium 
citrate 
serum 1:100 for an 
hour at room 
temperature 
1:250 for 1 
hour 
Caspase 3 Abcam Heat 
Pressure 
Sodium 
citrate 
serum 1:50 for an 
hour at room 
temperature 
1:250 for 1 
hour 
 
 
 
IHC Analysis 
CD34 staining was analysed using the chalkley grid method with 5 regions of the tumour 
section being analysed. Ki67 and Caspase 3 staining was analysed by imaging 5 regions of 
each tumour section and the number of positively stained cells were counted and the average 
of the 5 regions was calculated.  
 
Table 2.6 IHC Conditions: 
The table summaries the optimised conditions used in the IHC staining protocol for each of the 
different proteins of interest that was required for post-in vivo tumour analysis.  
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Chalkley Grid 
H&E stains were performed prior to necrosis being established. The chalkley grid was used 
to measure tumour necrosis in the tumours. The 25-point grid was placed in the lens of the 
Leica upright microscope and the number of corresponding points that were in contact with 
both a necrotic area and a viable area to allow percentage necrosis to be calculated. Necrosis 
scoring was performed on the entire tumour tissue to accurately measure the level of 
necrosis.  
 
    
   
 
        
 
 
 
 
 
 
Caspase 3 
positive 
stained cells 
Ki67 positive stained cells 
CD34 positive stained Vessel 
T 
N 
H&E staining, 
identifying 
areas of 
necrosis (N) in 
the tumour 
tissue (T) 
Figure 2.11  Markers of Tumour Activity: 
Representative images of the different parameters measured to assess the effects of drug 
treatment on the tumour. H&E staining allows analysis and quantification of tumour 
morphology and necrosis. Ki67 measures tumour cell proliferation. Caspase 3 measures 
apoptotic activity and CD34 quantifies newly formed vessels 
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2.8.3 Bone Metastasis Model 
Bone metastasis is a frequent occurrence in breast cancer, and is more commonly the cause 
of morbidity and mortality then the primary disease itself (Lu et al, 2009) and therefore is an 
important process to investigate.  
Models of Bone Metastasis 
There are three commonly used models for assessing bone metastasis using injection of 
tumour cells, (1) intra-cardiac, (2) intra-tibial and (3) mammary fat pad (Campbell et al, 
2012). All three offer advantages as models of bone metastasis depending on the primary 
aim of investigation. The intra-cardiac model allows assessment of the tumour cells to 
migrate and survive in the bone environment (and other metastatic sites) and form 
established tumours. Whereas the intra-tibial model looks more closely at the interaction of 
the tumour and surrounding bone cells once the tumour cells have successfully established 
themselves in the bone environment (Campbell et al, 2012). The mammary fat pad (MFP) 
model does not consistently result in metastasis to the bone from the primary site and very 
few cell lines have success in this model, with the most commonly used cell line being the 
4T1 cells (Campbell et al, 2012). Since we were interested in the effects of Bz on reducing 
the metastatic tumour burden, the intra-cardiac model of bone metastasis was most 
appropriate, and we had already determined that the MDA-MB-231 cell line pre-dominantly 
metastasises to the bone when administered via this route (Yoneda et al, 1994; Yoneda, 
1997; Jenkins et al, 2005). 
IVIS Lumina II Imaging 
The IVIS Lumina II imaging system allows for live non-invasive imaging of pre-clinical 
tumour models over time, which allowed monitoring and quantification of tumour 
metastasis/burden in the intra-cardiac model. In the bioluminescent system, tumour cells 
tagged with luciferase are injected into the animals. D-Luciferin (firefly potassium salt) is a 
freely diffusible organic compound that is oxidised by luciferase (tagged to the tumour cells) 
to oxyluciferin in the presence of oxygen and co-factors, ATP and Mg2+. This oxidation 
reaction at 370C is visualised at ~ 560nm (Caliper Life Sciences, UK).  
Animal Husbandry 
Athymic BALB/C nude female mice were delivered at 4-5 weeks of age from Harlan, the 
animals were allowed to acclimatise to the housing facility (University of Sheffield, Field 
Labs) for a one week period following which experimental procedures were performed. 
Animals were exposed to a 12:12 hour light-dark cycle in humidity and temperature 
controlled environment and allowed access to water and food ad libitum. BALB/C nude 
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mice are immuno-compromised and are therefore housed in a ‘sterile’ environment, where 
all food and bedding is appropriately autoclaved. For recovery procedures such as tumour 
implantation, sterile techniques were essential and were carried out where possible. All 
surfaces and equipment to be in direct contact with the animals were sprayed and cleaned 
with 70% ethanol. All procedures were performed in accordance with UK Home Office 
Animal Procedures Act (1986) under project license number 40/3531 (NJB). 
2.8.4 Intra-cardiac Bone Metastasis Model 
Six week old BALB/C nude females were anaesthetised using isoflurane (2.5%) and each 
mouse was subsequently injected via an intra-cardiac injection into the left ventricle with 
luciferase2 tomato labelled MDA-MB-231 breast cancer cells (1x105/100μl). MDA-MB-231 
cells were used in this model because they have previously been shown to metastasise to the 
bones following intra-cardiac injection (Brown et al, 2012) whereas ‘homing’ of MDA-MB-
436 breast cancer cells via intra-cardiac injection to the bone in vivo has not been published 
(PubMed). The animals were placed in a 37oC incubator to allow recovery from the 
anaesthesia and returned to the cages. Two days after the initial injection of MDA-MB-231 
cells the animals were anaesthetised and imaged using the IVIS Lumina II (described 
above).  
After injection of cells into the left ventricle, generally the tumours cells initially migrate to 
the skull of the animal, after which the cells then slowly begin to migrate through the body 
and eventually form distant metastasis in the bones. Animals were imaged twice a week, 
once a signal was detected in any of the hind legs, treatment with either Bz (0.1mg/kg and 
0.5mg/kg) or the control vehicle for Bz (CV) was commenced (twice weekly i.p injection, 
n=10/group). IVIS imaging was carried out to monitor tumour growth in the bone twice a 
week on the same day as the i.p injections. Once treatment began the experiment lasted for a 
maximum experimental time of six weeks. During this time the animals were monitored 3 
times a week, body weight was measured throughout the entire experiment, if a loss of more 
than 10% body weight was observed, the animal was culled. Neurological side effects, such 
as the ability to walk properly were also monitored throughout the entire experiment to 
ensure that brain metastasis had not occurred.  At the end of the experiment the hind legs of 
the animals that had a tumour signal were removed.  The skin and muscle was removed from 
the bone and then the harvested tibia was fixed in ice-cold 4% paraformaldehyde (PFA) 
solution (appendix) that was freshly prepared at 4oC for a maximum of 72 hours. Once 
fixed, the bones were scanned using the X-ray computated micro-tomograph (Micro-CT- 
Skyscan), after which the bone tissue was decalcified at 4oC using an EDTA decalcifying 
buffer (appendix). Decalcification removes the mineral from the bone to preserve the 
integrity of bone elements. The decalcification process takes 14-18 days, during which time, 
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fresh decalcification buffer was added every 2 days to ensure complete removal of calcium 
salts. Once the bones were decalcified, they were washed in 1xPBS three times for an hour 
each, at room temperature, after which the bones were wax embedded. 
2.8.5 Ex Vivo Analysis of Bone Sections  
IVIS Analysis 
Tumour burden analysis was performed (from ventral images) with use of the Living Image 
acquisition and analysis software (Caliper Life Sciences, UK). Signal intensity was 
quantified as the total photon count, manually selected within individual regions of interest 
(ROI) present in each animal (Figure 2.12 and Figure 2.13).  
                
 
 
 
 
 
 
Figure 2.13  
Hind Limb Tumour Burden 
The total radiance 
corresponding to tumour 
burden in each individual 
animal for the hind limbs only 
is the sum of the radiance in 
each of the ROIs drawn around 
tumours in the hind limbs only. 
Figure 2.12  
Total Tumour Burden 
The total radiance 
corresponding to tumour 
burden in each individual 
animal is the sum of the 
radiance in each of the ROIs. 
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Micro-CT 
Prior to decalcification, micro-CT analysis was performed using the Skyscan 1172 X-ray 
micro-CT (Skycan) on representative animals (n=3/group). Imaging was carried out at a 
voltage of 49kV and a current of 200μA, an aluminium filter of 0.5mm and a pixel size set to 
a dimension of 4.3μm, with scanning initiated from the growth plate of the tibia. Cross-
sectional images were reconstructed using NRecon software (version 1.4.3 Skyscan). 
Following re-construction trabecular volume, trabecular number and thickness amongst other 
parameters were also defined using a manual drawing tool on the 2D acquisition images. 3D 
modelling and analysis to measure bone mineral density were performed using CTAn 
software (version 1.5.02). Below is a representative image (Figure 2.14) of the 
reconstructions of the micro-CT scanned bones. These images were used to manually draw 
around the trabecular bone region, from which the bone histophometry parameters were 
calculated.  
 
H&E Staining 
Bone sections (3μM) were incubated in xylene twice for five minutes each, and hydrated 
through a series of alcohol (IMS) washes (99% x2, 95% x1 and 70% x1) for five minutes 
each. Following de-hydration, the bone sections were washed with tap water for a minutes, 
incubated in Gill’s II haematoxylin for 90 seconds and ‘blued’ in running tap water for five 
minutes. The sections were then incubated in 1% aqueous eosin (with 1% calcium carbonate) 
for five minutes, washed in tap water for 30 seconds and then hydrated through a series of 
alcohols for ten seconds each (70%, 95%, 99% x2). The sections were then incubated in 
xylene for three minutes and the mounted with DPX and left to dry prior to analysis or 
imaging. 
Figure 2.14  
Micro-CT reconstruction 
Representative images of the 
micro-CT scan that were used 
to measure bone density 
parameters.  
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TRAP Staining 
Tartrate-resistant-acid-phosphatase (TRAP) staining is a marker for osteoclasts. Bone 
sections (3μM) were de-waxed and hydrated (as in the H&E protocol) and then incubated in 
pre-warmed (2-4 hours) acetate buffer (appendix) in a pre-warmed coplin jar at 37oC for 
five minutes. The bone sections were then incubated in Napthol/dimethylformamide buffer 
(appendix) for thirty minutes at 37oC. The sections were then transferred and incubated in 
sodium nitrite solution (appendix) for fifteen minutes, after which the sections were rinsed 
gently in running tap water and counter-stained for twenty minutes with Gill’s haematoxylin 
and ‘blued’. The bone sections were then de-hydrated quickly through ethanol and mounted  
in DPX as in the H&E staining protocol. TRAP stained osteoclast were quantified (per mm 
trabecular bone surface not in contact with the tumour) using a Leica RMRB upright 
microscope with a 10x objective and Osteomeasure software (Osteometrics 31). Osteoblast 
quantification was performed on the same sections that were TRAP stained. Osteoblast were 
identified and quantified based on morphology.  
2.8.6 Statistical Analysis 
Following assessment of normality, statistical analysis was performed using either the One 
Way ANOVA followed by the Holm-Sidak post-hoc test or the Kruskal-Wallis (Sigmaplot 
11 software).  
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3. Introduction 
Microvascular endothelial cells are the key components of angiogenesis, and when activated 
undergo a number of key steps that leads to the formation of new vessels from the pre-
existing vasculature. VEGF was initially identified as a vascular permeability factor, acting 
primarily on endothelial cells (Senger et al. 1983) and over the years it has become apparent 
that VEGF is important in exerting stimulatory effects on survival, migration, proliferation 
and differentiation of endothelial cells.  
 
The expression of VEGF-R1 and VEGF-R2 on endothelial cells has been well defined as has 
the functional role of VEGF-R2 on these cells. The role of VEGF-R1 has for a long time been 
thought to be solely as a negative regulator of VEGF function. However, it has become 
apparent that VEGF-R1 also plays an important role in promoting tumour angiogenesis (Zeng 
et al, 2001). The dual role that VEGF-R1 plays in tumour angiogenesis may be important to 
assess, if the role of VEGF-R1 in endothelial cell function is unclear, the implications of 
blocking this receptor alongside VEGF-R2, may not be clearly understood which could result 
in ineffective use of receptor targeting agents such as Bz. 
 
The neuropilin receptors have been identified as alternative VEGF receptors and the role 
played by Np1 in endothelial activity in vitro appears to be increasingly evident. There is 
evidence to suggest that Np1 plays an important role in EC migration and differentiation thus 
the following experiments aimed to assess whether 4 Np1 peptides exerted any biological 
activity in inhibiting HuDMEC function in a number of in vitro functional assays. If any 
inhibitory effects with the Np1 peptides were observed, combination experiments with Bz 
were carried out.  
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3.1 Materials & Methods 
Initially, Western blot analysis was carried out to establish VEGF and VEGF receptor 
expression (section 2.2.4) on HuDMECs. Cells were serum starved overnight in 1% serum 
media after which protein was extracted and quantified using the BCA method. The samples 
were stored at -80oC in aliquots until required. Once receptor expression was established 
functional angiogenesis related assays were performed.  
The Matrigel assay (section 2.4) was used to measure the effects of Bz, the four Np1 peptides 
and a commercially available Np1 and Np2 blocking antibody on HuDMEC differentiation in 
vitro. The Matrigel assay mimics the process of tubular morphogenesis and capillary 
formation resulting in the formation of cord like structures in vitro. HuDMECs were serum 
starved for 6 hours in 1% serum media to deplete the cells of endogenous growth factors, so 
that the effects of exogenous VEGF165 at a known concentration (20ng/ml) could be analysed. 
HuDMECs were then plated on growth factor reduced Matrigel in the presence or absence of 
20ng/ml VEGF165 either alone or in combination with the above treatments and then 
incubated at 37oC for 16 hours, after which images were taken and then analysed. Data from 
the Matrigel assay is presented either as percentage cord or branch point formation compared 
with the VEGF165 alone control (as all drug treatments were carried out in the presence of 
exogenous VEGF165).  
The MTS assay (section 2.5.1) was used to measure the effects of Bz and the four Np1 
peptides on HuDMEC proliferation in vitro. HuDMECs were serum starved for 6 hours in 1% 
serum media to deplete the cells of endogenous growth factors. HuDMECs were plated in the 
presence or absence of 20ng/ml VEGF165 either alone or in combination with the treatments 
and incubated at 37oC for 24 and 48 hours. The MTS solution was added to the cells 3 hours 
prior to the end of each experimental time point, after which absorbance readings were taken. 
Data from the MTS assay is presented as percentage absorbance compared with the VEGF165 
alone control at 24h (as all the drug treatments were carried out in the presence of exogenous 
VEGF165).   
The scratch assay (section 2.6.1) was used to measure the effects of Bz and the four Np1 
peptides on HuDMEC cell migration in vitro. A central scratch was made on a confluent 
monolayer of HuDMECs and then incubated with 1% media alone or media containing 
20ng/ml VEGF165 in the presence or absence of the treatments at 37oC for 32 hours. Images of 
the gap were taken at 0 and 32 hours after which the gap closure was calculated using ImageJ 
software (version 1.42q). Data from the scratch assay is presented as percentage gap closure 
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compared with the VEGF165 alone control at 0 hours (as all the drug treatments were carried 
out in the presence of exogenous VEGF165).    
All assays that investigated the effects of Bz in vitro, also included a control vehicle (CV). In 
breast cancer patients, Bz is reconstituted in this control vehicle and then administered via i.v. 
infusion (Avastin® SPC, 2010). Thus, it was vital to include this control, in order to 
confidently attribute any biological effect observed with Bz, to the targeted therapy itself and 
not due to non-specific actions of the vehicle components.  
 
Statistical Analysis 
After assessment of normality statistical analysis was performed using a student’s t test or 
Mann-Whitney U Test (Sigmaplot 11 software).  
 
3.2 Results 
3.2.1 Protein Expression  
VEGF protein expression was detected in the cell lysate of cultured HuDMECs, with a range 
of bands being observed between 42-50kDa (Figure 3.1a) which was expected as the 
antibody used in the western blot experiments is known to detect the different pro-angiogenic 
VEGF isoforms. Only the dimeric form of VEGF was detected in the HuDMECs as no 
smaller bands (21-25kDa) that would correspond to the monomeric forms of VEGF were 
detected. No protein expression was detected in the conditioned media from the HuDMECs. 
VEGF165b protein expression was undetected in both the cell lysate and media of cultured 
HuDMECs (Figure 3.1b).  
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VEGF-R1 protein expression was detected in the cell lysates of cultured HuDMEC cells, with 
two bands being observed, one at approximately 180kDa and the other at ~200kDa.  VEGF-
R1 protein expression was not detected in the conditioned media of the HuDMEC cells 
(Figure 3.2a). VEGF-R2 protein expression was also detected in the cell lysates of cultured 
HuDMEC cells, with two bands spanning approximately 200-230kDa being observed (Figure 
3.2b). These two bands are thought to correspond to the glycosylated form of VEGF-R2 
(Takahashi & Shibuya. 1996). Similar to VEGF-R1, VEGF-R2 protein expression was not 
detected in the conditioned media of cultured HuDMEC cells.  
 
Np1 protein expression was also detected in the cell lysates of cultured HuDMEC cells with a 
large singular band observed at approximately 130kDa (Figure 3.2c). Np1 protein expression 
was not observed in the conditioned media from cultured HuDMEC cells. Np2 protein 
expression was observed in the cell lysates and conditioned media of cultured HuDMEC 
cells, with several bands observed in the cell lysate fraction and a single secreted band in the 
media (Figure 3.2d).  In the cell lysate fraction of the cultured HuDMEC cells 3 distinct 
bands were observed at ~135kDa, ~90kDa and ~75kDa. The ~135kDa band corresponds to 
the known size of full length Np2 (Barr et al, 2005) and it is possible that the lower two 
bands correspond to soluble forms of the Np2 receptor (Lu et al. 2009). A soluble form of the 
Figure 3.1 VEGF165 and VEGF165b Protein Expression: 
 (A) VEGF165 protein expression was detected in the cell lysate fraction of cultured HuDMECs. 
Additional bands in the blot represent the different VEGF isoforms. Secreted VEGF was not 
detected in the conditioned media. (B) VEGF165b remained undetected in both cell lysate and 
conditioned media 
 
Images are representative of protein expression detected in triplicate experiments. 
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Np2 receptor also appears to be present in the conditioned media of the cultured HuDMECs at 
~75kDa.  
 
 
 
 
                                                                                           
 
 
 
                                                        
                    
 
 
 
 
 
 
 
3.2.2 Effects of Bz on HuDMEC Function 
Differentiation 
The majority of in vitro data that is published in the literature assess the effects of Bz using 
macrovascular endothelial cells; human umbilical vein endothelial cells (HuVECs). However, 
the main cells to undergo angiogenesis in vivo are microvascular endothelial cells; therefore 
HuDMECs were the chosen as the relevant cell type, in all the following experiments. 
Previous experiments measuring the effects of Bz on endothelial cells used a range of 
Figure 3.3 Protein Expression; VEGF Receptors:   
Expression of all the VEGF receptors were observed in the cell lysates of cultured HuDMECs (A) 
VEGF-R1 (B) VEGF-R2 (C) Np1 (D) Np2 with soluble Np2 also being observed in the 
conditioned media. Several forms of VEGF-R1, VEGF-R2 and Np2 were observed, whereas only a 
single band corresponding to the full length Np1 receptor was observed. 
 
Images are representative of protein expression detected in triplicate experiments 
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concentrations and since the current experiments were assessing the effects of Bz on 
microvascular endothelial cells, it was decided that the effects of both high and low 
concentrations of Bz would be tested. In vitro, endothelial cell differentiation is represented 
by the formation of cord-like structures on a thin layer of growth factor reduced Matrigel. 
Representative images of these cord-like structures after 16h are shown in Figure 3.3.  
 
Bz significantly (P = 0.008) inhibited HuDMEC cord formation in vitro at both the 2.5mg/ml 
and 5mg/ml dose compared with the VEGF165 alone control (85.9% SEM± and 79.1% SEM± 
versus 100% respectively) (Figure 3.4a). In addition, Bz (1mg/ml and 5mg/ml) significantly 
(P = 0.008) inhibited, the complexity of the network when measured as percentage branch 
point formation at the compared with the VEGF165 alone control (79.5% SEM± and 75.1% 
SEM± versus 100% respectively) (Figure 3.4b). Interestingly, the control vehicle (CV) also 
exhibited similar significant (P = 0.008) inhibitory effects on HuDMEC cord formation at the 
2.5mg/ml and 5mg/ml equivalent dose compared with the VEGF165 alone control (85.9% 
SEM± and 80.5% SEM± versus 100% respectively) (Figure 3.5a). However, unlike Bz, CV, 
had no inhibitory effect on the complexity of the network (Figure 3.5b).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells alone VEGF165 5mg/ml Bz 
Figure 3.3 Matrigel Assay: Representative images of cord-like structures formed when HuDMECs 
are plated alone, in the presence of VEGF165 alone (20ng/ml) and Bz (5mg/ml). The number of cord 
like structures was manually counted to determine the level of in vitro endothelial cell 
differentiation.  
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Figure 3.4 Effects of High Doses of Bz on HuDMEC Differentiation.  
In the presence of recombinant VEGF165, plus varying doses of Bz, HuDMEC differentiation was 
inhibited. (A) Bz at 2.5 and 5mg/ml exerted a significant (P = 0.008) inhibitory effect on 
HuDMEC cord formation when expressed as a percentage of the VEGF165 alone control. (B) Bz at 
1 and 5mg/ml significantly (P =0.008) inhibited HuDMEC branch point formation when expressed 
as a % of the VEGF165 alone control.  
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165 
alone;  n=5, p=0.008. Statistical analysis was carried out using the Mann-Whitney U Test 
(Sigmaplot 11 software). 
 
A 
 
 
 
B 
A B 
Figure 3.5 Effects of High Doses of CV on HuDMEC Differentiation:  
In the presence of recombinant VEGF165, plus varying doses of CV, HuDMEC differentiation was 
inhibited. (A) CV at 2.5 and 5mg/ml exerted a significant (P = 0.008) inhibitory effect on 
HuDMEC cord formation when expressed as a % of the VEGF165 alone control (B) No effects on 
HuDMEC branch point formation were observed in the presence of CV when expressed as a % of 
the VEGF165  alone control.  
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=5, p=0.008. Statistical analysis was carried out using the Mann-Whitney U Test (Sigmaplot 11 
software). 
 
 
* 
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Since CV, exerted similar inhibitory effects as those observed with Bz on HuDMEC cord 
formation in vitro, it was important to further investigate this effect. CV is made up of sodium 
salts and tween20 (Avastin® SPC), and since tween20 is used as a detergent in many 
denaturing solutions, it was decided that the effects of tween20 in CV, should be tested. All 
the different components of CV exerted an inhibitory effect on HuDMEC differentiation in 
vitro, and the data is summarised below in Table 3.1. This assay aimed to determine which 
particular component of CV was responsible for the inhibitory effects observed in the 
Matrigel assay. However, unfortunately, differentiation was not achieved, due to varying 
effects on endothelial cell differentiation in the presence of all the components of CV. 
Experimental 
condition 
Cord formation  
(% compared with the 
VEGF165 alone control; 
100%) 
P value Branch point 
formation  
(% compared with the 
VEGF165 alone 
control; 100%) 
P value 
Bz (5 mg/ml) 38±12 <0.001 29±15 0.001 
CV 71±12 0.044 82±20 NS 
Tween20 alone  76±8 0.015 63±18 NS 
CV minus tween20 43±11 <0.001 62±17 0.008 
 
 
 
 
 
 
 
Lower doses of Bz (0.5mg/ml) exerted significant yet minimal inhibitory effects on VEGF165 
mediated HuDMEC differentiation (mean±SEM; Bz 0.5mg/ml versus VEGF165; 89±3.6% 
versus 100±0%; n=3, P = 0.034) when measured as cord formation (Figure 3.6a), however 
no inhibitory effects on branch point formation was observed. A stimulatory trend on   
network complexity was observed with Bz, compared with the VEGF165 alone control 
(mean±SEM; Bz 0.125, 0.25 and 0.5 mg/ml versus VEGF165; 213±87%, 195±81% & 
190±88% respectively versus 100±0%; n=3, NS) (Figure 3.6b). However, this was not 
significant (P = 0.263, 0.303 & 0.363 respectively). No inhibitory effects were observed on 
HuDMEC differentiation in the presence of the control vehicle when measured as cord 
formation (Figure 3.7a). Similar to Bz, branch point formation was stimulated (153, 218 & 
203%) compared with the VEGF165 control (Figure 3.7b), this was not significant (P = 0.167, 
0.302 & 0.382 respectively).    
 
Table 3.1 Inhibitory Effects of the Different Components of CV on HuDMEC Differentiation: 
The Matrigel assay determined that the different components of the control vehicle for Bz display 
biological activity. Differentiation of the different component of CV was not achieved, due to 
various inhibitory effects observed with all the different components.  
 
The data in the table is presented as mean±SEM (% cord or branch point formation compared 
with the VEGF165 control; n=5). Statistical analysis (t-test) was performed using Sigmaplot 11 
software. 
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Figure 3.7 Effects of Low Doses of Control Vehicle on HuDMEC Differentiation: 
In the presence of recombinant VEGF165 plus varying doses of CV, no inhibitory effects were 
observed on (A) cord formation or (B) branch point formation when expressed as a % of the 
VEGF165 alone control.  
 
Data is presented as mean±SEM (% cord or branch point formation compared with the VEGF165 
control; n=3, NS). Statistical analysis (t test) was performed using Sigmaplot 11 software. 
 
 
Figure 3.6 Effects of Low Doses of Bz on HuDMEC Differentiation:  
(A) In the presence of recombinant VEGF165, Bz at 0.5mg/ml exerted significantly (P=0.034) 
inhibited HuDMEC cord formation when expressed as a % of the VEGF165 alone control. (B) No 
significant effects were observed on branch point formation when expressed as a percentage of the 
VEGF165 alone control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with the VEGF165 
control; n=3, P = 0.034). Statistical analysis (t test) was performed using Sigmaplot 11 software. 
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Proliferation 
Under normal physiological conditions EC turnover is slow, with proliferation occurring very 
rarely. However, during tumour angiogenesis the rate of EC proliferation is increased to allow 
for the rapid expansion of the microvasculature that supports the growth of solid tumours. 
The addition of exogenous VEGF165 exerted a minimal yet significant increase in HuDMEC 
cell proliferation at 24h compared with cells alone (mean±SEM; VEGF165 vs. cells alone; 
100±0% vs. 96±%; n=4, P = 0.008). Although an increase in HuDMEC cell proliferation was 
maintained in the presence of exogenous VEGF165 at 48h (mean±SEM; VEGF165 vs. cells 
alone; 136±20% vs. 125±12%; n=4, NS) this was not significant (P = 0.841) (Figure 3.8). In 
the presence of VEGF165, the addition of high doses of Bz had no effect on HuDMEC cell 
proliferation at 24 or 48h (Figure 3.8a). A lack of inhibitory effects was also observed with 
equivalent volumes of CV (Figure 3.8b).    
 
 
 
 
 
 
 
 
 
 
Low doses (0.125, 0.25 and 0.5mg/ml) of Bz exerted a significant (P= 0.029), yet minimal 
inhibitory effect on HuDMEC cell proliferation at 24h (Figure 3.9a) (mean±SEM; Bz 0.125 
and 0.25 and 0.5 vs. VEGF165 alone control; 95±2% and 95±1% and 92±2% vs. 100±0%; n=4, 
P = 0.029). However, this initial inhibition was not maintained at 48h (Figure 3.9a). 
HuDMEC cell proliferation remained uninhibited in the presence of CV (Figure 3.9b).  
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Figure 3.8 Effects of High Doses of Bz and CV on HuDMEC Proliferation: (A) In the 
presence of recombinant VEGF165 with varying doses of (A) Bz, no significant inhibitory 
effects were observed on HuDMEC cell proliferation. (B) Similarly, no inhibitory effects were 
observed in the presence of equivalent volumes of CV at 24 or 48h. 
 
Data is presented as mean±SEM (% proliferation compared with the 24h VEGF165 control; 
n=4, p=0.008). Statistical analysis was performed using a Mann-Whitney U test (Sigmaplot 
11 software).  
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Migration 
Migration of endothelial cells in vitro can be measured by measuring the percentage gap 
closure formed on a monolayer of endothelial cells; this is represented in Figure 3.10.  
 
 
 
 
 
 
High doses of Bz in the presence of recombinant VEGF165 (1 and 5mg/ml) significantly (P = 
0.010 and <0.001 respectively) inhibited VEGF-mediated HuDMEC migration, compared 
with the VEGF165 alone control at 32h (mean±SEM; Bz 1 and 5mg/ml versus VEGF165; 
65±8% and 50±6% versus 100±0%; n=3) (Figure 3.11a). Unfortunately, a similar significant 
VEGF 
Figure 3.10 HuDMEC Migration  (A) Representative images of HuDMEC gap closure at 32h 
after creating a scratch in the presence VEGF165 alone (20ng/ml) or Bz at varying doses (1mg/ml 
and 5mg/ml).  
 
 
Figure 3.9 Effects of Low Doses of Bz and the CV on HuDMEC Proliferation: 
In the presence of recombinant VEGF165, with varying low doses of (A) Bz, a significant  
(P=0.029) inhibitory effect was observed on HuDMEC cell proliferation, compared with the 
VEGF165 alone control at 24h. However, this was not maintained at the 48h time-point. (B) No 
inhibitory effects were observed in the presence of equivalent volumes of CV at 24 or 48h. 
 
Data is presented as mean±SEM (% proliferation compared with the 24h VEGF165 control; n=4, 
p=0.029). Statistical analysis was performed using the Mann-Whitney U test (Sigmaplot 11 
software). 
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inhibition was observed with the equivalent volume of CV (5mg/ml) (mean±SEM; CV versus 
VEGF165; 31±15 versus 100±0%; n=3, P = 0.009) (Figure 3.11b). The CV at the equivalent 
volume (0.5 and 1mg/ml) exerted a stimulatory effect on HuDMEC migration (mean±SEM; 
CV 0.5 and 1 versus VEGF165; 113±51% and 195±66% versus 100±0%; n=3, ns) however, 
this did not reach significance (P = 0.814 and 0.221 respectively). 
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Low doses of Bz (Bz 0.125 and 0.25 and 0.5mg/ml) exerted no inhibitory effects on VEGF165 
HuDMEC migration. However, a stimulatory trend was observed with all three doses 
compared with the VEGF165 alone control (mean±SEM; Bz 0.125 and 0.25 and 0.5mg/ml 
versus VEGF165; 137±50% and 149±28% and 184±32% versus 100±0%; n=3, NS) (Figure 
3.12a), this was not significant (P = 0.499, 0.151 and 0.059 respectively). In contrast, CV, at 
an equivalent volume (0.25mg/ml and 0.5mg/ml) significantly inhibited HuDMEC migration 
in vitro at 32h compared with the VEGF165 alone control (mean±SEM; CV 0.25 and 0.5mg/ml 
versus VEGF165; 78±3% and 61±1% vs. 100±0%; n=3, P =0.002 and <0.001) (Figure 3.12b).  
 
 
 
 
 
Figure 3.11 Effects of High Doses of Bz and the Control Vehicle on HuDMEC Migration:   
In the presence of recombinant VEGF165, plus varying doses of (A) Bz (1mg/ml and 5mg/ml), 
resulted in significant (P= 0.010 and P= < 0.001 respectively) inhibitory effects at 32h 
compared with the VEGF165 alone control. (B)   CV (5mg/ml) significantly (P=0.009) inhibited 
HuDMEC migration at 32h compared with the VEGF165 alone control.  
 
Data is presented as mean±SEM (% gap closure compared with the VEGF165 control; n=3). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software).  
* 
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3.2.3 Effects of the Np1 peptides on HuDMEC Function 
The Np1 peptides have previously been tested for the ability to bind the human Np1 receptor 
in vitro (Cebe-Suarez et al, 2008). However, the effect on functional activity associated with 
these Np1 peptides has not previously been evaluated. The table below (Table 3.2) 
summarises the different properties of the four peptides used in this project. The peptides used 
in this project are designed primarily to bind Np1 and block the interaction with functional 
VEGF165. Np1 was the primary focus of the current project, as, to date (Sept 2013), the 
majority of research on the neuropilin receptors in breast cancer, was being carried out on 
Np1. In addition, substantially less was known about the role of Np2 in tumour angiogenesis 
and tumour progression. The affinity of these peptides were tested in a competitive binding 
assay with radiolabelled VEGF165, and it was observed that, a RPPR sequence demonstrated 
high affinity to Np1, and inhibited almost entirely binding of exogenous VEGF165. In contrast, 
a DKPRR sequence, displayed intermediate ability (Cebe-Suarez et al, 2008).  
 
 
 
Figure 3.12 Effects of Low Doses of Bz and CV on HuDMEC Migration: 
In the presence of VEGF165, plus varying doses of (A) Bz, no significant effects were observed 
on HuDMEC cell migration in vitro when expressed as % gap closure compared with the 
VEGF165 control at 32h. B) With the addition of CV (0.25mg/ml and 0.5mg/ml), significant (P= 
0.002 and P= < 0.001 respectively) inhibitory effects on HuDMEC cell migration in vitro was 
observed when expressed as % gap closure compared with the VEGF165 alone control at 32h. 
 
Data is presented as mean±SEM (% gap closure compared with VEGF165; n=3). Statistical 
analysis was performed using a t-test (Sigmaplot 11 software). 
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PEPTIDE ORIGIN SEQUENCE NP1 
BINDING 
1 Viral VEGF-E protein GSGSTRPPR Yes 
2 Human VEGF-A protein 
(control) 
GSGSTEPPR No 
7b Human VEGF-A protein GSGSTDKPRR Yes 
10 Viral VEGF-E protein GSGSTRPPRRRR Yes and 
potentially 
Np2 
 
 
 
 
Differentiation 
Matrigel Assay 
Peptide 1 (p1), significantly inhibited HuDMEC differentiation when measured as cord 
formation at the 10μM and 50μM concentration compared with the VEGF165 alone control 
(mean±SEM; p1 10µM and 50µM vs. VEGF165; 87±5% and 78±3% vs. 100±0%; n=4, P = 
0.029) (Figure 3.13a). The complexity of the network formed when measured as the number 
of branch points formed was not inhibited by p1 (Figure 3.13b). Surprisingly, peptide 2 (p2), 
which is a control peptide that does not bind to Np1 in vitro, also significantly inhibited 
HuDMEC differentiation when measured as cord formation at the 10μM and 50μM 
concentration compared with the VEGF165 alone control (mean±SEM; p2 10µM and 50µM 
vs. VEGF165; 57±10% and 54±15% vs. 100±0%; n=4, P = 0.029) (Figure 3.14a). Similar to 
p1, no significant inhibitory effects were observed on the complexity of the network in the 
presence in p2 (Figure 3.14b). The addition of peptide 7b (p7b), significantly inhibited cord 
formation at 1μM and 10μM compared with the VEGF165 alone control (mean±SEM; p7b 
1µM and 10µM vs. VEGF165; 54±11% and 85±5% vs.  100±0%; n=4, P = 0.029) (Figure 
3.15a). No effect on network complexity was observed with p7b (Figure 3.15b). Peptide 10 
(p10) is thought to bind both Np1 and Np2 (although this has not been confirmed). The 
addition of p10, significantly inhibited cord formation at the 10μM and 50μM concentration 
compared with the VEGF165 alone control (mean±SEM; p10 10µM and 50µM vs. VEGF165; 
63±10% and 44±12% vs. 100±0%; n=4, P = 0.029; Figure 3.16a) but no significant effects 
on network complexity was observed (Figure 3.16b). 
 
Table 3.2 Properties of the Four Np1 Peptides: 
The differences present in the sequence of the four Np1 peptides used during this project are 
outlined in the table. The RPPR sequence is thought to exhibit higher binding affinity to human 
Np1. Peptide 2 was used in the presents as a control peptide, as this peptide lacked Np1 binding 
affinity 
In Vitro Results-  
Targeting the Angiogenic Pathway 
 
SAPNA LUNJ Page 108 
 
 
 
%
 C
o
r
d
 F
o
r
m
a
t
io
n
 (
c
o
m
p
a
r
e
d
 t
o
 c
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
                  
%
 B
r
a
n
c
h
 P
o
in
t
s
 F
o
r
m
e
d
 (
c
o
m
p
a
r
e
d
 t
o
 c
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
 
 
 
 
 
 
  
 
 
 
%
 C
o
r
d
 F
o
r
m
a
t
io
n
 (
c
o
m
p
a
r
e
d
 t
o
 c
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
                  
%
 B
r
a
n
c
h
 P
o
in
t
s
 F
o
r
m
e
d
 (
c
o
m
p
a
r
e
d
 t
o
 c
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Effects of P1 on HuDMEC Differentiation:  
In the presence of recombinant VEGF165, plus p1 (10 and 50µM) a significant (P=0.029) effect 
was observed on (A) cord formation when expressed as a percentage of the VEGF165 alone 
control. (B) No significant effects were observed on branch point formation when expressed as a 
percentage of the VEGF165 alone control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared to VEGF165; 
n=4, p=0.029). Statistical analysis was performed using the Mann-Whitney U test (Sigmaplot 
11 software).  
A 
Figure 3.14 Effects of P2 on HuDMEC Differentiation: 
In the presence of recombinant VEGF165,, p2 at 10 and 50µM exerted significant (P=0.029) 
effects on  (A) cord formation when expressed as a % of the VEGF165 alone control (B) No 
significant effects were observed on branch point formation when expressed as a % of the 
VEGF165  alone control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, P = 0.029). Statistical analysis was performed using the Mann-Whitney U test (Sigmaplot 
11 software).  
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Figure 3.15 Effects of P7b on HuDMEC Differentiation:  
In the presence of recombinant VEGF165, p7b at 1µM and 10µM exerted significant (P=0.029) 
effects on (A) HuDMEC cord formation when expressed as a % of the VEGF165 alone control. 
(B) No significant effects were observed on branch point formation when expressed as a % of the 
VEGF165 control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, P = 0.029). Statistical analysis was performed using the Mann-Whitney U test (Sigmaplot 
11 software).  
Figure 3.16 Effects of P10 on HuDMEC Differentiation:   
In the presence of recombinant VEGF165, p10 at 10µM and 50µM exerted significant (P=0.029) 
effects on (A) HuDMEC cord formation when expressed as a % of the VEGF165 alone control. 
(B) No significant effects were observed on branch point formation when expressed as a % of the 
VEGF165  alone control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with the 
VEGF165 control; n=4, P = 0.029). Statistical analysis was performed using the Mann-Whitney 
U test (Sigmaplot 11 software).  
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3D Sprouting Angiogenesis Assay 
The 3D angiogenesis assay (PromoCell) utilises endothelial cell spheroids that are embedded 
in a collagen matrix and simulates the entire process of vessel formation; proteolytic activity, 
migration, proliferation and lumen formation. In this assay a significant stimulatory effect on 
percentage sprout formation was observed in the presence of VEGF165 compared with cells 
alone (mean±SEM; VEGF165 versus cells alone; 100±0% versus 31±5%; n=3, P <0.001) 
(Figure 3.17b).  Peptide 2 and p10 both exerted significant inhibitory effects on percentage 
sprout formation compared with the VEGF165 alone control (mean±SEM; p2 and p10 versus 
VEGF165; 80±6% and 60±11% versus 100±0%; n=3, P = 0.027 and 0.022) (Figure 3.17b). 
Although peptide 7b apparently reduced the percentage sprout formation compared with the 
VEGF165 alone control (mean±SEM; p7b versus VEGF165; 82±20% versus 100±0%; n=3, ns), 
however, this was not significant (P = 0.402) (Figure 3.17b). It is important to note, that 
although statistical significance was observed between treatments in this assay, the sprout 
formation was poor, even in the presence of VEGF (Figure 3.17), suggesting that the 3D 
angiogenesis assay may not be a reliable assay especially if the data produced is not 
biologically relevant.  
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P2 P7b P10 
Cells alone VEGF 
Figure 3.17 Effects of Np1 Peptides on 3D HuDMEC Sprout Formation: 
(A) Representative images of the sprouts formed in the 3D angiogenesis assay in the presence of 
VEGF165 and the Np1 binding peptides (B) P2 and p10 significantly (P=0.027 and P=0.022),  
inhibited HuDMEC sprout formation when expressed as a % of the VEGF165 alone control. No 
inhibitory effects were observed in the presence of p7b.   
 
Data is presented as mean±SEM (% sprout formation compared with VEGF165; n=3, p<0.001). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software).  
 
A 
B 
 * 
 * 
 * 
In Vitro Results-  
Targeting the Angiogenic Pathway 
 
SAPNA LUNJ Page 112 
 
Proliferation 
When cells were plated directly in media containing Np1 peptides, no effects on HuDMEC 
cell proliferation was observed in the presence of any of the peptides (Figure 3.18a-d). A 
second MTS experiment was set up, whereby the peptides were pre-incubated for 2h with the 
HuDMECs prior to adding VEGF165, to determine if this exerted an inhibitory effect on 
HuDMEC cell proliferation (Figure 3.19a-d). Pre-incubating p1 (50µM) (Figure 3.19a) and 
p10 (50µM) (Figure 3.19d) appeared to inhibit HuDMEC cell proliferation at 48h, however, 
these experiments were only carried out twice, therefore a trend can be suggested, but no 
significant analysis or conclusions can made as to whether pre-incubating the Np1 peptides 
inhibit HuDMEC cell proliferation.  
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Figure 3.18 Effects of Np1 Peptides on HuDMEC Proliferation: 
In the presence of recombinant VEGF165 plus varying doses of the four Np1 peptides, no 
inhibitory effects were observed on HuDMEC cell proliferation with (A) peptide 1 (B) peptide 2 
(C) peptide 7b and (D) peptide 10 compared with the VEGF165 alone control. 
 
 Data is presented as mean±SEM (% proliferation compared with VEGF165 alone at 24h; n=3).  
Statistical analysis was performed using a t-test (Sigmaplot 11 software).  
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Migration 
In the scratch assay, the presence of peptide 1, p2 and p7b all inhibited HuDMEC migration. 
However, this did not reach statistical significance (Figure 3.20a-c). Peptide 10 stimulated 
HuDMEC migration in vitro; however, this did not reach statistical significance (Figure 
3.20d). It is possible that the nature of the scratch assay increased the variability of the data 
observed as mitomycin C was added to minimise the proliferation activity to ensure that the 
closure of the gap was a result of migration alone. It was thus decided that a Boyden chamber 
assay should be performed to observe whether a chemotactic assay that created a VEGF 
gradient was more relevant when measuring HuDMEC cell migration in vitro. Peptide 7b was 
Figure 3.19 Effects of Pre-incubating the Np1 Peptides on HuDMEC Proliferation: 
Pre-incubating the Np1 peptides 2h prior to adding recombinant VEGF165, resulted an inhibitory 
trend with p1 and p10. However, since the experiment was only carried out twice, a conclusion 
cannot be made as to the effects of pre-incubating the peptides on HuDMEC cell proliferation, 
due to the lack to statistical analysis. 
 
Data is presented as mean±SEM (% proliferation compared with VEGF165 alone at 24h; n=2).   
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used in the Boyden assay as it demonstrated a inhibitory trend in HuDMEC migration in the 
scratch assay. Peptide 10 was also chosen as it was the only Np1 peptide to display a trend 
towards stimulatory effects on HuDMEC migration and it was important to assess, if 
consistent results could be obtained using different migration assays. In the Boyden chamber 
assay, as expected, VEGF165 alone significantly (P = 0.010) increased HuDMEC cell 
migration compared with cells alone (mean±SEM; VEGF165 vs. cells alone; 100±% vs. 
61±9%; n=3, p=0.010) (Figure 3.21). The presence of p7b significantly (P < 0.001) inhibited 
HuDMEC cell migration compared with the VEGF165 alone control (mean±SEM; p7b 
vs.VEGF165; 33±5% vs. 100±0%; n=3, p<0.001) (Figure 3.21). Unlike in the scratch assay, 
p10 exerted an inhibitory effect on HuDMEC cell migration compared with the VEGF165 
alone control ((mean±SEM; p710 vs.VEGF165; 57±38% vs. 100±0%; n=3, NS), however this 
inhibition failed to reach statistical significance (P = 0.552).  
 
 P e p t i d e  1
%
 G
a
p
 C
lo
s
u
r
e
 (
C
o
m
p
a
r
e
d
 t
o
 C
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
2 0 0
                    
 P e p t i d e  2
%
 G
a
p
 C
lo
s
u
r
e
 (
C
o
m
p
a
r
e
d
 t
o
 C
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
- 1 0 0
0
1 0 0
2 0 0
 
 P e p t i d e  7 b
%
 G
a
p
 C
lo
s
u
r
e
 (
C
o
m
p
a
r
e
d
 t
o
 C
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
2 0 0
                     
P e p t i d e  1 0
%
 G
a
p
 C
lo
s
u
r
e
 (
C
o
m
p
a
r
e
d
 t
o
 C
o
n
t
r
o
l)
c
e
ll
s
 a
lo
n
e
V
E
G
F
 
1

M
1
0

M
5
0

M
0
5 0
1 0 0
1 5 0
2 0 0
2 5 0
 
 
 
 
 
 
Figure 3.20 Effects of Np1 Peptides on HuDMEC Migration: 
In the presence of VEGF165, plus varying doses of the Np1 peptides, no significant effects were 
observed on HuDMEC cell migration in vitro; (A) peptide 1 (B) peptide 2 (C) peptide 7b and (D) 
peptide 10 when expressed as % gap closure compared with the VEGF165 alone control 
 
Data is presented as mean±SEM (% gap closure compared with VEGF165; n=3. 
Statistical analysis was performed using a t-test (Sigmaplot II software). 
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3.2.4 Combining Bz with the Np1 peptides on HuDMEC Function 
Differentiation 
In previous experiments p1, p2, p7b and p10 all showed a significant inhibition in HuDMEC 
differentiation, however only p2, p7b and p10 exerted a reduction of approximately 50% 
HuDMEC cord formation when compared with the VEGF165 alone control (Figure 3.13-
3.16). Thus, it was decided that p2, p7b and p10 would be used in combination with Bz at the 
following doses; 50μM, 1μM and 50μM respectively.  
As expected the addition of Bz (5mg/ml) significantly (P=0.029) inhibited HuDMEC cell 
differentiation when measured as cord formation compared with the VEGF165 alone control 
(mean±SEM; Bz 5mg/ml vs. VEGF165; 75±89% vs. 100±0%; n=4, p=0.029) (Figure 3.22a).  
However, the extent to which Bz inhibited cord formation was less compared with what was 
previously observed. Similarly, the level of inhibition previously observed with the addition 
of p2, was not evident in the combination experiments (54% vs, 94% cord formation). When 
Bz was combined with p2, a significant inhibition was observed (P = 0.029), however the 
efficacy of this inhibition was not greater than the inhibition observed with Bz alone (81% vs. 
75%) (Figure 3.22a). Bz alone, significantly (P=0.029) inhibited the network complexity 
compared with the VEGF165 alone control (mean±SEM; Bz 5mg/ml vs. VEGF165; 73±9% vs. 
100±0%; n=4, p=0.029). This inhibition, however was lost when Bz was combined with p2 
Figure 3.21 Effects of  the 7b and p10 on HuDMEC Migration; Boyden Chamber: 
In the presence of recombinant VEGF165, peptide 7b significantly (P <0.001) inhibited migration 
in the Boyden chamber, after 4 hours compared with the VEGF165 alone control. In contrast to 
the scratch assay, p10 reduced HuDMEC migration but this was not significant. 
 
Data is presented as mean±SEM (% Migration compared with VEGF165; n=3, *1 p<0.001). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software). 
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(mean±SEM; Bz/p2; 92±28%) (Figure 3.22b). No significant effects on HuDMEC cord 
formation or branch point formation were observed in the presence of CV alone or in 
combination with p2 (Figure 3.23). 
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Figure 3.22 Effects of Combining Bz and P2 on HuDMEC Differentiation: 
(A) In the presence of recombinant VEGF165, no additive inhibitory effects were observed on 
HuDMEC differentiation when Bz was combined with P2 on (A) cord formation and (B) branch 
point formation in the presence of Bz and p2 together compared with Bz alone. 
  
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, *p=0.029). Statistical analysis was performed using the Mann-Whitney U Test (Sigmaplot 
11 software) 
Figure 3.23 Effects of Combining CV and P2 on HuDMEC Differentiation: 
In the presence of recombinant VEGF165, no effects on HuDMEC cell differentiation were 
observed when CV and p2 were combined when measured as (B) cord and (C) branch point 
formation compared to Bz alone. 
  
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, NS). Statistical analysis was performed using the Mann-Whitney U Test (Sigmaplot 11 
software) 
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Similarly, the inhibition previously observed with p10 on HuDMEC cord formation was not 
evident in these experiments (44% vs. 90%) (Figure 3.24). Combining p10 with Bz, resulted 
in a significant (P=0.029) inhibition in cord formation. However, the combined inhibition 
was not much greater than that observed with Bz alone (73% vs. 75% respectively) (Figure 
3.24a). However, unlike p2 when combined with Bz, p10 did not reduce the efficacy of Bz 
alone. Combining Bz with p10 resulted in significant (P = 0.029) inhibition in branch point 
formation, this combined effect was greater than that observed with Bz alone (mean±SEM; 
Bz/p10 vs. Bz alone; 63±7% vs. 70±9%; n=4, NS). However this did not reach statistical 
significance (P = 0.686) (Figure 3.24b). When p10 was combined with CV a significant 
(p=0.029) inhibition in HuDMEC cord formation was observed when compared with the 
VEGF165 alone control (71% vs. 100% respectively) (Figure 3.25a). This was not expected, 
as neither p10 nor CV alone, exerted any inhibitory effects on cord formation in these 
experiments.   
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Figure 3.24 Effects of Combining Bz and P10 on HuDMEC Differentiation: 
In the presence of recombinant VEGF165, no significant (P=0.686) additive effect were observed 
on HuDMEC differentiation when Bz was combined with p10, when measured as (A) cord 
formation and (B) branch point formation compared to Bz alone. 
  
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, *p=0.029). Statistical analysis was performed using the Mann-Whitney U Test (Sigmaplot 
11 software) 
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Combining p7b with Bz, resulted in significant (P=0.002) inhibition in cord formation when 
compared with the VEGF165 alone control. However, this combined inhibition was not greater 
than that observed with Bz alone (87% vs. 83% respectively) (Figure 3.26a). In the p7b 
experiments, Bz and p7b alone failed to exert a significant (p=0.079 and p=0.942 
respectively) inhibitory effect on HuDMEC branch point formation compared with the 
VEGF165 control (mean±SEM; Bz alone and p7b alone vs. VEGF165; 72±10% and 102±20% 
vs. 100±0%; n=3, NS). However, combining Bz with p7b resulted in significant (P=0.002) 
inhibition in network complexity when compared with the VEGF165 alone control 
(mean±SEM; Bz/p7b vs. VEGF165; 71±7% vs. 100±0%; n=3, p=0.002) (Figure 3.26b). 
Combining p7b with CV resulted in a significant (P=0.012) inhibitory effect on HuDMEC 
cord formation (Figure 3.27a) compared with the VEGF165 alone control (mean±SEM; 
CV/p7b alone vs. VEGF165; 90±1% vs. 100±0%; n=3, p=0.012). No significant effects on 
HuDMEC branch point formation were observed with either the CV or p7b compared with 
the VEGF165 control (mean±SEM; CV alone and p7b alone vs. VEGF165; 103±6% and 
102±20% vs. 100±0%; n=3, NS). However, combining the two significantly (P=0.022) 
inhibited HuDMEC branch point formation compared with the VEGF165 alone control 
(85±10% vs. 100±0% respectively) (Figure 3.27b). In the combination experiments even 
though some of the treatments exerted significant inhibitory effects on HuDMEC 
Figure 3.25 Effects of Combining CV and P10 on HuDMEC Differentiation: 
In the presence of recombinant VEGF165, combining CV with p10 exerted a significant (P=0.029) 
inhibitory effect on HuDMEC differentiation when measured as (A) cord formation when 
compared with CV control. No significant inhibition was observed on (B) branch point 
formation.  
  
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=4, *p=0.029). Statistical analysis was performed using the Mann-Whitney U Test (Sigmaplot 
11 software) 
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differentiation, this was minimal compared with previous experiments observed during this 
study and could be due to batch to batch variation in the HuDMECs. This batch variation, 
may also explain the increased level of proliferating islands compared with previous Matrigel 
experiments, suggesting that the cells are not responding to stimuli as efficiently as previously 
observed.  
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Figure 3.26 Effects of Combining Bz and P7b on HuDMEC Differentiation: 
In the presence of recombinant VEGF165, although significant (P=0.002) reductions were 
observed when Bz was combined with P7b, this inhibition had no additive inhibitory effects in 
(B) cord and (C) branch point formation compared to Bz alone. 
  
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n3,* p<0.05). Statistical analysis was performed using a t-test (Sigmaplot 11 software) 
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Figure 3.27 Effects of Combining CV and P7b on HuDMEC Differentiation: 
In the presence of VEGF165, although a significant (P=0.012) combined effect was observed on 
cord formation, no additive inhibitory effects were displayed on HuDMEC differentiation, when 
measured as (A) cord formation when compared with p7b alone. (C) No inhibitory effects on 
branch point formation were observed compared with p7b alone. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=3,* p<0.05). Statistical analysis was performed using a t-test (Sigmaplot 11 software) 
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Proliferation 
Since there were no inhibitory effect observed on HuDMEC cell proliferation in the presence 
of any of the four Np1 peptides alone or Bz, a combination MTS assay was not deemed 
relevant.  
 
Migration 
Similar to previous experiments, both Bz and CV (5mg/ml) significantly (P=<0.001) 
inhibited HuDMEC migration in vitro compared with the VEGF165 alone control (9.8% SEM± 
and -1.2% SEM± vs. 100% respectively). However, the level of inhibition appeared to be 
much greater in the combination experiments, with CV alone resulting in regression of 
HuDMEC cells, from the area where the monolayer of cells were ‘wounded’ (Figure 3.29). 
The presence of p7b (1μM) significantly (P=<0.001) inhibited HuDMEC migration 
compared with the VEGF165 alone control (52% SEM± vs. 100% respectively) (Figure 3.28a 
& 3.29a). Combining p7b, with both Bz and CV, resulted in a additive effect on HuDMEC 
migration inhibition, which resulted in regression of the gap closure. However, this did not 
reach statistical significance (Figure 3.28a & 3.29a). Combining p10, with Bz exerted no 
additive inhibitory effects on HuDMEC cell migration in vitro compared with Bz or CV alone 
(Figure 3.28b & 3.29b).  
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Figure 3.28 Effects of Combining Bz with P7b and P10 on HuDMEC Migration:   
In the presence of recombinant VEGF165 (A) no significant additive effects on HuDMEC 
migration were observed when p7b was combined with Bz compared to Bz alone. Similarly, (C) 
no significant effects on HuDMEC migration were observed when p10 was combined with Bz 
 
Data is presented as mean±SEM (%gap closure compared with VEGF165; n=3, *p<0.001). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software) 
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3.2.5 Effects of Np1 and Np2 antibodies on HuDMEC Function 
As the Np1 peptides used in this study are small in nature and the efficacy of these peptides as 
biological inhibitors of Np1 and VEGF165 interactions are being tested for the first time, it was 
deemed important that an antibody against the neuropilin receptors also be tested. At the time 
of these experiments the only commercially available antibodies were from R&D systems 
(these antibodies have been tested for blocking ability in an ELISA based assay). The Np1 
and Np2 antibodies were thus purchased and utilised in subsequent experiments.  
Differentiation 
The Np1 antibody (5µg/ml and 10μg/ml) significantly inhibited HuDMEC differentiation 
when measured as cord formation compared with the VEGF165 alone control (mean±SEM; 
Np1 antibody 5 and 10μg/ml vs. VEGF165; 93±2 and 94±3% vs. 100±0%; n=3, p=0.008 and 
p=0.028) (Figure 3.30a). No significant effects were observed on HuDMEC branch point 
formation in the presence of the Np1 antibody when compared with the VEGF165 alone 
control (Figure 3.30b). The addition of an Np2 antibody (20μg/ml) also significantly 
(P=0.004) inhibited HuDMEC cord formation compared with the VEGF165 alone control 
(mean±SEM; Np2 20μg/ml vs. VEGF165; 89±3% vs. 100±0%) (Figure 3.31a). Similar to the 
Np1 antibody, no significant effects on the complexity of the network was observed with the 
Np2 antibody (Figure 3.31b). The inhibition in cord formation observed with the Np1 and 
Np2 antibodies was less then that observed with the Np1 peptides suggesting that at the 
concentrations used, the peptides appear to display greater biological activity.  
A B 
Figure 3.29 Effects of Combining CV with P7B and P10 on HuDMEC Migration: 
In the presence of recombinant VEGF165 (A) no additive effects on HuDMEC cell migration 
were observed when p7b or (B) p10 was combined CV compared to CV alone. 
 
Data is presented as mean±SEM (%gap closure compared to VEGF165; n=3, *p<0.001). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software) 
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Figure 3.30 Effects of Np1 antibody on HuDMEC Differentiation: 
In the presence of recombinant VEGF165 plus varying doses of an Np1 antibody (A) a significant 
(P=0.008 and P=0.028, respectively) inhibitory effect on cord formation, was observed at 
5µg/ml and 10µg/ml when expressed as a percentage of the VEGF165 alone control. (B) No 
significant effects on branch point formation were observed in the presence of the Np1 antibody 
when expressed as a % of the VEGF165 control. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=3, *p<0.05). Statistical analysis was performed using a t-test (Sigmaplot 11 software). 
Figure 3.31 Effects of Np2 antibody on HuDMEC Differentiation: 
In the presence of recombinant VEGF165 plus varying doses of an Np2 antibody (A) a significant 
(P=0.004) inhibition in cord formation was observed with 20µg/ml of the Np2 antibody when 
expressed as a percentage of the VEGF165 alone control. (B) No effects on HuDMEC branch 
point formation were observed. 
 
Data is presented as mean±SEM (% cord or branch point formation compared with VEGF165; 
n=3, p<0.004). Statistical analysis was performed using a t-test (Sigmaplot 11 software) 
A 
B 
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Migration 
The presence of the Np1 antibody appeared to have no inhibitory effect on HuDMEC 
migration in vitro (Figure 3.32a). In contrast, the Np2 antibody appeared to have a plausible 
inhibitory effect on HuDMEC cell migration at 10µg/ml, whereby regression of the gap was 
observed (Figure 3.32b). However, since these experiments were only carried out twice, due 
to time constraints, no conclusive deduction can be made as to the effect of the Np1 and Np2 
antibodies on HuDMEC cell migration in vitro and would require further analysis. 
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A B 
Figure 3.32 Effects of the Np1 and Np2 antibody on HuDMEC Migration: 
In the presence of recombinant VEGF165 plus varying doses of the Np1 antibody (A) no 
inhibitory effects were observed on HuDMEC migration after 32h compared with the VEGF165 
alone control. In contrast, (B) Np2, 10µg/ml caused regression of the gap created, however 
without statistical analysis, conclusions can not be made.  
 
Data is presented as mean±SEM (% gap closure compared with VEGF165; n=2) 
Statistical analysis was not carried out due to the lack of adequate experimental replicates. 
 
KEYPOINT 
In vitro results that represent ‘true’ activity of Bz on HuDMEC activity include 
inhibitory effects on endothelial cell cord formation and network complexity   
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3.3 DISCUSSION 
3.3.1 Characterisation of Factors 
VEGF 
VEGF is a multi-functional molecule that is critical to tumour growth and as mentioned is a 
potent pro-angiogenic factor. The role of VEGF on endothelial cell biology is crucial, with a 
number of processes involved in the angiogenic process being regulated by VEGF, such as 
endothelial cell survival, migration, differentiation and proliferation (Byrne et al, 2005).  
 
VEGF protein expression was detected in the cell lysate of HuDMEC cells cultures in vitro, 
with a range of bands being observed between 42-50kDa in size. Several bands were expected 
as these represent the different VEGF isoforms that exist. Interestingly, only the dimeric 
forms of VEGF were detected, suggesting that the VEGF produced by the HuDMECs is 
functional since VEGF can only active receptor signalling when present as a dimer. This is 
important and should ideally be measured, since the level of dimeric VEGF present in 
‘resting’ endothelial cells forms the baseline for VEGF expression. If baseline expression is 
relatively high, then the presence of exogenous VEGF may saturate the system, thus leading 
to no further stimulation by additional VEGF. Interestingly; no VEGF was detected in the 
media fraction, however it is possible that the levels were too low to detect using western blot 
methods, thus an ELISA assay would have been useful to measure the levels of VEGF 
released into the media. An ELISA assay would also have proved useful in potentially 
measuring the different levels of VEGF isoforms present. This is important as the different 
isoforms have differential receptor expression profiles with regards to the neuropilin receptors 
and thus the levels of each individual isoform is potentially important in the response to 
targeted therapy. 
 
VEGF165b 
The discovery of VEGF165b and the suggestion that these isoforms are anti-angiogenic implies 
a potentially important role in the efficacy of VEGF targeted therapy.   
 
VEGF165b protein expression remained undetected in the cell lysate and media fractions of the 
cultured HuDMEC cells in vitro.  This finding was unexpected, as the VEGF165b protein is 
thought to be a negative regulator of angiogenesis, thus would be expected to be present in 
‘resting’ or inactivated endothelial cells.  The cells were serum starved prior to protein 
extraction, as this process is thought to increase protein expression, and therefore it is possible 
that a stress response was activated as a result of the serum starvation thus activated the 
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HuDMECs, and reduced the levels of VEGF165b. A PCR experiment was carried out to 
determine, if the lack of VEGF165b expression was due to the antibody not working or if the 
absence of expression was a true reflection. However, the quality of the DNA extracted was 
poor as there was evidence of smearing on agarose gel and therefore may be masking the 
presence or the absence of VEGF165b. The expression of VEGF165b can not be completely 
ignored in this instance.  
 
VEGF Receptors 
Protein expression of all four VEGF receptors was observed in the cell lysate fractions of the 
HuDMEC cells suggesting that targeting the VEGF pathway via these receptors is feasible.  
In hindsight however it would have been useful to measure the levels of receptor expression 
both on the surface of the HuDMECs and internally using flow cytometry. Measuring the 
different levels of receptor expression could aid in identifying which cell types are likely to 
respond to a treatment that is either targeting the classical VEGF receptors or the alternative 
newly identified, neuropilin receptors, as the levels of surface receptor expression are 
extremely important. Additionally it would have been useful to measure the levels of VEGF 
receptors under both normoxic and hypoxic conditions especially since within the tumour 
microenvironment, the microvascular endothelial cells, along with other cells are subjected to 
low oxygen. The low oxygen tension could potentially result in a different VEGF receptor 
expression profile in the HuDMEC cells resulting in different levels of sensitivity of 
HuDMECs to VEGF receptor targeted therapy such as Bz.  VEGF-R1 mRNA expression has 
been observed to be greatly up-regulated under different hypoxic conditions (Barleon et al, 
1997 & Gerber et al, 1997). These studies also observed an increase in soluble VEGF-R1 
mRNA expression. Whereas VEGF-R2 mRNA expression under hypoxia is variable with 
some studies showing no detectable increase in VEGF-R2 expression in HuVEC cells under 
hypoxic conditions (Barleon et al, 1997 & Gerber et al, 1997) whereas other have observed 
increased up-regulation of VEGF-R2 (Waltenberger et al, & Brogi et al, 1996). The presence 
of hypoxia appears to reduce or diminish Np1 protein expression by HuVEC cells in vitro 
(Bae et al, 2008) whereas Np2 expression appears to be unaffected (Bae et al, 2008).  
 
It is important to note that although the protein expression data is based on triplicate results, 
the western blot experiments were carried out a number of times, as variable results with the 
VEGF receptors was observed. This variability in protein expression of all four VEGF 
receptors may be representative of the mixed endothelial cell populations present in the 
different batches of cultured HuDMECs utilised in these experiments.  
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3.3.2 Functional Activity  
Bz 
The extent to which Bz inhibited HuDMEC differentiation, varied across Matrigel 
experiments during this current project. It is possible that the variation in response to Bz 
treatment, is due to fluctuations in the level of VEGF-R1 and VEGF-R2 surface expression. 
Additionally, the HuDMECs used in these experiments are isolated from the dermis thus are a 
mixture of both vascular and lymphatic endothelial cells (Promocell). Lymphatic endothelial 
cells predominantly express VEGF-R3 and may not respond to Bz treatment as effectively as 
vascular endothelial cells and since Bz only inhibits VEGF isoforms from binding to VEGF-
R1 and VEGF-R2, the ratio of vascular versus lymphatic endothelial cells present in the 
HuDMEC culture is important.  
 
It has previously been observed that treatment of serum-starved HuVECs with exogenous 
VEGF for 24h resulted in reduced (upto 66%) levels of VEGF-R1 and VEGF-R2 cell surface 
expression in vitro. This loss in cell surface expression was quickly reversed with the removal 
of exogenous VEGF (Wang et al, 2000). This observation may in part explain why there was 
little stimulation in HuDMEC activity in the presence of recombinant VEGF165 compared with 
the cells alone, in the majority of experiments carried out during this PhD project. The group 
also observed that although exogenous VEGF treatment reduced VEGF receptor cell surface 
expression, mRNA of both receptors was increased in the presence of VEGF in conditioned 
media (24h- from tumour cells), suggesting that the exogenous VEGF regulates a 
compensatory modulation of VEGF receptor production when cell surface expression is lost. 
Interestingly, treating the HuVECs (that were exposed to conditioned media) with A4.6.1 
(Bz) for 2h decreased the mRNA production of VEGF-R1 and VEGF-R2. This suggests that 
pre-treating the HuDMECs in the current set experiments with exogenous VEGF165 followed 
by Bz treatment, could potentially increase or improve the inhibitory effects observed on 
HuDMEC cell activity in vitro, in response to VEGF165 stimulation. Additionally a VEGF165 
rescue experiment could have proved useful in establishing the effectiveness and duration of 
Bz treatment in maintaining an inhibitory effect on HuDMEC cell function in vitro.  
 
Unfortunately the control vehicle (CV) in which Bz is re-suspended also exerted similar 
effects on HuDMEC differentiation in vitro. The majority of other studies that measure the 
effects of Bz use either a human IgG1 (Hoang et al, 2012) or do not describe the nature of the 
control used. The only study that used the same control vehicle used in this current study, did 
not observe any effects with the vehicle on HuVEC activity, however, the volumes at which 
the vehicle was used was not stated (Carneiro et al, 2009). It was initially thought that the 
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presence of the control vehicle might be causing the media in which Bz was added to the cells 
to change, however this was tested and was found not to be any different between the 
different treatment groups.  
 
The effects of Bz on cell differentiation of pre-screened HuDMECs were also tested, with the 
thought that, if the cells have previously been tested for the response to VEGF treatment, 
these cells in theory would respond to anti-VEGF targeted therapy to a greater extent and thus 
would allow for a more reliable assessment of the hypothesis which was proved to be the 
case, as the pre-screened HuDMECs responded to a much greater extent to Bz treatment in 
the cell differentiation assay, suggesting that if the level of VEGF-R1 and VEGF-R2 is 
adequate and available on the cell surface, targeting these receptors is an effective means for 
targeting the tumour vasculature (data not shown).  
 
High doses of Bz exerted no inhibitory effects on HuDMEC proliferation in vitro during this 
study, this differs to what has been observed in the literature, whereby the presence of Bz 
resulted in inhibition of HuDMEC cell proliferation (Li et al, 2007). However in the Li et al, 
2007 study the HuDMECs were incubated with Bz (10μg/ml) for 72h therefore it is possible 
that the proliferation assay carried out in this project was not long enough to observe 
inhibitory effects on proliferation as the latest time point observed was 48hours. Bz also 
significantly inhibited HuDMEC migration, this was expected since it has previously been 
shown that VEGF-R2 is important in VEGF165 induced EC migration and when blocking the 
interactions of VEGF-R2 with VEGF with Bz inhibits HuDMEC migration in vitro (Costa et 
al, 2009). Unfortunately the control vehicle also exerted similar effects on HuDMEC 
migration, the reason why the control vehicle is acting as an anti-angiogenic agent in vitro has 
yet to be determined and is a cause for concern as the extent to which the control vehicle is 
inhibiting HuDMEC function in vitro is similar to that observed with Bz.  
 
Np1 Peptides 
The Np1 peptides exerted inhibitory effects on HuDMEC differentiation and migration, 
suggesting that Np1 plays an important role in some key steps of the angiogenic process. 
However these inhibitory effects were variable over the course of the in vitro experiments. As 
mentioned previously, the HuDMEC cells utilised in these experiments were a mixture of 
both venous and lymphatic ECs. These two endothelial cell types observe differential 
expression of Np1 with venous ECs expressing Np1 to a greater extent and lymphatic ECs 
expressing pre-dominantly Np2. Thus if the ratio of lymphatic ECs to venous ECs was greater 
in the HuDMEC cultures used in different experiments, it is possible that the response to the 
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Np1 peptides would be greatly reduced or diminished due to the lack of Np1 receptor 
expression.  
 
Peptide 1, 7b and 10 all exerted inhibitory effects on HuDMEC differentiation, and was 
expected as it has previously been observed that Np1 plays a role in EC differentiation in 
vitro (Uniewicz et al, 2011). Peptide 2, which is a control peptide that does not bind Np1, also 
exerted significant inhibitory effects on HuDMEC in vitro activity. There is a lot of 
controversy surrounding the ability of VEGF121 to bind Np1, with some studies showing that 
even though VEGF121 does not bind Np1 directly, yet it is still capable of transducing 
downstream signalling that results in EC biological activity. However, it is possible that the 
peptides are having a toxic effect on the cells, which may explain the effects observed with 
the control peptide (p2). A toxicity assay would have been useful to assess this, prior to 
commencing functional assay analysis.  
No inhibitory effects on HuDMEC cell proliferation were observed with any of the four Np1 
peptides, again this may be a result of the experimental time points measuring the effects on 
cell proliferation being too short, thus longer time point beyond 72h may prove more useful.  
 
Migration 
Although no significant effects were observed on HuDMEC migration with the Np1 peptides 
in the scratch assay, there was an obvious inhibitory trend present, and the fact that no 
significance was reached may be due to the nature of the technique. In hindsight, the scratch 
assay may not be the ideal assay to measure cell migration, since mitomycin C pre-treatment 
may have caused the cells added stress during the process of making a ‘wound’, thus 
rendering the cells less efficient in terms of migration and partly for this reason the boyden 
chamber was carried out to assess the effects of p7b and p10 on HuDMEC cell migration. It is 
also important to note that the Boyden chamber induces chemotactic migration towards a 
VEGF gradient, this gradient may be important in the response of HuDMECs to VEGF. 
Interestingly, it appears that the gradient formed by VEGF in a chemotactic assay such as the 
boyden chamber is important, as the HuDMECs appeared to migrate more readily in this 
assay. Interestingly, it is important to note that results obtained on a particular effect on one 
function can not necessarily be compared over different techniques for that function, since in 
these experiments, the boyden chamber and scratch assay resulted in different observations. 
At least in relation to p10, whereby a trend suggesting stimulatory effect was observed with 
the scratch assay with the opposite being observed in the boyden assay. This emphasises that 
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when comparing data in the literature, the technique used is important.  The observation that 
the Np1 peptides alone inhibit HuDMEC differentiation and migration (Boyden chamber) 
suggests that the peptides potentially display biological activity. 
 
Combination 
Combining p2, p7b or p10 with Bz resulted in no additive inhibitory effects on HuDMEC cell 
differentiation when compared with Bz alone. However, in the combination experiments all 
three Np1 peptides tested failed to inhibit HuDMEC differentiation when added alone, 
compared with previous experiments carried out, where a minimum of a 50% reduction in 
cord formation was observed with all three peptides. Again, it is possible that the extent, to 
which the HuDMECs responded to anti-Np1 treatment, is all dependent on the level of Np1 
available on the cell surface. As mentioned with VEFG-R1 and VEGF-R2 previously, the 
addition of exogenous VEGF results in down-regulation of the receptors on the surface of the 
cell. This may also be the case with Np1, which could be tested using flow cytometry to 
measure the level of surface Np1 that present, in the presence and absence of exogenous 
VEGF over a time course and whether the Np1 expression profile changes after the removal 
of excess VEGF. Since there were no inhibitory effects observed with the three peptides 
alone, an additive effect could not be expected.  
 
Interestingly, when p2 was combined with Bz, the significant inhibitory effect that was 
observed with Bz alone on branch point formation was lost. This suggests that p2 and Bz are 
interacting in some way and subsequently impacting on HuDMEC activity in vitro. It is also 
possible that the peptides (p2 and p7b) are promoting angiogenesis to a certain extent by 
inducing signalling via Np1 rather than blocking it, which might explain why p2 caused the 
efficacy of Bz in inhibiting HuDMEC differentiation to be reduced somewhat. Therefore 
measuring the level of receptor activation in the presence and absence of the Np1 peptides 
would prove useful in establishing if the process of angiogenesis is being promoted. It is also 
possible that the blockade of the VEGF pathway through inhibiting interactions with both 
receptor families causes a compensatory effect via the up-regulation of alternative pro-
angiogenic factors such as FGF, thus any additive effects expected are lost. Additionally, the 
peptides used in these experiments are Np1 targeting and Np2 binding has not been reported 
(although p10 is thought to potentially also bind Np2, but this has not been confirmed). Since 
the peptides are confirmed to bind Np1 only, it is possible that Np2 signalling may 
compensate for the loss of Np1. Treating the cells with a peptide that effectively blocks both 
Np1 and Np2 could prove useful. Additionally, pre-treating the HuDMECs with Bz followed 
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by treatment with the Np1 peptides may prove a more useful regime in inhibiting the VEGF 
pathway.  
 
Similar to the differentiation assay, no significant additive inhibitory effects on HuDMEC cell 
migration were observed when p7b and p10 were combined with Bz, compared with Bz 
alone. However, there was a trend that suggested the p7b might have additive effects with Bz 
and the control vehicle, this was not significant but may be a result of the nature of the scratch 
assay. With this in mind, the transwell or Boyden chamber would prove to be a more useful 
method for measuring cell migration for future experiments.  
 
Np1 and Np2 antibodies 
Interestingly, the commercially available Np1 antibody (R&D Systems) inhibited HuDMEC 
differentiation to a lesser extent then any of the four Np1 peptides as observed in the primary 
experiments. The antibody available at the time, has been tested for receptor-ligand blockade 
in an ELISA assay using immobilised human Np1. It is therefore possible, that the level of 
Np1 expressed on the cell surface of the HuDMECs in the Matrigel assay was higher than that 
tested in the ELISA assay, thus suggesting the use of higher doses of both neuropilin receptor 
antibodies in future experiments to allow for more effective blocking of the receptor.  
Interestingly, the Np2 antibody inhibited HuDMEC differentiation to a slightly greater extent 
then the Np1 antibody, however this was still considerably lower then the inhibition observed 
with the Np1 peptides. This suggests that Np2 is also important in endothelial cell biology 
and could prove a useful anti-angiogenic target, thus it would have been interesting to test the 
Np1 and Np2 antibodies alone and in combination with one another to assess if inhibiting 
both neuropilin receptors is more effective at inhibiting and maintaining inhibitory actions of 
HuDMEC function in vitro. 
 
3.4 CHAPTER CONCLUSION 
The data from the in vitro experiments carried out, provide further evidence for the 
importance of VEGF and the VEGF receptors on microvascular endothelial cell activity in 
vitro. Additionally, the data shows that not only is Np1 protein expressed on human 
microvascular endothelial cells but also plays a functional role in endothelial cell biology (in 
vitro). The inhibition in HuDMEC cell differentiation and migration observed in the assays 
suggest that the Np1 peptides are biologically active as inhibitors of VEGF165 and Np1 
interactions on microvascular endothelial cells in vitro.  
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The peptides have shown that they are potentially capable of acting as anti-angiogenic agents 
in the in vitro setting. However, since Np1 is also thought to be expressed on breast cancer 
cells, it is also important to assess if these peptides have the potential to act as dual targeting 
agents. If this is the case, the use of Np1 targeting agents, could lead to more effective 
inhibition of tumour progression, as these peptides may be capable of targeting tumour 
progression via indirect (endothelial cells) and direct (tumour cells) mechanisms. The next 
chapter investigates the role that Np1 plays on breast cancer cell activity in vitro and whether 
this can be blocked with the Np1 peptides.  
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4. INTRODUCTION 
For a tumour to progress, breast cancer cells must exhibit a versatile phenotype whereby, 
they are able to effectively migrate and proliferate at both the primary tumour site and, the 
secondary metastatic niche.  
The expression and functional role of VEGF-R1 and VEGF-R2 with regards to endothelial 
cells, is relatively well established. However, the expression and function of these two 
receptors in conducting autocrine VEGF signalling in breast cancer cells is less defined. The 
expression of VEGF-R1 and VEGF-R2 on breast cancer cells is controversial with some 
studies observing expression whilst others, detect no expression at all. However, when the 
receptors are present they do appear to play a functional role on breast cancer cell activity. 
VEGF-R1 exerts a survival effect on MDA-MB-231 breast cancer cells (Lee et al, 2007). 
Suggesting that anti-angiogenic agents that target VEGF signalling, such as  Bz may in fact 
be acting on both the tumour vasculature and the breast cancer cells.  
The more recent identification of Np1 and Np2 as VEGF receptors further suggests an 
autocrine role for VEGF in breast cancer cells activity. To date (Sept 2014), Np1 has been 
show to play an important role in VEGF signalling, involved in breast cancer progression.  
Np1 acts as both a survival factor for breast cancer cells in vitro (Bachelder et al, 2001 and 
Barr et al, 2008) and has been implicated in promoting the breast cancer cell invasion, 
(Bachelder et al, 2002), migrate (Nasarre et al, 2003) and metastasis (Wanami et al, 2008). 
Thus inhibiting both the classical VEGF receptors and Np1 appears to be an interesting 
target. 
VEGF165b is thought to exhibit anti-angiogenic properties (Qiu et al, 2009) and is down 
regulated in other cancer cells such as renal cell carcinoma (Bates et al, 2002). The presence 
or absence of the suggested anti-angiogenic isoform has potential implications on the 
efficacy of VEGF targeted therapy and therefore, it was important to assess the expression 
profile of VEGF165b in the breast cancer cells.  
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4.1 MATERIALS & METHODS 
The MDA-MB-231 and MDA-MB-436 breast cancer cells are triple negative cells lines that 
resemble basal like breast cancer (Kao et al, 2009). Bz was approved for metastatic breast 
cancer and with the increased interest in personalised therapy, the use of two metastatic 
breast cancer cell lines with relatively similar profiles was deemed important in this current 
project.  
Western blot analysis was carried out, to characterise protein expression of VEGF and its 
receptors, VEGF-R1, VEGF-R2, Np1 and Np2, as well as the anti-angiogenic isoform, 
VEGF165b (section 2.2). Once the expression of the receptors was established, functional 
assays were performed. 
The MTS assay was used to measure the effects of Bz and the four Np1 peptides on breast 
cancer cell proliferation in vitro. For the MDA-MB-231 and MDA-MB-436 breast cancer 
cells, the proliferation assay was carried out in the absence of exogenous VEGF165 
(rhVEGF165) since optimisation of the MTS assay observed non-significant stimulatory 
effects of rhVEGF165 (20ng/ml) on these two metastatic breast cancer cells lines in 
comparison to cells alone in 1% serum media (section 2.5.2). 
The Scratch/wound healing assay was used to measure the effects of the above treatment 
groups on breast cancer cell migration in vitro. Similar to the MTS assay, the scratch assay 
was carried out in the absence of rhVEGF165 as optimisation of the assay observed non-
significant stimulatory effects of rhVEGF165 on MDA-MB-231 and MDA-MB-436 breast 
cancer cell migration compared with the cells alone in 1% serum media (2.6.1). 
The Boyden chamber was used to measure the effects of the Np1 peptides on directional 
migration of the breast cancer cells in vitro. Unlike the scratch assay, the Boyden chamber 
with the breast cancer cells was carried out in the presence of rhVEGF165 (50ng/ml) (section 
2.6.2), as initial experiments using this assay demonstrated the requirement of exogenous 
VEGF165 for sufficient migration of the breast cancer cells.  
Similar to the HuDMEC experiments (Chapter 3), all in vitro functional assays measuring 
the effects of Bz, were carried out in the presence of a control vehicle (CV) at equivalent 
volumes as those used for the Bz treatment wells. All experiments were carried out in 
triplicate and the graphs are a representative mean of the 3 separate experiments, allowing 
for statistical analysis to be carried out on the data using Sigmaplot software. Following 
assessment of normality, a t-test or a Mann-Whitney U Test was performed using Sigmaplot 
11 software. Significance was considered at P= 0.05. 
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4.2 RESULTS 
4.2.1 Characterisation of Factors 
Characterisation of all VEGF related proteins, was carried out using MDA-MB-231 and 
MDA-MB-436 cell lines to establish, which of these breast cancer cell lines would be most 
appropriate to utilise in the in vivo experiments.  
Protein expression of different VEGF isoforms was detected in both MDA-MB-231 and 
MDA-MB-436 breast cancer cell lysates as represented by several bands ranging from ~ 30-
50kDa (Figure 4.1a). VEGF protein expression was not detected in the conditioned media 
from either cell line. The anti-angiogenic isoform of VEGF, VEGF165b, was not detected in 
the cell lysates or conditioned media of either MDA-MB-231 or MDA-MB-436 breast 
cancer cells (Figure 4.1b).  
 
 
                                                                                                   
 
 
                                                            
 
VEGF-R1 protein expression was detected in the cell lysates of both MDA-MB-231 and 
MDA-MB-436 breast cancer cells (Figure 4.2a). A band was observed at ~180kDa in the 
MDA-MB-436 cells and to a lesser extent in the MDA-MB-231 cells, although flow 
cytometry would be required to more accurately compare the levels of VEGF-R1 between 
the two breast cancer cells. VEGF-R1 was not detected in the conditioned media of either 
MDA-MB-231 or MDA-MB-436 breast cancer cells.  
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Figure 4.1 VEGF is Expressed by Breast Cancer Cells: 
(A)The active form of VEGF is secreted as a dimer and from the western blot above it is 
evident that the various VEGF isoforms are expressed by both MDA-MB-231 and MDA-MB-
436 breast cancer cells. (B) No VEGF165b was detected in the breast cancer cell lines.  
Images are representative of protein expression detected in triplicate experiments 
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VEGF-R2 protein expression was detected in the cell lysates of both the MDA-MB-231 and 
MDA-MB-436 breast cancer cells (Figure 4.2b). Interestingly, different forms of VEGF-R2 
were detected in the two breast cancer cells. In the MDA-MB-231 cell lysates, two bands 
were detected, one at ~200/230kDa, representing the mature glycosylated form of VEGF-R2 
(Takahashi et al, 1996) and the other at ~ 80kDa, representing a product of partial 
degradation of the receptor (cell signalling antibody datasheet). The MDA-MB-436 breast 
cancer cells also expressed both these forms of VEGF-R2, and an additional band at ~ 
150kDa, thought to represent the immature form of VEGF-R2 (Takahashi et al, 1996). 
VEGF-R2 protein expression was not detected in the conditioned media of either breast 
cancer cell line. 
Np1 protein expression was detected in the cell lysates of both MDA-MB-231 and MDA-
MB-436 breast cancer cells (Figure 4.2c). A single band at ~130kDa, representing full 
length Np1 was observed. No Np1 protein expression was detected in the conditioned media 
of either breast cancer cell line. Full length Np2 protein expression was also detected in the 
cell lysate of both MDA-MB-231 and MDA-MB-436 breast cancer cells (band at ~135kDa), 
(Figure 4.2d) although from the Western blot, the levels of Np2 protein expression in the 
cell lysate fraction appears to be greater in the MDA-MB-436 breast cancer cells compared 
with the MDA-MB-231 cells. However, overall protein expression of Np2 appears to be 
greater in the cultured HuDMECs cells (Figure 3.2D) compared with the breast cancer cell 
lines, although flow cytometry would be required to confirm this. No protein expression of 
Np1 or Np2 was detected in the conditioned media of either the MDA-MB-231 or MDA-
MB-436 breast cancer cells. In contrast to the MDA-MB-231 cells, two prominent bands 
were detected in the cell lysate of the MDA-MB-436 breast cancer cells, one at ~135kDa 
and the other at ~75kDa, with the latter band thought to correspond to the soluble form of 
Np2. 
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4.2.2 Effects of Bz on breast cancer cell function  
Bz is thought to primarily inhibit tumour growth indirectly via its effects on ECs. However, 
expression of both VEGF-R1 and VEGF-R2 was observed on the two metastatic breast 
cancer cell lines (MDA-MB-231 & MDA-MB-436) investigated in this study (Figure 
4.2a&b) and increasing evidence in the literature supports a direct functional role of VEGF-
R1 and VEGF-R2 on breast cancer cells (Liang et al, 2006; Lee at al, 2007). Therefore, it 
was important to assess the effects of Bz on breast cancer cell function in vitro.  
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Figure 4.2 VEGF Receptors are Expressed on Breast Cancer Cells: 
(A) VEGF-R1 protein expression was detected in both MDA-MB-231 and MDA-MB-436 cell 
lysates. (B) Various forms of the VEGF-R2 receptor was detected in both cell lines (C) Np1 
was largely evident in both cell lines (D) Np2 appears to be expressed to a lesser extent then 
Np1 but was detected in MDA-MB-436 cells and very slightly in the MD-MB-231 breast 
cancer cells.  
Images are representative of protein expression detected in triplicate experiments 
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Proliferation 
Bz treatment (0.25, 1 & 2.5mg/ml) significantly increased MDA-MB-231 breast cancer cell 
proliferation (0.25, 1 and 2.5 mg/ml Bz vs. cells alone control; 12 SEM±3.5%, 13 SEM±4.8 
and 20% SEM±2.2 vs. 100% SEM±0; n=3; p=0.029, 0.049, 0.001 respectively) compared 
with the cells alone control at 24 hours (Figure 4.3a). However, this significant increase was 
lost by the 48h time point, although the trend remained. Furthermore, there was also a 
significant increase (P=0.032) observed when the MDA-MB-231 cells were treated with CV 
(at the equivocal dose of 1mg/ml) (Figure 4.3b) at 24 hours compared with the cells alone 
control (14% increase SEM±4.2). However, this inhibition was lost due by 48h.  
No inhibitory effects on MDA-MB-436 breast cancer cell proliferation (Figure 4.3c) were 
observed, in the presence of increasing doses of Bz, at both 24 and 48h. Furthermore no 
effects on MDA-MB-436 breast cancer cell proliferation were observed with the addition of 
equivalent doses of CV (Figure 4.3d).   
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Migration 
Bz displayed no inhibitory effects on MDA-MB-231 breast cancer cell migration compared 
with the cell alone control at 24 or 48h (Figure 4.4a&b). Similarly, no inhibitory effects 
were observed on MDA-MB-231 cell migration in response to CV (Figure 4.4c). In 
contrast, MDA-MB-436 breast cancer cell migration was significantly (P=0.044 and 
P=0.003) inhibited in the presence of Bz at 0.125 and 1mg/ml compared with the cells alone 
* 
* 
* * 
A B 
C D 
Figure 4.3 Effects of Bz on Breast Cancer Cell Proliferation: 
In the absence of recombinant VEGF165, (A) treatment of MDA-MB-231 breast cancer cells with 
Bz resulted in an initial dose dependent increase in cell proliferation at 24h when expressed as a 
% of the cells alone control at 24h which was significant (P= 0.029,P=0.049 and P=0.001). 
However, this was not maintained. (B) CV (1mg/ml) also significantly (P=0.032) stimulated 
MDA-MB-231 breast cancer cell proliferation at 24h but again was lost b 48h. In contrast (C) Bz 
or the (D) CV exerted no significant effects on MDA-MB-436 breast cancer cells proliferation. 
Data is presented as mean±SEM (% proliferation compared with cells alone; n=3, *p<0.05). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software). 
* 
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control at 24h (mean±SEM; Bz 0.125 and 1mg/ml vs. cells alone; 86±5% and 75±4% vs. 
100±0%; n=3, p=0.044 and p=0.003) (Figure 4.5a). However, the significant inhibitory 
effects were not maintained after 48h. The CV at the 0.125mg/ml dose also displayed a 
significant (P=0.004) inhibitory effect on MDA-MB-436 breast cancer cell migration 
compared with the cells alone control at 24h (mean±SEM; CV 0.125mg/ml vs. cells alone; 
67±5% vs. 100±0%; n=3, p=0.004) (Figure 4.5b). Similar to Bz, the significant inhibitory 
effect observed with the control vehicle was not maintained after 48h.  
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Full media Cells alone 
Figure 4.4 Effects of Bz and CV on MDA-MB-231 Breast Cancer Cell Migration: 
(A) Representative images of MDA-MB-231 gap closure 48h after creating a scratch in the 
presence of cells alone or Bz. In the absence of recombinant VEGF165, no inhibitory effects on 
MDA-MB-231 breast cancer cell migration  was observed with the addition of (B) Bz or (C) CV, 
when expressed as the % gap closure compared with the cells alone control at 24h.  
 Data is presented as mean±SEM (% gap closure compared with cells alone at 24h; n=3, NS). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software).  
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4.2.3 Effects of the four Np1 Peptides on Breast Cancer Cell Function 
In order to assess, whether the Np1 peptides detailed in Chapter 3 had a direct effect on 
breast cancer cells, their efficacy was tested in the in vitro functional assays.  
Proliferation 
None of the, Np1 peptides had any effect on MDA-MB-231 breast cancer cell proliferation 
in vitro after 24 or 48h of treatment (Figure 4.6). 
 
Full Media Cells alone 
Figure 4.5 Effects of the Bz and CV on MDA-MB-436 Breast Cancer Cell Migration: 
(A) Representative images of MDA-MB-436 gap closure 48h after creating a scratch in the 
presence of cells alone or Bz In the absence of recombinant VEGF165, (B) MDA-MB-436 breast 
cancer cell proliferation was significantly (P= 0.044 and P=0.003) inhibited at 24h in response to 
Bz treatment (0.125 & 1mg/ml) compared with the cells alone control. However, this was lost by 
48h. (C) CV at 0.125mg/ml significantly (P=0.004) inhibited  
 Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, p<0.05). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software). 
A 
B 
* 
2.5mg/kg Bz 
* * 
C 
KEYPOINT 
The effects of Bz on breast cancer cell activity compared with the control vehicle (CV) 
could not be differentiated.  
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Peptide 1 and p2 had no significant effects (Figure 4.7a&b), whereas Peptide 7b at the 
highest dose (50μM) significantly inhibited (P=0.021), MDA-MB-436 breast cancer cell 
proliferation (Figure 4.7c) after 48h compared with the 48h cells alone control (31±5% 
decrease). Similarly, peptide 10, which is thought to bind both Np1 and Np2, significantly 
inhibited (P=0.021) MDA-MB-436 breast cancer cell proliferation (Figure 4.7d) compared 
with the cells alone control at 24h (mean±SEM; 11±5%; 11±3% and 17±1% decrease 
respectively). However, only the 1μM dose of Peptide 10 significantly (P=0.021) 
maintained an inhibitory effect on MDA-MB-436 breast cancer cell proliferation after 48h 
when compared with the 48h cells alone control (mean±SEM; 32±4% decrease).  
 
Figure 4.6 Effects of the Np1 Peptides on MDA-MB-231 Proliferation No inhibitory effects on 
MDA-MB-231 breast cancer cell proliferation was observed in the presence of any of the four 
Np1 peptides (A) P1 (B) P2 C) P7b or (D) P10  
Data is presented as mean±SEM (% proliferation compared with the cells alone; n=3, NS).  
Statistical analysis was carried out using a t-test (Sigmaplot 11 software). 
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Migration 
Scratch Assay 
In the Np1 migration experiments, MDA-MB-231 breast cancer cells treated with the full 
media control displayed a significantly lower rate of migration after 24h compared with the 
cells alone grown in low serum media (mean±SEM; full media vs. low serum; 52±16% vs. 
100±0%; n=3, p=0.037) (Figure 4.8a-d). However by 48h, there was no significant 
difference in the rate of MDA-MB-231 breast cancer cell migration when treated with full 
media or low serum (cells alone control). No significant effects were observed on MDA-
MB-231 breast cancer cell migration in vitro, in the presence of any of the Np1 peptides 
compared with the cells alone control at either 24 or 48h (Figure 4.8a-d). Similarly, no 
* 
* * 
Figure 4.7 Effects of the Np1 peptide on MDA-MB-436 Breast Cancer Cell Proliferation: 
In the absence of recombinant VEGF165, (A) P1and (B) p 2 exerted no inhibitory effects on 
MDA-MB-436 breast cancer cell proliferation. Whereas both (C) p7b and (D) p10 significantly 
inhibited MDA-MB-436 breast cancer cell proliferation in vitro. 
Data is presented as mean±SEM (% gap closure compared with cells alone; n=4, *p=0.021). 
Statistical analysis was performed using the Mann-Whitney U Test (Sigmaplot 11 software). 
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significant effects were observed on MDA-MB-436 breast cancer cell migration, in the 
presence of any of the Np1 peptides (Figure 4.9a-d). 
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Figure 4.8 Effects of Np1 Peptides on MDA-MB-231 Breast Cancer Cell Migration: 
In the absence of recombinant VEGF165, neither, (A) p1, (B) p2, (C) p7b or (D) p10 exerted any 
significant inhibitory effects on MDA-MB-231 breast cancer cell migration in vitro when 
expressed as a % of the cells alone control 
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, *p=0.037). 
Statistical analysis was performed using t-test (Sigmaplot 11 software). 
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Boyden Chamber 
The Boyden chamber assay measures directional migration and potentially is a better 
method for assessing the effects of drugs on breast cancer migration. Recombinant VEGF165  
was added to the breast cancer cells in the Boyden chamber assay, as an initial experiment 
prior to treating with the peptides demonstrated that insufficient breast cancer chemotaxis 
occurred in the absence of exogenous VEGF165. However, in these Boyden experiments, 
VEGF did not significantly increase migration of MDA-MB-231 breast cancer cells, 
suggesting that there is a high level of heterogeneity in the response to VEGF by the 
cultured breast cancer cells. Since, no inhibitory effects on breast cancer cell migration were 
observed with any of the peptides in the scratch assay, one human derived peptides (p7b) 
A B 
C D 
Figure 4.9 Effects of Np1 Peptides on MDA-MB-436 Breast Cancer Cell Migration: 
In the absence of recombinant VEGF165, neither, (A) p1, (B) p2, (C) p7b or (D) p10 exerted any 
significant inhibitory effects on MDA-MB-231 breast cancer cell migration in vitro when 
expressed as a % of the cells alone control 
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, NS).  
Statistical analysis was performed using t-test (Sigmaplot 11 software). 
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and the other peptide with potential Np1 and Np2 binding (p10) were chosen to measure the 
effects on breast cancer cell migration, in the chemotactic migration assay.  
There was a trend that suggested that the presence of p7b and p10 stimulated MDA-MB-231 
breast cancer migration in vitro compared with the VEGF165 alone control (mean±SEM; p7b 
and p10 vs. VEGF165; 410±287% and 363±262% vs. 100±0%; n=3, NS). (Figure 4.10a) 
However, this trend was not significant (p= 0.341 and p=0.372 respectively). In the Boyden 
chamber assay, the addition of VEGF165 (50ng/ml) significantly (P=0.013) increased MDA-
MB-436 breast cancer migration compared with the cells alone control (mean±SEM; 
VEGF165 vs. cells alone; 100±0% vs. 53±11%, n=3, p=0.013) (Figure 4.10b). Similar to the 
MDA-MB-231 breast cancer cells, p7b and p10 both increased MDA-MB-436 breast cancer 
cell migration compared with the VEGF165 alone control (mean±SEM; p7b and p10 vs. 
VEGF165; 272±40% and 211±37% vs. 100±0%; n=3, p= 0.013 and p=0.039), this however 
was significant (P=0.013 and P=0.039) (Figure 4.10b). 
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4.2.4 Effects of combining Bz with Np1 Peptides on Breast Cancer Cell Function  
As no inhibitory effects on MDA-MB-231 breast cancer cell proliferation or migration were 
observed in the presence of Bz or any of the four Np1 peptides, a combination experiment 
was deemed irrelevant. Similarly, as no overall inhibitory effect with Bz or any of the four 
Np1 peptides was observed, on MDA-MB-436 breast cancer cell migration, a combination 
experiment was not carried out. Peptide7b and p10 alone, both significantly inhibited MDA-
Figure 4.10 Effects the Np1 Peptides on Breast Cancer Cell Migration; Boyden Chamber: 
In the presence of recombinant VEGF165, (A) P7b and p10 stimulated MDA-MB-231breast 
cancer cell migration. However this increase was not significant. (B) In contrast significant 
(P=0.013 and P=0.039) stimulatory effects were observed on MDA-MB-436 breast cancer cell 
migration in the presence of p7b and p10 respectively. 
 Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, p<0.05). 
Statistical analysis was performed using the t-test (Sigmaplot 11 software).  
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MB-436 breast cancer cell proliferation in previous experiments; therefore the effects of 
combining Bz with p7b and p10 on MDA-MB-436 breast cancer cell proliferation were 
assessed. 
No significant inhibition on MDA-MB-436 proliferation was observed when the cells were 
treated with 5mg/ml Bz at 24 and 48h compared with the relevant cells alone control. This is 
consistent with the previous results looking at the effects of varying doses of Bz on MDA-
MB-436 proliferation (section 4.2.1). There was a significant (P< 0.001) reduction (34%) in 
MDA-MB-436 proliferation at 24h in the presence of CV (5mg/ml) compared with the 24h 
cells alone control. However, this inhibition was lost by the 48h time point (Figure 4.11). 
There was also a significant (P<0.001) inhibitory effect (42%) on MDA-MB-436 
proliferation when the cells were treated with a combination of CV and p7b (5mg/ml and 
50μΜ respectively) compared with the 24h cells alone control which was maintained at the 
48h time point (P=0.029). However, there was no significant additive effect of the 
combination compared with CV alone (P=0.159) at 48h (Figure 4.11).  
At the 24h time point, combining Bz (5mg/ml) with p10 (1μM) resulted in a significant 
(P=0.011) inhibitory effect in MDA-MB-436 proliferation (23% decrease) compared with 
the 24h cells alone control (Figure 4.12). However, this combined inhibition was not 
significantly different when compared with Bz alone (P=0.925), despite the fact that there 
was no inhibition observed in the presence of Bz alone at either concentration. 
Unfortunately, the inhibition observed at 24h was not maintained at 48h. Combining CV 
with p10 demonstrated no additive effects in MDA-MB-436 cell proliferation (Figure 4.12). 
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Figure 4.11 Effects of Combining Bz and CV with P7b on MDA-MB-436 Breast Cancer Cell 
Proliferation:  In the absence of recombinant VEGF165, combining (A) p7b with Bz exerted no 
additive effects on MDA-MB-436 breast cancer cell proliferation in vitro when compared with 
Bz alone. (B) Combining p7b with CV, displayed no significant additive effects on MDA-MB-
436 breast cancer cell proliferation in vitro when compared to the CV alone 
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, *p<0.001). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software).  
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4.2.5 Effects of a Np1 and Np2 Antibody on Breast Cancer Function 
Migration 
It was thought that looking at the effects of Np2 along with Np1 was also important, so a 
Np1 and Np2 blocking antibody (R&D Systems) that blocks VEGF165 binding to Np1 or 
Np2, was used to assess if an antibody against Np1 or Np2 had greater inhibitory effects 
than those observed with the peptides. The addition of the Np1 or Np2 antibody exerted no 
inhibitory effects on MDA-MB-231 breast cancer cell migration (Figure 4.13), whereas, the 
Np1 antibody at 5μg/ml significantly (P=0.001) inhibited MDA-MB-436 breast cancer cell 
migration compared with the cells alone control at 24h (mean±SEM; Np1 antibody 5μg/ml 
vs. cells alone; 97±0.4% vs. 100±0%; n=3, p=0.001) (Figure 4.14a). However, although the 
trend remained, the inhibition with this dose of the Np1 antibody, compared with the cells 
alone control at 48h (mean±SEM; Np1 antibody 5μg/ml vs. cells alone; 110±13% vs. 
132±8%; n=3, NS) did not reach statistical significance (P=0.414). The addition of the Np2 
antibody to the MDA-MB-436 breast cancer cells, did not significantly (P=0.062 and 
P=0.161) inhibit cell migration at either, 24h (mean±SEM; Np2 antibody 10μg/ml vs. cells 
alone; 87±5% vs. 100±0%; n=3, NS) or 48h (mean±SEM; Np2 antibody 10μg/ml vs. cells 
alone; 103±15% vs. 132±8%; n=3, NS) (Figure 4.14b). 
 
Figure 4.12 Effects of Combining Bz and CV with P10 on MDA-MB-436 Breast Cancer Cell 
Proliferation: 
In the absence of recombinant VEGF165, combining (A) p10 with Bz exerted no additive effects 
on MDA-MB-436 breast cancer cell proliferation when compared with Bz alone. (B) Combining 
p10 with CV displayed no significant additive effects on MDA-MB-436 breast cancer cell 
proliferation when compared with CV alone.  
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, *p<0.05). 
Statistical analysis was performed using a t-test (Sigmaplot 11 software). 
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Figure 4.13 Effects of the Np1 and Np2 Antibody on MDA-MB-231 Breast Cancer Cell 
Migration: 
In the absence of recombinant VEGF165, (A) the Np1 antibody exerted no significant effects on 
MDA-MB-231 breast cancer migration in vitro when expressed as a % of the cells alone control. 
(B) Neither did the Np2 antibody exert any inhibitory effects on breast cancer cell migration.  
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, NS). 
Statistical analysis was carried out using the t-test (Sigmaplot 11 software).  
A B 
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Figure 4.14 Effects of the Np1 and Np2 Antibody on MDA-MB-436 Breast Cancer Cell 
Migration: 
In the absence of recombinant VEGF165, (A) the Np1 antibody exerted significant (P=0.001) 
inhibitory effects on MDA-MB-436 breast cancer migration when expressed as a % of the cells 
alone control at 24h. However, this inhibition was not maintained at 48h. (B) The Np2 antibody 
did not exert significant inhibitory effects on breast cancer cell migration.  
Data is presented as mean±SEM (% gap closure compared with cells alone; n=3, p=0.001). 
Statistical analysis was carried out using the t-test (Sigmaplot 11 software).  
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4.3 CHAPTER DISCUSSION 
 4.3.1 Characterisation of VEGF Related Proteins 
VEGF and VEGF165b 
VEGF protein expression was detected in both MDA-MB-231 and MDA-MB-436 breast 
cancer cell lysates, with a number of bands being observed, which corresponds to the 
presence of the various VEGF isoforms produced. However no expression was observed in 
the conditioned medium of either cell line, which was surprising as VEGF is secreted and 
would be expected to be present in the medium. It is possible that western blotting 
techniques are not sensitive enough to detect secreted VEGF, thus an ELISA assay may 
prove useful in determining the levels of VEGF that are secreted by the breast cancer cells in 
vitro.  
VEGF165b protein expression was not detected in the cell lysate or the conditioned medium 
of either the MDA-MB-231 or MDA-MB-436 breast cancer cells. Initially, this was not 
surprising as VEGF165b is thought to be an endogenous regulator of VEGF activity, thus 
potentially displaying anti-angiogenic activity (Qiu et al, 2009) and the levels of this anti-
angiogenic isoform are thought to be markedly decreased in tumours such as renal 
carcinoma (Bates et al, 2002) and prostate cancer (Woolard et al, 2004). Therefore it could 
be assumed that aggressive breast cancer cells such as MDA-MB-231 and MDA-MB-436 
cells would down-regulate VEGF165b expression. However, more recently it has been 
observed that VEGF165b is in fact up-regulated in malignant breast tissue compared with 
normal breast epithelium (Catena et al, 2010), although there are no reports in the literature 
of VEGFxxxb being detected in the breast cancer cell lines, the role of VEGF165b as a negative 
regulator of VEGF165 activity and the role, if any, that this isoform plays in breast cancer 
progression needs further investigation. 
VEGF Receptors 
Assessment of VEGF receptor expression in breast cancer cells in the literature is mostly 
measured by mRNA levels; however protein expression is a better reflection of functional 
relevance of the receptors. VEGF-R1 and VEGF-R2 protein expression was observed on 
both breast cancer cells lines. The presence of a partially degraded product of VEGF-R2 in 
the breast cancer cells suggests that the breast cancer cells were activated in culture in a 
autocrine manner, as degradation of tyrosine kinase receptors is thought to occur upon 
ligand binding (Grunewald et al 2010 & Goh et al, 2013) and the presence of the immature 
form of VEGF-R2 may be indicative of newly synthesised VEGF-R2. The observation of a 
partial degradation product and the immature form of VEGF-R2, suggests that the 
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expression of cell surface VEGF-R2 is transient, and therefore, recycling, degradation and 
synthesis of VEGF-R2 could potentially occur in breast cancer cells as a result of autocrine 
VEGF signalling. No VEGF-R1 and VEGF-R2 protein expression was detected in the 
conditioned medium of both breast cancer cells despite soluble forms of both receptors 
existing. As with VEGF, it is possible that an ELISA assay may prove more sensitive in 
detecting soluble VEGF receptor expression.  
Np1 and Np2 protein expression were detected in both breast cancer cell lines, although to 
varying degrees, with Np2 expression appearing to be greater in the MDA-MB-436 breast 
cancer cells as only a faint band was observed in the MDA-MB-231 cells, although flow 
cytometry would be required to confirm this. The MDA-MB-436 cells, similar to the 
HuDMECs, also appear to express soluble form of Np2. The expression of all four VEGF 
receptors on the breast cancer cell lines, suggested that targeting both VEGF receptor 
families is a feasible therapeutic measure. Np1 protein expression in the MDA-MB-231 cells 
has been previously observed (Barr et al, 2005; Lee et al, 2007), and Np2 mRNA 
(Timoshenko et al, 2007) whereas Np1 and Np2 expression on MDA-MB-436 breast cancer 
cells has not been investigated (PubMed). 
As with the HuDMEC receptor expression discussion (3.3.2), analysis of cell surface 
receptor expression using flow cytometry would prove useful in determining the levels of 
different receptor expression and would allow for direct comparison on the levels of 
receptors that are present on the two different breast cancer cell lines.  Also as suggested for 
the HuDMEC cells, receptor expression under normoxic and hypoxic conditions would be 
useful, as hypoxia can affect the level of receptors present on the cell surface of breast 
cancer cells. Differential receptor expression has been observed by MDA-MB-231 breast 
cancer cells under stress conditions such as hypoxia, although the observations varied, with 
one group observing an increase in Np1 expression in MDA-MB-231 under hypoxic 
conditions (Barr et al, 2008), whereas, another study observed, a slight decrease in Np1 
protein expression in these cells under hypoxic conditions (Bae et al, 2008).  
 
4.3.2 Effects of Bz on Breast Cancer Cell Function In Vitro 
Since VEGF-R1 and VEGF-R2 protein expression was observed on both MDA-MB-231 and 
MDA-MB-436 breast cancer cells, assessing the direct effects that Bz had on these breast 
cancer cells in vitro was important prior to commencing any in vivo experimentation.  
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Proliferation 
Overall, longer experimental time points for assessing effects on cell proliferation may prove 
more informative, especially to establish if the stimulatory effects observed on MDA-MB-
231 breast cancer cell proliferation in the presence of Bz are maintained over time. The 
results in this current study differ from those previously observed, where no effects on 
MDA-MB-231 breast cancer cell proliferation, in response to Bz treatment have been noted 
( Roland et al, 2009 & Ortholan et al, 2010).  
In the current studies the control vehicle for Bz at the 1mg/ml dose also exerted a 
stimulatory effect on MDA-MB-231 breast cancer cell proliferation in a similar manner to 
the equivalent dose of Bz. Therefore the effects seen with Bz, that are mirrored by the CV, 
can not be taken as positive data, as these are not a reflection of ‘true’ Bz activity. There is 
very little literature that investigates the effects of the vehicle in which Bz is re-suspended, 
and studies that contain a control treatment group generally use PBS or saline as a control. 
The Bz vehicle and therefore the control vehicle used in this study consists of sodium salts 
and tween, thus we initially thought that CV alone may cause a change in pH in the medium. 
However, we tested this, and there was no difference in pH, between the medium containing 
CV alone or Bz. It is important to further determine why CV, itself appears to exhibit effects 
on breast cancer function, which was at times comparable to the effects observed with Bz. 
More recently, there have been some studies investigating the effects of tween20 (which is 
in the CV) on cell activity, including breast cancer cells (Yamagata et al, 2009, Yang et al, 
2012 & Eskandani et al, 2013). These studies suggest that the tween20 present in CV may 
partly be responsible for the in vitro activity observed on the breast cancer cells. 
The MDA-MB-231 and MDA-MB-436 cell lines phenotypically appear very similar, in that 
both are ER/PR/HER receptor negative, and both are aggressive cell lines that show 
metastatic capability in vivo (Iorns et al, 2012). However, the two cell lines responded 
differently to Bz treatment, as no significant effects were observed on MDA-MB-436 breast 
cancer cell proliferation. It is possible that, the levels of VEGF-R1 and VEGF-R2 expression 
differ between the two metastatic breast cancer cells, resulting in differences in the response 
to VEGF receptor targeted therapy, such as Bz. It is thought that VEGF-R1 expression in 
breast cancer cells is detected mostly on the nuclear envelope rather then the cell surface 
(Lee et al, 2007), thus inhibitors that are unable to penetrate into the nucleus may not be able 
to maintain VEGF-R1 signalling inhibition. Therefore the location of the VEGF receptors 
and ability of subsequent inhibitors to penetrate into the nucleus could prove crucial in 
designing effective inhibitors.  
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Migration 
No inhibitory effects on breast cancer cell migration were observed in response to Bz 
treatment in vitro in the scratch assay. These finding differ to what has been observed in the 
literature, whereby Bz inhibited MDA-MB-231 breast cancer migration (Roland et al, 2009 
and Prager et al, 2010). In the above studies, different formats of the transwell assay were 
used to assess the effects of Bz on MDA-MB-231 cell migration. In the Prager et al study 
MDA-MB-231 breast cancer cells were seeded on a monolayer of endothelial cells in the 
upper chamber of a transwell assay. It is possible that, differences in migration assays used 
(scratch vs. transwell in the presence of endothelial cells or a Matrigel monolayer), may 
explain why the results from the current study differ from previous publications as the 
scratch assay measures unidirectional migration and the transwell and Boyden chamber both 
measure directional chemotaxis. The various VEGF isoforms, in vivo, create a VEGF 
gradient that is important for appropriate VEGF signalling and orchestrating the formation 
of the vasculature, with this in mind, it may have proved more informative to have carried 
out transwell assays to measure the effects of Bz on breast cancer cell migration in vitro, 
however, time constraints prevented this. 
Overall, Bz displayed no inhibitory effects on MDA-MB-231 or MDA-MB-436 breast 
cancer cell proliferation or migration in vitro.  As both the breast cancer cell lines used in 
these experiments exhibit an aggressive phenotype, it is possible that these cells are less 
dependent on the VEGF signalling pathway. It is also possible that upon VEGF blockade, 
these aggressive cells are capable of up-regulating factors that will compensate for the loss 
of VEGF. The presence of VEGF165b  renders Bz treatment ineffective as unlike other tumour 
types, it has been observed that VEGF165b is up-regulated in breast cancer (Catena et al, 
2010) and since VEGF165b also binds Bz (Varey et al, 2008) it is possible that VEGF165b 
sequesters Bz, making the more pro- active form of VEGF available to maintain tumour 
growth. However, as VEGF165b was not detected in these cell lines this makes it less likely, 
although it is possible that the antibody used in the Western blot analysis was not sensitive 
enough to detect VEGF165b levels. 
 
4.3.3 Effects of the Np1 Peptides on Breast Cancer Function In Vitro 
Since Np1 and Np2 protein expression was observed on both MDA-MB-231 and MDA-MB-
436 breast cancer cells and as previous studies suggest Np1, at least is involved in 
prevention of breast cancer cell apoptosis (Bachelder et al, 2001 and Barr et al, 2008 ), it is 
possible that Np1 and Np2 are feasible targets for breast cancer therapy. As previously stated 
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there appears to very little difference in phenotype between the MDA-MB-231 and MDA-
MB-436 cells, however the two cell lines responded differently to treatment with the Np1 
peptides.  
Proliferation 
Treatment with the four Np1 peptides exerted no inhibitory effects on MDA-MB-231 breast 
cancer cell proliferation. The Np1 peptides exerted significant inhibitory effects on MDA-
MB-436 breast cancer cell proliferation in vitro. The inhibitory effects on MDA-MB-436 
breast cancer cell proliferation in the presence of the peptides, although minimal, differ to 
that observed with Bz treatment. Suggesting that not only does Np1 play a vital role in 
VEGF autocrine signalling, but it may also act as the primary receptor for VEGF induced 
activity on breast cancer cells, at least in relation to breast cancer cell proliferation in vitro. 
The differences observed in the response to Np1 treatment by the MDA-MB-231 and MDA-
MB-436 breast cancer cells, may be a result of higher Np1 expression by the MDA-MB-436 
breast cancer cells, which thus respond better to Np1 targeted therapy. Although from the 
Western blotting techniques, there were no obvious differences (quantification would 
confirm this). Alternatively, the levels of other angiogenic factors expressed by the two 
breast cancer cells, may allow the MDA-MB-231 cells to elicit a stronger compensatory 
response in vitro, thus flow cytometry and a cytokine array would be useful to test these 
potential hypotheses. The use of peptides in inhibiting neuropilin interactions with VEGF in 
vitro, have previously has been investigated (Barr et al, 2005) and this study demonstrated 
significant apoptotic activity when MDA-MB-231 cells were treated with a 24-mer anti-Np1 
peptide (Barr et al, 2005). Although this study was investigating the effects on the peptide 
on MDA-MB-231 breast cancer apoptosis, it is important to note that the level of biological 
activity was similar in the Barr et al, 2005 study, to the peptides used in this current study in 
the MDA-MB-436 proliferation assay. Overall, the MTS assays, as a measure of 
proliferation may not have been the most appropriate assay. As dying cells, also require 
energy, which is the indirect parameter that is the principle behind the MTS assay. Thus, no 
differentiation was made in these assays, which would allow determination of whether the 
effects observed with the peptides was a consequence of toxic effects of the peptides or a 
true anti-proliferative effect.    
Migration 
No significant effects on MDA-MB-231 or MDA-MB-436 breast cancer cell migration were 
observed in the presence of any of the four Np1 peptides, when assessed using the scratch 
assay. However, the Boyden chamber assay resulted in a trend that suggested p7b and p10 
exert stimulatory effects on breast cancer cell migration in vitro, with significant stimulatory 
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effects being observed on the MDA-MB-436 breast cancer cells. This has previously been 
observed in the literature, whereby treatment with an anti-Np1 antibody caused a stimulatory 
effect on MDA-MB-231 migration in vitro (Bachelder et al, 2003). The group suggested 
that the reason for this stimulatory effect may be due to the VEGF/SEMA ratio present in 
the breast cancer cells. The binding site for the SEMA proteins lies within the a1/a2 domain 
of Np1, with the VEGF binding site lying within the b1/b2 domain. However, there is 
thought to be some over-lap in binding, suggesting that the SEMA proteins may act as 
antagonists. The group therefore suggested that the anti-Np1 and anti-Np2 antibody might 
also block the SEMA binding site, thus potentially decreasing the regulatory role that the 
SEMA proteins may play.  
It is not known if these peptides are capable of simultaneously inhibiting the other isoforms 
of VEGF, as the other VEGF isoforms, are also capable of transducing alternative VEGF 
signals via Np1. VEGF189 has been observed to induce apoptosis of breast cancer cells via 
Np1 (Vintonenko et al, 2011) thus if the peptides also inhibit VEGF189 from binding Np1, 
the apoptotic activity that VEGF189 induces on the MDA-MB-231 breast cancer cells in vitro 
may potentially be lost, thus maintaining breast cancer activity.  
 
4.3.4 Effects of Combining Bz with the Np1 Peptides on Breast Cancer Function 
As MDA-MB-436 breast cancer cell proliferation was the only breast cancer activity that 
was significantly inhibited in the presence of the Np1 peptides, a combination assay was 
only carried out. However, no additive effects were observed on MDA-MB-436 breast 
cancer cell proliferation in vitro when compared with the peptides alone. This, however 
could be expected as no inhibitory effects on breast cancer cell activity was observed with 
Bz alone, thus it would perhaps have been useful to carry out co-culture experiments 
whereby the breast cancer cells were cultured with the HuDMECs and then the effects of 
combining the peptides with Bz compared with Bz alone be evaluated. Since the two 
different cell types responded differently to Bz and Np1 peptide treatment, a co-culture 
assay may have proved more informative when trying to establish whether blocking both 
VEGF receptor families limits the resistance to therapy by targeting both the endothelial and 
the cancer cells.  
In the combination experiments, the initial inhibitory effect displayed with p7b and p10 on 
MDA-MB-436 breast cancer cell proliferation was not observed, this inconsistency in 
response is potentially due to trafficking and recycling of the Np1 receptors on the cell 
surface of the MDA-MB-436 breast cancer cells. Subtle changes in the microenvironment, 
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stress, or over confluency of cells may have affects on the levels of Np1 present on the 
surface, thus altering the response of these breast cancer cells to the peptides, although 
further work is needed to confirm this.  
4.3.5 Effects of a Np1 and Np2 Antibody on Breast Cancer Cell Function  
When commercially available antibodies against Np1 and Np2 were used in the scratch 
assay, no inhibitory effects were observed on MDA-MB-231 breast cancer cell migration. 
Similarly, no effects on MDA-MB-231 breast cancer cell migration were observed in the 
presence of the Np2 antibody. An inhibitory effect on MDA-MB-231 breast cancer cell 
migration was not necessarily expected as in the literature the presence of an anti-Np1 
antibody displayed stimulatory effects on MDA-MB-231 migration (Bachelder et al, 2003). 
Furthermore, the MDA-MB-231 cells had minimal Np2 expression. In contrast, the MDA-
MB-436 cells, which did express Np2, demonstrated an inhibitory trend which suggests that 
Np2 may play an important role in MDA-MB-436 breast cancer cell migration. However, 
additional repeats would be required to confirm the initial trend observed.  
Overall, the use of the scratch assay to measure migration may not be the best technique as 
although a number of trends were observed, no statistical significance was reached due to 
variability. When inhibiting receptor-ligand interactions, a certain amount of variability can 
be expected, especially since the expression of cell surface receptors can be transient and can 
change under various environmental conditions. However, it seems that the variability in the 
scratch assay may be partly due to the nature of the technique itself. The addition of MITC 
to limit cell proliferation, thus ensuring gap closure is due to cell movement. The ‘wound’ 
itself may have stressed the breast cancer cells, causing them to release factors that may 
affect breast cancer cell migration, thus changing or affecting the response of the breast 
cancer cells to Bz or anti-Np1 treatment. 
4.4 CHAPTER CONCLUSION 
The in vitro functional assays carried out, suggest that the Np1 peptides used in this study 
could potentially have some limited anti-tumourgenic effects on some breast cancer cell 
lines. However, VEGF is not the main cytokine involved in breast cancer cell function, thus 
blocking the VEGF system alone may not be the most effective method, especially when 
targeting the breast cancer cells. The nature of the neuropilin receptors, acting as both co-
receptors and independent receptors, suggest that they exert wide spread function and that 
the neuropilin receptors are a feasible target. However, blocking the interactions of Np1 
and/or Np2 with other cytokines as well as or instead of VEGF may prove more beneficial 
and effective at inducing or maintaining an inhibitory effect on breast cancer cell activity. 
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When aiming to improve the efficacy of Bz in breast cancer treatment, having a secondary 
treatment that blocks Np1 interactions with a number of ligands, that are up-regulated in 
response to VEGF inhibition, such as FGF and TGF-β may prove more efficacious. 
The differences that exist between the two breast cancer cell lines tested, need to be 
investigated further as the differential response to the Np1 peptides may prove to be very 
important in mirroring differences that are apparent in individual breast cancer patients. This 
also highlights the importance of finding biomarkers that will allow identification of 
individuals that will respond to Np1 therapies. At first glance, there appears to be very little 
difference in the phenotype between the MDA-MB-231 and MDA-MB-436; however 
analysis carried out more recently has identified the presence of different mutations in the 
two cell lines (Lehmann et al, 2011). Further analysis, using microarrays, on these 
supposedly similar breast cancer cell lines may enable identification of downstream events 
that may be responsible for differential responses to Bz and the Np1 peptides. 
4.5 IN VITRO RESULTS CONCLUSION 
From the in vitro experiments performed in Chapters 3 and 4, it is confirmed that Bz 
primarily inhibits tumour growth via its effects on the endothelial cells. As the in vitro data 
observed no significant effects on breast cancer cell proliferation or migration in the 
presence of Bz. The role of Np1, however, appears to be widespread across the two cell 
types, as the Np1 peptides significantly inhibited both microvascular endothelial and breast 
cancer cell activity in vitro albeit to a limited extent. The interplay between the 
microvascular and breast cancer cells is important in cancer progression and the 
communication between these two cell types is vitally important especially when assessing 
the effects of treatments such the Bz and anti-Np1 targeting agents.  
From the in vitro data it was decided that the MDA-MB-436 cells would be the most 
appropriate to follow up in the in vivo experiments, as expression of all four receptors 
appeared to be greater in these cells compared with the MDA-MB-231 cells. In terms of the 
Np1 peptides, both p7b and p10 exerted significant inhibitory effects on both the HuDMECs 
(differentiation and migration) and MDA-MB-436 (proliferation) breast cancer cells in vitro. 
This suggested that combining either of these two peptides with Bz may allow for a dual 
targeting approach in vivo, thus enhancing tumour inhibition and potentially overcoming 
resistance to Bz therapy.  
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5. INTRODUCTION 
The in vitro experiments allowed for direct investigation of the interaction of VEGF165 with 
the Np1 receptor and the potential role that this interaction has on breast cancer progression 
and resistance to Bz therapy. However, to assess if the Np1 peptides can be developed into 
clinically or biologically relevant targets for breast cancer therapy the evaluation of in vivo 
models was essential. The initiation of tumour development and metastasis is a dynamic 
process involving a number of other cell types that reside within the tumour 
microenvironment such as ECs, fibroblasts and macrophages. These different cell types 
produce and release a variety of growth factors and cytokines that can have various effects 
on the tumour cells. The relevance of blocking the interaction between VEGF165 and Np1 in 
vivo in both the primary and metastatic setting is important to assess.  
Bz was granted accelerated approval by the FDA in 2008 for use in the clinic in treatment of 
mBC. The clinical trial that lead to the approval of Bz in mBC resulted in an significant 
increase in PFS but with no additive effect on OS in the Bz containing arm compared with 
the paclitaxel alone (Miller et al, 2008).  However, since FDA approval combination therapy 
with Bz has mostly resulted in modest effects in mBC, with no reported increase in OS. A 
retrospective study reported that several compensatory factors were up-regulated in response 
to Bz treatment, with potential impact on response to Bz therapy (Jubb et al, 2011), Np1 was 
amongst these factors. This suggests that Np1 may play an important role in providing an 
alternative signalling pathway for VEGF, thus enabling tumours to escape therapy. 
The majority of preclinical data available using Bz in breast cancer treatment is limited 
mostly to adjuvant therapy which investigates combining Bz with standard chemotherapeutic 
agents or radiotherapy. This is due to the proposed vascular mechanism of action for Bz, 
which is thought to primarily act on the endothelial compartment, thus exerting indirect 
effects on the breast cancer cells. The emerging role of Np1 in breast cancer progression via 
actions on both the angiogenic pathway and the breast cancer cells directly, suggests that 
targeting Np1 alongside the classical VEGF receptors is a feasible approach that may have 
more wide-spread effects on the tumour micro-environment. In addition to this, there are also 
indications that lower tumour Np1 expression favours a positive Bz response in breast cancer 
patients (Jubb et al, 2011) suggesting that combing Bz with agents that target the Np1 
receptor may potentially overcome the problem of resistance that is now apparent in a 
proportion of some Bz treated mBC patients. Thus, Bz was combined with two neuropilin 
peptides (p7b or p10) to achieve both an anti-angiogenic and an anti-tumourgenic effect in 
the combination groups, thus increasing tumour inhibition.  
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5.1 MATERIALS & METHODS 
5.1.1 Cell Lines 
In the current project two human metastatic breast cancer cells were utilised (MDA-MB-231 
and MDA-MB-436) to test the hypothesis that combination treatment targeting the VEGF 
pathway in metastatic breast cancer, demonstrates enhanced efficacy. Additionally, with the 
increased interest in personalised medicine, the use of two metastatic cell lines may prove 
more informative and allow identification of downstream effectors that might be responsible 
for any differential responses observed to therapy in the clinical setting.  
Both cell lines are identified as representing triple negative breast cancer (TNBC) with a 
Basal B phenotype and both display a histology that is reflective of invasive ductal 
carcinoma (Lehmann et al, 2011). The two cell lines display a similar morphology in 
culture, are known to form tumours in vivo and display metastatic potential when implanted 
in a murine model. However, although both are metastatic, the MDA-MB-436 are thought to 
be moderately metastatic compared with MDA-MB-231 cells, which are known to be highly 
metastatic (Tu et al, 2011). In addition, molecular analysis has brought to light a number of 
mutational differences that are present between the two cell lines (Lehmann et al, 2011), 
with some of these mutations having various potential effects on the VEGF pathway.  
 
5.1.2 Sub-Cutaneous Murine Breast Cancer Model 
Growth Kinetics 
A GFP-labelled MDA-MB-436 cell line had been previously generated in the laboratory for 
use in vivo. GFP-labelled human MDA-MB-436 breast cancer cells were implanted into the 
flank region of anaesthetised (isofloarine) athymic CD1 nude female mice (4–5weeks old) at 
three different cell densities (1x105, 1x106 and 5x106; administered in a total volume of 
100µl). The three different densities were used to establish growth kinetics and the minimum 
treatment window. Once a palpable tumour had developed (100mm3), tumour growth was 
measured twice weekly using callipers. At the end of the study (4 weeks post development of 
a treatable tumour) tumours were excised and wax embedded to allow optimisation of 
staining protocols.  
 
Combination Studies 
For the treatment experiments, 1x106 GFP-labelled human MDA-MB-436 breast cancer cells 
were injected via a sub-cutaneous (s.c.) injection into the left flank of anaesthetised 
(isofloarine) CD1 nude female mice (4-5weeks old). Tumours were measured using callipers 
twice weekly and treatment with either Bz, CV, p7b, p10, Bz/p7b, Bz/p10 or saline began 
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when tumours reached a tumour volume of 100mm3. (Table 5.1-5.3). The 5mg/kg dose of Bz 
used in the initial in vivo studies was chosen as a result of a literature search (PubMed) that 
demonstrated several breast cancer in vivo experiments administered the same dose with 
tumour growth delays (Higgins et al, 2007; Xue et al, 2008; Borgan et al, 2012; Conley et 
al, 2012). In addition this dose was chosen due to results obtained from the in vitro studies 
(see section 3.2.2). During combination experiments animals received both Bz and one of the 
Np1 peptides on the same day; the peptides were administered one hour after the Bz 
injection. The end of the experiment was determined when either 1) the Home Office (HO) 
tumour diameter limit was reached (15mm), (2) the tumour ulcerated or (3) the animals lost 
greater than 10% body weight due to tumour development. Following cull, tumours were 
excised, divided in two and either frozen or formalin fixed prior to wax-embedding. Tumour 
sections were cut (5μM from the blocks) and stained with H&E for measuring tumour 
necrosis. CD34, Ki67 and Caspase 3 staining was carried out to assess the formation of new 
vessels, proliferation and apoptosis respectively. Normal tissues were also resected (liver, 
lungs, kidney and spleen) divided in two and frozen or formalin fixed to allow for further 
analysis to determine drug ‘off-target’ effects.  
 
5.1.3 Tumour Analysis 
Assessment of tumour necrosis was carried out on H&E stained tumour sections, using the 
chalkley grid (section 2.8.2), whereby the entire tumour section scored for positive and 
negative areas of necrosis allowed for the overall percentage necrosis to be calculated. 
Assessment of Ki67, Caspase 3 and CD34 staining was carried out by quantifying the mean 
number of positive cells or vessels present in 5 random fields of view. This methodology and 
analysis was used in all in vivo subcutaneous experiments described in the following results 
section. 
 
 
 
 
 
 
 
 
 
 
 
In Vivo Results-  
Effects on Primary Breast Cancer Growth 
 
SAPNA LUNJ Page 160 
 
Treatment Dose Frequency of 
Injection 
Route of 
Administration 
Volume 
of 
Injection 
n= 
(injected) 
Saline Not 
applicable 
Each time a 
Bz/peptide 
treatment was 
administered 
i.p. 100µl 5 
Bz 5mg/kg Twice weekly i.p. 100µl 
 
5 
CV Equivalent 
volume to 
Bz at 
5mg/kg 
Twice weekly i.p. 100µl 
 
 
 
5 
p7b 1µM Twice weekly i.p. 100µl 
 
5 
p10 50µM Twice weekly i.p. 100µl 
 
5 
Bz/p7b Bz: 5mg/kg 
 
p7b: 1µM 
 
Both twice 
weekly 
i.p. 
 
(p7b 
administered 
1hour after Bz 
injection) 
100µl 5 
Bz/p10 Bz: 5mg/kg 
 
p10: 50µM 
 
Both twice 
weekly 
i.p. 
 
(p10 
administered 
1hour after Bz 
injection) 
100µl 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Dosing regimens for Experiment One: Outlines the dosing regimen for the initial Bz 
and peptide combination study detailed in section 5.2.2.1–5.2.2.3.  
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Treatment Dose Frequency of 
Injection 
Route of 
Administration 
Volume of 
Injection 
n= 
(injected) 
Saline Not 
applicable 
Each time a 
Bz/peptide 
treatment was 
administered 
i.p. 100µl 6 
Bz 5mg/kg Twice weekly i.p. 100µl 6 
CV Equivalent 
volume to 
Bz at 
5mg/kg 
Twice weekly i.p. 100µl 6 
Bz 2.5mg/kg Twice weekly i.p. 100µl 6 
CV Equivalent 
volume to 
Bz at 
2.5mg/kg 
Twice weekly i.p. 100µl 6 
Bz 1mg/kg Twice weekly i.p. 100µl 6 
CV Equivalent 
volume to 
Bz at 
1mg/kg 
Twice weekly i.p. 100µl 6 
Bz 0.5mg/kg Twice weekly i.p. 100µl 6 
Bz 0.1mg/kg Twice weekly i.p. 100µl 6 
   
 
 
Treatment Dose Frequency of 
Injection 
Route of 
Administration 
Volume of 
Injection 
n= 
Saline Not 
applicable 
Each time a 
Bz/peptide 
treatment was 
administered 
i.p. 100µl 5 
Bz 0.1mg/kg Twice weekly i.p. 100µl 5 
Bz/p7b Bz: 
0.1mg/kg 
 
P7b: 1µM 
Twice weekly 
 
 
Three times a 
week 
i.p. 
 
 
(p7b administered 
1hour after Bz 
injection) 
100µl 5 
 
 
 
 
 
 
 
 
Table 5.2 Dosing regimens for the Bz Dose Study: Outlines the dosing regimen for the Bz dose 
study detailed in section 5.2.2.4. 
 
Table 5.3 Dosing regimens for Experiment Three: Outlines the dosing regimen for the second 
Bz combination study (with low doses of Bz) detailed in section 5.2.2.5.  
In Vivo Results-  
Effects on Primary Breast Cancer Growth 
 
SAPNA LUNJ Page 162 
 
5.1.4  Statistical Analysis 
Following assessment of normality statistical analysis was performed using the Mann-
Whitney U Test or a student’s t test. When comparing multiple groups the One Way 
ANOVA, followed by the Holm-Sidak’s post-hoc test or the Kruskal-Wallis was used 
(Sigmaplot 11 software). Statistical significance was considered at P = 0.05.  
5.2 RESULTS 
5.2.1 Optimisation of Cell Density for s.c MDA-MB-436 Implantation 
The optimal cell density required for s.c. tumour implantation was initially assessed. 
Implantation of  5x105 MDA-MB-436 GFP labelled breast cancer cells into the left flank 
resulted in 50% tumour uptake in athymic CD1 nude females (n=4), with two animals 
demonstrating small palpable tumour growth at 21 days and treatable tumours (100mm3) 
within 4.5 weeks post injection (Figure 5.1), however two animals had no detectable 
tumours. One animal with tumour growth demonstrated ulceration five days after reaching 
treatable tumour volume, thus had to be culled. In contrast, implantation of 1x106 MDA-
MB-436 GFP labelled breast cancer cells (n=3) resulted in 100% tumour take. Tumour 
growth was observed at 6 days post injection and treatable tumours (100mm3) within four 
weeks post injection (Figure 5.1). Implantation of 5x106 MDA-MB-436 breast cancer cells 
resulted in 67% tumour uptake (n=3), with two animals developing a palpable tumour 
(Figure 5.1). All three cell densities tested resulted in a tumour treatment window of 
approximately 4 weeks, before the end of procedure (EOP) was reached. All tumours from 
this study were excised and wax embedded to allow for optimisation of staining protocols for 
the IHC studies. This initial pilot study demonstrated that the optimal cell density for 
subcutaneous tumour implantation was 1x106 when taking into account the growth kinetics 
and volume (100mm3) required for the commencement of treatment.  
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Figure 5.1 Optimising MDA-MB-436 Breast Cancer Cell Density: MDA-MB-436 GFP 
breast cancer cells were implanted at varying concentrations into the left flank of CD1 nude 
female mice under anaesthesia (isoflurane). 5x105, (n=1)  1x106 (n=3) and 5x106 (n=2) 
 
# denotes individual animals that developed tumours 
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5.2.2 Primary Tumour Growth 
5.2.3 Effects of Bz on Subcutaneous Breast Cancer Growth 
Bz 
Having established the concentration of cells required to induce s.c. primary tumour growth 
a therapeutic intervention study was planned with Bz alone, the control vehicle for Bz (CV), 
p7b alone, p10 alone and Bz in combination with p7b and p10. Peptide 7b and p10 were 
chosen as the most efficacious neuropilin peptides from the in vitro study (see chapter 3&4). 
The EOP for individual animals was determined by one of the following criteria (1) once 
tumour diameter reached 15mm as measured by callipers (2) if the tumour ulcerated or (3) if 
greater than 10% body weight was lost due to tumour development. When EOP was reached 
for each individual animal, both tumour and normal organs (lung, liver, kidney and spleen) 
were excised, divided into two and frozen or formalin fixed to allow for subsequent ex vivo 
analysis. 
Control 
Following tumour implantation (MDA-MB-436; 1x106), an equal number of animals were 
randomly assigned to each treatment group (n=5/group). On the day treatment commenced, 
all five animals assigned to the saline control group had palpable tumours. Twenty-nine days 
post initial injection of saline treatment; two of the five animals were culled due to tumours 
reaching the maximum tumour size permitted by the Home Office and NCRI guidelines 
(15mm diameter) (Workman et al, 2010). By day forty-two post initial injection, all 
remaining animals (n=3) in the saline treated group were culled, due to tumour volume being 
reached or tumour ulceration (792.7±319.9mm3). In the Bz (5mg/kg) alone group, three of 
the five animals implanted with MDA-MB-436 breast cancer cells developed palpable 
tumours and were treated with Bz twice weekly via i.p injection, as one animal was culled 
prior to the start of treatment due to ulceration of the tumour and the second failed to develop 
a palpable tumour. By day twenty-one post initial injection, one of three remaining animals 
treated with Bz alone was culled due to tumour ulceration (864mm3). The remaining two 
animals continued to be treated until the end of the experiment (day 42). At the end of the 
experiment, treatment with Bz (n=2) resulted in inhibition of tumour growth compared with 
the saline (n=3) group (mean±SEM; Bz vs. saline control; 184±0mm3 vs. 793±320mm3; 
n=2/3) (Figure 5.2), however statistical analysis was not possible due to numbers. Therefore 
an earlier time point (day seventeen) was chosen for statistical analysis. It is important to 
note that throughout the Bz treatment period, a relatively cytostatic effect on tumour growth 
was observed (Figure 5.2). At day seventeen, Bz (n=3) inhibited tumour growth compared 
with the saline control (n=5) group (mean±SEM; Bz vs. saline control; 164±47mm3 vs. 
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406±103mm3; n=3/5, ns), this was not significant (P = 0.970) (Figure 5.2). In the group 
treated with the control vehicle for Bz (CV) at an equivocal volume of animals receiving 
5mg/kg Bz, four of the five animals implanted with MDA-MB-436 breast cancer cells 
developed palpable tumours and were treated with CV twice weekly via i.p. injection. By 
day thirty-five, post initial injection, one of the four animals treated with CV was culled due 
to tumour ulceration (900mm3). The remaining three animals continued to be treated with 
CV until the end of experiment (day 42). At day seventeen, when statistical analysis was 
performed, CV (n=4) resulted in inhibition in tumour growth compared with the saline (n=5) 
group (mean±SEM; CV vs. saline control; 212±60mm3 vs. 406±103mm3; n=4/5, ns), this 
was not significant (P = 0.173) (Figure 5.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Effects of Bz and CV on Breast Cancer Growth In Vivo.: Administration of Bz 
(5mg/kg) and CV; twice weekly (i.p.) reduced tumour growth compared with the saline control 
group. 
 
Data is presented as mean±SEM tumour volume (mm3); n=3-5, NS. Statistical analysis was 
performed on day seventeen using the One Way ANOVA (Sigmaplot 11 software).  
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5.2.4 Tumour Histology and Immunohistochemistry 
Due to the inhibitory trend observed with Bz and CV on of tumour growth in vivo, it was 
important to establish if there were any differences in tumour morphology or histology 
between experimental groups. Normal tissue was harvested from each animal at the EOP 
however; histology was only carried out on the tumour tissue. Wax embedded blocks and 
frozen sections for normal tissue are available for any further analysis required, especially to 
establish, if any effects observed with the treatment groups are tumour specific or more 
wide-spread. 
 
VEGF and VEGF Receptor Expression in MDA-MB-436 Tumours In Vivo 
From the in vitro experiments (section 4.2.1) it was evident that VEGF, VEGF-R1, VEGF-
R2, Np1 and Np2 were all expressed by MDA-MB-436 breast cancer cells in culture. 
However it was important to determine the in vivo expression of these molecules.  
VEGF expression was observed in the tumours from all the different treatment groups with a 
diffuse distribution being observed across the tumour tissue (Figure 5.3). The Bz treated 
tumours observed the weakest intensity of VEGF expression (Figure 5.3).  In general 
VEGF-R1 staining was observed across the tumour tissue, however, interestingly, stronger 
staining was evident within the necrotic areas of the tumour tissue (Figure 5.4). In the saline, 
Bz alone and Bz/p7b treated tumours VEGF-R1 expression was mostly weak to moderate in 
75% of the cells that expressed the receptor. In contrast, CV and Bz/p10 treated tumours 
expressed moderate to strong VEGF-R1 staining (Figure 5.8a).   
 
VEGF-R2 staining was observed in the tumours and displayed a wide-spread distribution 
pattern (Figure 5.5). The saline control, Bz/p7b and Bz/p10 treated tumours VEGF-R2 
staining was weak to moderate, whereas both CV and Bz treated displayed moderate to 
strong VEGF-R2 expression (Figure 5.8b) 
Np1expression was observed in the tumours but in contrast to the other VEGF receptor it 
was neither as wide-spread nor as strong (Figure 5.6), with the different treatment groups 
observing mostly weak staining (Figure 5.8c). Np2 expression was only observed in the 
control and Bz/p7b treated tumours (Figure 5.7 and Figure 5.8d). However, as the tumours 
were resected at different time-points an accurate endpoint comparison can not be made 
between the different treatment groups.  
 
 
In Vivo Results-  
Effects on Primary Breast Cancer Growth 
 
SAPNA LUNJ Page 167 
 
VEGF 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
100µM
Saline control
100µM
Bz (5mg/kg)
100µM 
100µM 
Bz/p7b
100µM
100µM
Bz/p10
100µM
100µM
Figure 5.3 Expression of VEGF by MDA-MB-436 Breast Cancer Tumours: 
Representative images to that demonstrate the presence of VEGF expression in the tumours. 
Diffuse, cytoplasmic VEGF staining was observed in all the tumours from the different treatment 
groups. Images were taken at x10 (main panel) and x60 (insert panel) magnification to visualise 
the pattern of VEGF staining.  
 
NB: It is important to note that VEGF staining was carried out using tumours taken at 
different experimental time-points, and therefore are not completely comparable.  
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VEGF-R1 
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IgG Saline control 
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100µM
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100µM100µM 100µM 
100µM 
CV 
100µM
100µM
Bz/p7b 
100µM100µM
Bz/p10
Figure 5.4 Expression of VEGF Receptor 1 by MDA-MB-436 Breast Cancer Tumours: 
Representative images to that demonstrate the presence of VEGF expression in the tumours. 
VEGF-R1 staining was observed in all the tumours from the different treatment groups. Images 
were taken at x10 (main panel) and x60 (insert panel) magnification to visualise the pattern of 
VEGF staining.  
 
NB: It is important to note that VEGF-R1 staining was carried out using tumours taken at 
different experimental time-points, and therefore are not completely comparable.  
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VEGFR2 
 
 
 
 
 
 
 
 
 
 
100µM 
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G  
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Saline control 
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100µM
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100µM
100µM
CV 
Bz/p7b 
100µM
100µM
100µM
100µM
Bz/p10
Figure 5.5 Expression of VEGF Receptor 2 by MDA-MB-436 Breast Cancer Tumours: 
Representative images to that demonstrate the presence of VEGF-R2 expression in the tumours. 
VEGF-R2 staining was observed in all the tumours from the different treatment groups. Images 
were taken at x10 (main panel) and x60 (insert panel) magnification to visualise the pattern of 
VEGF –R2 staining.  
 
NB: It is important to note that VEGF-R2 staining was carried out using tumours taken at 
different experimental time-points, and therefore are not completely comparable.  
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NP1 
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100µM 
100µM 
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Figure 5.6 Expression of NP1 by MDA-MB-436 Breast Cancer Tumours: 
Representative images to that demonstrate the presence of Np1expression in the tumours. Np1 
staining was observed in all the tumours from the different treatment groups but was much 
weaker compared to the other VEGF receptors. Images were taken at x10 (main panel) and x60 
(insert panel) magnification to visualise the pattern of Np1 staining.  
 
NB: It is important to note that Np1 staining was carried out using tumours taken at different 
experimental time-points, and therefore are not completely comparable.  
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Figure 5.7  Expression of NP2 by MDA-MB-436 Breast Cancer Tumours: 
Representative images to that demonstrate the presence of Np2 expression in the tumours. Np2 
staining was observed in the saline control tumours, with very little expression observed in the 
drug treatment groups. Over-all expression of Np2 was much weaker compared with the classical 
VEGF receptors. Images were taken at x10 (main panel) and x60 (insert panel) magnification to 
visualise the pattern of Np2 staining.  
 
NB: It is important to note that Np2 staining was carried out using tumours taken at different 
experimental time-points, and therefore are not completely comparable.  
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5.2.4 Breast Tumour Histology Evaluation 
Following tumour histological analysis was carried out to investigate the mechanism of 
action of the various drug treatments. Due to the pharmacological action of the agents used, a 
number of markers were identified. Ki67 is a nuclear marker that detects cell proliferation. In 
addition, the use of an anti-human antibody allowed assessment of treatment effects on the 
breast cancer cells directly (Figure 5.9).  
 
 
Figure 5.9 Nuclear staining of Ki67 positive breast cancer cells from a control tumour 
tissue fixed with formalin and wax embedded.  
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Figure 5.8IHC Scoring of VEGF Receptor in Treated Tumours: 
VEGF receptor IHC staining was scored by the intensity of staining observed within the tumour 
of the different treatment groups.  
 
NB: It is important to note that staining was carried out using tumours taken at different 
experimental time-points, and therefore are not completely comparable.  
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Caspase 3 is an important marker for measuring tumour apoptosis. Caspase 3 can be 
observed in both cytoplasmic and membranous locations, with the location of staining 
indicating the stage of apoptosis. The caspase 3 antibody reacts with both human and 
murine, therefore the direct effects on breast cancer cells as a result of different treatments 
could not be determined (Figure 5.10). 
 
 
 
Figure 5.10 Cytoplasmic and membranous staining of Caspase 3 positive cells from a 
Bz treated breast xenograft tumour tissue fixed with formalin and wax embedded. 
 
CD34, an endothelial marker is important for assessing the effects of anti-angiogenic agents 
such as Bz, as it identifies newly formed vessels and also haematopoietic progenitor cells 
(Figure 5.11).  
 
 
 
Figure 5.11 Positive CD34 vessels staining from a p10 treated breast xenograft tumour 
tissue fixed with formalin and wax embedded. 
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The tumours when resected at the end of the experiment demonstrated more than 60% 
necrosis in all experimental groups. However, no significant effects on tumour necrosis were 
observed when comparing tumours treated with Bz (5mg/kg), the CV or the saline control 
(mean±SEM; Bz (5mg/kg) and CV vs. saline control; 73±5% and 66±6% vs. 66±9%; n=3, ns  
(Figure 5.12). The number of proliferating breast cancer cells in the Bz treated tumours 
compared with saline control tumours, when measured as the number of Ki67 positive cells 
was not significantly (P = 0.086) different (mean±SEM; Bz 5mg./kg vs. saline control; 
110±11 vs. 133±2; n=3, ns) (Figure 5.13). Treatment with CV significantly increased the 
number of proliferating tumour cells compared with the saline control (mean±SEM; CV vs. 
saline control; 160±8 vs. 133±2; n=3, P = 0.030) (Figure 5.13).  
Bz significantly increased the number of apoptotic cells compared with tumours from the 
saline control group (mean±SEM; Bz vs. saline control; 33±2 vs. 21±1; n=3, P = 0.008) 
(Figure 5.14). A significant increase in caspase 3 positive cells was also observed in the CV 
treated tumours compared with the saline control group (mean±SEM; CV vs. saline control; 
30±46 vs. 21±1; n=3, P = 0.031) (Figure 5.14). 
Treatment with Bz (5mg/kg) resulted in a reduction in the number of CD34 positive vessels 
compared with the saline control group (±SEM; Bz vs. saline control; 9±3 vs. 19±7; n=3, 
ns), however this reduction did not reach statistical significance (P = 0.311) (Figure 5.15). 
Interestingly, the pattern of CD34 staining in the CV treated tumours differed to that 
observed with Bz treatment, whereby a mix of CD34 vessels were detected in addition to 
individual cells CD34 positive cells that were present in clusters (Figure 5.15).  
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Figure 5.12 Effects of Bz and the CV on Tumour Necrosis:  
 (A) Representative images taken at x10 and x60 magnification, illustrate an area of necrosis 
within the MDA-MB-436 tumour tissue. (B) A high level of necrosis was present in the MDA-
MB-436 tumours (~60%) and remained unchanged after treatment with both Bz (5mg/kg) and 
the CV. 
 
Data is presented at mean±SEM (% tumour necrosis); n=3, NS. Statistical analysis was 
performed on using a t-test (Sigmaplot 11 software).  
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points.  
 
 
 
 
B 
A 
In Vivo Results-  
Effects on Primary Breast Cancer Growth 
 
SAPNA LUNJ Page 176 
 
 
 
 
K i 6 7
M
e
a
n
 N
u
m
b
e
r
 o
f
 K
i6
7
 P
o
s
it
iv
e
 T
u
m
o
u
r
 C
e
ll
s
S
a
li
n
e
 C
o
n
t
r
o
l
B
z
 (
5
m
g
/k
g
)
C
V
0
5 0
1 0 0
1 5 0
2 0 0
 
 
 
 
 
 
 
 
Saline control 
100µM 100µM 
IgG 
100µM 100µM 
A 
B 
Figure 5.13 Effects of Bz and the Control Vehicle on Tumour Proliferation 
(A) Representative images taken at x 10 and x 60 magnification, illustrating Ki67 positive 
staining. (B) The level of breast cancer cell proliferation remained unchanged after treatment 
with Bz (5mg/kg) twice weekly (i.p.). In contrast, treatment with CV twice weekly (i.p.) 
significantly (P = 0.030) increased proliferation of the tumour cells. 
 
Data is presented as mean±SEM (Ki67+ cells); n=3, p=0.030 w.r.t to saline control. Statistical 
analysis was performed using the One Way ANOVA, followed by the Holm-Sidak post hoc test 
(Sigmaplot 11 software).  
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points.  
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Figure 5.14 Effects of Bz and CV on Apoptosis: 
 (A) Representative images of caspase 3 staining taken at x 10 and x 60 magnification. (B) Bz 
(5mg/kg) and CV significantly (P = 0.008 and P = 0.031 respectively) increased the level of 
apoptosis within the tumour tissue compared with the saline control group. 
 
Data is presented as mean±SEM (Caspase 3+ cells); n=3, p<0.05 w.r.t saline control. 
Statistical analysis was performed using the One Way ANOVA followed by the Holm-Sidak 
post hoc test (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points.  
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Figure 5.15 Effects of Bz and CV on CD34 Vessel Formation: 
(A) Representative images of CD34 positive vessels taken at x 10 and x 60 magnification. (B) Bz 
(5mg/kg) reduced the formation of new vessels in the tumour tissue compared with the saline 
control; however this was not significant (P 0.311). As the CV treated tumours had a mix of 
CD34+ vessels and individual cells, comparing between groups was difficult. 
 
Data is presented as mean±SEM (CD34+ vessels); n=3, NS. Statistical analysis was performed 
using a t-test (Sigmaplot 11 software).  
 
NB: It is important to note that analysis of CD34 was carried out using tumours taken at 
different experimental time-points 
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5.2.5 Effects of the Np1 Peptides on Subcutaneous Breast Cancer Growth 
Peptide 7b 
Following tumour implantation, an equal number of animals were assigned to each treatment 
group (n=5/group). All five animals developed palpable tumours and were subsequently 
treated with two weekly injections of p7b (1μΜ). On day twenty-one post initial injection of 
p7b, two of the animals were culled due to tumour ulceration (with tumour volumes of 
525mm3 and 817mm3) , with the remaining three continuing treatment until the end of 
experiment (day 31). However, as only 2 animals remained in the saline control group on 
day thirty-one, statistical analysis was performed on day twenty-one. At this time point p7b 
alone (n=5) had no inhibitory effects on tumour growth when compared with the saline (n=3) 
treated group (mean±SEM; p7b vs. saline control; 422±133mm3 vs. 467±138mm3; n=5/4, ns) 
(Figure 5.16). 
Peptide 10  
In the p10 treated group, four of the five animals implanted with MDA-MB-436 breast 
cancer cells developed palpable tumours and were treated with p10 (50μΜ) twice weekly via 
i.p injection. On day seventeen post initial injection of p10 alone, one animal was culled due 
to maximum tumour growth (1688mm3) with the remaining three animals continuing 
treatment with p10 until the end of experiment (day 42). At the end of the experiment, 
treatment with p10 alone (n=3) reduced tumour growth compared with the saline (n=3) 
group (mean±SEM; p10 vs. saline control; 329±111mm3 vs. 793±320mm3; n=3, ns) (Figure 
5.17), however this inhibition did not reach statistical significance (P = 0.242).  
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Figure 5.17 Effects of P10 on Breast Cancer Growth In Vivo:  
Treatment with p10 (50µM) alone when administered twice weekly (i.p.) exerted no significant 
inhibitory effects on MDA-MB-436 breast cancer growth in vivo compared with the saline 
control when analysed at day 42.  
 
Data is presented as mean±SEM tumour volume (mm3); n=3, NS. Statistical analysis was 
performed on Day 42 using the One Way ANOVA (Sigmaplot 11 software). 
 
Figure 5.16 Effects of P7b MDA-MB-436 Breast Cancer Growth In Vivo: 
Twice weekly injections with peptide 7b (1µM) alone (i.p.) displayed no inhibitory 
effects on MDA-MB-436 breast cancer growth in vivo compared with the saline 
control group when analysed at day 21. Data points for the saline group, post day 
21 are representative of the two remaining animals in this treatment group.  
 
Data is presented as mean±SEM tumour volume (mm3); n=4/5, NS. Statistical 
analysis was performed on Day 21 using the One Way ANOVA 
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Histology and Morphology 
Similar to the Bz treated tumours, a high level of tumour necrosis was present in the p7b 
treated tumours. However, no significant (P= 0.571) difference was observed when 
compared with the saline treated tumours (mean±SEM; p7b vs. saline control; 72±3% vs. 
65±11%; n=3, ns) (Figure 5.18). Treatment with p7b did not significantly (P = 0.432) effect 
the number of proliferating breast cancer cells compared with the saline control 
(mean±SEM; p7b vs. saline control; 48±18 vs. 31±7; n=3, ns) (Figure 5.19). Peptide 7b 
reduced the number of caspase 3 positive cells within the tumour compared with the saline 
control (mean±SEM; p7b vs. saline control; 8±4 vs. 16±0.4; n=3, ns) (Figure 5.21). 
However, this reduction did not reach statistical significance (P= 0.127). Interestingly, p7b 
alone treated tumours resulted in a different CD34 staining pattern then that observed with 
the other treatment groups. The staining pattern for p7b treated tumours displayed CD34 
positive single cells rather then vessel structures, much like that observed with the CV 
treated tumours (Figure 5.23).  
Treatment with p10 alone reduced tumour necrosis (mean±SEM; p10 vs. saline control; 
45±9% vs. 66%±9%; n=3, ns) (Figure 5.18) however, this was not significant (P = 0.160). 
Breast cancer cell proliferation remained similar in p10 treated tumours compared with the 
saline control group (mean±SEM; p10 vs. saline control; 145±13 vs. 133±2; n=3, ns) 
(Figure 5.20). Similarly, no effect on apoptosis was observed after p10 treatment compared 
with the saline control group (mean±SEM; p10 vs. saline control; 18±4 vs. 21±1; n=3, ns) 
(Figure 5.22). The number of CD34 positive vessels remained the same after p10 treatment 
compared with the saline control (mean±SEM; p10 vs. saline control; 23±1 vs. 19±7; n=3, 
ns) (Figure 5.24).  
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Figure 5.18 Effects of P7b and P10  on Tumour Necrosis (A) Representative image of an 
area of necrosis within the MDA-MB-436 tumour tissue taken at x10 (main panel) and x60 
(insert panel) magnification (B) Treatment with p7b (1μΜ) did not alter the level of tumour 
necrosis present. Whereas, p10 (50µM) reduced the level of tumour necrosis within the tumour 
tissue, however this was not significant (NS) (p=0.160).  
 
Data is represented as mean±SEM (% tumour necrosis); n=3, NS. Statistical analysis was 
performed using the One Way ANOVA (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points 
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Figure 5.19 Effects of P7b on Tumour Cell Proliferation In Vivo 
(A)Representative images of Ki67 staining taken at X40 magnification (B) Treatment with two 
weekly injections (i.p.) of p7b (1µM) did not significantly affect the level of breast cancer 
proliferation occurring within the tumour tissue compared with the saline control 
 
Data is presented as mean±SEM (Ki67 positive cells); n=3, NS. Statistical analysis was 
performed using the One Way ANOVA (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of Ki67 staining was carried out using tumours taken 
at different experimental time-points 
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Figure 5.20Effects of P10 on Tumour Cell Proliferation In Vivo: 
(A) Representative images of Ki67 staining taken at x40 magnification (B) Treatment with two 
weekly injections (i.p.) of p10 (50μM) did not alter the level of breast cancer proliferation 
occurring within the tumour tissue compared with the saline control. 
 
Data is presented at mean±SEM (Ki67 positive cells); n=3, NS. Statistical analysis was 
performed using the Kruskal Wallis One Way ANOVA on Ranks (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of Ki67 staining was carried out using tumours 
taken at different experimental time-points 
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Figure 5.21 Effects of P7b on Tumour Apoptosis 
(A) Representative images of Caspase 3staining taken at x40 magnification (B) Treatment with 
p7b twice weekly (i.p.) demonstrated no significant effects on the level of apoptosis occurring 
in the tumour tissue 
 
Data is presented as mean±SEM (Caspase 3+ cells); n=3, NS. Statistical analysis was 
performed using the One Way ANOVA (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of tumour apoptosis was carried out using tumours 
taken at different experimental time-points 
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Figure 5.22 Effects of P10 on Tumour Apoptosis 
(A) Representative images of Caspase 3staining taken at x10 (main panel) and x60 (insert) 
magnification (B) Treatment with p10 twice weekly (i.p.) demonstrated no significant effects 
on the level of apoptosis occurring in the tumour tissue 
 
Data is presented as mean±SEM (Caspase 3+ cells); n=3, NS. Statistical analysis was 
performed using the One Way ANOVA (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of tumour apoptosis was carried out using tumours 
taken at different experimental time-points 
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Figure 5.23 Effects of P7b on Micro-Vessel Density 
(A) Representative images of CD34 staining taken at x magnification  (B) Treatment 
with two weekly (i.p.) injections of p7b (1µM) demonstrates an uncharacteristic staining 
pattern for CD34; rather than vessel, CD34 positive cells were present in clusters in the 
tumour tissue. 
 
 
Figure 5.24 Effects of P10 on Micro-Vessel Density 
(A) Representative images of CD34 staining taken at x 60 magnification  (B) Treatment with 
two weekly (i.p.) injections of p10 (50µM) demonstrates an uncharacteristic staining pattern 
for CD34; rather than vessel, CD34 positive cells were present in clusters in the tumour tissue. 
 
Data is presented at mean±SEM (CD34 positive vessels); n=3, NS. Statistical analysis was 
performed using the Kruskal Wallis One Way ANOVA on Ranks (Sigmaplot 11 software).  
 
NB: It is important to note that analysis of tumour apoptosis was carried out using tumours 
taken at different experimental time-points 
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5.2.6 Combined Effects of the  Np1 Peptides with Bz on Breast Cancer Growth In Vivo 
 
Bz/ p7b 
Following tumour implantation of MDA-MB-436 (1x106 cells), an equal number of animals 
were assigned to each treatment group (n=5/group). In the Bz/p7b combination group all five 
animals developed palpable tumours and were subsequently treated with Bz (5mg/kg) and 
p7b (1μM) twice weekly via i.p. injection with Bz being administered 1 hour prior to p7b 
injection. Ten days post initial administration of Bz/p7b one animal was culled due to 
tumour ulceration (239.1mm3) with the remaining four animals continuing treatment with 
Bz/p7b until the end of the experiment (day 42). At the end of the experiment combining p7b 
with Bz (n=4) reduced MDA-MB-436 tumour growth in vivo compared with the saline 
control group (mean±SEM; Bz/p7b vs saline control; 227±61mm3 vs. 726±313mm3) 
however this inhibition did not reach statistical significance (p=0.229), due to the wide 
variation in the treatment group. However, the combination of p7b with Bz (n=4) exerted no 
additive inhibitory effects on tumour growth when compared with Bz alone (n=2) treated 
group (mean±SEM; Bz/p7b vs. Bz; 227±61mm3 vs. 184±0mm3) (Figure 5.25). As only n=2 
remained in the Bz treatment group at the end of the experiment, an earlier time point at day 
seventeen post initial injection of Bz, was used to carry out statistical analysis. At this time 
point combining p7b with Bz (n=4) displayed no significant additive effects on tumour 
growth in vivo when compared with the Bz alone (n=3) group (mean±SEM; Bz/p7b vs. Bz 
189±66mm3 vs. 164±47mm3).  
 
Bz/ p10 
In the Bz/p10 combination group, all five animals that underwent tumour implantation 
developed palpable tumours and were treated with Bz (5mg/kg) and p10 (50μM) twice 
weekly via i.p injection. Bz was administered 1 hour prior to p10 injection. All five animals 
continued to receive Bz/p10 treatment until the end of the experiment (day 42), with 
treatment resulting in a reduction in tumour growth in vivo compared with the saline (n=3) 
treated group (mean±SEM; Bz/p10 vs. saline control; 299±70mm3 vs. 726±313mm3) 
(Figure 5.26).  However, this reduction did not reach statistical significance (p=0.393), 
again due to wide variation in the control treatment group. The combination displayed no 
additive inhibitory effects on tumour growth when compared with the Bz alone (n=2) group 
(mean±SEM; Bz/p10 vs. Bz; 299±70mm3 vs. 184±0mm3) (Figure 5.26). Again, statistical 
analysis was carried out on day seventeen post initial injection when comparing the effects 
of Bz alone versus Bz/p10 as at day forty-two, only n=2 remained in the Bz group. At day 
seventeen, Bz/p10 (n=5) resulted in a reduction in efficacy in inhibiting tumour growth in 
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vivo compared with the Bz (n=3) alone group (mean±SEM; Bz/p10 vs. Bz; 320±69mm3 vs. 
164±47mm3; n=5/3, NS) (Figure 5.26) however this reduction did not reach statistical 
significance (p=0.704).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25 Effects of Combining Bz with P7b MDA-MB-436 Breast Cancer In 
Vivo.  
Combined treatment of Bz (5mg/kg) with p7b (1μM) twice weekly (i.p.) displayed no 
additive effects on tumour growth in vivo compared to the Bz (5mg/kg) alone treated 
group. In the combination group, p7b was administered 1 hour after Bz injection. 
 
Data is presented as mean±SEM tumour volume (mm3); n=3-5, NS. Statistical 
analysis was performed on day 17 using the One Way ANOVA (Sigmaplot 11 
software). 
Figure 5.26 Effects of Combining Bz with P10 MDA-MB-436 Breast Cancer In Vivo.  
Combined treatment of Bz (5mg/kg) with p10 (50μM) twice weekly (i.p.) displayed no additive 
effects on tumour growth in vivo compared to the Bz (5mg/kg) alone treated group. In the 
combination group, p10 was administered 1 hour after Bz injection. 
 
Data is presented as mean±SEM tumour volume (mm3); n=, NS. Statistical analysis was 
performed on day 17 using the One Way ANOVA (Sigmaplot 11 software). 
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Histology 
Bz/p7b 
Treatment with a combination of Bz/7b resulted in high level of tumour necrosis, however 
no additive effects were observed on the level of necrosis when compared with the Bz alone 
treated tumours (mean±SEM; Bz/p7b vs. Bz; 71±16 vs. 72±5%; n=3, ns) (Figure 5.27). 
Combined Bz with p7b significantly inhibited the number of Ki67 positive proliferating 
breast cancer cells compared with the saline control (mean±SEM; Bz/p7b vs. saline control; 
101±10 vs. 133±2; n=3, p=0.031) (Figure 5.28). However, the inhibitory effect observed 
with Bz/p7b exerted no significant (p=0.544) additive effect when compared with Bz alone 
treated tumours (mean±SEM; Bz/p7b vs. Bz (5mg/kg); 101±10 vs. 110±11; n=3, ns). 
Treatment with Bz/p7b resulted in an increase in apoptotic activity compared with the saline 
control group (mean±SEM; Bz/p7b vs. saline control; 32±6 vs. 21±1; n=3, ns) when 
measured as the number of Caspase 3 positive cells (Figure 5.29) however this increase did 
not reach statistical significance (p=0.132). In addition, treatment with Bz/p7b displayed no 
additive effects on apoptotic activity compared with the Bz alone treated tumours 
(mean±SEM; Bz/p7b vs. Bz (5mg/kg; 32±6 vs. 33±2; n=3, ns). Combining Bz with p7b 
resulted in a decrease in the number of CD34 positive vessels compared with the saline 
treated tumours (mean±SEM; Bz/p7b vs. saline control; 8±3 vs. 19±7; n=3, ns) (Figure 
5.30) however this did not reach significance (p=0.262). Additionally, treatment with Bz/p7b 
did not exert an additive inhibitory effect on vessel formation, when compared with the Bz 
alone treated tumours (mean±SEM; Bz/p7b vs. Bz (5mg/kg); 8±3 vs. 9±3; n=3, ns) (Figure 
5.30). 
Bz/p10 
Combining Bz with p10 reduced the levels of tumour necrosis compared with the Bz alone, 
treated tumours (66.7±4.5% vs. 72.5±4.8% respectively) (Figure 5.27) however this did not 
reach statistical significance (p=0.432). Combining p10 with Bz displayed no significant 
(p=0.238) effects on tumour breast cancer proliferation compared with the saline control 
(mean±SEM; Bz/p10 vs. saline control; 125±5 vs. 133±2; n=3, NS) when measured as the 
mean number of Ki67 positive cells (Figure 5.28). In addition there were no additive effects 
on breast cancer proliferation when Bz was combined with p10 compared with Bz alone 
(mean±SEM; Bz/p10 vs. Bz (5mg/kg); 125±5 vs. 110±11; n=3, NS).  Combination treatment 
of p10/Bz displayed no further apoptotic effects compared with the saline control 
(mean±SEM; Bz/p10 vs. saline control; 21±2 vs. 21±1; n=3, NS) (Figure 5.29). However, 
combining p10 with Bz caused a significant loss in the apoptotic activity observed with Bz 
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alone (mean±SEM; Bz/p10 vs. Bz (5mg/kg); 21±2 vs. 33±2; n=3, p=0.008) (Figure 5.29). 
Combining p10 with Bz resulted in abnormal vessel formation (Figure 5.31).  
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Figure 5.27 Effects of Combining Bz with P7b and P10  on Tumour Necrosis 
(A)Representative images taken at x10 (main panels) and x60 (insert) magnification, of necrotic 
areas within the MDA-MB-436 tumour tissue. (B) No effects on tumour necrosis were observed 
with any of the treatment.  
 
Data is presented as mean±SEM (% tumour necrosis); n=3, NS.  
Statistical analysis was performed using the One Way ANOVA (Sigmaplot 11 software). 
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points 
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Figure 5.28 Effects of Combining Bz with P7b and P10 on Tumour Cell Proliferation In Vivo 
 (A)Representative images of Ki67staining taken at x10 (main panel) and x60 (insert) 
magnification (B) Combined treatment with Bz/p7b twice weekly (i.p.) significantly inhibited the 
level of breast cancer proliferation occurring within the tumour compared to the saline control. 
However, no additive effects on tumour proliferation in either Bz/p7b or Bz/p10 combined group 
compared to Bz alone (5mg/kg). 
 
Data is presented as mean±SEM; n=3, p=0.031 w.r.t the saline control. Statistical analysis was 
performed using the One Way ANOVA followed by Holm-Sidak post-hoc test (Sigmaplot 11 
software). NB: It is important to note that analysis of tumour necrosis was carried out using 
tumours taken at different experimental time-points 
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Figure 5.29 Effects of Combining Bz with P7b and P10  on Tumour Apoptosis 
(A)Representative images of Caspase 3 staining taken at x10 (main panel) and x60 (insert) 
magnification (B) Combining Bz with p10 caused a significant decrease in apoptotic activity 
associated with Bz (5mg/kg) alone.  
 
Data is presented as mean±SEM (Caspase 3+ cells); n=3, p=0.008. 
 Statistical analysis was performed using (Sigmaplot 11 software).  
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points 
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Figure 5.30 Effects of Combining Bz with P7b on CD34 Vessel Formation 
(A)Representative images taken at x10 (main panel) and x60 (insert) magnification of 
CD34positive vessels (B) No additive effects were observed on inhibiting CD34 positive vessel 
formation after combined treatment of Bz/p7b (5mg/kg and 1μM) twice weekly (i.p.) compared 
to Bz alone (5mg/kg) twice weekly (i.p.) 
 
 Data is presented as mean±SEM (CD34+ vessels); n=3, NS. Statistical analysis was performed 
using the One Way ANOVA (Sigmaplot 11 software).  
 
NB: It is important to note that analysis of tumour necrosis was carried out using tumours 
taken at different experimental time-points 
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5.2.7 Dose Response Study 
In the previous studies conducted during this project, Bz (5mg/kg) displayed an inhibitory 
trend on MDA-MB-436 tumour growth in vivo. Thus, a potential additive effect in the 
presence of the neuropilin peptides may have been masked due to the efficacy of Bz 
treatment. It was therefore decided, that a dose response study was required to evaluate the 
tumour responses to Bz alone and determine a sub-optimal Bz dose to assess the effects of 
combining Bz with the Np1 peptides. Since CV also displayed an inhibitory trend this was 
added for each of the equivalent doses of Bz.  
Following tumour implantation (1x106) an equal number of animals were assigned to each 
treatment group (n=6/group). In the saline treated group four of the six animals developed 
palpable tumours and were treated with saline. Twenty-four days post initial injection of the 
saline control, one animal was culled due to reaching maximum tumour burden (1276mm3). 
The remaining three animals continued treatment with saline until the end of the experiment 
where the animals were culled due to tumour ulceration (Day 59). However, as only one 
animal remained in the saline control group ay Day 59, statistical analysis was carried out on 
Day 42. In the Bz group, four of the six animals implanted with MDA-MB-436 breast cancer 
cells were treated with Bz (5mg/kg) twice weekly via i.p injection, with the remaining two 
animals failing to develop palpable tumours. On day forty-two, one animal was culled due to 
tumour ulceration (1140.75 mm3) with the remaining three animals continuing with Bz 
100µM 100µM 
Bz/p10 
100µM 100µM 
Bz (5mg/kg) 
Figure 5.31 Effects of Combining Bz with P10 on CD34 Vessel Formation 
Representative images taken at x10 (main panel) and x60 (insert) magnification.  (Bz/p10 
combination) demonstrates to distinct staining patterns for CD34. The Bz alone treated tumours 
demonstrate CD34 positive staining for newly formed vessels within the tumour. However, 
combined treatment of Bz/p10 (5mg/kg and 50μM) twice weekly (i.p.) demonstrates a more 
individual CD34 positive staining pattern. Due to this irregular pattern of CD34 staining in the 
combination treated tumour, comparison of MVD was not possible.  
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treatment until the end of the experiment (day 59). However, as all but one animal in the 
saline control group were culled at day forty-two statistical analysis was carried at this time 
point (Day 42). Bz at 5mg/kg (n=3) significantly inhibited the tumour growth in vivo 
compared with the saline (n=3) control group (mean±SEM; Bz 0.5mg/kg vs. saline control; 
198±22mm3 vs. 713±82mm3; n=3, p<0.001) (Figure 5.32).  
In the CV group, five of the six animals implanted with MDA-MB-436 (1x106) breast cancer 
cells developed palpable tumours and were injected with CV at the appropriate volume. On 
day fifteen post initial administration of CV, one animal was culled due to tumour ulceration 
(650mm3), with a second animal culled nineteen days after initial injection of CV due to 
tumour ulceration (786.5mm3). The remaining three animals continued treatment with CV 
until the end of the experiment (day 59). Similar to Bz, statistical analysis was carried out on 
day forty-two. At day forty-two CV also (n=3) significantly inhibited tumour growth when 
compared with the saline control (n=3) group (mean±SEM; CV vs. saline control; 
249±31mm3 vs. 713±82mm3; n=3, p<0.001) (Figure 5.32). No significant (p=0.243) 
differences were observed in tumour growth between Bz and the CV.  
In the second Bz treated group, four of the six animals that underwent tumour implantation 
developed palpable tumours and were treated with Bz (2.5mg/kg) twice weekly via i.p 
injection with all four animals continuing treatment until the end of the experiment (day 59). 
Again statistical analysis was carried out on day forty-two. Bz, 2.5mg/kg (n=4) also 
significantly inhibited tumour growth compared with the saline control (n=3) group 
(mean±SEM; Bz 2.5mg/kg vs. saline control; 213±26mm3 vs. 713±82mm3; n=4/3, p<0.001) 
(Figure 5.32). In the second CV treated group, five of the six animals that underwent tumour 
implantation developed palpable tumours and were injected with CV at an equal volume to 
that used with Bz 2.5mg/kg. On day eight post initial CV administration, one animal was 
culled due to tumour ulceration (171.5mm3), with a second being culled forty-two days after 
starting treatment with CV due to maximum tumour burden (1140.75mm3). The remaining 
three animals continued treatment with CV until the end of experiment (day 59). At day 
forty-two, CV (2.5) also significantly inhibited tumour growth in vivo when compared with 
the saline control group (mean±SEM; CV vs. saline control; 184±9mm3 vs. 713±82mm3; 
n=3, p<0.001) (Figure 5.32). No significant (p=0.559) differences on tumour growth were 
observed between Bz and the CV. 
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In the third Bz treated group, five of the six animals implanted with MDA-MB-436 tumour 
cells developed palpable tumours and were treated with a lower dose of Bz (1mg/kg) twice 
weekly via i.p injection. On day forty-two post initial injection of Bz, one animal was culled 
due to (288mm3), with a second being culled on day fifty-two (171.5mm3) due to the animal 
looking weak and generally unhealthy. The remaining three animals continued treatment 
with Bz until the end of the experiment (day 59). Again, statistical analysis was performed at 
day forty-two. Bz, 1mg/kg (n=4) significantly inhibited tumour growth in vivo compared 
with the saline control (n=3) group (mean±SEM; Bz 1mg/kg vs. saline control; 405±55mm3 
vs. 713±82mm3; n=4/3, p<0.001) (Figure 5.32). In the equivalent CV treated group, five of 
the six animals that underwent tumour implantation developed palpable tumours and were 
treated with CV at the appropriate equivalent volume. On day forty-two post initial treatment 
with CV, two animals were culled due to tumour ulceration with the remaining three 
continuing treatment with CV until the end of experiment (day 59). On day forty-two the CV 
(n=3) also significantly inhibited tumour growth in vivo when compared with the saline 
control (n=3) group (mean±SEM; CV vs. saline control; 256±42mm3 vs. 713±82mm3; n=3, 
p=0.001). Again, there was no significant (P=0.527) difference between Bz at the 1mg/kg 
dose and the CV (Figure 5.32).  
In the Bz 0.5mg/kg treated group, four of the five animals implanted with MDA-MB-436 
breast cancer cells developed palpable tumours and were injected with Bz (0.5mg/kg) twice 
weekly via i.p. injection. On day twenty-four all animals in the saline control group were 
culled due to maximum tumour burden and tumour ulceration. Four of the five animals in the 
treatment group developed palpable tumours and were administered with Bz (0.5mg/kg 
twice weekly via i.p. injection). On day twenty-four, Bz (0.5mg/kg) (n=4) inhibited tumour 
growth in vivo compared with the saline control (n=3) group (mean±SEM; Bz 0.5mg/kg vs. 
saline control; 195±53mm3 vs. 1022±220mm3; n=4/3, ns), this was not significant (p=0.057) 
(Figure 5.32). In contrast the lowest dose of Bz (0.1mg/kg) tested did not display tumour 
growth inhibition (mean±SEM; Bz 0.1mg/kg vs. saline control; 213±30 vs. 467±138; n=5/4, 
NS) (Figure 5.32). In these 0.5mg/kg and 0.1mg/kg Bz dosing experiments a CV group was 
not added as at this point a sub-optimal dose of Bz was required rather than assessment of 
differences between Bz and the CV. Therefore, with this and the HO 3R guidance in mind a 
CV treatment control was not added.  
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Figure 5.32 Dose Curve (Bz 0.1-5mg/kg) 
Bz effectively inhibits MDA-MB-436 tumour growth in vivo at a number of doses. A relatively 
cytostatic effect on tumour growth is observed in all treatment groups, with only the 0.1mg/kg 
dose beginning to lose this cytostatic effect. 
 
For 5-1mg/kg graphs, data is presented at mean±SEM tumour volume (mm3); n=3/4, 
p=<0.001) w.r.t saline control. Statistical analysis on Day 42 was performed using the One way 
ANOVA followed by the Holm-Sidak post hoc test for multiple comparisons 
 
For the 0.5mg/kg graph, data is presented at mean±SEM tumour volume (mm3); n=3/4, NS) 
w.r.t saline control. Statistical analysis was performed on Day 24 using the Kruskal-Wallis 
One way ANOVA on ranks.  
 
The tumour growth after Day 42 for the control group is representative of one animal. The 
time points past Day 42 were left to allow visualisation of the tumour growth in the tumours in 
animals that continued to receive Bz treatment.  
 
             Indicates both Bz and CV as being significant compared with the saline group * 
* 
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5.2.8 Effects of Combining P7b with Lower Doses of Bz on Tumour Growth In Vivo 
From the Bz dose-response studies it was decided that Bz 0.1mg/kg dose would be used in 
the final combination experiment. Due to time constraints it was decided that p7b would be 
used in the combination study with Bz. Due to time constraints a pre-determined treatment 
period of thirty-one days was set as the final end point.  
In the group treated with saline four of the five animals implanted with MDA-MB-436 
(1x106) breast cancer cells developed palpable tumours. On day twenty-one post initial 
injection of saline, two animals were culled due to tumour ulceration. At the end of the 
experiment (day 31) there were still two animals remaining that had not reached the EOP 
criteria. In the Bz treated group, all five animals that underwent tumour implantation 
developed palpable tumours and were treated with a lower dose of Bz (0.1mg/kg) twice 
weekly via i.p injection. At the end of the experiment (day 31) all five animals in the Bz 
treated group had not reached EOP criteria. However, as only two animals in the saline 
treated group remained at day thirty-one, statistical analysis was performed at day twenty-
one post initial injection. At this time point Bz (n=5) reduced tumour growth compared with 
the saline (n=4) group (mean±SEM; Bz 0.1 vs. saline control; 213±30mm3 vs. 467±138mm3; 
n=5/4, ns) however, again due to variability this reduction did not reach statistical 
significance (p=0.084) (Figure 5.33).  
In the Bz/p7b combination group, all five animals that were implanted with tumour cells 
developed palpable tumours and were treated with a combination of Bz (0.1mg/kg) twice 
weekly and p7b (1μM) three times a week via i.p. injection. At the end of the experiment 
(day 31), similar to the Bz alone treated group, all five animals had not reached EOP criteria. 
Again, end point statistical analysis was carried out at day twenty-one. At this time point 
combined Bz/p7b treatment (n=5) reduced tumour growth compared with the saline (n=4) 
treated animals (mean±SEM; Bz/p7b vs. saline control; 286±101mm3 vs. 467±138mm3; 
n=5/4, ns) but again did not reach statistical significance (p=0.316) (Figure 5.33). However, 
although combining lower doses of Bz with p7b resulted in a trend that displayed reduced 
tumour growth, no additive effects were observed when compared with Bz alone 
(mean±SEM; Bz/p7b vs. Bz; 287±101mm3 vs. 213±30mm3; n=5, ns). This suggests Bz 
(0.1mg/kg) was not masking any inhibitory effects of p7b. 
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Histology 
The tumours that were treated with Bz (0.1mg/kg) were necrotic as seen with previous doses 
of Bz in the earlier experiments. However, no differences were observed between the Bz 
(0.1mg/kg) and saline treated tumours (mean±SEM; Bz vs. saline control; 68±15% vs. 
65±11%; n=3, ns) (Figure 5.34). No additive effects were observed on tumour necrosis 
when tumours were treated with Bz/p7b compared with Bz alone (mean±SEM; 65±9% vs. 
68±15%; n=3, ns) (Figure 5.34).  
Bz (0.1mg/kg) exerted a proliferative effect on primary tumour growth, as a statistical 
increase (p=0.044) in the number of Ki67 positive cells was observed in the Bz treated group 
compared with the saline control (mean±SEM; Bz vs. saline control; 73±13 vs. 31±7; n=3, 
p=0.044) (Figure 5.35).  Combining Bz with p7b displayed no additional effects on tumour 
proliferation compared with the Bz alone treated tumours (mean±SEM; Bz/p7b vs. Bz; 
72±11 vs. 74±13; n=3, ns). The level of apoptosis occurring was significantly (p=0.017) 
lower in the Bz treated tumours compared with the saline control tumours (mean±SEM; Bz 
vs. saline control; 9±0.4 vs. 16±0.4; n=3, p=0.017) (Figure 5.36).  This is in contrast to what 
was observed with the higher dose of Bz (5mg/kg).  
Interestingly, the CD34 staining pattern in this final cohort was similar to that observed with 
treatment with CV, Bz/p10 and p7b alone in previous experiments, whereby single cells 
Figure 5.33 Effects of Combining Lower Dose of Bz with p7b: 
No additive effects on tumour growth in vivo were observed when p7b was combined 
with lower doses of Bz. 
 
Data is presented as mean±SEM tumour volume (mm3); n=4/5, NS.  
Statistical analysis was performed using a One Way ANOVA (Sigmaplot 11 software). 
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stained positively for CD34 rather than the vessels (Figure 5.37). However combining Bz 
with p7b resulted in a loss of inhibitory effects observed on CD34 positive cells compared 
with the Bz alone tumours (mean±SEM; Bz/p7b vs. Bz; 12±1 vs. 9±3; n=3, ns) (Figure 
5.37), which was not statistically significant (p=0.700). 
 
 
 
 
 
 
 
Saline Control 
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Figure 5.34 Effects of Combining Low Doses of Bz with p7b on Tumour Necrosis (A) 
Representative images at x4 magnification of necrotic areas (N) within the MDA-MB-436 
tumour tissue (T) (B) No additive effects on tumour necrosis were observed when Bz was 
combined with p7b (1μM) compared to Bz alone (0.1mg/kg) 
 
 Data is presented as mean±SEM (%tumour necrosis); n=3; NS. Statistical analysis was 
performed using test (Sigmaplot 11 software). 
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Figure 5.35 Effects of Combining Low Doses of Bz with p7b on Tumour Cell Proliferation 
(A) Representative images of Ki67 staining taken at x20 magnification (B) No additive effects 
on tumour cell proliferation was observed when Bz was combined with p7b compared with Bz 
alone 
 
Data is presented as mean±SEM Ki67 positive cells; n=3; p=0.044. Statistical analysis was 
performed using a t-test (Sigmaplot software). 
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Figure 5.36 Effects of Combining Low Doses of Bz with p7b on Tumour Apoptosis  
(A) Representative images of Caspase 3 staining taken at X40  (B) No additive effects on tumour 
apoptosis was observed when Bz was combined with p7b compared to Bz alone. However Bz 
(0.1mg/kg) significantly reduced the number of apoptotic events occurring within the tumour 
tissue. 
 
Data is presented as mean±SEM positive Caspase 3 cells; n=3; p=0.017w.r.t saline control.  
Statistical analysis was performed using a t-test (Sigmaplot software) 
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Figure 5.37 Effects of Combining Low Doses of Bz with p7b on CD34 Positive Cells  (A) 
Representative images of CD34 positive staining taken at X60  (B) No additive effects on CD34 
positive cells reduction was observed when Bz was combined with p7b compared to Bz alone  
 
Data is presented as mean±SEM CD34 positive cells; n=3 NS. 
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5.3 DISCUSSION 
5.3.1 VEGF and VEGF Receptor Protein Expression 
VEGF and all four VEGF receptors were expressed by MDA-MB-436 tumours in vivo. The 
diffuse staining pattern for VEGF has previously been observed in breast xenograft tumour 
tissue (Banerjee et al, 2011 & Chougule et al, 2011). VEGF appeared to be localised within 
the cytoplasmic regions, with some membranous staining. It is possible that this 
membranous staining is representative of secreted VEGF.   
Expression of VEGF-R1 was wide-spread through-out the tumour but moderate in intensity 
in the viable regions of the tumour, which has previously been observed in both breast 
cancer patient samples (Schmidt et al, 2008) and in breast xenograft tissue (Wu et al, 2006). 
The stronger expression in the necrotic areas of the tumour tissue appeared associated with 
macrophages. VEGF-R1 expression has previously been observed on macrophages 
(Muramatsu et al, 2010). The role of macrophages in breast cancer progression is 
contradictory; with as some studies suggesting anti-tumour effects whereas, others have 
shown that macrophages act in a pro-tumourgenic manner. Macrophages are also known to 
be a rich source of angiogenic cytokines and induce increased tumour vessel formation. It is 
thought that the tumour associated macrophages can shift from a anti-tumourgenic to a 
tumour promoting phenotype depending on the cytokines released by the tumour (Biswas et 
al, 2010 & Zamarron et al, 2011). Therefore F4/80 staining on frozen tumour sections 
would be interesting to perform to any altered levels of F4/80 macrophages infiltrating into 
the tumour, in the treatment groups especially. Bz has been shown to alter the levels of 
macrophage infiltration into breast tumours (Roland et al, 2009). More recently the use of 
F4/80 as a macrophage specific marker has been questioned, as neutrophils also express this 
marker. Therefore double staining with a neutrophils marker on frozen sections to identify 
which immune cells are reduced and which are increased and what implications this may 
have on breast cancer progression would be informative. 
Np1 expression was weak and not as widely distributed as the other VEGF receptors, 
suggesting that within the tumour, Np1 expression appears to be restricted to specific clones 
of cells, identification of which requires double staining using confocal microscopy. Np2 
expression was in the MDA-MB-436 tumours. Previously Np2 expression has been observed 
in tissue from breast cancer patients with strong Np2 staining observed in both the blood and 
lymph vessels and all invasive breast cancer cells (Yasuoka et al, 2009). A similar staining 
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pattern for Np2 in murine mammary tumours (TBP) thought to develop a phenotype similar 
to TNBC has also been observed (Goel et al, 2013).   
Generally the level of VEGF and VEGF receptor expression was relatively similar between 
the different treatment groups. Although analysis of the intensity of staining was carried out, 
the data is not comparable as staining was carried out on tumour tissue that was taken at 
different experimental time-points. The primary aim was to assess tumour growth and 
observe is any added effects on growth were observed in the combination experiments, 
therefore the studies were designed to assess if resistance was observed and causes tumour 
re-growth. Going forward analysis of tumour activity would require all tumours to be 
removed at the same time-point. In addition, although IHC is a good technique for assessing 
the location of expression of different factors within the context of the tumour as a whole 
and provides useful information regarding the morphology of the tumour, flow cytometry is 
an alternative technique that may have been more useful. Flow cytometry more accurately 
measuring changes in receptor expression with the added advantage of allowing 
identification of which cell types are expressing VEGF and the VEGF receptors in the 
tumour tissue.  
5.3.2 Bz alone 
We tried to source murine/human Bz derivative from Genentech but this was not possible 
thus the humanised monoclonal VEGF antibody Bz, was used in all studies. Bz alone at a 
dose-range of (5mg/kg-0.5mg/kg) significantly inhibited MDA-MB-436 breast cancer 
growth in vivo compared with the saline treated group with a cytostatic effect on tumour 
growth being observed. This cytostatic effect is typical of anti-angiogenic agents such as Bz, 
(Loges et al, 2009). In contrast to chemotherapeutics, Bz primarily acts on the ECs thus 
inhibiting the availability of essential nutrients. This mechanism is the main reasoning for 
combining anti-angiogenic agents such as Bz with chemotherapy or radiotherapy which 
target the tumour cells. In the current study Bz inhibited tumour growth which confirms the 
previously reported data in an orthotopic model of breast cancer (Roland et al, 2009). 
Consequently, the Bz dose-response study should have been carried out prior to starting the 
combination in vivo experiments to ensure that the in vitro doses translated to the in vivo 
experiments. The dramatic inhibitory effects on breast cancer growth in vivo by Bz in the 
current study, along with previous literature suggests that tumour derived VEGF plays an 
extremely important role on breast cancer progression. This maybe more than effects on 
stromal derived VEGF at least in a animal model, as Bz only inhibits human VEGF isoforms 
from binding VEGF-R1 and VEGF-R2, therefore only inhibits tumour derived VEGF in 
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murine models. This notion that the tumour derived VEGF drives primary tumour growth is 
further supported by Roland et al, 2009, whereby MDA-MB-231 tumours treated with Bz or 
an antibody that inhibits both human and murine VEGF from binding VEGF-R2 (r84) had 
similar final tumour volumes after 4 weeks of treatment. The anti-apoptotic effects observed 
in response to Bz (5mg/kg) treatment in the MDA-MB-436 tumours may be a result of 
apoptotic activity in either the breast cancer cells, the endothelial cells or other cell types that 
have infiltrated into the tumour micro-environment. VEGF is a survival factor for vascular 
endothelial cells, and Bz appears to inhibit the pro-survival effect of VEGF on newly formed 
vessels and by maintaining the integrity of existing vasculature (Fujii et al, 2009).  
Therefore it is most likely that the apoptotic effect observed in the current study is a result of 
endothelial cell death, for which there was some evidence in the tumour sections, however 
there were other cell types present that were positive for CD34, which would be worth 
investigating.  
To date the majority of clinical studies in mBC combine Bz with a number of different 
targeting agents, particularly chemotherapeutic agents with eventual escape from treatment. 
Although a dramatic inhibition was observed on primary tumour growth with Bz alone in 
this current study, resistance to Bz is ultimately inevitable as targeting one signalling 
pathway alone is insufficient, particularly in metastatic disease as the metastatic cells are 
thought to be phenotypically more aggressive.  
The control vehicle for Bz (CV) also exerted effects in vivo similar to Bz efficacy, however 
in the previously published studies saline is used as a control. The control vehicle consists 
mainly of sodium salts with a low level of the detergent tween20. Cells are sensitive to high 
levels of detergent and changes in pH. Additionally during the in vitro the pH of CV and 
media were tested and no differences were detected. However, accumulation of the CV over 
time in the in vivo studies may have resulted in changes in pH within the microenvironment, 
leading to cell death and the reduced tumour growth observed, resulting in the similar 
histological changes observed in tumours treated with the CV or Bz. In addition there are 
some recent studies that access the anti-tumour effects of tween20, and it appears that the 
effects observed with the control vehicle for Bz, may not be due to changes in micro-
environmental alone, but due to activation of downstream signalling events that are activated 
by tween20 (Yamagata et al, 2009, Yang et al, 2012 & Eskandani et al, 2013).  
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5.3.3 Np1 Peptides 
Pre-clinical data using Bz provided encouraging results however in the clinic, Bz failed to 
increase OS in breast cancer patients with metastatic disease (Miller et al, 2007). 
Retrospective biomarker analysis suggested that the presence of Np1 in breast cancer 
patients post Bz therapy, indicates a poor prognosis (Jubb et al, 2011 ). Additionally, over 
recent years there is ample data to suggest that the neuropilins are important VEGF receptors 
that play an important role in breast cancer cell activity (Bachelder et al, 2001, 2003 and 
Barr et al, 2005 ). The binding site for the neuropilin receptors lies downstream of the 
binding site for the classic VEGF receptors thus when Bz binds to VEGF the neuropilin 
binding site remains un-inhibited, suggesting that these receptors may provide VEGF with an 
alternative signalling pathway. This alternative signalling pathway may allow escape from 
Bz therapy and therefore based on this argeting the neuropilin receptors both alone and in 
combination with the classical VEGF receptors (VEGF-R1 and VEFG-R2) is a feasible 
target.  
The neuropilin peptides (p7b and p10) used in the current in vivo studies had previously been 
tested for binding ability to Np1 in vitro (Cebe-Suarez et al, 2008). However, no previous in 
vivo studies have been performed using these peptides. The two peptides demonstrate 
different binding affinities to the Np1 receptor with p10 (RPPR) displaying  a higher binding 
affinity then that observed with p7b (DKPRR) (Cebe-Suarez et al, 2008).  
Based on the literature available on inhibiting neuropilin 1 in breast cancer tumour growth 
(Lee et al, 2013 & Starzec et al, 2006)  it was assumed that treatment with p7b and p10 
would induce some inhibitory effects on breast cancer growth in vivo, especially since both 
peptides displayed both anti-angiogenic and minimal anti-tumourgenic activity in vitro 
(Chapter 3 & 4). However, neither p7b nor p10 alone exerted any significant inhibitory 
effects on MDA-MB-436 breast cancer growth in vivo compared with the saline control 
treated tumours although p10 alone did reduce tumour volume but was reduction did not 
reach significance. A reduction in tumour growth despite not being significant suggested that 
p10 at least was reaching the tumour. As p10 is thought to bind both Np1 and Np2, it is 
possible that this dual inhibition resulted in p10 alone exerted more of an inhibitory effect on 
tumour growth then that observed with p7b alone. Additionally, the dose administered for 
p7b was much lower then that of p10, therefore it is possible that the peptides were degraded 
rapidly and therefore insufficient amounts of the peptide reached the tumour and the 
surrounding vasculature.  Np1 expression is wide-spread in other healthy organs such as 
liver, lungs and kidneys, therefore is it possible that the peptides were directed in high 
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amounts to the healthy organs rather then the tumour itself. This has recently been 
investigated, whereby the distribution of an anti-Np1 antibody was measured in non-tumour 
bearing mice and tumour bearing mice to assess how much of the antibody (after i.v 
injection) is cleared (Bambaca et al, 2012). The group found that non-tumour Np1 ‘sinks’ 
required saturating before sufficient amounts of the Np1 antibody was delivered to the 
tumour and that delivery to the healthy organs was greater possibly due to the fact these 
tissues are better perfused then the tumour tissue  (Bambaca et al, 2012). This is an 
important observation, as the group found that relatively high concentrations of the Np1 
antibody were required to achieve adequate tumour levels. It is therefore possible that the 
peptides were sequestered within these non-tumour ‘sinks’ and higher doses of both peptides 
would be required in order to observe any significant inhibitory effects on tumour growth in 
vivo. It would therefore be informative and useful to tag the peptides to monitor the 
distribution to the tumour and other tissues following in vivo administration.  
 
The literature available that investigates the effects of blocking VEGF-Np1 interactions, 
utilise peptides that are designed to bind VEGF which leads to subsequent inhibition of Np1 
receptor activation (Starzec et al, 2006) or inhibit both neuropilin receptors (Lee et al, 2013). 
The peptides used in the current study are derived from the human VEGF sequence, which 
bind Np1 and are thought to block functional VEGF from interacting with the Np1 receptor. 
However, as the peptides are derived from the VEGF sequence it is possible that both in 
vitro and in vivo these peptides are activating Np1 rather then blocking downstream 
signalling, therefore designing peptides that bind VEGF may prove more effective in 
blocking VEGF-Np1 signalling. Additionally blocking only Np1 may lead to compensatory 
up-regulation of the Np2 receptor and therefore negate any inhibitory effects exerted with a 
Np1 targeting peptide only, such as p7b. Neuropilin 2 is thought to be involved in lymph-
angiogenesis and subsequent metastatic events (Yasuoka et al, 2009). This potentially 
suggests that Np2 may induce a more aggressive phenotype in breast cancer cells in order to 
allow them to metastasis to distant sites, thus up-regulating Np2 as a compensatory 
mechanism, may result in a more aggressive response to treatment with p7b in particular, as 
this peptide is thought to bind Np1 only.  
 
Additionally Np1 also exists as a soluble form (Cackowski et al, 2004) and it is therefore 
possible that the peptides are also binding this inactive form of the receptor, thereby 
increasing the availability of the ‘active’ receptor. Therefore the ratio of soluble versus 
membrane bound Np1 is potentially important in determining the response to p7b/p10 
treatment in vivo.  
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It is also possible that in vivo the effects of the Np1 peptides alone displayed no inhibitory 
effects on MDA-MB-436 breast cancer growth due to the lack of Np1 expression on both the 
tumour and endothelial cells, as it has been shown that both HuVECs and MDA-MB-231 
breast cancer cell protein expression of Np1 is down-regulated in the presence of hypoxia 
(Bae et al, 2008). A key characteristic of solid tumours such as breast carcinomas is the 
presence of hypoxic regions. Interestingly, it has been observed that in contrast to Np1, 
expression of Np2 is maintained over long periods of exposure to hypoxia (up to 5 days) 
(Bae et al, 2008). This also suggests that a therapy that targets both neuropilin receptors may 
prove more effective in inhibiting tumour progression and may explain why p7b and p10 
failed to effectively inhibit breast cancer growth in vivo. Interestingly, the MDA-MB-436 
breast cancer cell line is thought to predominantly express VEGF121 mRNA compared with 
the other VEGF isoforms (Stimpfl et al, 2002). The Np1 peptides used in the experiments 
were derived from the VEGF165 sequence, if the affinity of VEGF121 in the MDA-MB-436 
breast cancer cells is higher for Np1 compared with VEGF165; it is therefore possible that 
endogenous levels of VEGF121 displaced the peptides therefore rendering them ineffective.  
Histological analysis of the tumour tissue after treatment with p7b or p10 observed some 
interesting changes in some of the different parameters measured, however these changes did 
not reach statistical significance but do suggest an interesting trend. Interestingly, p10 but 
not p7b reduced tumour necrosis; however this reduction was not significant. Necrosis is cell 
death that occurs as a result of micro-environmental changes, thus the reduction in tumour 
necrosis in the p10 alone treated tumours (despite not reaching statistical significance) 
suggests that treatment with p10 is in some manner changing the micro-environment within 
the tumour. A decrease in tumour necrosis is potentially favourable as extensive necrosis is 
thought to indicate rapid growth in breast cancer patients (Santamaria et al, 2010). Neither 
peptide displayed any inhibitory effects on breast cancer cell proliferation when measured as 
the number of positively stained Ki67 cells; this was not surprising for p10, as in the in vitro 
MTS assay no inhibitory effects on MDA-MB-436 breast cancer cell proliferation were 
maintained at the p10 dose (50μM) used in the in vivo experiments. However, p7b in vitro 
significantly inhibited MDA-MB-436 breast cancer cell proliferation, however the MTS 
assay measured effects on proliferation up to 48h, therefore it is possible that p7b in vitro did 
not maintain inhibitory effects of breast cancer cell proliferation, which is what was 
observed in vivo. Caspase 3 staining suggested that p7b alone reduced the level of apoptosis 
occurring within the tumour tissue, which may in part explain why p7b alone exerted no 
inhibitory effects on MDA-MB-436 tumour growth, this observation however was surprising 
as in vitro, Np1 has been shown to be an autocrine survival factor for breast cancer cells 
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(Barr et al, 2005). The peptides designed for use in this project are derived from the human 
VEGF165 protein sequence and are designed to bind to Np1 or potentially both Np1 and Np2 
(in terms of p10), it is therefore possible that the peptides are activating the receptor 
signalling pathway instead of inhibiting it, thus peptides designed to bind VEGF and inhibit 
VEGF from binding to the neuropilin receptors may be more effective in blocking VEGF 
induced signals. No effects on CD34 positively stained cells or vessels were observed with 
either p7b or p10.  
Abnormal Vasculature 
Abnormal vasculature appeared to be formed in the MDA-MB-436 breast tumours, whereby 
clusters of single cell CD34 staining were present in the tumours from some of the treatment 
groups rather then the typical vessel structure. CD34 is expressed by other cells types in 
addition to endothelial cells, such as haematopoietic stem cells and mesenchymal cells. The 
antibody purchased from Abcam used in the current studies detects CD34 on murine 
endothelial cells and murine leukocytes (monocytes and granulocytes). Co-staining on frozen 
sections would be useful in identifying which cells are being detected in the MDA-MB-436 
treated tumours. Additionally, two markers would prove useful for determining vessel counts 
in these tumours. In addition, CD31 staining would be informative in terms of assessing of 
the different treatments are able to exert effects on the more mature vessels. Initially when 
the project began, a CD31 antibody for use on formalin fixed tissue was not available 
therefore CD31 staining on the formalin fixed tumour tissue could not be carried out. 
However, more recently, a CD31 specific antibody is now commercially available for use on 
formalin fixed tissue, thus could be used on the remaining tumours to assess if the different 
treatments have any vascular disrupting effects 
 
Overall the differences observed between treatment with p7b and p10 in vivo may be due to 
lack of delivery of p7b, which may be a result of rapid degradation, especially since p7b 
(1μM), was administered at a much lower dose compared with p10 (50μM) based on the in 
vitro studies (see chapter 3&4). Additionally, the affinity of p7b for Np1 in vitro has been 
shown to be less then that observed with p10. Peptide 10 in a competitive binding assay 
almost completely inhibited labelled VEGF from binding Np1 whereas p7b displayed 
intermediate effects therefore it is possible that p7b is easily displaced in vivo by tumour 
derived VEGF, thus resulting in little inhibition in tumour growth. This may also explain 
why the inhibitory effects observed in vitro with p7b on both microvascular endothelial cells 
and the breast cancer cells did not translate to the in vivo setting.  
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5.3.4 Combination 
Previously combining Bz with an antibody targeting Np1 observed an additive effect on lung 
tumour growth in vivo compared with Bz alone (Pan et al, 2007). However there are no 
studies that look at the combination in breast cancer in vivo (PubMed).  
 
Bz/p7b 
Although combining either p7b or p10 with Bz displayed no additive effects in vitro on the 
endothelial cells or the breast cancer cells, a potential additive effect in vivo was not 
dismissed as it was thought that treating the breast cancer cells separately to the endothelial 
cells in the in vitro studies may not have represented the interaction between these two cell 
types accurately. However, similar to what was observed in vitro; combining Bz with p7b 
exerted no additive effects on MDA-MB-436 breast cancer growth in vivo or on the tumour 
histology when compared with Bz alone. Since no inhibitory effects were observed with p7b 
alone in vivo an additive effect could not be expected. As previously mentioned it is possible 
that the dose of p7b required to be delivered to the tumour required to exert a biological 
effect was not adequate in these current experiments, especially if the p7b is being delivered 
to other organs that also express Np1.  
 
Bz/p10 
Although p10 alone did not exert a significant inhibitory effect on breast cancer growth in 
vivo, a reduction in tumour volume was observed when compared with the saline treated 
tumours, therefore when combining Bz with p10 as additive effect on tumour growth was 
expected. However, combining Bz with p10 resulted in reduced efficacy of Bz on inhibiting 
MDA-MB-436 breast cancer growth. However, from the histology is appears that the loss of 
Bz efficacy when Bz is combined with p10 is not a result of changes in necrosis, tumour cell 
proliferation, apoptosis or vessel formation as these parameters remained similar in the 
combination and Bz alone group. It is also possible that downstream activation of the Np1 
receptor occurs upon peptide binding. Since p10 is thought to bind both Np1 and Np2 it is 
possible that when p10 binds the neuropilin receptors in this model, the activation of these 
two receptors compensates for the inhibitory effects observed with Bz alone. This is feasible 
as it has been shown that treatment of tumours with Bz up-regulates the expression of Np1 
and Np2 and if p10 is activating rather then inhibiting neuropilin receptor signalling this may 
abolish Bz induced inhibitory effects as observed in the current experiments. What external 
factors might be determining whether the peptides inhibit or activate neuropilin receptor 
signalling is yet unclear. 
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It is also possible that the order in which Bz and the peptide are injected plays an important 
role in the response of tumours to combination therapy, therefore further work into the drug 
regime may prove more effective (Ottewell et al, 2010). Also heavily pre-treating one group 
with Bz prior to introducing the peptides, might also prove useful, as administering both 
treatments at the same time may result in resistance to the VEGF pathway at a much quicker 
rate, therefore rendering the combination therapy ineffective. 
 
2.3.5 Models of Primary Breast Cancer Growth 
In this project a subcutaneous model was used to test the effects of Bz and the neuropilin 
peptides on breast cancer growth in vivo. Mammary fat pad tumour implantation represents 
an orthotopic model of breast cancer, as injection of human breast cancer cells into the 
mammary fat pad allows the cells to grow and establish within a micro-environment that 
would be reflective of the human disease. The subcutaneous model was used to initially 
allow for optimisation of drug doses and combinations in vivo, prior to mammary fat pad 
studies, as the subcutaneous model would allow for a greater ‘treatment window’ as stated 
by HO regulations . However due to time constraints, the mammary fat pad studies were not 
carried out, as treatment with the peptides, in particular have not been concluded in the sub-
cutaneous model therefore an optimal treatment combination was not feasible to take 
forward into an orthotopic model.  
Although a number of questions are still unanswered with regards to inhibiting the neuropilin 
receptors during primary breast cancer growth, it was deemed important that analysis of the 
metastatic process also be investigated as currently, there is a lack of preventative therapy for 
breast cancer induce bone metastasis and since the secondary disease accounts for a high 
morbidity rate in breast cancer patients, the bone metastasis model was essential to 
investigate. Since the efficacy of the peptide design and general dosing issues were raised at 
the end of the sub-cutaneous experiments, it was deemed sensible to take only Bz forward to 
the metastasis experiments. As Bz effectively inhibited primary tumour growth at a number 
of doses, two low doses of Bz were used to assess if low doses could inhibit both primary 
and secondary tumour growth. The MDA-MB-231 breast cancer cells are known to ‘home’ 
to the bone after intra-cardiac injection and unfortunately due to time constraints, we did not 
have time to first test the homing ability of the MDA-MB-436 breast cancer cells to the 
bone, therefore the metastasis model was carried out with the MDA-MB-231 breast cancer 
cells.  
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6.1 INTRODUCTION 
6.1.1 Breast Cancer Induced Metastasis 
Breast cancer metastasis is a major clinical problem, with the secondary disease accounting 
for approximately 90% of the mortality rates (Suva et al, 2009). The prognosis of patients 
with mBC is poor, as the median survival time from diagnosis from the metastatic disease is 
between 24-48 months (Gennan et al, 2005).  The major sites of breast cancer metastases are 
to the bone, lungs and liver, with bone being the primary site for metastasis for 
approximately 25% of breast cancer patients, for which there is currently no curative 
treatment.  
6.1.2 The Process of Metastasis 
The process of metastasis involves a number of key steps which must be successfully 
completed in order to establish metastasis in a distant tissue. According to Paget’s ‘seed and 
soil’ hypothesis (section 6.1.3), the first step involved in metastasis is the formation of a pre-
metastatic niche, whereby tumour cells prepare a specific tissue to colonise. Secondly, once 
an efficient vasculature (tumour angiogenesis) has formed within the primary tumour mass, 
the tumour cells must detach from the primary site (Weilbaecher et al, 2011). Thirdly, 
tumour cells must be able to invade into the surrounding ECM, via the process of 
proteolysis, which is aided by MMPs. Once the ECM has been degraded intravasation of the 
tumour cells into the newly formed tumour vasculature allows for migration of tumour cells 
via capillaries, venules or lymphatic vessels (Langley & Fidler, 2011; Talmadge & Fidler et 
al, 2010). The fourth step in the metastatic process requires tumour cells forming aggregates 
with other cells such as the hematopoietic cells that are present in the circulation. The fifth 
and crucial step requires the tumour aggregates to be able to survive, evade immune 
detection and successfully migrate through the circulatory system. After which the tumour 
aggregates, arrests in a capillary bed and undergo extravasation into the surrounding tissue. 
Finally, once the tumour cells have ‘homed’ to the secondary site, the cells must be able to 
colonise and proliferate in the secondary site in order for metastasis to be successfully 
established. Once a tumour metastasis has formed in the secondary site, a new vasculature is 
formed to maintain tumour growth and to allow further disseminate to distant sites (Langley 
& Fidler, 2011; Mathot & Stenninger, 2012; Talmadge & Fidler et al, 2010) (Figure 6.1).  
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6.1.3 ‘Seed and Soil’ Hypothesis 
The ‘homing’ of tumour cells to the secondary site is thought to be a specific process 
whereby the tumour cells migrate towards a specific tissue in a pre-determined manner, this 
is known at Paget’s ‘Seed and Soil’ hypothesis. Paget’s ‘seed and soil’ hypothesis has three 
main principles, the first principle states, the tumour mass contains both tumour and host 
cells (including ECs, fibroblast and infiltrating leukocytes) and that not all tumour cells 
possess the ability to successfully establish secondary disease. The second principle states 
that early identification of the cells that possess the ability to metastasise is crucial, with the 
third principle stating that metastasis only occurs in specific tissues (Talmadge & Fidler et 
al, 2010). These principles are derived from initial observations that demonstrated 
preferential spread of breast cancer cells to the liver and not the spleen. Paget stated that 
tumour cells will only metastasise to specific tissues that possess an optimal micro-
environment in which the tumour cells will be able to survive and proliferate. To support this 
theory, studies looking at the expression profile of certain host cells demonstrated 
differences in cell surface expression of receptors on ECs residing in different tissues 
(Langley & Fidler, 2011; Talmadge & Fidler et al, 2010).  
 
In light of Paget’s hypothesis, there is evidence that suggests that the tumour cells that 
establish distant metastasis acquire a phenotype that allows for successful completion of the 
metastatic process (Yokota et al, 2000), thus making these tumours cells more difficult to 
treat using conventional therapy. The process of metastasis appears to select aggressive 
tumour cells with metastatic capacities that have acquired many mechanisms to survive, 
proliferate, evade and resist anti-cancer therapy. Studies assessing marker profiles to identify 
‘metastatic’ tumour cells could prove beneficial in treating and preventing bone metastasis. 
Research into these metastatic-initiating cells is currently under investigation with the 
suggestion that these cells have self-renewal properties and give rise to phenotypically 
diverse tumour cell population that are efficient in evading therapy and survival in hostile 
environments once de-attached from the primary tumour site (Mimeault and Batra, 2010).   
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Figure 6.1 The Metastatic Cascade (A) Once a tumour reached a diameter of 1-2mm, it can no 
longer obtain nutrients via diffusion, there the process of (B) tumour angiogenesis is initiated 
primarily through the actions of VEGF. (C) Once a tumour vasculature has established, tumour 
cell must detach from the primary tumour and invade the surrounding ECM. (D) Entry into the 
vasculature and extravasation precedes (E) entry into the secondary site of metastasis (e.g. bone). 
(F) Lastly, once the tumour cells have colonised the secondary tissue, process of tumour 
angiogenesis is re-initiated to allow further dissemination of the tumour cells.  
Adapted from Mathot & Stenninger, 2012. Behaviour of seeds and soil in the mechanism of 
metastasis: A deeper understanding 
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6.1.4  Breast Cancer Induced Bone Metastasis 
Post mortem examinations of breast cancer patients demonstrate approximately 70% of all 
patients have evidence of bone metastasis (Suva et al, 2009).  Understanding the mechanism 
by which breast cancer cells metastases to and survive within the new bone environment will 
allow for a more effective means of treatment and potential preventative measures. Bone 
metastasis associated with breast cancer has a higher mortality rate than the primary disease 
as the metastatic tumour cells affect the health of the bone both via direct effects of the 
tumour cells and indirect effects of treatment, which may lead to rapid loss of bone. 
Symptoms associated with bone metastasis include, hypocalcaemia, bone pain, fractures and 
nerve compressions (Korzlow et al, 2005).There are two types of bone metastasis; osteolytic 
and osteoblastic. Osteolytic metastasis results in bone destruction whereas osteoblastic 
activity is associated with new bone formation (Rose & Siegel, 2006). Although there is 
evidence of both types of bone metastasis occurring, breast cancer patients commonly 
develop osteolytic lesions (Zhang et al, 2009).  
The bone offers a favourable micro-environment for breast cancer metastasis due to a variety 
of growth factors and cytokines present in the bone matrix. Bone tissue is constantly 
undergoing remodelling during development, physiological adult skeletal remodelling and 
during trauma repair. The process of bone remodelling requires vascularisation thus the 
network formed between these two processes indicates an important link between factors 
that drive both vascularisation and bone remodelling, such as VEGF.  
Under physiological conditions the direct communication between osteoclasts and 
osteoblasts through cytokine signalling is important in maintaining bone turnover events, as 
the ratio of these two cell types is required to maintain bone homeostasis (Yang et al, 2012). 
In the case of breast cancer-induced bone metastasis, excessive bone destruction is 
demonstrated as a result of increased osteoclast numbers. It is thought that the increase in 
osteoclast numbers present in bone metastasis is a result of indirect or direct effects of the 
tumour cells on osteoclast activity. Excessive bone destruction leads to an increase in 
cytokines and growth factors released from the bone matrix, which subsequently leads to the 
process known as the ‘vicious cycle’, as increased cytokine release from the matrix leads to 
further bone destruction (Guise, 2002). In addition osteoblasts demonstrate a regulatory role 
in osteoclast differentiation (Yang et al, 2012) therefore suggesting that treatments that alter 
either of the two cell types involved in bone remodelling must take into account the link that 
exists between osteoblasts and osteoclasts. 
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Bisphosphonates 
Current treatment of bone metastasis for breast cancer patients is the use of bisphosphonate 
drugs (BPs), which are anti-resorptive agents that primarily target the bone osteoclasts 
(Figure 6.2A&B). Nitrogen-containing bisphosphonates (N-BPs) such as Risedronate and 
Zoledronic acid, are routinely used for treatment of lytic metastatic bone disease and are 
thought to elicit an anti-resorptive effect by altering bone metabolism (Fournier et al, 2010). 
Inhibition of key enzymes in the mevalonate pathway is thought to be the mechanism by 
which N-BPs modulate bone turnover activity, which leads to an improvement in bone 
health in patients with bone metastasis (Fournier et al, 2010). Generally BPs are known 
more for the palliative effects that they induce as they reduce bone loss, thus reducing the 
number of skeletal complications observed in breast cancer patients with bone metastasis. 
However, more recently, the effects of BPs on tumour cell activity are being investigated 
with evidence both in vitro and in vivo that suggests that BP display a level of anti-tumour 
activity (Fournier et al, 2010). Risedronate displays anti-proliferative activity on a range of 
breast cancer cell lines in vitro, including the highly metastatic MDA-MB-231 cells 
(Fournier et al, 2010). In addition daily injection of Risedronate also reduced the size of 
bone metastasis formed in the hind limbs of BALB/c nude mice that were injected with 
human B02 breast cancer cells (MDA-MB-231-BO2) via tail vein injection (Fournier et al, 
2010). In the Fournier et al study, risedronate treatment commenced on the same day that 
the tumours were injected, however the majority of breast cancer patients already have signs 
of metastasis when diagnosed, therefore investigating whether N-BPs are able to reduce 
tumour burden once the breast cancer cells have colonised the secondary site of metastasis 
may be more relevant to the clinical settings.  
A 1 to 6% incident rate of osteonecrosis of the bone has been reported with the use of BPs 
alone in the clinic (Guarneri et al, 2010). In a high portion of the in vitro and pre-clinical 
studies, anti-tumour activity associated with BPs is a result of high doses that are not 
clinically relevant (Fournier et al, 2010) There are other studies that combine clinically 
relevant doses of Zoledronic acid with chemotherapeutic agents (such as doxorubin) that 
have shown synergistic effects of combining N-BPs with standard anti-tumour therapy 
(Ottewell et al, 2009). However the use of BPs as anti-tumour agents is still being 
investigation.  
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6.1.5  Role of VEGF in  Bone Metastasis 
The literature available concerning the role of VEGF in tumour progression is vast and 
supports the importance of VEGF in many aspects of tumour progression, including both 
primary and secondary metastatic disease as serum levels of VEGF165 and VEGF121 in breast 
cancer patients demonstrate a positive association with bone metastasis (Voorzanger-
Rousselot et al, 2006), with increased plasma VEGF levels being observed in many patients 
with metastasis compared with patients that do not have metastasis. The evidence from the 
literature suggests that VEGF is a feasible target for treating the metastatic disease (Pluijm et 
al, 2001). In addition targeting bone metastasis specifically is justified as breast cancer cells 
expression of VEGF mRNA is thought to be significantly up-regulated in bone metastasis 
compared with soft tissue metastasis in experimental models (Pluijm et al, 2001). 
VEGF although originally identified as an angiogenic mitogen for vascular endothelial cells, 
is a multi-functional molecule that exerts effects on a variety of different cell types. VEGF 
receptors have been identified on the surface of osteoclast and osteoblast cells in the bone 
matrix and thus suggest a role for VEGF in bone remodelling. The role of VEGF in bone 
metastasis is two-fold, (1) as an angiogenic factor and (2) via effects on osteoclasts and 
Resorptive effects of 
osteoclasts on bone in 
the absence of BPs    
1. Osteoclasts numbers 
increase in the bone 
micro-environment 
2. Activated osteoclast 
cause excessive 
resorption 
3. Increased bone 
resorption results in 
bone loss leading to 
skeletal complications 
Resorptive effects of 
osteoclasts on bone in 
the presence of BPs    
Bone 
1.BPs home and adhere 
to the bone. 
2. Activated osteoclast 
uptake BPs. 
3. Uptake BPs results in 
apoptosis of osteoclast. 
A B 
Bone 
Figure 6.2 Effects of Bisphosphonates: 
(A) In the absence of BPs, increased osteoclast numbers recruited by tumour cells results in 
excessive bone destruction which is the primary cause of morbidity in patients with bone 
metastasis (B) BPs, have high affinity for bone , therefore rapidly ‘home’ to the bone and are 
taken up by osteoclasts. The presence of BPs in osteoclasts causes apoptosis of osteoclasts by 
inhibiting key enzymes involved in the metabolism of these cells (via the mevalonate pathway).  
 
Adapted from Drake &Cremers, 2010.  Bisphosphonates Therapeutic in Bone: the Hard and 
SOFT Data on Osteoclast Inhibition.   
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osteoblasts. Osteoblasts and osteoclasts are located in close proximity to ECs, haemopoietic 
cells and stromal cells in the bone micro-environment and the concordant actions of these 
different cell types is important in maintaining healthy bone tissue (Deckers et al, 2000 & 
Street et al, 2009).  
 
The Effects of VEGF on Osteoblasts 
VEGF-R1 and VEGF-R2 are both expressed on human osteoblasts, however functional 
activity of VEGF on osteoblasts is thought to be via VEGF-R1, as an in vitro kinase assay 
failed to demonstrate activation of VEGF-R2 after stimulation with VEGF (Yang et al, 
2012). VEGF regulates differentiation of primary human osteoblasts (Yang et al, 2012) and 
osteoblast cell survival in vitro (Street & Lenehan, 2009). In addition to expressing VEGF 
receptors, osteoblasts are also known to produce VEGF under certain conditions, including 
hypoxia (Street & Lenehan, 2009) suggesting both a paracrine and autocrine role for VEGF 
in osteoblast activity.  
 
The Effects of VEGF on Osteoclasts 
VEGF receptor protein expression is detected on isolated osteoclasts (Nakagawa et al, 2000; 
Street & Lenehan, 2009). VEGF demonstrates a pro-survival activity on mature osteoclasts 
isolated from rabbits bones in vitro as well as increasing the level of bone resorption 
(Nakagawa et al, 2000) suggesting that the increased osteoclast resorption induced by 
VEGF, is potentially due to increased osteoclast survival.  
 
VEGF also regulates osteoclast invasion as the addition of exogenous human VEGF 
increased osteoclast invasion in vitro by approximately 40 to 50% compared with non-
stimulated controls (Henriksen et al, 2003). Two forms of VEGF inhibition were utilised in 
this study, (1) addition of soluble VEGF-R1 and (2) treatment of cells with endostatin. 
Endostatin is an endogenous C-terminal fragment derived from type XVIII collagen and 
demonstrates anti-VEGF effects by blocking VEGF from binding VEGF-R2 and subsequent 
activation of ERK and p38 MAPK (Kim et al, 2002). The addition of soluble VEGF-R1 
resulted in inhibition of VEGF mediated osteoclast invasion. The presence of endostatin had 
a similar effect on osteoclast invasion. However, this was only observed when the osteoclasts 
were pre-incubated with endostatin for 30 minutes (Henriksen et al, 2003). VEGF is also 
involved in osteoclast recruitment (Yang et al, 2012) which is important in breast cancer-
induced bone metastasis, where an increase in osteoclast number is observed.  
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These functional studies and the clinical assessment of VEGF expression in patients with 
bone metastasis, provide evidence and rationale for targeting the VEGF pathway as an 
approach to inhibit or reduce breast cancer-induced bone metastasis. There is also evidence 
suggesting a link between tumour angiogenesis and metastasis (Weidner et al, 1991) which 
suggests the potential for anti-VEGF treatment to target both primary tumour angiogenesis 
and bone remodelling process that occur during bone metastasis.  
 
6.2 MATERIALS & METHODS 
6.2 Bone Metastasis Model 
6.2.1 Luciferin Imaging 
The luciferin is a bioluminescence in vivo imaging system that allows for non-invasive 
tumour monitoring over time. D-Luciferin is a low molecular weight organic compound that 
freely diffuses across membranes. In the in vivo system, animals are injected with tumour 
cells that are tagged with luciferase. When injected, luciferase catalyses the oxidisation of D-
luciferin to oxyluciferin in the presence of oxygen, and the co-factors, ATP and Mg2+. This 
oxidisation reaction produces a yellow/green light which in vivo at 37oC is visualised at 
560nm. Since ATP is required for the reaction to occur, the imaging can also be used as an 
indicator of live/dead tumour staining.  
 
6.2.2 Protocol 
Luciferase labelled MDA-MB-231 (1x105) breast cancer cells were injected via intra-cardiac 
injection into the left ventricle of anesthetised (isoflurane) 6 week old BALB/C nude female 
mice (performed by Dr Kim Reeves, University of Sheffield). BALB/C nude mice were used 
as previously, studies comparing that ‘homing’ of MDA-MB-231 breast cancer to the tibia in 
three different nude mouse strains (1) nude SCIDs, (2) CD1 and (3) BALB/C observed that a 
higher incidence of breast cancer metastasis to the bone was observed in the BALB/C nude 
mice compared with the other two strains (Dr Holen group, Sheffield, data not published).   
 
Mice were imaged twice weekly using the IVIS Lumina II bioluminescence system for the 
presence of tumours by injecting (150mg/kg) of D-luciferin (potassium salt) via i.p. injection 
(200μl) 15 minutes prior to imaging. Once a bioluminescence signal was detected in the 
bone, treatment with Bz (0.5mg/kg), Bz (0.1mg/kg) and the control vehicle (0.5mg/kg) 
commenced. The control vehicle was deemed a relevant control for these experiments as the 
control vehicle displayed similar inhibitory effects on primary tumour growth as those 
observed with Bz. Tumours were monitored for approximately 5 week, twice weekly by 
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IVIS imaging. The end of procedure (EOP) was marked as no more then six weeks after 
administration of the first treatment, as at this time point, increased tumour burden could 
lead to morbidity. Animals were culled prior to this if required. All animals were culled at 
the same time point (56 days post injection of the MDA-MB-231 Luciferase labelled cells). 
Hind limbs were removed, decalcified and processed (2.8.4) for micro-CT analysis and bone 
histomorphometry. Following micro-CT analysis bones were wax embedded and sectioned 
to allow for Tartrate-resistant acid phosphatase (TRAP) staining in osteoclasts to assess bone 
cell turnover events.  
 
6.2.3 Analysis 
Analysis of the IVIS data was carried out using the IVIS software (Caliper Life Sciences, 
UK). Images observed were loaded and regions of interest (ROIs) drawn around each 
individual metastasis, present in individual animals. The total flux measured as radiance was 
then calculated for each individual animal from the signal obtained from the ventral side  
(section 2.8.4).  
Micro-computed tomography (μ-CT) analysis was carried out using a Skyscan 1172 X-ray-
computed micro-tomograph (Skyscan) on representative animals (n=3) from each treatment 
group (Bz 0.1mg/kg, Bz 0.5mg/kg and CV). Imaging was carried out at a voltage of 49kV 
and a current of 200μA, an aluminium filter of 0.5mm and a pixel size was set to a 
dimension of 4.3μm. Scanning was initiated from the growth plate and images were 
reconstructed with NRecon software. The volume of interest was specified by drawing on 
the two-dimensional (2D) acquisition images from which trabecular bone mineral density 
was calculated. In addition other trabecular bone morphometric analysis was calculated 
using the SkyScan software including trabecular thickness, trabecular bone volume and 
trabecular number. 
Bone Turnover Analysis 
Osteoclasts and osteoblasts are the two main cell types involved in bone remodelling and the 
ratio of these two cells present in bone is crucial for maintaining ‘healthy’ bone. An increase 
in osteoclast number is usually associated with breast cancer-induced bone metastasis and 
therefore these cells are the main target for reducing bone loss in metastatic disease.  TRAP 
staining measured the number of osteoclasts present in the bone sections whereas osteoblast 
numbers were measured based on morphological identification of the cells in the bone 
sections (Figure 6.3).  In this project, osteoclast and osteoblast that were not in direct contact 
with the tumour were quantified.  
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Figure 6.3 (A) Example of TRAP staining: identifying osteoclasts present in a wax-
embedded bone section from a control treated animal. (B) Osteoblast quantification 
was carried out on the same sections that were stained for TRAP. Osteoblasts were 
identified from the unique morphology.  
 
6.2.4 Statistical Analysis 
Following assessment of normality statistical analysis was performed using the non-
parametric test, Mann-Whitney U Test or a student’s t test. When comparing multiple groups 
the One Way ANOVA, followed by the Dunn’s post-hoc test was used to determine any 
differences between groups.  Data is presented as mean±SEM and statistical significance was 
considered at p=0.05. All statistical analysis was performed using the Sigmaplot package 
(version 11). 
 
6.3 RESULTS 
6.3.1 Effects of Bz on Breast Cancer Induced Bone Metastasis 
Due to time constraints and resources and since no inhibition on primary tumour growth 
were observed with either neuropilin binding peptide it was decided that the preliminary 
bone metastasis experiments be carried out with Bz alone and the control vehicle. In these 
experiments, the MDA-MB-231 breast cancer cells rather then the MDA-MB-436 breast 
cancer cells were utilised, as they have previously been shown to migrate to the bone 
following intra-cardiac injection.  
 
At the end of the experiment (day 56 post injection of MDA-MB-231 Luciferase cells), 
treatment with Bz (n=4) at 0.1mg/kg reduced the total bone tumour burden (hind limbs, jaw, 
shoulders and rib cage) present compared with the CV (n=8) control group (Figure 6.4 and 
TRAP stained 
osteoclast cell 
Morphological 
identification of 
osteoblast cell 
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Figure 6.5a), when measured as the total bioluminescence signal produced from the IVIS 
LuminaII software (mean±SEM total flux; Bz (0.1mg/kg) vs. CV; 2264563±747005 vs. 
9154359±7344633; n=4/8, NS) which did not reach statistical significance (p=0.808). 
Additionally Bz (n=4) at 0.1mg/kg also reduced tumour burden present in the hind limbs 
only compared with the CV (n=5) control group (mean±SEM total flux; Bz (0.1mg/kg) vs. 
CV; 1921925±623456 vs. 4373306±36684411; n=4/5, ns) (Figure 6.6a), but again this did 
not reach statistical significance (p=0.413).  
 
In contrast, treatment with Bz (n=4) at 0.5mg/kg increased the total tumour burden present 
when compared with the CV (n=8) control group (mean±SEM total flux; Bz (0.5mg/kg) vs. 
CV; 17591394±11493360 vs. 9154359±734463; n=4/8, ns) (Figure  6.5b) but this was not 
significant (p=0.808). Similarly, the total tumour burden present in the hind limbs after 
treatment with Bz (0.5mg/kg) (n=3) also demonstrated an increase compared with the CV 
(n=5) control group (mean±SEM total flux; Bz (0.5mg/kg) vs. CV; 22660207±14051318 vs. 
4373306±36684411; n=3/5, ns), which was not significant (Figure 6.6b).  
 
Interestingly, the number of metastasis present in each individual animal at the end of the 
experiment (day 56) was lower in both of the Bz treated groups (0.1mg/kg n=4 & 0.5mg/kg 
n=4) compared with the CV (n=8) control group (mean±SEM; Bz (0.1mg/kg) and Bz 
(0.5mg/kg) vs. CV; 2.8±0.5 and 2.3±1.3 vs. 4.3±0.6; n=4/8, ns) (Figure 6.7), but this was 
not statistically significant (p=0.164 and p=0.170 respectively), potentially due to low 
numbers. This trend observed with Bz (0.1mg/kg) treatment suggests both a reduction in the 
number of bone metastasis and the overall bone tumour burden. 
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Control Vehicle (CV) Bz 0.5mg/kg Bz 0.1mg/kg 
Figure 6.4 Effects of Bz on Overall Tumour Burden: 
Representative images of ventral IVIS Lumina II images of the luciferase signal after 
injection of D-luciferin taken on 56 days post injection of Luciferase labelled MDA-MB-231 
breast cancer cells (i.c.) The number and size of the metastatic burden present was lower in 
the Bz treated animals compared with the control vehicle (CV) group.  
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Figure 6.5 Effects of Bz on Overall Tumour Burden (A) Bz at 0.1mg/kg reduced the total 
tumour burden compared to the control vehicle (CV), this was not significant at any time point 
(B) In contrast, Bz at 0.5mg/kg increased the total tumour burden compared to the control 
vehicle (CV), this was not significant at any time point.  
 
Data is presented as mean±SEM total flux; CV n=8 and Bz (0.1mg/kg & 0.5mg/kg) n=4, NS.  
Statistical analysis was performed using the One Way ANOVA (Sigmaplot 11 software). 
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Figure 6.6 Effects of Bz on Metastasis in the Hind Limbs: 
(A) Bz at 0.1mg/kg reduced hind leg tumour burden compared with the control vehicle (CV), 
this was not significant at any time point (B) In contrast, Bz at 0.5mg/kg increased the hind leg 
tumour burden compared with the control vehicle (CV), this was not significant at any time 
point. 
 
Data is presented as mean±SEM total flux; CV n=8 and Bz (0.1mg/kg & 0.5mg/kg) n=4, NS 
Statistical analysis was performed using The One Way ANOVA (Sigmaplot 11 software) 
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Figure 6.7 Effects of Bz on the Number of Bone Metastasis Present:  
(A) A representative image illustrating how the mean number of bone metastasis in each 
individual animal at the end of the experiment (Day 56) was measured. (B) Both Bz  (0.1mg/kg) 
and Bz (0.5mg/kg) reduced the number of metastasis present in each individual animal compared 
with the control vehicle (CV) 
 
Data is presented as mean±SEM number of metastasis; CV n=8 and Bz (0.1mg/kg & 
0.5mg/kg) n=4, NS. Statistical analysis was performed using a t-test (Sigmaplot software) 
A 
B 
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Bone metastasis was evident in the jaw, shoulders, hind legs and rib cage of animals injected 
with MDA-MB-231 breast cancer cells by the end of the study (day 56). There was also 
differences in the of location of the breast cancer induced bone metastasis between the 
different treatment groups, with the control vehicle treated animals observing a higher 
incidence of metastasis (Figure 6.8) to the jaw and the rib cage compared with the Bz treated 
animals (Figure 6.8). In animals treated with Bz there was a higher incidence of bone 
metastasis to the hind legs (Figure 6.8).  
 
 Jaw Shoulder Hind Legs Rib Cage 
CV (n=8) 71.4% 42.9% 71.4% 85.7% 
Bz 0.1mg/kg (n=4) 50% 50% 100% 0 
Bz 0.5mg/kg (n=4) 0 33.3% 100% 33.3% 
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Figure 6.8 Incidence of Bone Metastasis: 
(A) Summarises the incidence of metastasis in different locations with the two doses of Bz 
(0.1mg/kg and 0.5mg/kg) (B) Treatment with Bz with both doses reduces the further 
dissemination of breast cancer cells to distant sites compared with the control vehicle (CV). 
 
Data is presented as % of incidence; CV n=8 and Bz (0.1mg/kg & 0.5mg/kg) n=4. 
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B 
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6.3.2 Effects of Bz on Bone Structure 
The mechanism of the reduction in MDA-MB-231Luciferase tumour burden in the tibia of 
mice treated with Bz was investigated. Micro-CT analysis was carried out to assess the 
effects of Bz on trabecular bone, including a list of parameters (Figure 6.9).  
Bone mineral density was measured with no differences observed between Bz treated 
(0.1mg/kg and 0.5mg/kg) compared with the CV control group (respectively). However, 
further analysis was carried out on the trabecular bone to establish if any changes in the 
micro-architecture were observed after treatment with Bz.  
 
Trabecular Bone Morphometry 
A number of parameters can be quantified using μCT that assess the effects of Bz treatment 
on the micro-architecture of the trabecular bone with the following five considered the most 
relevant, 1) trabecular bone volume (bv/tv) 2) trabecular number (Tb) (3) trabecular 
thickness, (4) trabecular separation and (5) the structure model index (SMI) (Bouxsein et al, 
2010). The SMI measures the change in trabecular bone structure from a plate-like to rod-
like morphology. These measures are reflective of the strength and health of the bone 
structure.  For the analysis on bone histomorphometry, a representative number of hind limbs 
with a tumour signal at the end of the experiment (n=3/group) were assessed using μ-CT. 
 
Bone Volume: Trabecular Bone Volume (bv/tv) 
The bv/tv measure is indicative of total bone volume occupied by mineralised bone, with a 
higher bv/tv value indicating healthier bone. In the current study, treatment with Bz 
(0.1mg/kg) significantly (p=0.031) increased the percentage bv/tv compared with the CV 
control group (mean±SEM % bv/tv; Bz (0.1mg/kg) vs. CV; 12±0 vs. 9±0; n=3, p=0.031) 
(Figure 6.10). A similar trend was observed with Bz (0.5mg/kg), (mean±SEM % bv/tv; Bz 
(0.5mg/kg) vs. CV; 12±1 vs. 9±0.4; n=3, p=0.074) however this increase did not reach 
statistical significance (p=0.074) (Figure 6.10).  
 
Trabecular Number 
This quantifies the average number of trabeculae per unit length. Treatment with Bz 
(0.1mg/kg) significantly (p=0.022) increased the Tb number compared with the CV control 
group (mean±SEM number (mm3); Bz (0.1mg/kg) vs. CV; 3±0.3 vs. 2±0.1; n=3, p= 0.022) 
(Figure 6.10). The higher dose of Bz (0.5mg/kg) displayed a similar trend (mean±SEM 
number (mm3); 3±0.3 vs. 2±0.1; n=3, p=0.100) however the increase did not reach statistical 
significance (p= 0.100) (Figure 6.10).  
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Trabecular Thickness 
Treatment with Bz (0.1mg/kg) displayed no significant (p=0.065) effects on Tb. thickness 
compared with the CV control group (mean±SEM thickness (mm); Bz (0.1mg/kg) vs. CV; 
0.04±0.002 vs. 0.05±0.002; n=3, p=0.065) (Figure 6.10). In contrast, Bz (0.5mg/kg) 
significantly reduced the Tb. thickness compared with the CV control group (mean±SEM 
thickness (mm); Bz (0.5mg/kg) vs. CV; 0.04±0.001 vs. 0.05±0.002; n=3, p=0.011) (Figure 
6.10).  
 
Trabecular Separation 
Measurement of Tb.Sp demonstrated a significant decrease in trabecular separation after 
treatment with Bz (0.1mg/kg) compared with the CV control group (mean±SEM Tb.Sp; Bz 
(0.1mg/kg) vs. CV; 0.2±0.01 vs. 0.3±0.01; n=3, p=0.017) (Figure 6.10). Similarly Bz 
(0.5mg/kg) demonstrated Tb. separation compared with the CV control group (mean±SEM 
Tb.Sp; Bz (0.5mg/kg) vs. CV 0.2±0.01 vs. 0.3±0.01; n=3, p=0.005) (Figure 6.10).  
 
Structure Model Index (SMI) 
Treatment with Bz at both concentrations (0.1mg/kg and 0.5mg/kg) significantly (p=0.024 
and p=0.008 respectively) decreased the SMI ratio compared with the CV control group 
(1.7±0.05 and 1.7±0.01 vs. 1.9±0.1 respectively) (Figure 6.10).  
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Control Vehicle Bz 0.1mg/kg Bz 0.5mg/kg 
Control 
Vehicle 
Bz 0.1mg/kg 
A 
B 
Figure 6.9 Effects of Bz on Bone Structure: 
Representative images from the (A) micro-CT scan of the tibia that were used to create the 2D 
and 3D required for further analysis of the bone structure. (B)  3D reconstructions of the 
trabecular. From the images, it can be observed that the spacing of the trabecular bone is more 
compact in the Bz treated animals, suggesting that Bz is modulating the bone micro-
environment.  
Bz 0.5mg/kg 
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Figure 6.10 Effects of Bz on Bone Micro-architecture: 
From the different measures above, it appears that Bz treatment is modulating the bone 
environment and is aiding health of the bone. The different parameters indicate the bone 
strength and from data, there is evidence to suggest that Bz is interacting with the bone 
remodelling cells, either directly or indirectly, in order to modulate changes in the bone micro-
environment, leading to increased bone strength. 
 
Data is presented as mean±SEM; n=3, p<0.05. Statistical analysis was performed using a t-
test (Sigmaplot 11 software). 
*p=0.074; *1 p=0.022; *2 p= 0.011; *3 p=0.005; *4 p=0.024 and *5 p=0.008  
 
 
 
* 
*2 
*1 
*5 *6 
*3 *4 
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6.3.3 Effects of Bz on Bone Turnover 
As most breast cancer induced bone metastasis is of an osteolytic nature, the bone 
remodelling process is usually favoured towards a higher presence of osteoclast numbers 
versus osteoblast, as this allows for bone destruction and tumour cell expansion in the new 
bone environment, thus balancing this ratio would be an important mechanism of therapy.  
Treatment with Bz with either dose did not change the number of osteoclasts per mm of 
trabecular bone surface that was not in contact with the tumour, compared with the CV 
control group (mean±SEM; Bz 0.1 and 0.5mg/kg vs. CV; 11±19 and 0.4±0.4 vs. 3±5; n=3, 
ns) (Figure 6.11). Similarly, the number of osteoblast numbers not in contact with the 
tumour after treatment with either Bz dose remained unchanged compared with the CV 
control group (mean±SEM; Bz 0.1 and 0.5mg/kg vs. CV; 1±2 and 3±3 vs. 4±6; n=3, ns) 
(Figure 6.11). The number of osteoclast and osteoblasts in the sections were relatively low. 
Analysis on these bone sections were carried out  at a depth of 3μM , thus analysis of 
sections cut deeper into the bone may reflect more accurately, the bone remodelling events 
occurring in both the control and the Bz treated groups.  
Additionally due to the nature of Bz and the proposed mechanism of action associated with 
this anti-angiogenic drug, CD34 analysis was carried out on the bone sections. However 
CD34 staining on the bone sections was not as obvious as that observed in the earlier tumour 
sections and due to time constraints, a repeat staining experiment could not be carried out, 
however this is a potential stain that would be useful in establishing further the role of Bz in 
breast cancer induced bone metastasis. 
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Figure 6.11 Effects of Bz on Bone Remodelling:  
(A) Representative image of TRAP staining and morphological identification of osteoblasts (B) 
The levels of osteoclasts and osteoblast remained unchanged following treatment with Bz 
 
Data is presented as mean±SEM osteoclast or osteoblast number; n=3; NS. 
Statistical analysis was performed using test (Sigmaplot software).  
Mineralised Bone 
Osteoclasts 
Osteoblasts 
KEYPOINT 
The bone metastasis model demonstrated clear distinction between the actions 
of Bz compared with the control vehicle 
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6.4 BONE METASTASIS 
DISCUSSION 
 
6.4.1 Effects of Bz on Breast Cancer Induced Bone Metastasis 
Breast cancer induced metastasis is a major cause of morbidity in breast cancer patients with 
no current curative treatment.  The current pilot study suggests that Bz (0.1mg/kg) is capable 
of both reducing the number of bone metastasis present and also the size of the metastasis., 
however a larger data set would be required to confirm this data, as the decrease in tumour 
burden, suggested as trend but was not significant. 
The bone mineral density remains unchanged after treatment. VEGF is an important 
regulator of bone cell activity, and although TRAP staining allows osteoclast and osteoblast 
numbers to be quantified, this does not necessarily reflect the functional ability of these cells. 
Thus treatment with Bz may effect bone turnover via direct actions on the bone cells, which 
may not be reflected by the numbers present. The different parameters measured to assess 
trabecular bone morphometry suggested that Bz is capable of modulating the bone micro-
environment to induce micro-architectural changes allowing improvement of bone strength. 
This is an important finding as many breast cancer patients that have bone metastasis suffer 
from fractures and bone pain. This suggests that VEGF inhibition, maybe offer an 
enhancement to the treatment currently provided by BPs, in that it could exert both palliative 
effects (see with the BPs), in addition to limiting metastatic  tumour burden. Although there 
is increasing evidence that suggests that BPs display some anti-tumour activity there are still 
advantages for using anti-VEGF agents such as Bz in addition to BPs. The use of BPs in 
bone disease is ideal as these agents have a high affinity for bone (Holen & Coleman et al, 
2010) and rapidly ‘home’ to the bone after administration where they are retained for long 
periods of time, up-to several years (Holen & Coleman et al, 2010). However this suggests 
that the distribution of BPs outside the bone maybe limited, thus the use of BPs as anti-
cancer agents alone, may not be as efficacious as using drugs that display a more wide-
spread distribution, such as Bz.  
There is minimal literature available (PubMed) assessing the effects of Bz on breast cancer 
induced bone metastasis in experimental model. The majority of pre-clinical translation 
studies investigate the use of Bz for lung and lymph metastasis (Matsui et al, 2008 &Volk et 
al, 2011). In these studies MDA-MB-231 fragments were implanted into the mammary fat 
pad, allowed to grow for two weeks, after which treatment with Bz commenced. The 
experiment lasted for 56 days and the number of animals with metastasis in the lung and 
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lymph nodes were measured. Bz reduced the number of metastasis present in both lymph and 
the lungs, with a significant reduction being observed with lung metastasis (Matsui et al, 
2008). To my knowledge this pilot study is novel, assessing the role of Bz therapy in breast 
cancer induced bone metastasis. There has been a similar study (Bauerle et al, 2008) that 
assessed the effects of Bz on breast cancer-induced bone metastasis. However, the analysis 
carried out during the above study focused on imaging analysis of vessel formation and 
oseotolysis but effects on tumour metastasis on the bone micro-environment were not 
identified, therefore the mechanism by which Bz acts as both an inhibitor of primary and 
secondary tumour growth can not be established using the method in the Bauerle et al study.  
In addition, the model required injection of cancer cells into the femoral artery of the hind 
leg. This method is much more invasive then the intra-cardiac technique used during this 
PhD. This is important, as VEGF is a stress related protein and an invasive technique is more 
likely to cause an increase in VEGF expression around the bone micro-environment, thus 
creating false positive results. With that in my, the technique used during this PhD is more 
relevant and simulates bone metastasis to a greater extent than that observed in the Bauerle 
et al paper.  
 
However, it is important to note that the data from this bone metastasis study is preliminary 
and further experiments are required to make a full assessment of any role for Bz in bone 
metastasis, however the results are promising. Further studies are required to confirm the 
preliminary experiments and investigate the mechanism by which Bz is modulating the bone 
micro-environment. 
 
 
6.5 CHAPTER CONCLUSION 
 
From the in vivo experiments, it can be concluded that the classical VEGF signalling 
pathway plays an important role in both primary breast cancer growth and subsequent 
progression to metastasis as Bz effectively reduced both breast tumour growth and the 
tumour burden associated with breast cancer induced metastasis. Further work enabling 
mechanistic studies would be useful.  
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7.  FINAL DISCUSSION 
Breast cancer represents a major challenge for researchers due to the heterogeneous nature of 
the disease and the more recent sub-classification of invasive breast cancer. The key 
proposition initially suggested by Folkman (1973) that angiogenesis plays a crucial role in 
solid tumour development and the subsequent development of the anti-angiogenic agent, Bz, 
the first agent of its kind to gain FDA approval provided great promise for breast cancer 
therapy. As angiogenesis is a perquisite for all solid tumours, it was thought that anti-
angiogenic therapy could be applied universally to all tumours that require establishment of a 
vasculature in order to progress. This would over-come the common side effects associated 
with chemotherapy and resistance to systemic therapy, since this anti-angiogenic therapy 
primarily targets the endothelial cells, a cell type thought to be genetically more stable then 
cancer cells. However, the results of clinical trials have modest effects with Bz even in 
combination with chemotherapy. Therefore this project aimed to test the hypothesis ‘that 
inhibition of both VEGF receptor families simultaneously, enhances the efficacy of Bz’. 
 
7.1 Breast Cancer Cell Lines as Representative Models of Breast Cancer 
The relevance of using breast-tumour cell-lines to represent breast cancer has been 
questioned, especially after the identification of further molecular classifications of invasive 
breast cancer (Holliday & Speirs, 2011 ). However, it has been shown that specific breast 
cancer cell lines display similar molecular profiles and characteristics of the different sub-
types of invasive breast cancers, such as luminal, basal, HER breast cancer types (Holliday 
& Speirs, 2011).   
 
The two metastatic breast cancer cell lines (MDA-MB-231 and MDA-MB-436) used in this 
study displayed differential responses to treatment with the Np1 peptides in vitro. This 
further confirms the heterogeneous nature of breast cancer, as despite displaying similarities 
in hormone receptor status, morphology and other features that classify both cell lines as 
being reflective of basal B, triple negative breast cancer types (Lehmann et al, 2011) these 
two cell lines also have different mutations (such as BRCA1), expression of factors and 
preferentially metastasise to different locations (Chavez et al, 2010 & Lehmann et al, 2011). 
These variations are the potential explanation for the differential responses to targeted 
therapy, including the Np1 peptides. These findings emphasise the need for personalised 
medicine or biomarker analysis (Lambrechts et al, 2013) in identifying patients or cancer 
sub-types that would benefit from different therapies. Grouping sub-types of breast cancer is 
not likely to be an adequate approach for assigning therapy.  
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Xenograft models of primary breast cancer commonly consist of either implantation of 
human tumour cells via sub-cutaneous injection into the flank region or orthotopic injection 
into the mammary fat pad. It can be argued that implantation of tumour cells does not 
represent the entire process of breast cancer development described in the human disease and 
that the Polyoma middle T antigen (MMTV-PyMT) mouse models offers certain advantages 
over xenograft models of breast cancer. In the MMTV-PyMT murine model, mice develop 
the spectrum of breast disease (hyperplastic, in situ, invasive and metastatic stages) in the 
mammary fat pad and thereby more accurately reflecting the development of breast cancer 
(Lin et al, 2003). However, obviously, human cells are more relevant to human breast 
cancer, being syngenic, and of the same origin for which the drugs or therapy are designed. 
Thus drugs that are effective in a murine model of breast cancer may not translate to the 
human disease. The MMTV-PyMT model is difficult to monitor tumour growth over time, as 
the lesions are not clearly visible, making accurate caliper measurements of tumour volume 
difficult. Thus, unless MMTV-PyMT tumour implants are used, the use of the MMTV-
PyMT may be limited to experiments that are looking at specific experimental time points or 
specific stages of the disease process, rather then monitoring tumour growth over time. More 
recently, a breast cancer metastasis model has been developed, that measures the entire 
process of metastasis (Iorns et al, 2012). In this model breast cancer cell injected into the 
mammary fat pad resulted in spontaneous and frequent, metastasis to the lungs, lymph nodes 
and liver and interestingly, found that the cells present in these distant metastasis, differ 
greatly in gene expression. In addition, breast cancer-induced bone metastasis is a focus in 
this project as the majority of breast cancer patients with metastasis have evidence of bone 
metastasis. In the PyMT metastatic model, disease tends to localise to the lung, making the 
process of breast cancer-induced bone metastasis impossible to assess. There are several in 
vivo models of breast cancer available, however all have limitations, and therefore utilising 
the appropriate model to address the objectives of the study is an important consideration. 
 
7.2 Bevacizumab 
Bevacizumab (Bz) is a monoclonal antibody that binds to VEGF and subsequently blocks 
interactions with the classical VEGF receptors; VEGF receptor 1 and 2. Bz is considered an 
anti-angiogenic agent, that primarily targets the vasculature, (rather then the tumour 
epithelium) and therefore inhibits tumour progression indirectly. As expected Bz inhibited 
both microvascular endothelial cell differentiation and migration in vitro (Chapter 3) with no 
effects on the breast cancer cells. The effects of Bz on primary breast cancer growth in vivo 
confirms previous literature that Bz has the ability of effectively inhibiting breast cancer 
growth in vivo, both alone (alone) and in combination with other agents 
(paclitaxel/doxectaxel) (Chapter 5). Unfortunately, in the current study the control vehicle 
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for Bz displayed similar effects on primary breast cancer growth in vivo, as those observed 
with Bz. Closer inspection of the literature reveals that the vehicle in which Bz is 
reconstituted has not been used in previous experimental in vitro and in vivo studies.  Based 
on the data from this current study the effects of the control vehicle itself require further 
investigation and future experiments assessing the effects of Bz should always include the 
control vehicle to allow discrimination between control vehicle induced effects and direct 
anti-angiogenic. The control vehicle consists of mostly sodium salts and tween20. More 
recent papers have demonstrated the effects of excipients such as tween20 on a number of 
cell types including breast cancer cell activity (Yamagata et al, 2009, Yang et al, 2012 & 
Eskandani et al, 2013). One paper reported inhibition of the levels of breast cancer 
resistance protein, BCRP/ABCG2 in response to tween20 both in vitro and in vivo. This 
provides confirmatory evidence suggesting that the inhibition induced by the Bz control 
vehicle may be a result of direct anti-tumour activity on the breast cancer cells and/or 
endothelial cells, due to the presence of tween20, especially since the control experiments in 
showed significant inhibition in endothelial cell differentiation in the presence of tween20 
alone. Although the mechanism by which the control vehicle is inducing inhibitory effects is 
not likely to be via BCRP/ABCG2, the study by Yamagata et al, supports the data from the 
current project. Treating breast cancer cells and endothelial cells in vitro with tween20 alone 
and then using either Western blotting or protein arrays, to measure the downstream 
effectors associated with inhibiting breast cancer growth would be an informative study.  
 
7.3 Neuropilin Peptides 
Neuropilin receptors were originally identified as receptors for the semaphorin protein 
family involved in neuronal guidance (Staton et al, 2007). More recently the role of the 
neuropilin receptors in VEGF signalling is associated with angiogenesis and hence are being 
investigated (Staton et al, 2007).  To date the majority of breast cancer research has focused 
on Np1, however the potential for Np2 in tumour progression is currently under 
investigation.  
 
The responses to dual targeting observed in vitro with p7b (Np1) and p10 (Np1 and 2) in 
combination with Bz on both the microvascular endothelial cells and the breast cancer cells 
suggests that inhibition of VEGF interaction with either Np1 alone or both neuropilin 
receptors may be more beneficial then Bz alone. However, in vivo p7b alone failed to inhibit 
breast cancer growth whereas p10 displayed an inhibitory trend. The amino acid structure of 
the carboxy-terminus of the two peptides differs; p7b (DKPRR) and p10 (RPPR) and leads 
to differences in Np1 affinity. The RPPR sequence displays greater affinity to Np1 in vitro 
(Cebe-Suarez et al, 2008 ) and also shows the greatest ability to inhibit radio-labelled 
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VEGF165 from binding to Np1 (Cebe-Suarez et al, 2008). In addition, p10 is thought to also 
bind Np2, therefore it is possible that in vivo p7b is readily displaced by endogenous 
VEGF165, which provides an explanation for the disparity in the results between the in vitro 
and in vivo studies.  
 
The design of the peptides could potentially be modified to produce a more effective 
inhibition of neuropilin activity both in vitro and in vivo and we are in discussion with Prof. 
Ballmer-Hofer regarding this. The neuropilin blocking peptides are short in length and also 
potentially have a short half-life and therefore may not be able to maintain long-term 
inhibition due to displacement of the peptides and subsequent instability. However 
limitations in the design of the peptide can be solved by peptide modification such as 
incorporation of a cyclic structure.  
 
7.4 Combination Studies 
In summary, the Np1 binding peptides displayed no additive inhibition on breast cancer 
growth compared to Bz alone either in the in vitro or in vivo setting.  However the potential 
role that the neuropilin receptors play in providing a mechanism of escape following Bz 
treatment remains inconclusive, as a number of questions with regards to the design and the 
efficacious of the inhibitory activity of the neuropilin peptides have been raised. In addition, 
inhibitory effects with the two peptides alone were observed in vitro, however this did not 
translate to the in vivo setting for p7b, therefore raising the question of efficient delivery of 
p7b into the tumour. An important note to also consider is the dosing regime in combination 
therapy, as the order of administration of two adjuvant therapies could prove to be essential 
as to whether a combination treatment will ultimately prove efficacious (Ottewell et al, 
2009). As p10 alone suggested a trend that reduced tumour growth, however, when 
combined with Bz, a reduction in efficacy was observed, suggesting that either the 
combination of p10 and Bz does not work or that the order in which these two treatments are 
given is essential (van der Veldt et al, 2012). Therefore based on some of the questions 
raised in the discussion, the data from this current study is not enough to dismiss the 
potential of inhibiting neuropilins in breast cancer therapy.   
 
Additionally targeting the VEGF pathway alone may not be sufficient in maintaining 
inhibitory effects observed with either Bz alone, anti-Np1 agents or a combination of the 
two, as breast cancer cells produce a repertoire of cytokines and growth factors/receptors 
 that can aid progression of the tumour such as IL-6, IL-8, MCP-1 , RANTES (Chavey et al, 
2006) , transforming growth factor beta (TGF-β) (Barcellos-Hoff & Akhurst, 2009) and 
fibroblast growth factor receptor (FGFR) (Tenhagen et al, 2012). Therefore combining Bz 
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or anti-neuropilin agents with inhibitors of other cytokines involved in breast cancer 
progression may prove more effective especially when aiming to over-come resistance 
associated with targeted therapy. Resistance to Bz activity is not only associated with up-
regulation of factors involved in compensatory signalling pathways but can occur due to (1) 
induction of a more aggressive phenotype post Bz treatment, (2) selection of cancer stem cell 
(CSC) sub-populations and (3) induction of autophagy (Giuliano & Pages et al, 2013). 
Therefore combining anti-VEGF or other anti-angiogenic agents with a therapy that may 
limit the occurrence of the above mechanism may prove more beneficial in providing long-
term inhibitory effects on breast cancer.  
 
A major challenge in the use of Bz and other targeted agents, is the identification of a sub-
population of patients that are likely to respond to and benefit from Bz therapy. Two recent 
papers reviewed the status of biomarker identification for Bz (Lambrechts et al, 
2013&Maru et al, 2013). The papers highlighted the current challenges associated with 
finding useful predictive biomarker, the first being due to the vast number of angiogenic 
factors that are produced by tumour cells, such as FGF, angiopoeitin and PDGFs, any one of 
these factors could elicit a compensatory response to Bz, resulting in escape from therapy 
(Lambrechts et al, 2013). Secondly, pre-clinical analysis suggests that inhibiting VEGF 
results in a diverse response that ranges from inhibiting the formation of newly formed 
vasculature, causing regression of the pre-existing vessels and inhibiting the recruitment of 
bone–derived and endothelial progenitor cells (Lambrechts et al, 2013), these differing 
responses potentially lead to consequential events that may effect the outcome of response to 
Bz therapy in different patients. Lastly, the end points that measure clinical outcome may not 
allow identification of patients likely to respond to Bz (Lambrechts et al, 2013). High levels 
of VEGF correlated to significantly higher response rates to Bz treatment in breast cancer 
patients (Lambrechts et al, 2013). 
 
7.5 Bone Metastasis 
Although there are studies that investigate the use of Bz in lymph and lung metastasis (Volk 
et al, 2012) a less studied avenue of breast cancer research is the use of Bz in breast cancer 
induced bone metastasis in vivo.  The current project observes very preliminary data that 
suggests that treatment with Bz alone could potentially be used as a curative therapy for bone 
metastasis, as not only was a trend that suggested a reduction in metastatic tumour burden 
evident but also significant improvements in the bone micro-architecture of Bz treated 
animals was observed. Currently, there is very little treatment beyond the use of 
bisphosphonates as palliative therapy for bone metastasis therefore the potential effects 
observed with Bz is encouraging. In addition combining Bz with a peptide that inhibits the 
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neuropilin receptors would be useful as in the clinical setting Bz treatment is thought to 
induce a more aggressive phenotype post-treatment, thus combining Bz with anti-neuropilins 
peptides may have more potential in reducing metastasis then Bz alone, especially with the 
identification of stem cell like cells that express Np1 (Glinka et al, 2012) making the 
neuropilin receptors an even more attractive target for bone metastasis. However, 
combination treatment with Bz should be investigated with some caution as there is some 
evidence in the literature that suggests that osteonecrosis is a side-effect associated with both 
BP and Bz treatment. Since bone remodelling requires angiogenic signalling pathways 
combining agents that target this process may lead to serious side effects, therefore 
investigating the mechanism by which Bz is reducing bone metastasis is required initially 
prior to any combination studies. 
 
However, despite the encouraging data obtained with Bz treatment the translation of pre-
clinical success of such agents to the clinic have yet to be observed in breast cancer 
treatment. Bz in the clinic has proven successful for other solid tumours such as metastatic 
colorectal cancer, therefore, identifying potential differences between these different tumour 
types could prove useful in establishing why the same success in the clinic has not been 
observed with Bz in breast cancer patients. Bz was the first anti-angiogenic inhibitor to be 
approved for use in the clinic thus more basic research needs to be carried out on the 
mechanisms and subsequent effects that Bz has both locally and systemically. This ‘back to 
basics’ approach might aid in the appropriate use of Bz in the right setting for breast cancer 
therapy which might then allow better understanding of how Bz is working . With all the 
data and literature in mind, the studies with anti-VEGF agents such as Bz highlight that 
tumour development and progression is an extremely dynamic process that involves a whole 
host of different cell types and the plethora of cytokines that are released by these different 
cells types that may provide mechanisms of resistance to anti-VEGF therapy thus as 
mentioned previously, combining anti-VEGF therapy with inhibitors of alternative pathways 
or functions (such as immune modulators) may prove more efficacious.  
 
Ultimately the use of peptides is an important step in cancer research as peptides offer 
certain advantages over monoclonal antibody therapy that may help to over-come some of 
the problems that arise in the clinic as a result of antibody therapy. Monoclonal antibodies 
are large in size, which can result in poor delivery to the tumour, and are often associated 
with higher levels of toxicity (Thundimadathil et al, 2012). Additionally, monoclonal 
antibodies are expensive to produce, whereas in contrast peptides are easier to manufacture 
and are cheaper to produce, therefore decrease the financial burden required to pay for these 
treatments. Peptides are also smaller in size and therefore penetrate into the tumour more 
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easily and issues such as rapid degradation can be over-come by modification to the peptide 
design (Thundimadathil et al, 2012). Currently, peptide therapies have been approved for 
either use in breast cancer patients in the clinic such as Zoladex or are undergoing clinical 
trails (Triptorelin) in ER+ patients (Thundimadathil et al, 2012) suggesting the application 
of peptide targeted therapy is relevant to the biological treatment of breast cancer.  
 
With all the data in mind, Figure 7.1 summarises the potential in vivo actions of peptide 7b., 
which may help explain why this peptide failed to enhance inhibit breast cancer growth 
when the in vitro data suggested that this human Np1 binding peptide exerted inhibitory 
activity on both breast cancer and micro-vascular endothelial cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
External 
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B 
Activation of 
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via Np1 
Tumour or 
EC 
P7b intraperitoneal 
injection 
A 
1. Liver 
2. Kidney 
3. Tumour 
P7b intraperitoneal 
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signalling via Np1 
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angiogenic 
signalling via 
Np1 
Figure 7.1 Peptide 7b- Potential Mechanisms of Action: 
(A) Post i.p. injection of p7b, the peptide is distributed throughout the circulatory system. The 
liver and kidneys highly express Np1 and since the circulation delivers p7b to these organs prior 
to reaching the tumour, it is possible that delivery of p7b at the dose administered results in 
inefficient delivery to the tumour, resulting in the lack of breast cancer growth in vivo, as 
observed in this current study after p7b treatment alone . (B) Alternatively, as p7b is derived 
from the VEGF165 sequence, it is possible that the peptide is being delivered to the tumour, but is 
activating the Np1 receptor, rather then inhibiting it. The stimulus that dictates whether p7b 
inhibits or stimulates breast cancer activity either in vitro or in vivo is yet unknown. 
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7.6 FUTURE WORK 
The future work based on the studies from this project are either work that can be carried out 
on the samples collected from this current study or ideas that have stemmed from the work 
from this project but would require additional studies to be set up.  
 
Firstly, from the samples already available, Ki67, Caspase 3 and CD34 staining analysis  
needs to be carried out on the normal tissue harvested from the different treatment groups is 
an important future experiment to carry out to establish if there are any ‘off-target’ effects 
exerted by either Bz , p7b/p10  or the combination treatment. This is especially important 
since the recent revoking of Bz from use in breast cancer therapy is partly due to a high and 
serious toxicity profile. Of interest the difference, if any, in ‘off-target’ effects between the 
higher dose of Bz (5mg/kg) versus the lower ranges (1-0.1mg/kg) could potentially prove 
interesting and useful if a lower dose of Bz with less severe side effects can translate to the 
clinical setting. In addition, a toxicity test should be carried out to determine if the inhibitory 
effects observed with the Np1 peptides is a result of a toxic effect, rather then a functional 
consequence. It was discussed that the MTS assay may have reflected this to some level as 
the assay requires ATP for the colour reaction to occur, which can also be produced by dying 
cells. Therefore, a cell viability test would be more appropriate. 
 
As mentioned in the earlier in vitro discussions (see section 3.3.1), in vitro flow cytometry 
studies that allow for the assessment of differential receptor expression under normoxic and 
hypoxic conditions would be useful in determining the levels of VEGF cell surface receptor 
expression, especially since hypoxia is known to regulate receptor expression (Bae et al, 
2008 ) and is one of the hallmarks of cancer (Hannahan &Weinberg, 2011). In addition, as 
ELISA assay could then be used to measure the levels of secreted VEGF related factors such 
as soluble receptors or other angiogenic agents into the conditioned media from the hypoxia 
experiments. This would be would be useful in determining the ratio of soluble versus 
membrane bound receptor present, which might also explain why peptide required to reach 
active membrane bound receptors in order to produce a therapeutic effect that results in 
biological relevance. 
 
Protein arrays on protein extracted from the frozen tumour tissue would be useful in 
measuring the downstream activity occurring in response to the different treatment groups 
especially in the combination groups, as these arrays could provide information on the 
pathways that are potentially inducing resistance. There are a number of diverse pathways 
that can be either down-regulated or up-regulated in response to Bz or blockade of the 
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neuropilin/VEGF signalling pathway. One of the possible mechanisms of resistance to Bz 
treatment is the induction of a more aggressive phenotype after Bz treatment. Comparing the 
downstream signalling events associated with Bz and the combination therapy may prove 
useful as although the combination of Bz and p7b/p10 had no additive effects on primary 
growth, the array studies may identify a potential difference in downstream activity that may 
show that the combination treatment leads to a less aggressive response to therapy by the 
tumour and thus may provide more long term benefits, which potentially may relate to 
significant increases in overall survival in patients treated with a combination of Bz and anti-
Np1 therapy, a clinical end-point which has not yet been met in breast cancer clinical trials 
using Bz in combination with chemotherapy. Protein arrays (R&D Systems) that assess 
downstream signalling events associated with angiogenic activity are available to buy 
commercially therefore this analysis can easily be carried out on the frozen samples already 
collected from this study.  
 
The data from this project suggests that there are a numbers of different studies that can be 
designed or continued. The most interesting avenues of research that would be worth 
pursuing, as a result of this PhD is the potential role of Bz in inhibiting breast cancer-induced 
bone metastasis. The preliminary metastasis experiments are promising; yet future 
experiments to increase the numbers in the experimental groups are required to confirm these 
initial results. In addition the mechanism by which Bz alone is both reducing metastatic 
tumour burden and modulating the bone microenvironment to improve bone health in 
animals with breast cancer induced bone metastasis needs to be addressed.  As Bz is an anti-
angiogenic agent, CD31 or CD34 vessel staining would be useful to carry out on the bone 
sections, in order to establish a potential mechanism of action for Bz on reducing tumour 
metastatic burden.  
 
From the literature surrounding the role of the neuropilin receptors and some of the in vitro 
analysis, it would be worth pursing the neuropilin receptors as potential therapeutic targets. 
However, a slightly different approach to therapy may be required in order to assess if there 
is a potential role for the neuropilin receptors in combination therapy. Investing time into the 
downstream signalling pathway associated with Np1 signalling would be extremely 
beneficial. This could better inform the best downstream target that would provide a more 
wide-spread inhibitory action on Np1 function. As the neuropilin receptors act as co-
receptors for a number of different ligands, inhibiting these receptors may has the potential 
for a more wide-spread use in cancer therapy compared with agents that target VEGF alone. 
Designing a peptide that inhibits both Np1 and Np2 would prove beneficial. In addition, 
combining these re-designed peptides with an agent that targets another angiogenic activator, 
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such as FGF may prove beneficial although prior to carrying out any combination 
experiments, the use of anti-VEGF peptides alone needs to be tested.  
In light of potential binding of the Np1 peptides to other receptors an NCBI protein-protein 
BLAST (basic local alignment search tool) search was carried out on the four Np1 peptides 
using a position specific alignment search (PSI-BLAST). The PSI-BLAST search looks for 
conservation pattern alignments between the target sequence and proteins in a given 
database. Below is a table (Table 7.1) that summaries some of the more interesting protein 
matches to the four Np1 peptides that help to explain why the Np1 peptides failed display 
inhibitory effects of tumour growth. The list of all the protein matches for the peptides can 
be found in the appendix. The blast search confirmed that the peptides used during this PhD 
are not specific to Np1 and therefore may help to explain some of the results observed both 
in vitro (all four peptides) and in vivo (p7b and p10). For example multiple epidermal growth 
factor-like domains protein 8 is involved in cellular communication and Hsp70 is involved in 
increased breast cancer cell migration which may explain why p10 in combination with Bz 
resulted in reduced efficacy compared with Bz. Emphasis on blocking intracellular signalling 
pathways is backed by the blastp search cancer progression involved a plethora of cytokines 
and factors that will alternatively bind and activate downstream signalling pathways which 
promote tumour progression.  
p10 PSI-BLAST search Human Mus musculus 
Multiple epidermal growth factor-like domains 
protein 8 precursor 
Y Y 
PML-RARA-regulated adapter molecule 1 N Y 
Hsp70-binding protein 1 isoform 1 Y Y 
p7b PSI-BLAST search Human Mus musculus 
Protein Smaug homolog 2 Y N 
Heat shock protein beta-3 N Y 
Immunoglobulin super family member 1 
isoform 1 
Y N 
p1 PSI-BLAST search Human Mus musculus 
Arrestin domain containing protein 2 isoform 1 Y Not tested 
Hsp70-binding protein 1 isoform 1 Y Not tested 
WD repeat containing protein 7 isoform 1 Y Not tested 
p2 PSI-BLAST search Human Mus musculus 
Coiled-coil domain containing protein 107 
isoform A precursor 
Y Not tested 
Final Discussion 
 
SAPNA LUNJ Page 248 
 
Coiled-coil domain containing protein 107 
isoform B precursor 
Y Not tested 
 
 
 
 
 
In addition, tagging peptides with a detectable probe will allow quantitative analysis on 
delivery of the peptides to the tumour versus the normal organs. The IVIS imaging system 
not only measures bioluminescence but also detects a range of fluorophores therefore 
tagging peptides with a fluorescent tag would allow distribution analysis to be carried out. 
As the IVIS system is non-invasive it would also allow for continual monitoring of the 
movement of the peptide over the treatment period especially in terms of clearance of 
peptides from the body. Also delivery of the peptides to the tumour in a more targeted 
manner would improve delivery to the tumour thus enhance inhibitory actions and would 
also reduce any ‘off-target’ effects that may occur from targeting a receptor that is widely 
distributed under physiological conditions in other tissues other then the tumour. Examples 
of targeted therapy could include packaging the peptides in liposome that may be taken up 
by other cells types such as macrophages, and delivered to the tumour microenvironment.  
 
The VEGF splice variants are becoming increasingly important in cancer research. Initially, 
it was thought that the role of the different variants was to form a VEGF gradient and thus 
regulating VEGF bio-availability. However, the interaction of these splice variants with the 
VEGF receptors are potentially important in cancer progression. For example the MDA-MB-
436 tumours are thought to express higher levels of VEGF145 in comparison with the other 
VEGF variants (Stimpfl et al, 2002). In addition, VEGF145 binds to Np2 but not Np1 
(Gluzman-Poltorak et al, 2000) thus MDA-MB-436 tumours may be more responsive to 
Np2 inhibition due to the ratio of relevant VEGF isoforms being present, which may explain 
why treatment with p10 (potentially binds both Np1 and Np2) alone reduced tumour growth 
in comparison to p7b alone. The role of the different VEGF splice variants is therefore 
important to investigate when blocking receptor interactions. Lastly, similar to Bz not all 
breast cancer sub-types will respond to anti-neuropilin treatment therefore a tissue array that 
includes a large panel of breast cancer cell lines would be useful to identify more quickly 
breast cancer sub-types that are likely to respond to individual and combination anti-VEGF 
therapies prior to in vivo experimentation.  
 
Table 7.1. Protein Blast Search: 
The table summarises a few known proteins that share sequence alignment to the four Np1 
peptides. This suggests that the peptides are not necessarily specific to Np1. A full list of refseq 
proteins that matched the sequence of the peptides can be found in the appendix. 
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7.7 CONCLUSION 
 
To conclude, the data from this PhD project suggests that VEGF is a key player in breast 
cancer progression as inhibiting the VEGF pathway resulted in inhibition of primary breast 
cancer growth and a trend that suggested a reduction in the metastatic tumour burden after 
treatment with Bz. However, the use of short neuropilin peptides as inhibitors of subsequent 
cellular activity has not proved efficacious and the role of the neuropilin receptors in the 
resistance to current anti-angiogenic therapy in breast cancer still remains un-answered.  
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VI APPENDIX 
 
Acetate Buffer   
Sodium acetate 5.44g 
water 50ml 
Sodium tartrate 4.6ml 
 
Napthol/dimethyformide Buffer   
Napththol AS-BI Phosphate 0.02g 
Dimethlformamide 1ml 
Acetate Buffer 50ml 
 
PBS Buffer (5L)  
PBS Tablets 50 
dH2O 5000ml 
 
PBST Buffer (5L)  
PBS Tablets 50 
Tween20 5ml 
dH2O 5000ml 
 
4X Reducing Buffer VOLUME (ml) 
Stacking Buffer 2.5 
10% SDS 0.8g 
Glycerol 4 
2-mecaptoethanol 2 
dH2O 1.1 
Bromophenol Blue (1% stock) 0.1 
 
Resolving Gel (for 1 gel) VOLUME (ml) 
Resolving Buffer 2.5 
30% Arcrlaymide 2.5 
APS 50μl 
TEMED 5μl 
dH2O 4.85 
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Running Buffer (10x) pH 8.3 VOLUME (ml) 
Tris Base (25mM) 30g 
Glycine (0.192M) 144g 
SDS (0.1%) 10g 
dH20 1000 
 
Sodium Citrate Buffer (pH 6)  
Sodium citrate   
Tween20 0.5ml 
dH2O 1000ml 
Adjust to pH 6, add tween20 and make up to 
1L with dH2O. Store at r.t.p  
 
 
Sodium Nitrile Buffer   
Sodium Nitrile  0.08g 
water 2ml 
Pararosanliline 2ml 
Add 2.5ml of this solution to 50ml acetate 
buffer 
 
 
Stacking Gel (for 2 gels) VOLUME (ml) 
Stacking Buffer 2.5 
30% Arcrlaymide 1.3 
APS 100μ 
TEMED 10μl 
dH2O 6.1ml 
 
Transfer Buffer (10x) 
(25mM Tris, 192mM Glycine)  
pH 8.2-8,4 
VOLUME (ml) 
Tris Base 3.03g 
Glycine 14.10g 
dH2O 1000 
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Protein- p10 Blastp search  Human Mus musculus 
Arginine/serine-rich protein PNISR N Y 
Atrial natriuretic peptide receptor 3 
isoform a precursor 
N Y 
Atrial natriuretic peptide receptor 3 
isoform b precursor 
N Y 
Austism susceptibility gene 2 protein  N Y 
Austism susceptibility gene 2 protein 
isoform 3 
Y N 
Autism susceptibility gene 2 protein 
isoform 1 
Y N 
Autism susceptibility gene 2 protein 
isoform 2 
Y N 
Class A basic helix-loop-helix protein 
15 
Y Y 
Coiled-coil domain-containing protein 
74A isoform 1 
Y N 
Coiled-coil domain-containing protein 
74A isoform 2 
Y N 
Coiled-coil domain-containing protein 
74A isoform 3  
Y N 
Coiled-coil domain-containing protein 
74A isoform 4 
Y N 
Cystin-1 Y Y 
Dual specificity protein phosphatise 8 N Y 
Ecotropic viral integration site 5 
protein homolog 
Y N 
Endothelin-2 precursor N Y 
Endothelin-2 preproprotein Y N 
Fibrosin-1-like protein Y N 
Fibrosin-1-like protein isoform 1 Y Y 
Growth/differentiation factor 9 
precursor 
N Y 
G patch domain-containing protein 8 Y Y 
Helicase SRCAP Y N 
Hepatitis A virus cellular receptor 1 
homolog isoform b precursor 
N Y 
Hepatitis A virus cellular receptor 1 
homolog isoform a precursor 
N Y 
HHIP-like protein 1 precursor N Y 
Hsp70-binding protein 1 isoform 1 Y Y 
Hsp70-binding protein 1 isoform 2 Y N 
Laminin subunit alpha-2 isoform a 
precursor 
Y Y 
Laminin subunit alpha-2 isoform b 
precursor 
Y N 
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Meiotic recombination protein REC8 
homolog 
Y N 
MICAL-like protein 2 Y N 
Multiple epidermal growth factor-like 
domains protein 8 isoform 1 precursor 
Y N 
Multiple epidermal growth factor-like 
domains protein 8 isoform 2 precursor 
Y N 
Multiple epidermal growth factor-like 
domains protein 8 precursor 
N Y 
NK 1 transcription factor-related 
protein 2 
Y Y 
PML-RARA-regulated adapter 
molecule 1 
N Y 
Pre-mRNA-processing factor 40 
homolog B 
N Y 
Pre-mRNA-processing factor 40 
homolog B isoform 1 
Y N 
Pre-mRNA-processing factor 40 
homolog B isoform 2 
Y N 
Protein FAM189A2 N Y 
Protein LSM14 homolog B N Y 
PWWP domain-containing protein 
MUM1 
Y N 
Retinal dehydrogenase 8 N Y 
Rho-related GTP binding protein 
RhoV 
N Y 
Reproductive homeobox 13 N Y 
Serine/arginine repetitive matrix 
protein 1 
N Y 
Serine/arginine repetitive matrix 
protein 1 isoform 1 
N Y 
Serine/arginine repetitive matrix 
protein 2 
N Y 
Serine/arginine rich splicing factor 2 N Y 
Synaptonemal complex protein 2   
Thrombospondin-4 precursor   
Transcription factor SPT20 homolog-
like 1 
Y  
Ubiquitin carboxyl-terminal hydrolase 
1 
 Y 
Zinc finger CCCH domain-containing 
protein 18 isoform b 
 Y 
Zinc finger CCCH domain-containing 
protein 18 isoform a 
 Y 
Zinc finger protein 341  Y 
Zinc finger protein 414 isoform 1 Y  
Zinc finger protein 414 isoform 2 Y  
 
 
Appendix 
 
SAPNA LUNJ  
 
Protein- p7b Blastp search Human Mus musculus 
Arrestin domain containing 4 isoform 
1 
N Y 
Arrestin domain containing 4 isoform 
2 
N Y 
B cell CLL/lymphoma 7 protein 
family member C isoform 1 
Y N 
B cell CLL/lymphoma 7 protein 
family member C isoform 2  
Y N 
Coiled-coil domain containing protein 
13 
Y N 
Colorectal mutant cancer protein 
isoform 1 
Y N 
Colorectal mutant cancer protein 
isoform 2 
Y N 
Cyclin T1 domain Y Y 
DNA polymerase theta isoform 1 N Y 
DNA polymerase theta isoform 2 N Y 
E3 ubiquitin protein ligase HERC2 N Y 
G1/S-specific cyclin-E2 Y Y 
G1/S-specific cyclin-E2 isoform 1 N Y 
Glutamyl-Trna amidotransferase 
subunit A, mitochondrial  
Y Y 
Heat shock protein beta-3 N Y 
Immunoglobulin super family 
member 1 isoform 1 
Y N 
Immunoglobulin super family 
member 1 isoform 3 
Y N 
Immunoglobulin super family 
member 1 isoform 4 
Y Y 
Interleukin-1 receptor accessory 
protein-like 1 precursor 
N Y 
NAD-dependent protein deacetylase 
sirtuin 1 isoform a 
Y Y 
NAD-dependent protein deacetylase 
sirtuin 1 isoform b 
Y Y 
Pro-interleukin-16 isoform 2 Y N 
Pro-interleukin-16 isoform 3 Y N 
Protein PRR2C Y Y 
Protein PRRC2A Y Y 
Protein PRRC2B Y N 
Protein SCAI N Y 
Protein shroom2 isoform 4  N Y 
Protein Smaug homolog-2 Y Y 
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Protocadherin fat 2 precursor N Y 
RNA-binding E3 ubiqutin-protein 
ligase MEX3C 
Y Y 
Ryanodine receptor 3 isoform 1 Y N 
Ryanodine receptor 3 isoform 2 Y N 
Serine/threonine-protein kinase 
MARK2 isoform 1 
N Y 
Serine/threonine-protein kinase 
MARK2 isoform 2 
N Y 
Serine/threonine-protein kinase 
MARK2 isoform 3 
N Y 
Serine/threonine-protein kinase 
MARK2 isoform 4 
N Y 
SH3 and cysteine-rich domain-
containing protein 
N Y 
SIDI transmembrane family member 
2 isoform 1 precursor 
N Y 
SIDI transmembrane family member 
2 isoform 2 precursor 
N Y 
SPARC-related modular calcium 
binding protein 1 isoform 1 precursor 
Y N 
SPARC-related modular calcium 
binding protein 1 isoform 2 precursor  
Y N 
Spermatogenesis associated protein 6  N Y 
Spermatogenesis associated protein 6 
isoform 1 precursor 
Y N 
Spermatogenesis associated protein 6 
isoform 2 
Y N 
Spermatogenesis associated protein 6 
isoform 3 
Y N 
Transcription factor Sp7 N Y 
Transcription factor TFIIIB 
component B” homolog 
N Y 
Transcriptional adapter 2-alpha 
isoform a 
Y N 
Transcriptional adapter 2-alpha 
isoform b 
Y N 
Tyrosine-protein kinase SgK223 N Y 
WD repeat domain phosphoinositide-
interacting protein 3 
Y Y 
X-linked interleukin-1 receptor 
accessory  protein-like 2 precursor 
Y N 
X-linked interleukin-1 receptor 
accessory  protein-like 2 precursor 
N Y 
Zinc finger CCCH domain containing 
protein 4 
Y N 
Zinc finger CCCH-type with G patch 
domain containing protein isoform d 
Y N 
Zinc finger CCCH-type with G patch 
domain containing protein isoform c 
Y N 
Zinc finger CCCH-type with G patch 
domain containing protein isoform a 
Y N 
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Zinc finger FYVE domain-containing 
protein 26 
Y N 
Zinc finger protein 446 Y N 
Zinc finger protein 451 isoform 1 N Y 
Zinc finger protein 451 isoform 2 N Y 
Zinc finger protein 469 Y N 
Zinc finger protein 622 N Y 
 
Protein- p1 Blastp search Human 
55 kDa erythrocyte membrane protein 
isoform 1 
Y 
55 kDa erythrocyte membrane protein 
isoform 2 
Y 
55 kDa erythrocyte membrane protein 
isoform 3 
Y 
Arrestin domain containing protein 2 
isoform 1 
Y 
Arrestin domain containing protein 2 
isoform 2 
Y 
Arrestin domain containing protein 2 
isoform 3 
Y 
Aspartate beta-hydroxylase domain-
containing protein 1 
Y 
Ataxin-7-like protein Y 
Cat eye syndrome critical region 
protein 2 isoform 1 
Y 
Cat eye syndrome critical region 
protein 2 isoform 2 
Y 
Cholecystokinin receptor type A Y 
CUB-domain containing protein 2 
precursor 
Y 
Ectonucleoside triphosphate 
diphosphohydrolase 6 isoform 1 
Y 
Ectonucleoside triphosphate 
diphosphohydrolase 6 isoform 2 
Y 
FERM, RhoGEF and pleckstrin 
domain-containing protein 2 isoform a 
Y 
FH2 domain-containing protein 1  Y 
Hsp70-binding protein 1 isoform 1 Y 
Hsp70-binding protein 1 isoform 2 Y 
Hypermethylated in cancer 2 protein Y 
Iporin Y 
Melatonin receptor type 1B Y 
Methyl-CpG-binding protein 2 
isoform 1 
Y 
Methyl-CpG-binding protein 2 
isoform 2 
Y 
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Mucin-19 receptor Y 
Multiple epidermal growth factor-like 
domains protein 6 isoform 1 precursor 
Y 
Multiple epidermal growth factor-like 
domains protein 8 isoform 2 precursor 
Y 
Nesprin-2-isoform 4 Y 
Nesprin-2-isoform 5 Y 
OUT domain-containing protein7B Y 
Ras-interacting protein 1 Y 
RNA-binding protein raly isoform 1 Y 
RNA-binding protein raly isoform 2 Y 
Suppression of tumourgenicity 5 
protein isoform 1 
Y 
Thrombospondin-4 precursor Y 
Transcription factor Sp7 isoform a Y 
Transcription factor Sp7 isoform b Y 
Usherin isoform 8 Y 
WD repeat containing protein 7 
isoform 1 
Y 
WD repeat containing protein 7 
isoform 2 
Y 
WD repeat-containing protein 86 
isoform 1 
Y 
 
Protein- p2 Blastp search Human 
Activating transcription factor 7-
interacting protein 1 isoform 1 
Y 
Activating transcription factor 7-
interacting protein 1 isoform 2 
Y 
AF4/MR2 family member 1 isoform 1 Y 
AF4/MR2 family member 1 isoform 2 Y 
Arginine-fifty homeobox Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 2 
Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 3 
Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 4 
Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 5 
Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 6 
Y 
Aryl-hydrocarbon-interacting protein-
like 1 isoform 7 
Y 
Cat eye syndrome critical region 
protein 2 isoform 1 
Y 
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Cat eye syndrome critical region 
protein 2 isoform 2 
Y 
Cleavage and polyadenylation 
specificity factor subunit 7 isoform 3  
Y 
Cleavage and polyadenylation 
specificity factor subunit 7 isoform 2 
Y 
Cleavage and polyadenylation 
specificity factor subunit 7 isoform 1 
Y 
Coiled-coil domain containing protein 
107 isoform A precursor 
Y 
Coiled-coil domain containing protein 
107 isoform B precursor 
Y 
Coiled-coil domain containing protein 
107 isoform C precursor 
Y 
Coiled-coil domain containing protein 
107 isoform D precursor 
Y 
CUB domain containing protein 2 
precursor 
Y 
D-dopachrome decarboxylase Y 
D-dopachrome decarboxylase like 
protein 
Y 
D-dopachrome decarboxylase related 
protein 
Y 
Downs syndrome cell adhesion 
molecule-like protein 1 
Y 
G patch domain-containing protein 8 Y 
GRB2-asscoiated binding protein 4 Y 
GTP-binding protein 10 isoform 1 Y 
Hepatoma-derived growth factor-
related protein 2 isoform 1 
Y 
Hepatoma-derived growth factor-
related protein 2 isoform 2 
Y 
Integrin alpha-E precursor Y 
Interleuckin-17 receptor C isoform  2 
precursor 
Y 
Melanoma-associated antigen 1 Y 
Pro-neuregulin-3, membrane bound 
isoform 1 
Y 
Pro-neuregulin-3, membrane bound 
isoform 2 
Y 
Protein phosphatise slingshot homolog 
1 isoform 1 
Y 
Protein spire homolog 2 Y 
Rho/guanine nucleoside exchange 
factor 17 
Y 
Sarcalumenin precursor Y 
Sodium/hydrogen exchanger 1 Y 
Vacuolar fusion protein MON1 
homolog A 
Y 
Zinc finger protein 839 isoform 1 Y 
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